MXPA00009133A - Compounds and methods for therapy and diagnosis of lung cancer - Google Patents

Abstract

Compounds and methods for the treatment and diagnosis of lung cancer are provided. The inventive compounds include polypeptides containing at least a portion of a lung tumor protein. Vaccines and pharmaceutical compositions for immunotherapy of lung cancer comprising such polypeptides, or DNA molecules encoding such polypeptides, are also provided, together with DNA molecules for preparing the inventive polypeptides.

Description

COMPOUNDS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF LUNG CANCER TECHNICAL FIELD The present invention relates in general to compositions and methods for the treatment and diagnosis of lung cancer. The invention relates more specifically to nucleotide sequences that are preferably expressed in lung tumor tissue, together with polypeptides encoded by such nucleotide sequences. Inventive nucleotide sequences and polypeptides can be used in vaccines and pharmaceutical compositions for the treatment and diagnosis of lung cancer.

BACKGROUND OF THE INVENTION Lung cancer is the leading cause of cancer death among both men and women in the United States. , with an estimated 172,000 new cases reported in 1994. The survival rate in the fifth year among all patients with lung cancer, without considering the stage of the disease in diagnosis, is only 13%. This contrasts with a survival rate in the fifth year of 46% among the cases detected while the disease is still localized. However, only 16% of lung cancers are discovered before the disease expands. Early detection is difficult because clinical symptoms are often not seen until the disease has reached an advanced stage. Currently, the diagnosis is assisted by the use of chest X-rays, analysis of the type of cells contained in saliva and the examination of the fiber optic bronchial passages. Treatment regimens are determined by the type and stage of the cancer, and include surgery, radiation therapy and / or chemotherapy. Despite considerable research in therapies for the disease, lung cancer remains difficult to treat. In accordance with the foregoing, there remains a need in the matter of improved vaccines, methods of treatment and diagnostic techniques for lung cancer.

BRIEF DESCRIPTION OF THE INVENTION Briefly stated, the present invention provides compounds and methods for the therapy of lung cancer. In a first aspect, isolated polynucleotide molecules encoding lung tumor polypeptides are provided, such polynucleotide molecules comprising a nucleotide sequence selected from the group consisting of: (a) sequences provided in SEQ ID NO: 1 -3, 6 -8, 10-13, 15-27, 29, 30, 32, 34-49, 51, 52, 54, 55, 57-59, 61 -69, 71, 73, 74, 77, 78, 80-82 , 84, 86-96, 107-109, 1 1 1, 1 13, 125, 127, 128, 129, 131 -133, 142, 144, 148-1 51, 1 53, 154, 157, 1 58, 160 , 1 67, 168 and 171; (b) sequences complementary to a sequence provided in SEQ ID NO: 1 -3, 6-8, 10-13, 15-27, 29, 30, 32, 34-49, 51, 52, 54, 55, 57- 59, 61-69, 71, 73, 74, 77, 78, 80-82, 84, 86-96, 107-109, 111, 113, 125, 127, 128, 129, 131-133, 142, 144, 148-151, 153, 154, 157, 158, 160, 167, 168 and 171; and (b) sequences that generate hybrids to a sequence of (a) or (b) under moderately stringent conditions. In a second aspect, isolated polypeptides comprising at least an immunogenic portion of a lung tumor protein or a variant thereof are provided. In specific embodiments, such polypeptides comprise an amino acid sequence encoded by a polynucleotide molecule comprising a nucleotide sequence selected from the group consisting of (a) sequences recited in SEQ ID NO: 1-3, 6-8, 10-13 , 15-27, 29, 30, 32, 34-49, 51, 52, 54, 55, 57-59, 61-69, 71, 73, 74, 77, 78, 80-82, 84, 86-96 , 107-109, 111, 113, 125, 127, 128, 129, 131-133, 142, 144, 148-151, 153, 154, 157, 158, 160, 167, 168 and 171; (b) sequences complementary to a sequence provided in SEQ ID NO: 1-3, 6-8, 10-13, 15-27, 29, 30, 32, 34-49, 51, 52, 54, 55, 57- 59, 61-69, 71, 73, 74, 77, 78, 80-82, 84, 86-96, 107-109, 111, 113, 125, 127, 128, 129, 131-133, 142, 144, 148-151, 153, 154, 157, 158, 160, 167, 168 and 171 and (c) sequences that generate hybrids to a sequence of (a) or (b) under moderately stringent conditions. In related aspects, expression vectors comprising the inventive polynucleotide molecules, together with host cells transformed or transferred with such expression vectors are provided. In preferred embodiments, the host cells are selected from the group consisting of E. coli, yeast and mammalian cells. In another aspect, fusion proteins comprising a first and second inventive polypeptide or, alternatively, an inventive polypeptide and a known lung tumor antigen, are provided. The present invention further provides pharmaceutical compositions comprising one or more of the above polypeptides, fusion proteins or polynucleotide molecules and a physiologically acceptable carrier, together with vaccines comprising one or more such polypeptides, fusion proteins or molecules of polynucleotide in combination with an immune response enhancer. In related aspects, the present invention provides methods for inhibiting the development of lung cancer in a patient, comprising administering to the patient an effective amount of at least one of the above pharmaceutical compositions and / or vaccines. Additionally, the present invention provides methods for immunodiagnosis of lung cancer, along with equipment for use in such methods. Polypeptides are described which comprise at least an immunogenic portion of a lung tumor protein or a variant of said protein that is unique only in conservative substitutions and / or modifications, wherein the lung tumor protein comprises an encoded amino acid sequence by a polynucleotide molecule having a sequence selected from the group consisting of nucleotide sequences cited in SEQ ID NO: 1 -1 09, 11 11, 13 13 15 1 51, 53 53, 157, 157 1 58, 160, 162-164, 167, 168 and 171, and variants thereof. Such polypeptides can be usefully employed in the diagnosis and monitoring of lung cancer. In a specific aspect of the present invention, the methods are provided for detecting lung cancer in a patient, comprising: (a) contacting a biological sample obtained from a patient with a binder that is capable of binding to one of the above polypeptides; and (b) detecting in the sample a protein or polypeptide that binds to the binder. In preferred embodiments, the binder is an antibody, more preferably a monoclonal antibody. In related aspects, the methods are provided to monitor the advancement of lung cancer in a patient, comprising: (a) contacting a biological sample obtained from a patient with a binder that is capable of binding to one of the above polypeptides; (b) determining in the sample an amount of a protein or polypeptide that binds to the binder; (c) repeating steps (a) and (b); and comparing the amounts of polypeptide detected in steps (b) and (c). Within related aspects, the present invention provides antibodies, preferably monoclonal antibodies, which bind to the inventive polypeptides, as well as diagnostic kits comprising such antibodies, and methods for using such antibodies to inhibit the development of lung cancer. The present invention further provides methods for detecting lung cancer comprising: (a) obtaining a biological sample from a patient; (b) contacting the sample with a first and a second primary oligonucleotide in a polymerase chain reaction, at least one of the primary oligonucleotides being specific for a polynucleotide molecule encoding one of the above polypeptides; and (c) detecting in the sample a polynucleotide sequence that is amplified in the presence of the first and second primary oligonucleotides. In a preferred embodiment, at least one of the primary oligonucleotides comprises at least about 10 contiguous nucleotides of a polynucleotide molecule that includes a sequence selected from the group consisting of SEQ ID NO: 1-109, 11.1, 13.1 15-151, 1 53, 154, 157, 158, 160, 162-164, 167, 168 and 171. In a further aspect, the present invention provides a method for detecting lung cancer in a patient comprising: (a) obtaining a biological sample from the patient; (b) contacting the sample with an oligonucleotide probe specific for a polynucleotide molecule that encodes one of the above polypeptides; and (c) detecting in the sample a polynucleotide sequence that generates hybrids to the oligonucleotide probe. Preferably, the oligonucleotide probe comprises at least about 1 5 contiguous nucleotides of a polynucleotide molecule having a partial sequence selected from the group consisting of SEQ ID NO: 1-109, 11.1, 13.1-15-151, 153, 154, 157, 158, 160, 162-164, 167, 168, and 171. In related aspects, the diagnostic equipment comprising the oligonucleotide or primary probes is provided. In still a further aspect, methods for the treatment of lung cancer in a patient are provided, methods comprise obtaining PBMC from the patient, incubating the PBMC with a polypeptide of the present invention (or a polynucleotide encoding such a polypeptide) to provide cells T incubated and administer the T cells incubated to the patient. The present invention further provides methods for the treatment of lung cancer comprising incubating antigen-comprising cells with a polypeptide of the present invention (or a polynucleotide encoding such a polypeptide) to provide cells that contain incubated antigen and administer antigen-presenting cells. incubated the patient. In certain embodiments, the cells that present antigen are selected from the group consisting of dendritic cells and macrophages. Also provided are compositions for the treatment of lung cancer comprising T cells or antigen presenting cells that have been incubated with a polypeptide or polynucleotide of the present invention. These and other aspects of the present invention will become apparent in the reference to the following detailed description. All references described herein are incorporated by reference in their entirety as if each were incorporated individually.

DETAILED DESCRIPTION OF THE INVENTION As indicated above, the present invention is generally directed to compositions and methods for the therapy and diagnosis of lung cancer. The compositions described herein include polypeptides, fusion proteins and polynucleotide molecules. Also included within the present invention are molecules (such as an antibody or fragment thereof) that bind to the inventive polypeptides. Such molecules are referred to herein as "binders." In one aspect, the subject invention describes polypeptides comprising an immunogenic portion of a human lung tumor protein, wherein the lung tumor protein includes an amino acid sequence encoded by a polynucleotide molecule that includes a sequence selected from the group consists of (a) nucleotide sequences cited in SEQ ID NO: 1 -109, 1 1 1, 1 13, 1 1 5-1 51 -, 1 53, 1 54, 157, 1 58, 160, 162-164, 167, 168 and 171, (b) the complements of said nucleotide sequences, and (c) variants of such sequences. As used herein, the term "polypeptide" encompasses amino acid chains of any length, including full length proteins, wherein the amino acid residues are linked by covalent peptide bonds. In addition, a polypeptide comprising a portion of one of the above proteins of the lung tumor may consist of the entirety of the portion, or the portion may be present within a longer polypeptide containing additional sequences. Additional sequences may be derived from the native protein or may be heterologous, and such sequences may (but need not) be immunoreactive and / or antigenic. As detailed below, such polypeptides can be isolated from lung tumor tissue or prepared by recombinant or synthetic means. As used herein, an "immunogenic portion" of a lung tumor protein is a portion that is capable of eliciting an immune response in a patient afflicted with lung cancer and as such binds to the antibodies present within the serum of a lung cancer patient. Such immunogenic portions generally comprise at least about 5 amino acid residues, more preferably at least about 10, and more preferably at least about 20 amino acid residues. The immunogenic portions of the proteins described herein can be identified in the antibody binding assays. Such analyzes can generally be performed using any of a variety of means known to those of ordinary skill in the art, as described, for example, in Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1988. For example, a polypeptide can be immobilized on a solid base (as described below) and contacted with a patient's serum to allow binding of antibodies within the serum to the immobilized polypeptide. A loose serum can thus be removed and bound antibodies detected using, for example, 251-labeled Protein A. Alternatively, a polypeptide can be used to generate monoclonal and polyclonal antibodies for use in the detection of the polypeptide in the blood or other fluids of patients with lung cancer. Methods for preparing and identifying immunogenic portions of antigens of a known sequence are well known in the art and include those summarized in Paul, Fundamental Immunology, 3rd ed. , Raven Press, 1 993, pp. 243-247. The term "polynucleotide (s)", as used herein, means a double-strand polymer of deoxyribonucleotide or ribonucleotide bases and includes DNA and corresponding RNA molecules, including HnRNA and mRNA molecules, both sensitive and anti-aging filaments. sensitive, and includes cDNA, genomic DNA and recombinant DNA, as well as fully or partially synthesized polynucleotides. An HnRNA molecule contains introns and corresponds to a DNA molecule in a manner generally in exact correspondence. A mRNA molecule corresponds to a HnRNA molecule and DNA from which the introns have been excised. A polynucleotide can consist of a whole gene, or any portion thereof. The operable anti-sensitive polynucleotides may comprise a fragment of the corresponding polynucleotide, and the definition of "polynucleotide" therefore includes all operable anti-sensitive fragments. The compositions and methods of the present invention also encompass variants of the above polypeptides and polynucleotides. A "variant" of polypeptide, as used herein, is a polypeptide that differs from the cited polypeptide only in conservative modifications and / or substitutions, such that the therapeutic, antigenic and / or immunogenic properties of the polypeptide are conserved. In a preferred embodiment, the variant polypeptides are distinguished from a sequence identified by substitution, deletion or addition of five amino acids or less. Such variants can generally be identified by modification of one of the above polypeptide sequences, and evaluation of the antigenic properties of the modified polypeptide using, for example, the representative methods described herein. The polypeptide variants preferably exhibit at least about 70% more preferably at least about 90% and more preferably at least about 95% identity (determined as desorbed below) to the identified polypeptides. As used herein, a "conservative substitution" is one in which an amino acid is substituted by another amino acid having similar properties, such that a person skilled in the art of peptide chemistry would expect the secondary structure and the hydrophilic nature of the polypeptide is substantially unchanged. In general, the following amino acid groups represent the conservative changes: (1) wing, pro, gly, asp, gln, asn, ser, thr; (2) cys, ser, tyr, thr; (3) val, ¡le, leu, met, ala, phe; (4) lys, arg, his; and (5) phe, tyr, trp, his. The variants may also, or alternatively, contain other modifications including the deletion or addition of amino acids that have minimal influence on the antigenic properties, secondary structure and the hydrophilic nature of the polypeptide. For example, a polypeptide can be conjugated to a signal sequence (or leader) at the N-terminal end of the protein which directs co-translationally or post-translationally the transfer of the protein. The polypeptide can also be conjugated to a linker or other sequence for ease of synthesis, purification or identification of the polypeptide (e.g., poly-His), or to enhance the binding of the polypeptide to a solid base. For example, a polypeptide can be conjugated to an immunoglobulin Fc region. A "variant" of nucleotide is a sequence that is distinguished from the nucleotide sequence mentioned in having one or more deletions of nucleotides, substitutions or additions. Such modifications can be easily introduced using standard mutagenesis techniques, such as directed oligonucleotide-directed site-specific mutagenesis as taught, for example, by Adelman et al. (DNA, 2: 183, 1983). The nucleotide variants can be allelic variants that occur naturally, or variants that do not occur naturally. The variant nucleotide sequences preferably exhibit at least about 70%, more preferably at least about 80% and more preferably at least about 90% identity (determined as described below) to the cited sequence. The antigens provided by the present invention include variants that are encoded by polynucleotide sequences which are substantially homologous to one or more polynucleotide sequences specifically cited herein. "Substantial homology," as used herein, refers to polynucleotide sequences that are capable of generating hybrids under moderately stringent conditions. Suitable moderately stringent conditions include prewash in a solution of 5X SSC, 0.5% SDS, 1.0mM EDTA (pH 8.0); generating hybrids at 50 ° C-65 ° C, 5X SSC, during the night or, in the event of cross-species homology, at 45 ° C with 0.5X SSC; followed by a double wash at 65 ° C for 20 minutes with each of 2X, 0.5X and 0.2X SSC containing 0.1% SDS. Such hybrid-generating polynucleotide sequences are also within the scope of this invention, as are nucleotide sequences which, due to code degeneracy, encode an immunogenic polypeptide that is encoded by a polynucleotide sequence that generates hybrids. Two polypeptide or nucleotide sequences are said to be "identical" if the sequence of nucleotides or amino acid residues in the two sequences is the same when aligned by maximum correspondence as described below. Comparisons between the two sequences are typically performed by comparing the sequences on a comparison window to identify and compare the local regions of sequence similarity. A "comparison window", as used herein, refers to a segment of at least about 20 contiguous positions, usually 30 to about 75, 40 to about 50, in which a sequence can be compared to a sequence of reference of the same number of contiguous positions after the two sequences were optimally aligned. The optimal alignment of the sequences for comparison can be conducted using the Megalign program in the Lasergene sequence of the bioinformatics software (DNASTAR, Inc., Madison, Wl), using failure parameters. This program incorporates several alignment schemes described in the following references: Dayhoff, M.O. (1978) A model of evolutionary change in proteins - Matrices for detecting distant relationships. In Dayhoff, M.O. (ed.) Atlas of Protein Sequence and Structure, National Biomedical Research Foundation, Washington DC Vol. 5, Suppl. 3, pp. 345-358; Hein J, (1990) Unified Approach to Alignment and Philogenes pp. 626-645 Methods in Enzymology vol. 1 83, Academic Press, Inc., San Diego, CA; Higgings, D.G. and Sharp, P.M. (1989) Fast and sensitive multiple sequence alignments on a microcomputer CABIOS 5: 1 51-153; Myers, E.W. and Muller W. (1988) Optimal alignments n linear space CABIOS 4: 1 1-17; Robinson, E. D. (1 971) Comb. Theor 1 1: 105; Santou, N. Nes, M. (1987) The neighbor joining method. A new method for reconstructing phylogenetic trees Mol. Biol. Evol. 4: 406-425; Sneath, P. H.A. and Sokal, R.R. (1973) Numerical Taxonomy - the Principles and Practice of Numerical Taxonomy, Freeman Press, San Francisco, CA; Wilbur, W.J. and Lipman, D.J. (1983) Rapid similarity searches of nucleic acid and protein data banks Proc. Nati Acad., Sci. USA 80: 726-730. Preferably, the "percent sequence identity" is determined by comparing two optimally aligned series over a comparison window of at least 20 positions, wherein the portion of the polynucleotide sequence in the window comparison may contain additions or deletions ( ie, spaces) of 20 percent or less, usually 5 to 15 percent, or 10 to 12 percent, as compared to the reference sequences (which does not include additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions in which the identical nucleic acid bases or the amino acid residue occurs in both sequences to produce the number of equal positions, dividing the number of the equal positions by the total number of positions in the reference sequence (that is, the window size) and multiplying the results by 100 to produce the percentage of the sequence identity. Also included in the scope of the present invention are the alleles of the genes encoding the nucleotide sequences cited herein. As used herein, an "allele" or "allelic sequence" is an alternative form of the gene that can result from at least one mutation in the nucleic acid sequence. Alleles can result in altered mRNAs or polypeptides of which their structure or function may or may not be altered. Any given gene may not have any, one or several allelic forms. Common mutation changes which give rise to alleles are generally attributed to natural deletions, additions or substitutions of nucleotides. Each of these types of changes can occur alone or in combination with the others, one or more times in a given sequence. For lung tumor polypeptides with immunoreactive properties, the variants can alternatively be identified by modifying the amino acid sequence of one of the above polypeptides, and by evaluating the immunoreactivity of the modified polypeptide. For lung tumor polypeptides useful for the generation of diagnostic binders, a variant can be identified by evaluating a modified polypeptide for the ability to generate antibodies that detect the presence or absence of lung cancer. Such modified sequences can be prepared and tested using, for example, the representative methods described herein. The lung tumor polypeptides of the present invention and polynucleotide molecules that encode such polypeptides can be isolated from lung tumor tissue using any of a variety of methods well known in the art. The polynucleotide sequences that correspond to a gene (or a portion thereof) that encodes one of the inventive lung tumor proteins can be isolated from a set of lung tumor cDNAs using a subtraction technique as described in detail below. Examples of such polynucleotide sequences are provided in SEQ ID NO: 1 -1 09, 11 11, 11, 1 15-151, 153, 154, 1 57, 1 58, 160, 162-164, 167, 168, and 171. The partial polynucleotide sequences thus obtained can be used to design primary oligonucleotides for the amplification of full-length polynucleotide sequences from a set of human genomic DNA or a set of cDNAs from the lung tumor in a polymerase chain reaction (PCR). , using techniques well known in the art (see, for example, Mullis et al., Cold Spring Harbor Symp. Quant. Biol. 51: 263, 1987; Erlich ed. , PCR Technology, Stockton Press, NY, 1989). For this approach, the sequence-specific primaries can be designed based on the nucleotide sequences provided herein and can be acquired or synthesized. An amplified portion can be used to isolate a full-length gene from a suitable pool (e.g., a set of lung tumor cDNA) using well-known techniques. Within such techniques, a set (cDNA or genomic) is selected using one or more primary or polynucleotide probes suitable for amplification. Preferably, one set is selected in size to include larger molecules. Randomly prepared pools can also be preferred to identify upstream and 5 'regions of genes. Genomic assemblies are preferred to obtain introns and extend 5 'sequences. For hybridization techniques, a partial sequence can be labeled (e.g., by dot translation or final labeling with 3 P) using well-known techniques. A bacteriophage or bacterial pool is then selected by generating hybrids in filters containing denatured bacterial colonies (or screens containing phage plaques) with labeled probe (see Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratories, Cold Spring Harbor, NY, 1989). The hybrid generation plates or colonies are selected and expanded, and the DNA is isolated for further analysis. The cDNA clones can be analyzed to determine the amount of additional sequence by, for example, PCR using a primary of the partial sequence and a primary of the vector. Restriction maps and partial sequences can be generated to identify one or more coating clones. The entire sequence can then be determined using standard techniques, which may include generating a series of deletion clones. The resulting coating sequences are then assembled into a single contiguous sequence. A full-length cDNA molecule can be generated by ligating suitable fragments using well-known techniques. Alternatively, there are numerous amplification techniques to obtain a full-length coding sequence of a partial cDNA sequence. Within such techniques, amplification is generally done through PCR. Any of a variety of commercially available equipment can be used to perform the amplification step. The primaries can be designated using well known in the art (see, for example, Mullis et al., Cold Spring Harbor Symp., Quant. Biol. 51: 263, 1987, Erlich ed., PCR Technology, Stockton Press, NY, 1989) and Software well known in the art can also be used. The primers are preferably 22-30 nucleotides in length, have a GC content of at least 50% and anneal to the target sequence at temperatures about 68 ° C to 72 ° C. The amplified region can be sequenced as described above, and the coating sequences installed in a contiguous sequence. Such an amplification technique is inverse to PCR (see Triglia et al., Nucí Acids Res. 16:81 86, 1988), which uses restriction enzymes to generate a fragment in the known region of the gene. The fragment is then circularized by intramolecular ligation and used as a template for PCR with divergent primers derived from the known region. Within an alternative approach, sequences adjacent to a partial sequence can be recovered by amplification with a primer to a binding sequence and a specific primer to a known region. The amplified sequences are typically subjected to a second round of amplification with the same primary linker and a second primary specific for the known region. A variation on this procedure, which employs two primaries that initiate extension in opposite directions of the known sequence, is described in WO 96/38591. Additional techniques include capture PCR (Lagerstrom et al., PCR Methods Applic.f: 11-19 -1991) and oscillating PCR (Parker et al., Nucí.Aids.Res.-9: 3055-60, 1). 991). Transcription Mediated Amplification or TMA is another method that can be used for the amplification of DNA, rRNA, or mRNA, as described in Patent No. PCT / US91 / 03184. This method based on isothermal and autocatalytic non-PCR uses two primary and two enzymes: RNA polymerase and reverse transcriptase. A primer contains a promoter sequence for RNA polymerase. In the first amplification, the primary promoter generates hybrids to the target RNA at a defined site. The reverse transcriptase creates a DNA copy of the target RNA by extending the 3 'end of the primary promoter. The RNA in the resulting complex degrades and a second primary binds to the DNA copy. A new strand of DNA is synthesized from the end of the primary by reverse transcriptase that creates double-stranded DNA. The RNA polymerase recognizes the promoter sequence in DNA annealing and initiates transcription. Each of the newly synthesized RNA amplicons reintroduces the TMA process and serves as a quench for a new replication loop that leads to the expotential expansion of the RNA amplicon. Other methods employing amplification can also be employed to obtain a full-length cDNA sequence. In certain cases it is possible to obtain a full-length cDNA sequence by analyzing sequences provided in an expressed sequence fragment database such as that available from the Gene Bank. Searches for coating ESTs can generally be performed using well-known programs (for example, NCBI BLAST searches), and such ESTs can be used to generate a contiguous full-length sequence. Once a polynucleotide sequence encoding a polypeptide is obtained, the polypeptide can be produced recombinantly by inserting the polynucleotide sequence into an expression vector and expressing the polypeptide in an appropriate host. Any of a variety of expression vectors known to those of ordinary skill in the art can be used to express the recombinant polypeptides of this invention. Expression can be achieved in any appropriate host cell that has been transformed or transferred with an expression vector containing a polynucleotide molecule encoding the recombinant polypeptide. Suitable host cells include higher eukaryotic cells, insect, yeast, and prokaryotes. Preferably, the host cells employed are i. coli, yeast or a mammalian cell line, such as COS or CHO cells. The polynucleotide sequences expressed in this manner can encode naturally occurring polypeptides, naturally occurring portions of polypeptides, or other variants thereof. Supernatants of the appropriate host / vector systems that secrete the recombinant polypeptide can be first concentrated using a commercially available filter. The concentrate can then be applied to a suitable purification matrix, such as an affinity matrix or an ion exchange resin. Finally, one or more reverse phase HPLC steps can be used to further purify the recombinant polypeptide. The lung tumor polypeptides described herein can also be generated by synthetic means. In particular, synthetic polypeptides having less than about 100 amino acids and generally less than about 50 amino acids, can be generated using techniques well known to those of ordinary skill in the art. For example, such polypeptides can be synthesized using any of the commercially available solid phase techniques., such as the Merrifield solid phase synthesis method, wherein the amino acids are sequentially added to a developing amino acid chain (see, for example, Merrifield, J. Am. Chem. Soc. 85: 2149-2146, 1963 ). The equipment for the automatic synthesis of polypeptides is commercially available from suppliers such as Perkin Elmer / Applied BioSystems Division (Foster City, CA), and can be operated according to the manufacturer's instructions. In addition, lung tumor antigens can be identified by cloning T cell expression. A source of tumor-specific T cells is from tumors surgically excised from human patients. In a method for isolating and characterizing tumor-specific T cells, the excised tumor is crumbled and enzymatically digested for several hours to release the tumor cells and infiltrate the lymphocytes (T cells infiltrating the tumor, or TlLs). Cells are rinsed in regular HBSS and passed over a discontinuous Ficoll gradient (1 00% / 75% / HBSS) to separate tumor cells and lymphocytes from non-viable cells. Two bands are grown from the interfaces; the upper band at the 75% / HBSS interface contains predominantly tumor cells, while the lower band at the 100% / 75% interface / HBSS contains a majority of lymphocytes. The TlLs are expanded in culture by techniques well known in the art but preferably the culture medium supplemented with 10 ng / ml of IL-7 and 100 U / ml of IL-2, or alternatively they are cultured and expanded in culture plates. tissue that has been pre-absorbed with anti-CD3 monoclonal antibody (OKT3). The resulting TIL cultures are analyzed by FACS to confirm that the vast majority are CD8 + T cells (> 90% population provided). In addition, tumor cells are also expanded in culture using standard techniques well known in the art to establish a tumor cell line, which is ultimately confirmed to be lung carcinoma cells by immunohistochemical analysis. The tumor cell line is transduced with a retroviral vector to express human CD80. The tumor cell line is further characterized by FACS analysis to confirm the strong expression levels of CD80, MHC class I and II molecules. The specificity of the TIL lines for lung tumor is confirmed by the cytokine release analysis INF-? and / or TNF-a. For example, TIL cells from day 21 cultures are co-cultured with either autologous or halogenic tumor cells, LCL immortalized with EBV, or control cell lines Daudi and K562 and the culture supernatant monitored by ELISA for the presence of cytokines. The expression of these specific cytokines in the presence of negative control or tumor cells indicates whether the TIL lines are tumor specific and potentially recognize the tumor antigen presented by the autologous MHC molecules. The tumor-specific TIL lines characterized can be expanded and cloned by methods well known in the art. For example, TIL lines can be expanded to numbers suitable for cloning by expression of the T cell by using soluble CD3 anti-body in culture with irradiated EBV transformed LCLs and PBL feeder cells in the presence of 20 U / ml of IL- 2. the clones of the expanded TIL lines can be generated by standard limiting dilution techniques, in particular, the TIL cells are based on 0.5 cells / cavity in a 96-well U-bottom plate and are stimulated with translucent autologous CD tumor cells -80, LCL transformed from EBV, and PBL feeder cells in the presence of 50 U / ml of IL-2. these clones can be further analyzed for tumor specificity by 51 Cr microcytotoxicity and IFN-β bioassay. In addition, the MHC restriction element recognized by the TIL clones can be determined by antibody blocking studies well known in the art. The CTL lines or clones described above can be used to identify tumor-specific antigens. For example, autologous fibroblasts or LCL from a patient can be transferred or transduced with polynucleotide fragments derived from a set of lung tumor cDNA to generate target cells expressing tumor polypeptides. Target cells expressing tumor polypeptides in the context of MHC will be recognized by the CTL or clone line resulting in T cell activation, which can be monitored by cytokine detection assays. The tumor gene that is expressed by the target cell and recognized by the tumor-specific CTL is then isolated by techniques described above. In general, without considering the method of preparation, the polypeptides described herein are prepared in a substantially pure, isolated form (ie, the polypeptides are homogeneous as determined by the amino acid composition and primary sequence analysis). Preferably, the polypeptides are at least about 90% pure, more preferably at least about 95% pure and more preferably at least about 99% pure. In certain preferred modalities, described in more detail below, substantially pure polypeptides are incorporated into pharmaceutical compositions or vaccines for use in one or more of the methods described herein. In a related aspect, the present invention provides fusion proteins comprising a first and a second inventive polypeptide or, alternatively, a polypeptide of the present invention and a known lung tumor antigen together with variants of such fusion proteins. The fusion proteins of the present invention can (but need not) include linker peptide between the first and second polypeptides. A polynucleotide sequence encoding a fusion protein of the present invention is constructed using known recombinant DNA techniques to install the separate polynucleotide sequences encoding the first and second polypeptides into an appropriate expression vector. The 3 'end of a DNA sequence encoding the first polypeptide is ligated, with or without a peptide linker, to the 5' end of a DNA sequence encoding the second polypeptide so that the reading frames of the sequences are in phase to allow the translation of mRNA of the two DNA sequences into a single fusion protein that maintains the biological activity of both the first and second polypeptides. A peptide linking sequence can be used to separate the first and second polypeptides by a sufficient distance to ensure that each polypeptide is folded into its secondary and tertiary structures. Such a peptide linking sequence is incorporated into the fusion protein using standard techniques well known in the art. Suitable peptide linking sequences can be chosen based on the following factors: (1) their ability to adopt a flexible extended conformation; (2) its inability to adopt a secondary structure that could interact with functional epitopes on the first and second polypeptides; and (3) the lack of charged or hydrophobic residues that could react with the functional polypeptide epitopes. Preferred peptide linking sequences contain Gly, Asn, and Ser residues. Other near-neutral amino acids proximal in the linking sequence can also be used. The amino acid sequences that can be usefully employed as linkers include those described in Maratea et al., Gene 40: 39-46, 1985; Murphy et al., Proc. Nati Acad. Sci. USA 83: 8258-8262, 1986; U.S. Patent No. 4,935,233 and. U.S. Patent No. 4,751, 180. The binding sequence can be from 1 to about 50 amino acids in length. Peptide sequences are not required when the first and second polypeptides have non-essential N-terminal amino acid regions that can be used to separate functional domains and avoid steric interference. The ligated polynucleotide sequences are operably linked to translational or transcriptional regulatory elements. The regulatory elements responsible for polynucleotide expression are located only 5 'to the DNA sequence encoding the first polypeptides. Similarly, the stop codons required for the final transcription and translational termination signals are only present 3 'to the DNA sequence encoding the second polypeptide. Fusion proteins comprising a polypeptide of the present invention together with an unrelated immunogenic protein are also provided. Preferably, the immunogenic protein is capable of producing a reminder response. Examples of such proteins include hepatitis, tuberculosis and tetanus proteins (see, for example, Stoute et al., New Engl. J. Med., 336: 86-91 (1977)). The polypeptides of the present invention comprising an immunogenic portion of a lung tumor protein can generally be used for lung cancer therapy, wherein the polypeptide stimulates the patient's own immune response to the lung tumor cells. The present invention thus provides methods for using one or more of the compounds described herein (which may be polypeptides, polynucleotide molecules or fusion proteins) for the therapy of lung cancer of a patient. As used herein, a "patient" refers to any hemothermal animal, preferably a human. A patient may suffer from the disease or may be free of the detectable disease. Accordingly, the compounds described herein can be used to treat lung cancer or to inhibit the development of lung cancer. The compounds are preferably administered either before or after surgical removal of primary tumors and / or treatment by the administration of radiotherapy and conventional chemotherapeutic drugs. In these aspects, the inventive polypeptide is generally present within a pharmaceutical composition or a vaccine. The pharmaceutical compositions may comprise one or more polypeptides, each of which may contain one or more of the above sequences (or variants thereof) and a physiologically acceptable carrier. The vaccines may comprise one or more such polypeptides and a non-specific immune response enhancer, wherein the enhancer of the non-specific immune response is capable of producing or increasing an immune response to an exogenous antigen. Examples of non-specific immune response enhancers include adjuvants, biodegradable microspheres (eg, galactide, polygactics) and liposomes (in which polypeptides are incorporated). The pharmaceutical compositions and vaccines may also contain other epitopes of lung tumor antigens, either incorporated in a fusion protein as described above (i.e., a single polypeptide that contains multiple epitopes) or present within a separate polypeptide. Alternatively, a pharmaceutical composition or vaccine may contain polynucleotide that encodes one or more of the above polypeptides and / or fusion proteins, such that the polypeptides are generated in situ. In such pharmaceutical compositions and vaccines, the polynucleotide can be present within any of a variety of delivery systems known to those of ordinary skill in the art, including nucleic acid expression systems, bacteria and viral expression systems. Suitable nucleic acid expression systems contain the polynucleotide sequences necessary for their expression in the patient (such as a suitable promoter). Bacterial delivery systems include the administration of a bacterium (such as Bacillus-Calmette-Guerrin) that expresses an epitope of a lung cellular antigen on its cell surface. In a preferred embodiment, the polynucleotides may be introduced using a viral expression system (e.g., vaccinia or other pustular virus, retrovirus or adenovirus) which may include the use of a replication competent, non-pathogenic (defective) virus. Suitable systems are described, for example, in Fisher-Hoch et al., PNAS 86:31 7-321, 1989; Flexner et al., Ann. N. Y. Acad. Sci. 569: 86-103, 1989; Flexner er al., Vaccine 8: 17-21, 1990; US Patents Nos. 4,603, 1 12, 4,769,330, and 5,017,487; WO 89/01973; U.S. Patent No. 4,777, 127; GB 2,200,651; EP 0,345,242; WO 91/02805; Berkner, Biotechniques 6: 616-627, 1988; Rosenfeld et al., Science 252: 431-434, 1991; Kolls et al., PNAS 9: 21 5-21 9, 1994; Kass-Eisler et al., PNAS 90: 1 1498-1 1502, 1 993; Guzman et al., Circulation 88: 2838-2848, 1993; and Guzmán et al., Cir. Res. 73: 1202-1207, 1993. The techniques for incorporating the polynucleotide into such expression systems are well known to those of ordinary skill in the art. The polynucleotides can also be "deprotected", as described, for example, in the published PCT application WO 90/1 1092, and Ulmer et al., Science 259: 1745-1749, 1993; reviewed by Cohen, Science 259: 1691-1692, 1993. The incorporation of deprotected polynucleotides can be increased by coating the polynucleotides on biodegradable beads, which are transported efficiently in the cells. The routes and frequencies of administration, as well as the dose, will vary from individual to individual and may be parallel to those currently used in immunotherapy of other diseases. In general, the pharmaceutical compositions and vaccines can be administered by injection (intracutaneous, intramuscular, intravenous, or subcutaneous), intranasally (e.g., by aspiration) or orally. Between 1 to 10 doses can be administered over a period of 3-24 weeks. Preferably, 4 doses are administered, in a 3-month interval, and stimulant administrations can be given periodically from here on out. Alternate procedures may be appropriate for individual patients. A suitable dose is an amount of polypeptide or polynucleotide that is effective to elevate an immune response (cellular and / or humoral) against lung tumor cells in a treated patient. An adequate immune response is at least about 10-50% above the basal level (ie, untreated). In general, the amount of polypeptide present in a dose (or produced in situ by the molecule (s) of polypeptide in a dose) ranges from about 1 pg to about 100 mg per kg of host (typically from about 10 pg. up to about 1 mg, and preferably from about 100 pg to about 1 μg The appropriate dose sizes will vary with the size of the patient, but will typically range from about 0.01 mL to about 5 mL, although any suitable carrier known to those of ordinary experience In the field it can be used in the pharmaceutical compositions of this invention, the type of carrier will vary depending on the mode of administration For parenteral administration, such as subcutaneous injection, the carrier preferably comprises water, saline, alcohol, a lipid, a wax and or regulator For oral administration any of the previous carriers or a p solid support, such as mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, and / or magnesium carbonate can be used. Biodegradable mycospheres (eg, polyglycol glycolide) can also be used as carriers for the pharmaceutical compositions of this invention. Suitable biodegradable microspheres are described, for example, in U.S. Pat. Nos. 4,897,268 and 5,075,198. Any of a variety of immune response enhancers can be employed in the vaccines of this invention. For example, an adjuvant may be included. Most adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a non-specific stimulator of immune response such as lipid A, Bordella pertussis or Mycobacterium tuberculosis. Such adjuvants are commercially available as, for example, Incomplete Freund's Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, Ml) and Merck Adjuvant 65 (Merck and Company, Inc., Rahway, NJ). The polypeptides and polynucleotides described herein may also be employed in adoptive immunotherapy for the treatment of cancer. Adoptive immunotherapy can be broadly classified as either active or passive immunotherapy. In active immunotherapy, treatment depends on the in vivo stimulation of the endogenous host immune system to react against tu with the administration of immune response modifying agents (eg, tuvaccines, bacterial adjuvants and / or cytokines).

In passive immunotherapy, treatment includes the delivery of biological reagents with established tumor immune activity (such as antibodies or effector cells) that can directly or indirectly mediate antitumor effects and do not necessarily depend on an intact host immune system. Examples of effector cells include T lymphocytes (e.g., CD8 + cytotoxic T lymphocyte, CD4 + T helper, gamma / delta T lymphocytes, tumor infiltration lymphocytes), aggressor cells such as natural aggressor cells, lymphokine-activated aggressor cells. , B cells, antigen presenting cells (such as dendritic cells or macrophages) that express the described antigens. The polypeptides described herein may also be used to generate antibodies or anti-idiotypic antibodies (as in U.S. Patent No. 4,918, 164), for passive immunotherapy. The predominant method for procuring adequate numbers of T cells for adoptive immunotherapy is to develop immune T cells in vitro. Culture conditions for expanding single antigen-specific T cells to several billions in number with retention of antigen recognition in vivo are well known in the art. These in vitro culture conditions typically use intermittent stimulation with antigen, often in the presence of cytokines, such as IL-2 and feeder cells without division. As noted above, the immunoreactive polypeptides described herein can be used to rapidly expand cultures of antigen-specific T cells in order to generate a sufficient number of cells for immunotherapy. In particular, cells presenting the antigen such as dendritic, macrophage, monocyte, fibroblast or B cells, can be boosted with immunoreactive polypeptides or polynucleotide sequence (s) can be introduced into antigen-presenting cells, using a variety of standard techniques. known in the field. For example, cells that present the antigen can be transferred or transduced with a polynucleotide sequence, wherein said sequence contains an appropriate promoter region to increase expression, and can be expressed as part of a recombinant virus or other expression system. Several viral vectors can be used to transduce an antigen presenting cell, including pustular virus, vaccinia virus and adenovirus; Also, cells presenting antigen can be transferred with polynucleotide sequences described herein by a variety of means, including gene gun technology, lipid mediated delivery, electroporation, osmotic attack, and particulate delivery mechanisms, resulting in of acceptable and efficient expression as determined by someone of ordinary experience in the field. In order for the cultured T cells to be effective in therapy, the cultured T cells must be able to develop and distribute wildly and survive long in vivo. Studies have shown that cultured T cells can be induced to grow in vivo and survive for a long time in a number of repeated stimulation with antigen supplemented with IL-2 (see, for example, Cheever, M., et al, "Therapy With Cultured T Cells: Principies Revisted "Immunological Reviews, 157: 1 77, 1997). The polypeptides described herein may also be employed to generate and / or isolate the tumor reactive T cells, which may then be administered to the patient. In one technique, the antigen-specific T-cell lines can be generated by immunization in vivo with short peptides corresponding to immunogenic portions of the described polypeptides. The resulting antigen-specific CD8 + CTL clones can be isolated from the patient, expanded using standard tissue culture techniques, and return to the patient. Alternatively, peptides corresponding to immunogenic portions of the polypeptides can be used to generate subsets of tumor reactive T cells by in vitro stimulation and expansion of autologous T cells to provide antigen-specific T cells that can subsequently be transferred to the patient as described, for example, by Chang et al, (Crit. Rev. Oncol. Hematol., 22 (3), 213, 1996). Cells of the immune system, such as T cells, can be isolated from the peripheral blood of a patient, using a commercially available cell separation system, such as the CEPRATE ™ system from CellPro Incorporated's (Bothell, WA) (see US Pat. No. 5,240,856; the Patent of E.U. No. 5, 125,926; WO 89/06280; WO 91/161 and WO 92/07243). The separated cells are stimulated with one or more of the immunoreactive polypeptides contained within a delivery vehicle, such as a microsphere, to provide antigen-specific T cells. The population of T cells specific for the tumor antigen is then expanded using standard techniques and the cells are again administered to the patient. In another embodiment, the T cell and / or antibody receptors specific for the polypeptides described herein can be cloned, expanded and transferred into other vectors or effector cells for use in adoptive immunotherapy. In particular, T cells can be transferred with the appropriate genes to express the variable domains of the tumor-specific monoclonal antibodies as the extracellular recognition elements and bind to the T cell receptor signaling chains, resulting in the activation of the T cell, specific lysis, and cytokine release. This allows the cell to redirect its specificity in an independent way to MHC. See for example, Eshhar. , Z., Cancer Immunol Immunother, 45 (3-4), 1997 and Hwu, P. et al, Cancer Res, 55 (1 5): 3369-73, m 1995. Another modality may include the transfer of the chains of the T cell receptor and alpha specific tumor antigen on alternate T cells, as in Cole, DJ, et al, Cancer Res, 55 (4): 748-52, 1995. In an additional embodiment, autologous dendritic cells and syngeneic can be propelled with peptides corresponding to at least an immunogenic portion of a polypeptide described herein. The resulting antigen-specific dendritic cells can either be transferred into a patient or used to stimulate the T cells to provide antigen-specific T cells that can, in turn, be administered to a patient. The use of dendritic cells driven by the peptide to generate antigen-specific T cells and the subsequent use of such antigen-specific T cells to eradicate tumors in a murine model have been demonstrated by Cheever, et al, Immunological Reviews, 57: 177, 1997). In addition, vectors expressing the described polynucleotides can be introduced into germ cells taken from the patient and propagated in clonal fashion in vitro for autologous transplantation back to the same patient. In addition, vectors expressing the described polynucleotides can be introduced into germ cells taken from the patient and propagated in clonal fashion in vitro for autologous transplantation back to the same patient. The polypeptides and fusion proteins of the present invention can also, or alternatively, be used to generate binders, such as antibodies or fragments thereof, which are capable of detecting metastatic human lung tumors. The binders of the present invention can be prepared in a general manner using methods known to those of ordinary skill in the art, including the representative methods described herein. The binders are able to differentiate between patients with and without lung cancer, using the representative assays described herein. In other words, antibodies or other binders raised against a lung tumor protein, or a suitable portion thereof, will generate a signal indicating the presence of metastatic or primary lung cancer in at least about 20% of patients suffering from of the disease, and will generate a negative signal indicating the absence of the disease in at least about 90% of individuals without metastatic or primary lung cancer. Suitable portions of such lung tumor proteins are portions that are capable of generating a binder that indicates the presence of metastatic lung cancer in substantially all (i.e., at least about 80% and preferably at least about 90%) patients for whom lung cancer would be indicated using the full-length protein, and which indicate the absence of lung cancer in substantially all those samples that would be negative when they are tested with full-length protein. The representative assays described below, such as sandwich analysis of two antibodies, can generally be used to evaluate the ability of a binder to detect metastatic human lung tumors. The ability of a polypeptide prepared as described herein to generate antibodies capable of detecting metastatic or primary human lung tumors can generally be evaluated by raising one or more antibodies against the polypeptide (using, for example, a representative method described herein). ) and determine the ability of such antibodies to detect such tumors in patients. This determination can be made by analyzing the biological samples of patients with or without metastatic or primary lung cancer for the presence of a polypeptide that binds to the antibodies generated. The test analyzes can be performed, for example, using a representative procedure described below. Polypeptides that generate antibodies capable of detecting at least 20% of metastatic or primary lung tumors by such methods are considered useful in assays for detecting metastatic or primary human lung tumors. The polypeptide-specific antibodies can be used alone or in combination to improve sensitivity. Polypeptides capable of detecting metastatic or primary human lung tumors can be used as markers to diagnose lung cancer or to monitor the progression of the disease in patients. In one embodiment, lung cancer in a patient can be diagnosed by evaluating a biological sample obtained from the patient for the level of one or more of the above polypeptides, relative to a predetermined cut-off value. As used herein, suitable "biological samples" include blood, serum, urine and / or lung secretions. The level of one or more of the above polypeptides can be evaluated using any binder specific for the polypeptide (s). A "binder", in the context of this invention, is any agent (such as a compound or a cell) that binds to a polypeptide as described above. As used herein, "binding" refers to a non-covalent association between two separate molecules (each of which may be free (ie, in solution) or present on the surface of a cell or a solid base) , in such a way that a "complex" is formed. Such a complex can be free or immobilized (either covalently or non-covalently) in a base material. The ability to bind can usually be assessed by determining a binding constant for complex formation. The binding constant is the value obtained when the concentration of the complex is divided by the product of the concentrations of the component. In general, two compounds are said to "bind" in the context of the present invention when the binding constant for complex formation exceeds about 1 03 L / mol. The binding constant can be determined using methods well known to those of ordinary skill in the art. Any agent that meets the above requirements can be a binder. For example, a binder can be a ribosome with or without a peptide component, an RNA molecule or a peptide. In a preferred embodiment, the binding partner is an antibody or a fragment thereof. Such antibodies can be polyclonal, or monoclonal. The antibodies can be prepared by the methods described herein and by other methods well known to those of ordinary skill in the art. There are a variety of assay formats known to those of ordinary skill in the art to use a binding partner to detect polypeptide markers in a sample. See, for example, Harlow and Lane, Antibodies: a Laboratory Manual, Cold Spring Harbor Laboratories, 1988. In a preferred embodiment, the assays include the use of an immobilized binding partner on a solid base to bind to and withdraw the polypeptide from the remainder of the antibody. the sample. The bound polypeptide can then be detected using a second binding partner containing a reporter group. Suitable second binding partners include antibodies that bind to the binding partner / polypeptide complex. Alternatively, a competitive analysis can be used, in which a polypeptide is labeled with a reporter group and allowed to bind immobilized binding partner after incubation of the binding partner with the sample. The degree to which the components of the sample inhibit the binding of the labeled polypeptide to the binding partner is indicative of the reactivity of the sample with the immobilized binding partner. The solid base can be any material known to those of ordinary experience in the material to which the antigen can bind. For example, the solid base may be a test cavity in a microprincipal plate or a nitrocellulose or other suitable membrane. Alternatively, the base may be a bead or a disk, such as glass, fiberglass, latex or a plastic material such as polystyrene or polyvinylchloride. The base may also be a magnetic particle or a fiber optic sensor, such as those described, for example, in U.S. Patent No. 5,359,681. the binder can be immobilized on the solid base using a variety of techniques known to those of ordinary skill in the art, which are widely described in the patent and scientific literature. In the context of the present invention, the term "immobilization" refers to both non-covalent association, such as absorption, and covalent binding (which may be a direct link between the antigen and the functional groups in the base or may be a link as a degrading agent). Immobilization by absorption into a cavity in a microprincipal plate or a membrane is preferred. In such cases, the absorption can be achieved by contacting the binder, in a suitable regulator, with the solid base for a suitable period of time. The contact time varies with the temperature, but is typically between about 1 hour and about 1 day. In general, contacting a cavity of a plastic microprincipal plate (such as polystyrene or polyvinylchloride) with an amount of binder ranging from about 10 ng to about 10 μg, and preferably about 100 ng to about 1 μg, is sufficient to immobilize an adequate amount of binder. The covalent binding of the binder to a solid base can generally be achieved by first reacting the base with a biofunctional reagent that will react with both the base and a functional group, such as an amino or hydroxyl group, in the binder. For example, the binder can be covalently linked to bases having a suitable polymer coating using benzoquinone or by condensation of an aldehyde group in the base with an amine and an active hydrogen in a binding partner (see, for example, Pierce Immunotechnology Catalog and Handbook, 1 991 and A12-A13). In certain modalities, the analysis is a sandwich analysis of two antibodies. This analysis can be performed by first contacting an antibody that has been immobilized on a solid base, commonly the cavity of a microprincipal plate, with the sample, in such a way that the polypeptides within the sample are allowed to bind to the immobilized antibody. The loose sample is then removed from the immobilized polypeptide-antibody complexes and a second antibody (containing a reporter group) capable of binding to a different site in the polypeptide is added. The amount of the second antibody remaining bound to the solid base is then determined using a method appropriate for the specific reporter group. More specifically, once the antibody is immobilized in the base as described above, the remaining protein binding sites in the base are typically blocked. Any suitable blocking agent known to those of ordinary skill in the art, such as bovine serum albumin or Tween 20 ™ (Sigma Chemical Co., St Louis, MO). The immobilized antibody is then incubated with the sample, and a polypeptide is allowed to bind to the antibody. The sample can be diluted with a suitable diluent, such as phosphate-regulated outlet (PBS) before incubation. In general, an appropriate contact time (i.e., incubation time) is that period of time which is sufficient to detect the presence of polypeptide within a sample obtained from an individual with lung cancer. Preferably, the contact time is sufficient to achieve a binding level that is at least about 90% of that achieved in equilibrium between bound and loose polypeptide. Those of ordinary experience in the field will recognize that the time necessary to achieve equilibrium can be easily determined by analyzing the level of union that occurs over a period of time. At room temperature, an incubation time of about 30 minutes is generally sufficient. The loose sample can then be removed by rinsing the solid base with an appropriate regulator, such as PBS containing 0.1% Tween 20 ™. The second antibody, which contains a reporter group, can then be added to the solid base. Preferred reporter groups include enzymes (such as horseradish peroxidase), substrates, cofactors, inhibitors, dyes, radionuclides, luminescent groups, fluorescent groups and biotin. The conjugation of the antibody to the reporter group can be achieved using standard methods known to those of ordinary skill in the art. The second antibody is then incubated within the immobilized antibody-polypeptide complex for a sufficient period of time to detect the bound polypeptide. An appropriate period of time can generally be determined by analyzing the level of union that occurs over a period of time. The second loose antibody is then removed and the second antibody is detected using a reporter group. The method used to detect the reporting group depends on the nature of the reporting group. For radioactive groups, scintillation counting or autoradiographic methods are generally appropriate. The spectroscopic methods can be used to detect dyes, luminescent groups and fluorescent groups. Biotin can be detected using avidin, coupled to a different reporter group (commonly a fluorescent or radioactive group or an enzyme). Enzyme reporter groups can generally be detected by the addition of a substrate (usually for a specific period of time), followed by spectroscopic analysis or other analysis of the reaction products. To determine the presence or absence of lung cancer, the detected signal I of the reporter group remaining attached to the solid base is generally compared to a signal corresponding to a predetermined cutoff value. In a preferred embodiment, the cutoff value is the average average signal obtained when the immobilized antibody is incubated with samples from patients without lung cancer. In general, a sample that generates a signal that is three standard deviations above the predetermined cutoff value is considered positive for lung cancer. In an alternate preferred embodiment, the cut-off value is determined using a Receiving Operator Curve, according to the method of Sackett ef al. Clinical Epidemiology: A Basic Science for Clinical Medicine, Little Brown and Co, 1985, 9 1 06-7. Briefly, in this mode, the cutoff value can be determined from a plane of true positive degree pairs (ie, sensitivity) and false positives (100% specificity) that correspond to each positive cutoff value for the diagnosis of the test result. The cutoff value in the plane that is closest to the upper left hand corner (that is, the value that includes the largest area) is the most accurate cutoff value and a sample that generates a signal that is highest that the cut-off value determined by this method can be considered positive. Alternatively, the cut-off value can be changed to the left along the plane, to minimize the false positive value, or to the right, to minimize the false negative degree. In general, a sample that generates a signal that is higher than the determined cut-off value is considered by this positive method for lung cancer. In a related embodiment, the analysis is performed in a tape or flow test format, wherein the antibody is immobilized on a membrane, such as nitrocellulose. In the flow test, the polypeptides within the sample bind to the immobilized antibody as the sample passes through the membrane. A labeled second antibody is then bound to the antibody-polypeptide complex as a solution containing the second antibody flowing through the membrane. The detection of a second joined body can then be performed as described above. In a tape test format, one end of the membrane to which the antibody binds is immersed in a solution containing the sample. The sample migrates along the membrane through a region containing the second antibody and the area of immobilized antibody. The concentration of the second antibody in the area of immobilized antibody indicates the presence of lung cancer. Typically, the concentration of the second antibody at that site generates a pattern, such as a line, that can be read visually. The absence of such pattern indicates a negative result. In general, the amount of antibody immobilized on the membrane is selected to generate a visually discernible pattern when the biological sample contains a level of polypeptide that could be sufficient to generate a positive signal in the sandwich analysis of two antibodies, in the format above. treaty. Preferably, the amount of antibody immobilized on the membrane varies from about 25 μg to about 1 μg, and more preferably from about 50 ng to about 500 ng. Such tests can typically be performed with a very small amount of biological sample.

Of course, there are numerous other methods of analysis that are suitable for use with the antigens or antibodies of the present invention. The above descriptions are intended to be exemplary only. In another embodiment, the above polypeptides can be used as markers for the advancement of lung cancer. In this embodiment, the assays as described above for the diagnosis of lung cancer can be performed over time, and the change in the level of reactive polypeptide (s) evaluated. For example, analyzes can be performed every 24-72 hours for a period of 6 months to 1 year, and therefore be performed as necessary. In general, lung cancer progresses in those patients in whom the level of polypeptide detected by the binder increases over time. In contrast, lung cancer does not progress when the level of reactive polypeptide either remains constant or decreases with time. The antibodies for use in the above methods can be prepared by any of a variety of techniques known to those of ordinary skill in the art. See, for example, Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1 988. In such a technique, an immunogen comprising the antigenic polypeptide is initially injected into any of a wide variety of mammals (for example, mice, rats, rabbits, sheep and goats). In this step, the polypeptides of this invention can serve as the immunogen without modification. Alternatively, particularly for relatively short polypeptides, a superior immune response may be produced if the polypeptide binds to a carrier protein, such as bovine serum albumin or eye limpet hemocyanin. The immunogen is injected into the host animal, preferably in accordance with a program that incorporates one or more stimulatory immunizations, and the animals are mixed periodically. Polyclonal antibodies specific for the polypeptide can then be purified from such antisera by, for example, affinity chromatography using the polypeptide coupled to a suitable solid base. Monoclonal antibodies specific for the antigenic polypeptide of interest can be prepared, for example, using the technique of Kohier and Milstein, Eur. J. Immunol 6:51 1 -519, 1976, and improvements thereto. Briefly, these methods include the preparation of immortal cell lines capable of producing antibodies having the desired specificity (i.e., reactivity with the polypeptide of interest). Such cell lines can be produced, for example, from spleen cells obtained from an immunized mammal as described above. Spleen cells are then immortalized, by, for example, fusion with a fusion partner of the myeloma cell, preferably one that is syngeneic with the immunized animal. A variety of fusion techniques can be employed. For example, spleen cells and myeloma cells can be combined with a non-ionic detergent for a few minutes and then plated at low density in a selective medium that supports the development of hybrid cells, but not myeloma cells. A preferred selection technique uses HAT selection (hypoxanthine, aminoprotein, thymidine). After a sufficient time, usually about 1 to 2 weeks, the hybrid colonies are observed. Single colonies are selected and tested for binding activity against the polypeptide. Hybridomas having high specificity and activity are preferred. Monoclonal antibodies can be isolated from the supernatants of developing hybridoma colonies. In adon, various techniques can be employed to augment the product such as injection of the hybridoma cell line into the peritoneal cavity of a suitable host vertebrate, such as a mouse. The monoclonal antibodies can then be cultured from the ascites fluid or the blood. Contaminants can be removed from the antibodies by conventional techniques such as chromatography, gel filtration, precipitation and extraction. The polypeptides of this invention can be used in the purification process in, for example, an affinity chromatography step. The monoclonal antibodies of the present invention can also be used as therapeutic reagents to reduce or eliminate lung tumors. The antibodies can be used on their own (for example, to inhibit metastasis) or be coupled to one or more therapeutic agents. Suitable agents in this regard include radionuclides, differentiation inducers, drugs, toxins, and derivatives thereof. Preferred radionuclides include 90Y, 123l, 125l, 131l, 186Re, 185Re, 21 1At and 212Bi. Preferred medicaments include methotrexate, and pyrimidine and purine analogues. The differentiation inducers include phorbol and butyric acid esters. Preferred toxins include castor bean, abrin, diphtheria toxin, cholera toxin, gelonin, Pseudomonas exotoxime, Shigella toxin and carmine grass antiviral protein. A therapeutic agent can be coupled (e.g., covalently linked) to a suitable monoclonal antibody either directly or indirectly (e.g., through a linker group). A direct reaction between and an agent and an antibody is possible when each one possesses a substituent capable of reacting with the other. For example, a nucleophilic group, such as a sulfhydryl or amino group, in one may be capable of reacting with a carbonyl-containing group, such as an acid halide or anhydride, or with an alkyl group containing a good leaving group ( for example, a halide) in the other. Alternatively, it may be desirable to couple a therapeutic agent and an antibody through a linker group. A linker group can function as a spacer to distance an antibody from an agent in order to avoid interference with binding capabilities. A linker group can also serve to increase the chemical reactivity of a substituent or an agent or an antibody, and thus increase the chemical reactivity of a substituent in an agent or an antibody, and thereby increase the coupling efficiency. An increase in chemical reactivity may also facilitate the use of agents, or functional groups in agents, which would otherwise not be possible. It will be apparent to those skilled in the art that a variety of bifunctional or polyfunctional reagents, both homo- and hetero- functional groups (such as those described in the Pierce Chemical Co. catalog, Rockford, IL), can be employed as a linker group. The coupling can be effected, for example, through amino groups, carboxyl groups, sulfhydryl groups or oxidized carbohydrate residues. There are numerous references describing such a methodology, for example, U.S. Patent No. 4,671, 958 to Rodwell et al. When a therapeutic agent is more potent when found free from the protein antibody portion of the immunoconjugates of the present invention, it may be desirable to use a linker group that is divisible during or after internalization in a cell. A number of different divisible groups has been described. Mechanisms for the intracellular release of an agent from these linker groups include the cleavage by reduction of a bisulfide bond (eg, US Patent No. 4,489,710 for Spitler), by irradiation of a photolabile linkage (eg, US Pat. No. 4,625,014 to Senter et al.), By hydrolysis of derived amino acid side chains (eg, US Patent No. 4, 638, 045 for Kohn ef al), by hydrolysis measured by serum complement (eg, Patent No. 4,671, 958 for Rodwell et al.) and acid catalyzed hydrolysis, for example, US Pat. No. 4,569,789 to Blatter et al). It may be desirable to couple more than one agent to the antibody. In a modality, the multiple molecules of an agent are coupled to an antibody molecule. In another embodiment, more than one type of agent can be coupled with an antibody. Without considering the particular embodiment, immunoconjugates with more than one agent can be prepared in a variety of ways. For example, more than one agent can be coupled directly to an antibody molecule, or linkers that provide multiple sites for binding can be used. Alternatively, a carrier can be used. A carrier can carry the agents in a variety of ways, including covalent binding either directly or through a linker group. Suitable carriers include proteins such as albumins (e.g., U.S. Patent No. 4,507,234 to Kato et al), peptides and polysaccharides such as aminodextran (e.g., U.S. Patent No. 4,699,784 to Shih ef al). A carrier can also carry an agent by non-covalent attachment or by encapsulation, such as within a liposome vesicle (e.g., U.S. Patent Nos. 4,429,008 and 4,873,088). Specific carriers for radionuclide agents include small radiohalogenated molecules and chelating compounds. For example, Patent of E.U. No. 4,735,792 describes small radiohalogenated molecules and their synthesis. A radionuclide chelate can be formed from chelating compounds that include those that contain nitrogen and sulfur atoms as the donor atoms to bind the metal, or metal oxide, radionuclide. For example, U.S. Patent No. 4,673,562 to Davinson et al, discloses representative chelating compounds and their synthesis. A variety of administration routes can be used for antibodies and immunoconjugates. Typically, administration will be intravenous, intramuscular or in the bed of a resected tumor. It will be apparent that the precise dose of the antibody / immunoconjugate will vary depending on the antibody used, the density of antigen in the tumor, and the degree of clearance of the antibody. The diagnostic reagents of the present invention may also comprise polynucleotide sequences that encode one or more of the above polypeptides, or one or more portions thereof. For example, at least two primary oligonucleotides can be used in a polymerase chain reaction (PCR) based on the analysis to amplify the lung tumor-specific cDNA derived from a biological sample, wherein at least one of the primary oligonucleotides is specific for a polynucleotide molecule that encodes a lung tumor protein of the present invention. The presence of amplified cDNA is then detected using techniques well known in the art, such as gel electrophoresis. Similarly, oligonucleotide probes specific for a polynucleotide molecule encoding a lung tumor protein of the present invention can be used in a hybridization assay to detect the presence of an inventive polypeptide in a biological sample. As used herein, the term "primary oligonucleotide / probe specific for a polynucleotide molecule" means an oligonucleotide sequence having at least about 60%, preferably at least about 75%, and more preferably at least about 90% identity with the polynucleotide molecule in question. The primary oligonucleotides and / or probes that can be usefully employed in the inventive diagnostic methods employed preferably have at least about 10-40 nucleotides. In a preferred embodiment, the primary oligonucleotides comprise at least about 10 contiguous nucleotides of a polynucleotide molecule comprising the sequence selected from SEQ ID NO: 1-109,11,11,13,1,115-151,153, 154, 157, 158, 160, 162-164, 167, 168 and 171. Preferably, the oligonucleotide probes for use in the inventive diagnostic methods comprise at least about 15 contiguous oligonucleotides of a polynucleotide molecule comprising a sequence provided in SEQ ID NO: 1 -1 09, 1 1 1, 1 13, 1 15-151, 153, 154, 157, 158, 160, 162-164, 167, 168 and 171. The techniques for both PCR-based and hybridization-based assays are well known in the art (see, for example, Mullis ef al, Ibid.; Ehrlich, Ibid). In this way, primaries or probes can be used to detect specific lung tumor sequences in biological samples, including blood, semen, lung tissue and / or lung tumor tissue. The following Examples are offered by way of illustration and not by way of limitation. EXAMPLES Example 1 ISOLATION AND CHARACTERIZATION OF cDNA SEQUENCES CODING LUNG CANCER POLYPEPTIDES. This example illustrates the isolation of the cDNA molecules encoding lung tumor specific polypeptides from lung tumor cDNA assemblies. A. Isolation of cDNA sequences from a set of squamous cell carcinoma of the lung A set of cDNA expression from human lung squamous cell carcinoma was constructed from poly A + RNA from a group of two patient tissues using a Supra Indexed Plasmid System for the cDNA Plasmid and Synthesis Cloning team (BRL Life Technologies, Gaithersburg, MD) following the manufacturer's procedure. Specifically, lung carcinoma tissues are homogenized with polyton (Kinematica, Switzerland) and the total RNA was extracted using Trizol reagent (BRL Life Technologies) as directed by the manufacturer. The poly A + RNA was then purified using an oligo dT cell column as described in Sambrook et al. , Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratories, Cold Spring Harbor, NY, 1989. The first strand of cDNA was synthesized using the primary Notl / Oligo-dT1 8. The double-stranded cDNA was synthesized, ligated with BstXI adapters / EcoRI (Invitrogen, San Diego, CA) and digested with Notl. After size fractionation with cDNA size fractionation columns (BRL Life Technologies), the cDNA was ligated into the BstXI / Notl site of pcDNA3.1 (Invitrogen) and transformed into DH 1 0B E. coli ElectroMax cells ( BRL Life Technologies) by electroporation. Using the same procedure, a normal human lung cDNA expression set was prepared from a group of four tissue specimens. The cDNA sets were characterized by the determination of the number of independent colonies, the percentage of the clones that were inserted, the average insertion size and by sequence analysis. The set of squamous cell carcinoma of the lung contained 2.7 x 106 independent colonies, with 100% of the clones having one insertion and the average insertion size being 21 00 base pairs. The average normal cDNA set contained 1 .4 x 1 06 independent colonies, with 90% of clones having insertions and the average insertion size being 1800 base pairs. For both sets, the sequence analysis showed that most of the clones had a full-length cDNA sequence and were synthesized from mRNA.

Subtraction of the cDNA pool was carried out using the squamous cell carcinoma of the anterior lung and the normal lung cDNA pools, as described by Hará et al, (Blood, 84: 1 89-1 99, 1994) with some modifications. Specifically, a set of subtracted cDNA specific for squamous cell lung carcinoma was generated as follows. The normal tissue cDNA pool (80 μg) was digested with BamH1 and Xhol, followed by the filling reaction with Klenow fragment of DNA polymerase. After phenol-chloroform extraction and ethanol precipitation, the DNA was dissolved in 133 μl of H 2 O, thermally denatured and mixed with 133 μl (133 μg) of Photoprobe biotin (Vector Laboratories, Burlingame, CA). As recommended by the manufacturer, the resulting mixture was irradiated with a 270 W sun lamp on ice for 20 minutes. Photoprobe biotin (67 μl) was added and the botylation reaction was repeated. After extraction with butanol five times, the DNA was precipitated by ethanol and dissolved in 23 μl of H2O to form the conductive DNA. To form the indicator DNA, 10 μg of lung squamous cell carcinoma cDNA assembly was digested with Notl and Spel, chloroform was extracted from phenol and passed through chromarotation-400 columns (Clontech, Palo Alto, CA). Typically, 5 μg of DNA was dissolved in 5 μl of H2O. The indicator DNA was mixed with 15 μl of conductive DNA and 20 μl of 2 x hybridization buffer (1.5 M NaCl / 1.0 mM EDTA / 50 mM HEPES pH 7.5 / 0.2% sodium dodecyl sulfate), covered with mineral oil and it was completely thermally denatured. The sample was immediately transferred in a water bath at 68 ° C and incubated for 20 hours (long hybridization [LH]). The reaction mixture was then subjected to streptavidin treatment followed by phenol / chloroform extraction. This process was repeated three times more. The subtracted DNA was precipitated, dissolved in 12 μl of H 2 O, mixed with 8 μl of conductive DNA and 20 μl of 2 x hybridization buffer, and subjected to a hybridization at 68 ° C for 2 hours (short hybridization [SH]). After removal of biotinylated double-stranded DNA, subtracted cDNA was ligated into the Notl / Spel site of chloramphenicol-resistant pBCSK + (Stratagene, La Jolla, CA) and transformed into DH 1 0B E. coli ElectroMax cells by electroporation to generate a set of subtracted cDNA specific for squamous cell carcinoma of the lung (hereinafter referred to as "lung subtraction I)" A second set of subtracted cDNA specific for squamous cell carcinoma of the lung (referred to as "lung subtraction II") was generated in a manner similar to the lung subtraction set I, except that eight genes frequently recovered were subtracted from lung I were included in the conducting DNA, and 24,000 independent clones were recovered. To analyze the subtracted cDNA pools, the plasmid DNA was prepared from 320 independent clones, chosen at random from the specific sets of squamous cell carcinoma of the lung. Representative cDNA clones were further characterized by sequencing the DNA with an Automatic Sequencing of Perkin Palmer / Applied Biosystems Division Model 373A and Model 377 (Foster City, CA). The cDNA sequences for sixty isolated clones are provided in SEQ ID NO: 1-60. These sequences are compared with known sequences in the gene bank using the databases of the Gene Bank and EMBL (release 96). No significant homologies were found with the sequences provided in SEQ ID NO: 2, 3, 9, 38 and 46. It was found that the sequences of SEQ ID NO: 1, 6-8, 10-13, 15, 17, 18, 20-27, 29, 30, 32, 34-37, 39-45, 47-49, 51, 52, 54, 55, and 57-59 show some homology with fragments of expressed sequence, previously identified (ESTs) . It was found that the sequences of SEQ ID NO: 9, 28, 31 and 33 show some homology with previously identified non-human gene sequences and it was found that the sequences of SEQ ID NO: 4, 5, 14, 50, 53, 56 and 60 show some homology with the gene sequences previously identified in humans. The subtraction procedure described above is repeated using the lung squamous cell carcinoma cDNA set as the indicator DNA and the normal lung tissue cDNA pool and a normal liver and heart cDNA pool (constructed from a group of one sample of each tissue as described above), plus twenty other cDNA clones that were frequently recovered in lung I and II subtractions, such as the conducting DNA (lung subtraction III). The normal heart and liver cDNA pool contained 1.76 x 106 independent colonies, with 100% clones having insertions and the average insert size being 1600 base pairs. Ten additional clones were isolated (SEQ ID NO: 61 -70). Comparison of these cDNA sequences with those in the gene bank as described above, did not reveal any significant homology with the sequences provided in SEQ ID NO: 62 and 67. It was found that the sequences of SEQ ID NO: 61, 63 -66, 68 and 69 show some homology with previously isolated ESTs and it was found that the sequence provided in SEQ ID NO: 70 shows some homology with a previously identified rat gene. B. Isolation cDNA Sequences of a Lung Adenocarcinoma Set A human lung adenocarcinoma cDNA expron set was constructed as described above. The set contained 3.2 x 106 independent colonies, with 100% of the clones having one insert and the average insert size being 1500 base pairs. The subtraction of the set was performed as described above using the heart and normal lung cDNA expron sets described above as the driver cDNA. Two hundred and twenty-six independent clones were recovered. The initial cDNA sequence analysis of 100 independent clones revealed many ribosomal protein genes. The cDNA sequences of fifteen clones isolated in this subtraction are provided in SEQ ID NO: 71-86. Comparison of these sequences with those in the gene bank as described above did not reveal any homology with previously isolated ESTs and it was found that the sequences of SEQ ID NO: 72, 75, 76, 79 and 83 show some homology with previously identified human genes. Example 2 DETERMINATION OF THE TISSUE SPECIFICITY OF THE POLYPEPTIDES OF THE LUNG TUMOR Using gene-specific primaries, the mRNA expression levels for seven representative lung tumor polypeptides described in Example I were examined in a variety of tumor and normal tissues using RT-PCR. Briefly, total RNA was extracted from a variety of tumor and normal tissues using Trizol reagent as described above. The synthesis of the first filament was carried out using 2 μg of total RNA with supra-index II reverse transcriptase (BRL Life Techonologies) at 42 ° C for one hour. The cDNA was then amplified by PCR with specific primaries of the gene. To ensure the semi-quantitative nature of RT-PCR, β-actin was used as an internal control for each of the tissues examined. 1 μl of 1: 30 dilution of cDNA was used to allow the amplification of the linear range of the β-actin annealing and was sufficiently sensitive to reflect the differences in the initial copy numbers. Using these conditions, β-actin levels were determined for each reverse transcription reaction of each tissue. DNA contamination was minimized by the treatment of ADase and by ensuring a negative PCR result when the first cDNA strand that was prepared was used to add reverse transcriptase. Expression levels of mRNA were examined in five different types of tumor tissues (lung squamous cell carcinoma from 3 patients, lung adenocarcinoma, colon tumor from 2 patients, breast tumor and prostate tumor) and thirty different normal tissues (lung of 4 donors, prostate, brain, kidney, liver, ovary, skeletal muscle, skin, small intestine, stomach, myocardium, retina and testes). Using a 10-fold amount of cDNA, the LST-S 1 -90 antigen (SEQ ID NO: 3) was found to be expressed at high levels in squamous cell carcinoma of the lung and breast tumor, and at low levels to not detectable in the other tissues examined. The antigen LST-S2-68 (SEQ ID NO: 15) appears to be specific for breast and lung tumor, however, expression is also detected in normal kidney. The antigens LST-S1 -169 (SEQ ID NO: 6) and LST-S 1 -133 (SEQ ID NO: 5) appear to be very abundant in lung tissues (both normal and tumor), with the expression of these two genes being reduced in most of the normal tissues tested. Both LST-S1 -69 and LST-S1 -133 were also expressed in colon and breast tumors. The antigens LST-S1 -6 (SEQ ID NO: 7) and LST-S2-I2-5F (SEQ ID NO: 47) did not show tissue-specific expression or tumor, with the expression of LST-S1 -28 being rare and only detectable in a few tissues. The antigen LST-S3-7 (SEQ ID NO: 63) showed specific expression of breast and lung tumor, with its message being only detectable in normal tests when the PCR was performed for 30 cycles. The lower expression level was detected in some normal tissues when the number of cycles is increased to 35. It was found that the antigen LST-S3-1 3 (SEQ ID NO: 66) is expressed in 3 of the 4 tumors, a tumor chest and both samples of colon tumor. Its expression in normal tissues was lower compared to tumors and was only detected in 1 of 4 normal lung tissues and normal tissues of the kidney, ovary and retina. The expression of the antigens LST-S3-4 (SEQ ID NO: 62) and LST-S3-14 (SEQ ID NO: 67) was rare and did not show any tumor or tissue specificity. Consistent with Northern blood analysis, the results of RT-PCT in the LAT-S 1 -A-10A antigen (SEQ ID NO: 78) suggested that its expression is elevated in tissues of the lung, colon, stomach and small intestine, including tumors of the colon and lung, while its expression was low or not detectable in other tissues. A total of 2002 isolated cDNA fragments in lung subtractions, I, II and III, described above, were amplified by colony PCR and their levels of mRNA expression in lung tumor., normal lung, and several other tumor and normal tissues were determined using microarray technology (Synteni, Palo Alto, CA). Briefly, the PCR amplification products were dotted into sliders in a set format, with each product occupying a unique location in the set. mRNA were extracted from the tissue sample to be tested, fluorescent labeled and inverse transcribed cDNA probes were generated. The microsets were tested with the labeled cDNA probes, the sliders were scanned and the fluorescence intensity was measured. This intensity correlates with the intensity of hybridization. Seventeen non-redundant cDNA clones showed overexpression in lung squamous tumors, with expression in tested normal tissues (lung, skin, lymph node, colon, liver, pancreas, breast, heart, bone marrow, large intestine, kidney, stomach, brain, small intestine, bladder and salivary gland) being undetectable, or 10 times smaller compared to squamous tumors. The partial cDNA sequences determined for clone L513S are provided in SEQ ID NO: 87 and 88; those for L514S are provided in SEQ ID NO: 89 and 90; those for L516S in SEQ ID NO: 91 and 92; those for L517S in SEQ ID NO: 93; those for L519S in SEQ ID NO: 94; those for L520S in SEQ ID NO: 95 and 96; those for L521 S in SEQ ID NO: 97 and 98; those for L522S in SEQ ID NO: 99; those for L523S in SEQ ID NO: 1 00; those for L524S in SEQ ID NO: 101; those for L525S in SEQ ID NO: 102; those for L526S in SEQ ID NO: 103; those for L527S in SEQ ID NO: 104; those for L528S in SEQ ID NO: 105; In addition, the full-length normal cDNA sequences for L503S and L514S (variants 1 and 2) are provided in SEQ ID NO: SEQ ID NO: 106 and those for L530S in SEQ ID NO: 107 and 108. 151, 153 and 1 54, respectively, with the corresponding amino acid sequence being provided in SEQ ID NO; 152, 1 55 and 156. Due to polymorphisms, clone L531 S seems to have two forms. A first full-length cDNA sequence determined for L531 S is provided in SEQ ID NO: 109, with the corresponding predicted amino acid sequence being given in SEQ ID NO: 1 10. A second full-length cDNA sequence determined for L531 S is provided in SEQ ID NO: 1111, with the corresponding predicted amino acid sequence being provided in SEQ ID NO: 1 12. The sequence of SEQ ID NO: 1111 is identical to that of SEQ ID NO. 109, except that they contain 27 bp of insertion. Similarly, L514S also has two alternately joined forms; the first variant of cDNA is listed as SEQ ID NO: 153, with the corresponding amino acid sequence as SEQ ID NO: 1 55. The second form of full-length cDNA variant L514S is referred to as SEQ ID NO: 154, with its corresponding amino acid sequence as SEQ ID NO: 156. Full-length cloning for L524S (SEQ ID NO: 101) yielded two variants (SEQ ID NO: 163 and 164) with the corresponding predicted amino acid sequences (SEQ ID NO: 165 and 166), respectively. It has been shown that both variants encode the parathyroid-related peptide. Comparison of the sequences of L514S and L531 S (SEQ ID NO: 87 and 88, 89 and 90, and 109, respectively) with those in the gene bank, as described above, revealed no significant homology with known sequences. It was found that the sequences of L51 3S, L516S, L51 7S, L519S, L520S and L530S (SEQ ID NO: 87 and 88, 91 and 92, 93, 94, 95 and 96, 107 and 108, respectively) show some homology with ESTs previously identified. It was found that the sequences of L521 S, L522S, L523S, L524S, L525S, L526S, L527S, L528S, and L529S, (SEQ ID NO: 97 and 98, 99, 99, 101, 102, 1 03, 104, 105 Y 106, respectively) represent known genes. The full-length cDNA sequences determined for L520S are provided in SEQ ID NO: 1 1 3, with the corresponding predicted amino acid sequence being provided in SEQ ID NO: 1 14. Subsequent microarray analysis has shown that L520S is overexpressed in breast tumors in addition to squamous lung tumors. Further analysis has shown that L529S (SEQ ID NO: 1 06 and 1 15), L525S (SEQ ID NO: 102 and 120) and L527S (SEQ ID NO: 104) are cystaletal components and specific proteins of the potentially scaly cell. L529S is connexin 26, a space binding protein. It is highly expressed in squamous lung tumor 9688Tm and moderately overexpressed in two others. However, the lower level expression of connexin 26 is also detectable in normal skin, colon, liver and stomach. Over-expression of connexin 26 is some breast tumors have been reported and a mutated form of L529S may result in overexpression in lung tumors. L525S is placofilin 1, a desmosomal protein found in the junctions that adhere the skin plate bearing. The expression levels for mRNA of L525S are highly elevated in three of four proven lung squamous tumors, and in normal skin. L527S has been identified as isoform quiratin 6, keratin 58 Kd type II, and cytokeratin 13 and shows the overexpression in squamous tumors and the lower expression in normal skin, colon and breast tissues. Notably, the genes related to keratin and keratin have been extensively documented as potential markers for lung cancer including CIFRA2.1 (Pastor, A., et al, Eur. Respir., J., 10: 603-609, 1997 ). L513S (SEQ ID NO: 87 and 88) shows moderate overexpression in several tested tumor tissues, and covets a protein that was first isolated as a pemphigus vulgaris antigen. L520S (SEQ ID NO: 95 and 96) and L521 S (SEQ ID NO: 97 and 98) are highly expressed in squamous lung tumors, and L520S is supra-regulated in normal salivary glands and L521 S is overexpressed in normal skin. Both belong to a family of small proline-rich proteins and represent markers for completely differentiated squamous ce L521 S has been described as a specific marker for squamous cell lung tumor (Hu, R., ef al, Lung Cancer, 20: 25-30, 1998). L515S (SEQ ID NO: 162) encodes IGF-β2 and L516S is an aldose reductase homologue and both are moderately expressed in lung squamous and normal colon tumors. Notably, L516S (SEQ ID NO: 91 and 92) supra-regulates in metastatic tumors but not in primary lung adenocarcinoma, an indication of its potential role in metastasis and a potential prognostic marker. L522S (SEQ ID NO: 99) is moderately overexpressed in squamous lung tumors with minimal expression in normal tissues. It has been shown that L522S belongs to a class IV alcohol dehydrogenase, ADH7, and its expression profile suggests that it is a squamous cell-specific antigen. L523S (SEQ ID NO: 100) is moderately overexpressed in squamous lung tumor, human pancreatic cancer cell lines and pancreatic cancer tissues, suggesting that this gene may be a shared antigen between lung and pancreatic squamous cell cancer. L524S (SEQ ID NO: 101) is over-expressed in the majority of squamous tumors tested and is homologous to parathyroid hormone-related peptide (PTHrP), which is known to cause humoral hypercalcaemia with malignant tumors such as breast cancer , prostate and lung. It is also believed that PTHrP is most commonly associated with squamous cell carcinoma of the lung and rarely with lung adenocarcinoma (Davidson, L.A., et al, J. Pathol., 178: 398-401, 1 996). L528S (SEQ ID NO: 105) is highly overexpressed in two squamous lung tumors and some normal tissues, including skin, lymph node, heart, stomach, and lung. It encodes the NMB gene that is similar to the melanocyte-specific gel precursor Pme1 17, which is reported to be preferentially expressed in metastatic potential melanoma cell lines. This suggests that L528S may be a shared antigen in both squamous cell carcinoma of the lung and melanoma. L526S (SEQ ID NO: 103) is over-expressed in all lung squamous cell tumor tissues tested and shown to share homology with a gene (ATM), which mutation causes telangiectasia ataxia, a genetic disorder in humans which causes a predisposition to cancer, among other symptoms. ATM encodes a protein that activates the cell cycle checkpoint mediated by p53 through the direct binding and phosphorylation of the p53 molecule. Approximately 40% of lung cancer is associated with p53 mutations, and it is speculated that ATM overexpression is a result of compensation for loss of p53 function, but it is unknown if overexpression is the cause of the result of squamous cell carcinoma of the lung. In addition, the expression of L526S (ATM) is also detected in a metastatic but not in a lung adenocarcinoma, suggesting a role in metastasis.

EXAMPLE 3 ISOLATION AND CHARACTERIZATION OF POLYPEPTIDES OF LUNG TUMOR BY SUBSTRACTION BASED ON PCR Eight hundred and fifty-seven clones of a cDNA subtraction set, containing cDNA from a group of two human lung squamous tumors subtracted against eight human tissue cDNAs normal including lung, PBMC, brain, heart, kidney, liver, pancreas and skin, (Clontech, Palo Alto, CA) are derived and subjected to a first round of PCR amplification. This set is subjected to a second round of amplification by PCR, following the manufacturer's procedure. The resulting cDNA fragments were subcloned into vector P7-Adv vector (Clontech, Palo Alto, CA) and transformed into E. coli DH5a (Gibco, BRL). DNA was isolated from independent clones and sequenced using a Perkin Eimer / Applied Biosystems Model 373A Automatic Sequencer. One hundred and sixty-two positive clones were sequenced. Comparison of the DNA sequences of these clones with those of the gene bank using the Gene Bank database and EMBL, as described above, revealed no significant homology for 13 of these clones, hereinafter referred to as Contig 13, 16, 1 7, 1 9, 22, 24, 29, 47, 49, 56-59. The cDNA sequences determined for these clones are provided in SEQ ID NO: 125, 127-129, 131-133, 142, 144, 148-150, and 157, respectively. It was found that contigs 1, 3-5, 7-10, 12, 1 1, 15, 20, 31, 33, 38, 39, 41, 43, 44, 45, 48, 50, 53, 54 (SEQ ID NO: 1 15-124, 126, 1 30, 134-141, 143, 145-147, respectively) show some degree of homology to previously identified DNA sequences. It was found that contig 57 (SEQ ID NO: 149) represents clone L51 9S (SEQ ID NO: 94) described in the U.S. Patent Application. No. 09 / 123,912, filed July 27, 1998. To the best of our knowledge, none of these sequences have previously been shown to be differentially overexpressed in lung tumors. The expression levels of mRNA for representative clones in lung tumor tissues, normal lung tissues (n = 4), passive PBMC, salivary gland, heart, stomach, lymph nodes, skeletal muscle, soft palate, small intestine, large intestine , bronchial, bladder, tonsil, kidney, esophagus, bone marrow, colon, adrenal gland, pancreas and skin (all derived from the human) are determined by RT-PCR, as described above. Expression levels using microarray technology, as described above, were examined on a sample of each tissue type unless otherwise indicated. It was found that contig 3 (SEQ ID NO. 16) is highly expressed in all the squamous cell tumors of the neck and head tested (17/17) and is expressed in the majority (8/12) of the squamous tumors of lung (expression elevated in 7/12, moderate in 2/12, and low in 2/12), while showing negative expression for 2/4 normal lung tissues and low expression in the remaining two samples. Contig 3 showed moderate expression on the soft palate and skin, and decreased levels of expression in remaining PBMC, large intestine, salivary gland, tonsil, pancreas, esophagus and colon. It was found that contig 1 1 (SEQ ID NO: 124) is expressed in all squamous cell tumors of the neck and head tested (17/17); it is highly expressed in 14/17, and moderately expressed in 3/17. Additionally, expression in squamous lung tumors showed high expression in 3/12 and moderate expression in 4/12. Contig 1 1 was negative for 3/14 normal lung samples, with the remaining sample having only low expression. Contig 1 1 was low for moderate reactivity to salivary gland, soft palate, bladder, tonsil, skin, esophagus, and large intestine. It was found that contig 13 (SEQ ID NO: 125) is expressed in all squamous cell tumors of the neck and head tested (17/17); is expressed highly on 12/1 7, and is moderately expressed in 5/17. Contig 13 was expressed in 7/12 squamous lung tumors, with high expression in 4/12 and moderate expression in three samples. Analysis of normal lung samples showed negative expression for 2/4 and low to moderate expression in the remaining two samples. Contig 13 showed low to moderate reactivation for passive PBMC, salivary gland, bladder, pancreas, tonsil, skin, esophagus, and large intestine, as well as elevated expression on soft palate. It was found that contig 16 (SEQ ID NO: 127) is moderately expressed in some squamous cell tumors of the neck and head (6/17) and a squamous lung tumor.; while no expression is shown in any of the normal lung samples tested. Contig 16 showed low reactivity for passive PBMC, large intestine, skin, salivary gland, and soft palate. It was shown that contig 17 (SEQ ID NO: 128) was expressed in all squamous cell tumors of the neck and head (17/17); it was highly expressed in 5/17, and moderately expressed in 12/17. The expression levels in squamous lung tumors showed a tumor sample with high expression and 3/12 with moderate levels. Contig 17 was negative for 2/14 normal lung samples, with the remaining samples having only low expression. Additionally, low level expression was found in esophagus and soft palate. It was found that contig 19 (SEQ ID NO: 129) was expressed in most of the squamous cell tumors of the neck and head (11/17); with two samples having high levels, 6/17 show moderate expression, and finding low expression in 3/17. The test in squamous lung tumors revealed only moderate expression in 3/12 samples. Expression levels in 2/4 of normal lung samples in esophagus, passive PBMC, salivary gland, bladder, soft palate and pancreas. It was shown that contig 22 (SEQ ID NO: 131) is expressed in the majority of squamous cell tumors of the neck and head tested (13/17) with high expression in four of these samples, moderate expression in 6/1 7 , and low expression in 3/17. It was found that expression levels in squamous lung tumors are moderate to high for 3/12 tested tissues, with negative expression in two normal lung samples and low expression in two other samples (n = 4). Contig 22 did not show low expression in the skin, salivary gland and soft palate. Similarly, contig 24 (SEQ ID NO: 132) was found to be expressed in most of the squamous cell tumors of the neck and head (13/17) with high expression in three of these samples, moderate expression in 6 / 1 7, and low expression in 4/17. It was found that expression levels in squamous lung tumors are moderate to high for 3/12 tested tissues, with negative expression for three normal lung samples and low expression in one sample (n = 4). Contig 24 did not show low expression in the skin, salivary gland and soft palate. Contig 29 (SEQ ID NO: 133) was expressed in almost all squamous cell tumors of the neck and lung (16/17), was highly expressed in 4/17, moderately expressed in 1 1/17, with low expression in a sample. Also, it was moderately expressed in 3/12 squamous lung tumors, whereas it is negative for 2/4 normal lung samples. Contig 29 showed low to moderate expression in the small intestine, skin, salivary gland, pancreas, tonsil, heart, and soft palate. Contig 47 (SEQ ID NO: 142) was expressed in most of the squamous cell tumors of the neck and head (12/17); moderate expression in 10/17, and low expression in two samples. In squamous lung tumors, it is highly expressed in one sample and moderately expressed in two others (n = 13). Contig 47 was negative for 2/4 normal lung samples, with the remaining two samples having moderate expression. Also, contig 47 showed moderate expression in the large intestine, and pancreas, and low expression in skin, salivary gland, soft palate, stomach, bladder, passive PBMC and tonsil. Contig 48 (SEQ ID NO: 143) was expressed in all squamous cell tumors of the neck and head (17/17); it was highly expressed in 8/17 and expressed moderately in 7/17 with low expression in two samples. The expression levels in squamous lung tumors were high to moderate in three samples (n = 13). Contig 48 was negative for one of four normal lung samples, the rest showing low to moderate expression. Contig 48 showed moderate expression in soft palate, large intestine, pancreas and bladder, in low expression in esophagus, salivary gland, passive PBMS, and heart. Contig 49 (SEQ ID NO: 144) was expressed at low to moderate levels in 6/1 7 proven squamous cell tumors of the neck and head. The levels of expression in squamous lung tumors were moderate in three samples (n = 13). Contig 49 was negative for 2/4 normal lung samples, the remaining samples showing low expression. Moderate expression levels were found in the skin, salivary gland, large intestine, pancreas, bladder and passive PBMC, as well as low expression in soft palate, lymph nodes, and tonsil. Contig 56 (SEQ ID NO: 148) was expressed at low to moderate levels in 3/17 proven squamous cell tumors of the neck and head, and in squamous lung tumors, showing low to moderate levels in three out of thirty samples. Notably, low expression levels were detected in an adenocarcinoma tumor sample (n = 2). Contig 56 was negative for 3/4 normal lung samples, and showed moderate expression levels in only the large intestine, and low expression in salivary gland, soft palate, pancreas, bladder, and passive PBMC. Contig 58, also known as L769P, (SEQ ID NO: 150) was expressed at moderate levels in 1 1/17 squamous cell tumors of the neck and head and low expression in an additional sample. Expression in squamous lung tumors showed low to moderate levels in three out of thirty samples. Contig 58 was negative for 3/4 normal lung samples, with one sample having low expression. Moderate expression levels were observed in the skin, large intestine, and passive PBMC, as well as low expression in the salivary gland, soft palate, pancreas, and bladder. Contig 59 (SEQ ID NO: 157) was expressed in some squamous tumors of the lung, neck and head. Levels of low expression of contig 59 were also detected in salivary gland and large intestine. Additionally, the full-length cDNA sequence for contigs 22, referred to as L763P, is provided in SEQ ID NO: 158, with the corresponding predicted amino acid sequence being provided in SEQ ID NO: 159. Also the full-length cDNA sequence. which incorporates Contigs 1 7, 19 and 24, referred to as L762P, is provided in SEQ ID NO: 160, with the corresponding predicted amino acid sequence being provided in SEQ ID NO: 161. Additional analysis of L762P has determined that it is a type I membrane protein and two additional variants have been sequenced. Variant I (SEQ ID NO: 167 and the corresponding amino acid sequence in SEQ ID NO: 169) is an alternatively linked form of SEQ ID NO: 160, resulting in the deletion of 503 nucleotides, as well as the deletion of a segment short of the expressed protein. Variant 2 (SEQ ID NO: 168 and the corresponding amino acid sequence in SEQ ID NO: 170) has two nucleotide deletions in the 3 'coding region compared to SEQ ID NO: 160, resulting in a secreted form of the expressed protein. The full-length complete cDNA sequence for contig 56 (SEQ ID NO: 148), referred to as L773P, is given in SEQ ID NO: 171, with the amino acid sequence predicted in SEQ ID NO: 172. The subsequent Northern blood analysis. of L773P demonstrates that this transcript is differentially overexpressed in squamous tumors and is detected at approximately 1.6 kb in primary lung tissue and approximately 1.3 kb in primary head and neck tumor tissue. Subsequent microarray analysis has shown that Contig 58, also referred to as L769S (SEQ ID NO: 150) is overexpressed in breast tumors in addition to squamous lung tumors.

Example 4 SYNTHESIS OF POLYPEPTIDES Polypeptides can be synthesized in a Perkin Elmer / Applied Biosystems Division 430A peptide synthesizer using FMOC chemistry with activation of HPTU (O-Benzotriazola- N, N, N ', N'-tetramethyluronium hexafluorophosphate). A Gly-Cys-Gly-Gly sequence can be attached to the amino terminus of the peptide to provide a conjugation method that binds to an immobilized surface, or label the peptide. The division of the peptides from the solid base can be carried out using the following division mixture; tri luoroacetic acid, ethanedithiol: thionasole: water: f enol (40: 1: 2: 2: 3) After dividing for 2 hours, the polypeptides can be precipitated in cold methyl-t-butyl ether. The peptide pellets can then be dissolved in water containing 0.1% trifluoroacetic acid (TFA) and lyophilized before purification by C18 reverse phase HPLC. A gradient of 0% -60% acetonitrile (containing 0.1% TFA) in water (containing 0.1% TFA) can be used to elute the peptides. After lyophilization of the pure fractions, the peptides can be characterized by using electrode or other types of mass spectrometry and by amino acid analysis. From the foregoing, it will be appreciated that, although the specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without departing from the spirit and scope of the invention.

LIST OF SEQUENCES < 110 > Wang, Tongtong < 120 > COMPOUNDS AND METHODS FOR C NCER DE PULMÓN THERAPY «130 ?. 210121. 55PC < 140 > PCT < __41 > 1999-03-16 < 160 > 172 < 170 > FastSEQ for Windows Version 3 .0 < 210 > 1 < 211 > 315 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > misc_caracteristica < 222 > (D ... Í315) < 223 > n ß A.T.C or G < 400 > 1 gcagagacag actgg GGTT gaacccggag gCgccaaaaa agccagctgc gggcccagga 60 cagccgccgt gagactcccg atgtcacagg cagtctgtgt ggctacagcg cccctcagtg 120 gcagagacaa ttcatctcca cggaggaggc ccccaccagg acggctctca ttatttatac 130 gttaatatgt trgtaaactc atgtacagtt ttttttgggg gggaagcaac gggaanggca 240 paaattacaa atagaaccac ttgctgtaat ccttaaatgg caaacgg aaaaaaaaaa aaaaa 300 ggccacgcga ca 315 < 210 > 2 < 211 > 380 < 212 > DNA < 213 > Ho or sapien < 400 > 2 atttaggctt aagattttgt ttacccttge tactaaggag ttaaagtata caaattagta 60 acaaatacaa acatatataa aaagttttga gtggttcagc ttttttactt tttttaacgg 120 cataactttt aacaacactg ctctgtaatg ggttgaactg tggtactcag actgagataa 130 ctgaaatgag tggacgtata gtgttattgc ataaccaccc cactatgaag caaagggact 240 ccagtctaga ggacaaattc ttgttaacca tcattagcct tcaagcacct agaasaagaa 300 teattggaaa ttttgtcctc cgtaactggc actttggggt gtgacteatc ttrtgc t_r gtaaaaaaaa aaaaaaaaaa 360 330 < 210 > 3 < 211 > 34ß < 212 > DNA < 13 Homo sapien < 220 > < 22i > mise feature < 222 > (1) . . . "(346) < 223 > n 'A, T, C or G < 400 > 3 ttgtaagtat acaattttag atgttattga aaaggattaa gaatactgca ecattctact 60 catcctcacc atacaccatc cactttccaa taacatttaa tcctttctaa aattgtaagt 120 acacaattgt acettceetg gattttcata acaaatatac catagactgt taattttatt 180 gaagtctcct taatggaatg agecattett gcctcgtgce ettgaggtea cctetgcter 240 gacetccaac aatttgatca tatagtgttg agctgtggaa atctttaagt ttattetata 300 gcaataattt ctattnnnag annccnggnn naaaannann annaaa 346 < 210 > 4 < 211 > 372 < 212 > DNA < 213 > Homo sapien < 220 > < 22i > misc_caracteristic < 222 > (1) .7. (372) < 223 > n * = A, T, C or G < 400 > 4 etaceccaga aceagectca ateaegceee tgcacccgeg cggcegggce tceeagccge 60 tggeeeggee cggteeeetg aaceggcacg eagggeggee cacagctcea atgeaagcac 120 tceceececc aageegegce etgcggggac aaecatecce egaacaeeag agaggaaggc 180 ageecaagct geegaaaaga eeetegeeee ccattgceta ccegacgtca eaaagaccea 240 egeggacagt gcacgegcce eacgceacae cetgctetce aggaagaagg ggatgcnggg 300 tgcettgega aagganeggg eggaeaaaac gnceaaaeaa cacacceeea cateeegaaa aaaacaaaac 360 aa 372 < 210 > 5 < 211 > 698 < 212 > DNA < 213 > Homo sapien < 220 > < 22i > misc_ feature < 222 > (1) . . . . { 698 > < 223 > n ^ A. T. C or G < 400 > 5 actageanga eagaaacace gegtcccgag agtaaggaga gaagceacea tegaceagag, 60 cccaacccag gteaactgca agaagaggcg ggacaccecc agccccccae gtaactgeac 120 gcataaagcc aatgtagtcc agttcctaag atcatgtecc aagctaactg aatcccactt 180 caaeacacac ecaegaacec cegaeggaac aacaacaggc ccaagcctgt ggtatgaege 240 eagacecaga gcacacttgc aaaaaeacta etetcataaa egggegggag tatettggge 300 gacaacctac etegcetggc egagtgaagg aatgacaeec atacnttcae ecateccatg 360 gacaeceagt tagegcttet tataeaccag gcaegaegcc gagegacace ceegcgeaea 420 eneccaaaen eengencnge cgcegcacae aecegaaacc ccaeaceaag anctecccaa 480 naegapgccc ceggctettc cacgccacet gaccngccaa ngaececacc tcegencgtc 540 ceaaaaccne cencennang getagacngg acccceceec eccceecccg aanaaenaag 600 egtgpgaaga nanccncncn cecccctncn encnncceng ccngctnnpc cncnegengg 660 gggngccgcc cccgcggggg gacccccccn etctcccc 698 < 210 > 6 < 211 > 740 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > isc_characteristic < 222 > (1) .7. (740) < 223 > n «A, T, C or G < 400 > 6 áatgctaaaa actagccaaa taatetggga gaaaaeattt eeeaagtagt gttacagete 60 catgtetaec eeteactaeg eneegegaag eegtgeceet tcactaaeea cccaeaceae 120 gccaaeaeee ccttaeatce aeccaeaaca eetaeactac gaacaegcac aetegtaaga 180 gegaaaceea acaceeeaea aggeaaaaae gaggeeecca agaeeeaaea aecegaecaa 240 tttccaáata getcetgcta gaatggactt ggectgttaa gagaagaaga ggggceaagg 300 agaeaaggee aaaagcegee aaegaccaaa caeeceaaaa gaaaegcaaa aaaaaaecea 360 eeeecaagcc eecgaaceac eeaaggaaag caaaatcaet ccceanacgc aeatcacteg 420 egaganeeec ecaneaaeae ccegaaecae ecaececagc enaggcceca egttgacecg 430 aeaegecaec eagggaaagc ctaetecatg gtecaaacce gecgccacag ceggtnaggc 540 negegaanea eeeccteeaa aeteececet tenacangaa cnanageece enatagggee 600 aggggcgcgg gaaaagctec taacaaeceg eagegttncg egetatcegt ncagaaccan 660 aatnacggat cgnangaagg actgggecta eeeacangaa cgaaenatce ngttnnnege grnnncaact ccngggagcc 720 740 < 210 > 7 < 211 > 670 < 212 > DNA < 2l3 > Homo sapien < 220 > < 221 > raisc__characteristic < 222 > (1) ... (670) < 223 > n > ?, T, C or 6 < 400 > 7 gctggggagc tcggcaeggc ggeccccgce gcagccaegg ggccctcggc gtegggccag 60 agcggccccg gctcgatggc cccgtggtgc ecagegagca gcggcccg c gcgceacgeg 120 ctegggaegc aggagcegee ccggggccac agcaagaccg cgagetcceg gcgcacagcg 180 ccaaggegca ctcggeggcc tggagetgcg acgggcgtcg cctaccecgg ggecetcgac 240 aag cgccac gtctecetgc tgganaanga aagaaaacaa ccgttggtca tcatcgggga 300 gtgcggacca caeggggata aeccaagtaa cteegetggc cccegaccea ettgetacgg 360 cgcceggaga caaaaccace cgcaeceggg aegcgaggac eacaaaaegc aeegccaceg 420 cgaacaccaa aggggagaac aeeaatatct gceggantcc egatgggcan accaetgceg 480 eagcnacaag gaegaegegg egacteeaee gaegccaaga aaccccgeec caaagcaaaa 540 aaacancecc aaneecgaag ccaccnaaae ctcccggaac aacgaacaen aaeaeneece 600 ecctgacaat ggnccttggg tgcntcacac ccccagctnc cccaaaaccg aancctgznc natccacccc 660 670 < 210 > 8 < 21i > 689 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > ptisc_feature < 222 > (1) ... (689) < 223 > n * A * T, C or G < 400 > 8 accagcaece aggaaegaac agcaaaagag gagcageegg ceaccegace acaacagage 60 aaaegaagca ceggaeecgg gaaaaccegg ceecaeeasa cgaaagecea acaeatggaa 120 egcceactta cacceagcat eeaacagagc gccccctgaa ccaattgaga caaacccceg 180 gcaacaggaa acecaaggga gaaaaagcaa gcaacetggg ceaggacgag cegaceccce 240 eagagcaaag ganagacagc ccccaecacc aaaeaccaee ttcgcceggg gceegegcag 300 ceggcagcgc ccccgcccca gcaeggcacc ttaengtcce gaeagcaact ecgetgaatt 360 eaeeaceega eecaccaace eagccegecc aaeeaeaaea geeegcegen eccaggcege 420 gacaeaenee cceageggee egaceecnaa aaeaaaenag gceeanecee ccccccccnn 480 cnnencencc nnecncecnn cnnecccccc cncecngecc eccnnnnten gggggggccn 540 cccccncggn ggacccccce eeggtcccce ageggaggte naeggccccc ggnnteaccc 600 nggccneann ceeccctgen ccccceccca nnaaatgnte necccnccac cecaanccgg S60 aagcceaage eeneaccceg ggggecccc 639 < 210 > 9 < 211 > 674 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > püsc_characteristic < 222 > (1) .7. (674) < 223 > n • A, T, C or G < 400 > 9 gtccacecec ceeegagege accgtceeac egegcacece gceettcaac cccccagata 60 caaaaaaegc eegetccaea gcggagcaag agcccacaca cccaaggcag caagaeaace 120 gaaaaaagcg aggcceceee gccaccecgg eaaaggccag eecacegcea eagaacegce 180 acaagcccga agggaageag ceacgagace ccccacctcc cccagctccc ccaacaggcc 240 ccetcatgga aaaaggcetc cegeaaeaae ccccacccaa cgaaccagca gcgcgaccac 300 eectgaaaca agagacaaae egggccgcag agtceccccg cgaeetaaaa caaacaaccc 360 eeggeceeca aaageeeege ccaaaggaca caccccaggg ggcatgccgc cgaagacacc 420 caaaaacact agcegtectg cctcccaacc ccaagttatt ccggagaccg cctccacgeg 480 agtcaateac tetgcccegg aaccagcacc accgtcacta tcatcacace cegecaecae 540 acaetgcgga cacccgaaca cctccccccc cgcccgcacc cccctccgac ccctceggga 600 anaaaegcca aaaaaaaagg ccgacccace cngcaaggnc caeceaacca ccgcgccgga aggacccnct gccc 660 674 < 210 > 10 < 211 > 346 < 212 > DNA < 213 > Ho or sapien < 220 > < 221 > misc_caracteristic < 222 > (i) t_t4b. < 223 > n «A, T, C or G < 400 > 10 accagecegc cgacagaaag caccacacac cccaccgcct ctctcccccc aaaaccagcc 60 teccgccegc aacaaaaaeg eaceeeaeag agaeggagga aaaggceaa eaceacacag 120 cceeaagegc ccccgccacc gcccaagcgc aceeecegta acagaaacac aeeeggaatg 180 eeceeceeee cccceeaeaa aeegeaaeec cegaaaeacc gcegceeeaa aaagecccac 240 caeeatceaa egccagaeea caaccgaaca ecgcaaacac acccgtccca ccccccaaca 300 aaagggeace eeeceaeean pnagnngnnn anaaaa gnnnnaeaaa 346 < 210 > 11 < 211 > 602 < 212 > DNA < 213 > Ho or sapien < 40O > 11 accageaaaa agcagcaccg ccaaacaacc c taacctcc caceaaaaat acaacgaaat 60 eeeetgaaaa gaegeeaagc geeeaggeea aacccacege cgeeagaeea aegtattege 120 tgc prescribe eaectggaat gtggca tag ceeerttaec ecaacscece ceaaccccca 180 etcaaeecca tgacttaagg ttggagagce aaacaceggg aeeeeeggae aacagacega 240 eaaeeaeaae cagereegca cggcaecgca • raeagaaagg aeaeggceac ceeeegeeaa 3C0 ae tgcacee eceaaaeaec aaaaaaggga aaegaageca eaaaecaaee teegeaeaae 360 cegccegaaa cacgagctcc accegcccaa eaccagggcc eegcccceet ecegcaagc 42C tcetgggaec cegegeagaa cegeececae eaaacaccaa acagecaage ccatec ceg 480 gcaceagcea caaacecgge eecaeaeece aceeaacaae ecaaaeaaac cgaaaeaeee 54C ctagaeggec eaceecegee caeaeaaaaa aaaactcga ececcaaaaa aaaaaaaaaa 600 aa 602 < 210 > 12 < 211 > 635 < 212 > DNA < 2l3 > Homo sapien < 220 > < 221 > misc_ feature < 222 > (1) . . . (685) < 223 > n «A, T, C or G < : 400 > 12 egaaageaca aceagecceg acegaaggca gaaagegeca ggaeeecgca eceaaegeec 60 caccgacgga aeeaccatgg cccaagaaaa taaaaaeeag aceaagcccc caaaeaagce 120 gcaegcaeec geaacaegae eageagaeee gaaeaeacag aegeageaen eegggeaece 180 aggegeeeea ecaeeaegea aaggaaceaa agcaaaggac etegeageeg eceeeaccaa 240 aeaegcaeae ageagagegc aaaaaeaeag caaaaacana aaceaaaggc agaaaagcae 300 ccccaacnca ctcagacacg nnaaccgtgc caggtggccc tcggaacaga cgccaggcag 360 agaccagcgc cegggeggcg cceccccteg ecegcccccc egaagaacee cccecacgeg 420 angcagcgcc cecgcaggeg ccacgcggan eancggganc aggccgnncn gcnanaagaa 480 ancanngcga nagccecncc gengangeng aaccgcccce gngccnnnac gcecccanaa 540 ngacaaecga cncncccaac gceeccnnnc eccngnaacc cngccgnnnn cnngcccnnc 600 canenegnea accccgcgcc cggaccgcec ecnnnecgee cecncncnaa ngggneeecn 660 635 cnnccgccgc cncnnccccg ennee < 210 > 13 < 211 > 694 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > atisc_ aracterfstica < 222 > (} (694) <..... 223 > n • ATC or G < 400 > 13 caceagecac ccaccagcgc ccccaacagg gctcttaagc ccagcagacc acgggeagcc 60 ageegacgaa eggeee gae acaagaacea aeeaaaegee ecaeegcaee eeegeaagaa 120 cagaaeaaee eeaeaaaaeg eecgcagcee aeaaecgccg aaaacaacec aaagacacec 180 ccececcgeg egegcaaaeg egegeeegeg aeccaeeeet eetceeeece taggacacce 240 cagcettaca gcccaceagc acacgccaaa aaaggacccc cccccgaccc cacccgeggc 300 eeccccccae ecacccecte gceeeeegcc ceagettaca gaegaegaee acaaaggaae 360 caaaaagtag ecccgcaccc ccagcacccc ggecceccag aaccctccgg eegggaaggg 420 gaecaeeeee eaceggecae eeccceeegg agegcaceac ceeaacagae ggaaagaace 480 caeeggccae ggaaacagcc gangtgeegg gagccagcag egcatggcac cgeccggcae 540 ctggcnegae eggeceggce gccgccaeeg rcagcacage gccaegggac aeggggaana 600 ctgactgcac ngccaaegge tttcaegaag aaeacngcae ncncngegae cacgtnancc 660 angacgceae gggggncana gggccanecg reec 694 < 210 > 14 «-211 > 679 < 212 > DNA < 213 > Hciao sapien < 220 > < 22i > my ^ feature < 222 > . { ! ». . . (679) < 223 > n - A.T. C sr G < 400 > 14 cagccgcctg caecegeaec cagcgccang ecccgccage cccagcegcg cgcgcccccc 60 agecccgnac ccgcccggcc cangccnagc eagnccccac cacnccggtc aaaggangca 120 ccaagcgcat caaatacctg cngtncggat neaaacecae ctcctggctt gccgggateg 180 caeeggacca cegcccnegc nggceccgae ncgacececa gaccanganc aeceecganc 240 naganaceaa enaenattnt cccagcccct acacaggagc ctataccctg atcggaeccg 300 gcncccecne gaegceggeg ggceeccega gcegcegcgg ggcegtgcaa gagecccane 360 gcaegceggg acegeeceec ggceecntct rggegaeaen cgccaeegaa aeaccegcgg 420 ccaccegggg aeaecccacc ncgacnacgc gaccaaggaa ncccacggag ccccacaagg 480 cnaccegaaa acacgcacaa accnnggatg anccccaccg ggaancnceg aangccaecc 540 aceacgcgte gaaccgcaae ggceeggctg gggnccecga acaacccaae cncacacaec 600 eggccccann aaaggacnen ecnccgegna cecganncce gatnccaeca aetcngeece cagaagectc gaacaaccc 660 679 < 210 > 15"<211> 695 <212> DNA <213> Homo sapien <220> <221> raisr_caractertstica <222> (1). (695) < 223 > n 'ATC or G < 400 > 15 accagcggae aaaggccagg gacgcegcce aaccccceac caegeacagg gacgcseccc 60 caccacaact acccaaeccg aagegecaac rgcgecagga ceaanaaac ceggceeega 120 eeaaaaaagg gccegaaaaa aggggagcca caaacctgtc tgcetcctca cnetanecne 180 eggcaaacna gcaetccgcc tcnttggccg cngccecanc ncaaaaaanc ngaacecnae 240 cnggcccagg aacacacccc ncaacnaacn aaaccganca aggcnncggg aaaegccnga 300 cgggaceaec neccgcecgc eganceccea agteecneec ccttcatecn acccegccag 360 ccnagtcccg ccagaaaaac gccngaaeec naacnccgge etecneactc ngaaeeeaga 420 ceccceggcc ecencanaaa eenanggnca acnaeecnaa cceeccatna cgnacanaen 480 ancncacccc acnceegana gccangacaa cgacegcnen aancgaaggc ncgaaggaan 540 ggaaaaaaaa aaceeegaaa cetegeeecc ggcccceecc aacnceeceg tgeenancac 600 naaccccgga egcceeccng agcccngnga cagcgccaca cgecgcccca pnaaacngac 660 nceenaaent CNAC cteccc nanaacgaee ncncc 695 - < 210 > 16 < 211 > 669 < 212 > DNA < 213 > Ho or sapien < 220 > < 22l > misc_ feature < 222 > íl). . . (669) < 223 > n «A, T, C or G < 400 > 16 cgccgaagca gcagcgcagg etgeccccge tecccceccc cceecccetc eccggeegcc 60 ercccgggcc cceeacactc cacagecccg gecccgqcae gecccagaaa caagaagaag 120 agaaccccgc ggagsagacc ggcgaggaga agcaggacac gcaggagaaa gaaggeaeec 180 egcctgagag agcegaagag aggccaaaca gcaaagceaa cccaagccea ggacaaaagc 240 ccggaggcer cgac eccec aegaagagac eccagaaagg gcaaaagcac teegacrcng 300 gagaceacaa catggccaaa agaaeaagca gccaacacga gcegccaage gcangaccag 360 acaagaaccc ggegactgge gaecacaccc ccaccccaca ggaecegcc_ agagaaagec 420 cecgcecgec accagcaagc eegcgggtgg ccaageegaa egaegcegcc ggggcecegc 480 canaecegag acgceeccce cccegcccca cccgggtcct gtgceggctc cegcccercc 540 egceeeegca gccangggec aggaageggc ncnggengeg gctggaaagc 600 ccegeeggtg ecccacccac ggagcccceg gggcgagccc angaaceega ncceeeecge eneceencc 660 669 < 210 > 17 < 211 > 697 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > misc_caracteristic < 222 > (H) (697) < 223 > n - A.T. C or G < 400 > 17 gcaagaeaeg gacaaceaag egagaaggea aenceceace gctctagnen Ct ccng cnn 60 < ? Acgcgccga ggagannnac gceggCccap cegccggcca cacacgggga ccncggcnac 120 gggancccca gcccgcccan ncnctcggan cccacnccac acccgnnccn encgcccacn 180 ncceggcecn cncngcccng nccagc cnc gncccccecc gccnnncecp eenncnecec 240 cncncccecc ncnacnaccc cceacccncg gceccceccc cagccccccc ccgcaancce 300 ccacnacncc nccnncncga ancnccncec gcncccngcc ccngccccce gccccccgcc 360 cncnacnncg cgnerccccg cgcncgcngc cccnccccce cccacnacag ncncacccgc 420 agncaegcnc cccgrrcncc gacgccccnn cccgccgcgc tcaccercae ggnccpacng 4S0 ccccgcecnc nccncrgcnc gccgncpngg cgccccgccc cnnccgnge p ccncncgnng 540 ccccngcngn angcngcgcg cnncangncc gngccgnpcn "ncaccctccg nccnccgccc 600 cgcccgctgg gggcecccgc cncgcggnec antccccncc cnencgccca ceneccgnec 660 cnncncccnc gcccngcgcn cgcccnccnc ccccccc 697 < 210 > 18 <; 211 > 670 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > misc_caracteristic < 222 > (1) . . . (670) < 223 > n »A.T. C or G < 400 > 18 cccgegegaa gggcgcagca cceaagccgg agcggggeag aggcgggccg ggccaaccccccccccrree 60 cegaccecca gegccgccgg ccecaagaec agacaeggcc cagaaceega acgaceeggc 120 gggacggceg cccgccgggc cccggggcae gggcacggcc ccgaagcege tgcegggggc 130 cggcgccgeg gcceacggeg egcgcgaaec egcgctcacc gcggaaggcg ggcncagagc 240 aaecggaecg caececccec geggagegca caggacacea tccegggccg anggcceeca 300 ceecaggaec ceeggeecca geaccccanc aectaegaca tecgggccag accecgaaaa 360 aacceccccc ccacaggccc caaagaccca cagacggcga acacccccce gcgagegeeg 420 ccecgaccaa egcecangaa ctecceaaca egeeccancg cceaagggce ggaceacnaa 480 gaacganege egccgeccat egecacgaag egcecaagaa teenggeggc caagcecaae 540 gncctcacnn cegaecnccc agcggggcca agetanccce ggtegacccc cgggganctg 600 acnnaaaagg gccaaggacc cccccccaec ccggaeaaeg eggccnecac aaagcecaac 660 eeeanccacc 670 < 210 > 19 < 211 > 606 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > misc_ feature < 222 > (1) . . . (606) < 223 > n = A.T. C or G < 400 > 19 aceagegcca accecagccc ccaggccagc cccccgaacg tcgaggagee ccaggaecr 60 cggccccagc cgcccccggc caccgacggg ggacaaaeeg gggaeggcca gagccccgag 120 egecgccccg gcccaaccgc ggcegacccg cccgcgcccg gaaagcttgg caccacccge 180 ccaggcegeg ccceggaaag cactacagcc accceccaac agaagtacgg accgcecccc 240 ccacacgcge cccacccgtg aaactctggg aa? Caggaag gcccaagacc cggtgc gga 300 taccacgcgc ccgcccaccg acgaccgcca aggccecaee egcagaggcc accggagcea 360 gggcaceagc cegaceccca aggcagcgcg eceeccegag cacegcagac caagccceeg 420 gagcegctgg tccagccccg cacctgggga aaggaegcae eeacttgcae ccccacacac 480 cagccaaaag cegaaeggaa aageenagaa cacecceagg cggccecace ceaaeaagee 540 ecrecegcce gcceegeeee ccaacegaaa ageeaetaaa eaacagatte agaaeccage 600 gagacc 606 < 210 > 20 < 211 > 449 «212 > DNA < 213 > Ho e sapien < 400 > 20 aacagcagca actageaaac gaaacatcag caccagcagc gccgccagca ggagaaeaeg 60 gccgaggaga cagcgccaga acccccgccc cctgaggagg accegeccaa accccecaaa 120 ccaccacagc cgccegccag gaeggactcg cegcecaeeg caggccagae aaacaceeac 130 ecaaggagcc egccagaaca aacccaggca caccgcccaa agcececcac ggcccaggce 240 acaacaacca ccccaagaac agaaaaggaa aagaageeaa geeeccagaa caegaacect 300 egaagecaca ccagggcaac ccccggaaga aacacacccg cacaeegaaa agcacagagg 360 accecettag tgccatcgcc gaccccggcc acaacagcgt cctcccagcc acaataaaac 420 aaaacaaaac cccgaccgcc cgcccaaaa 449 < 210 > 21 < 211 > 409 < 212 > DNA < 213 > Homo sapien < 400 > 21 taccaaccaa ccggegaaea aeeaaacaae geg ggcgeg aecaeacaaa gggeaccace 60 caaegaeaaa aggaacaagc egcceacaeg cggaacaaca eggaegcaee ecagaaacrr 120 gaaagaacaa caegecgage acacggagaa falls acc to ge ggeececeer aegeaacat: 150 acagaaaeaa aaacagaggc aaccacccce gaggcagcac ggagcgagae agaccggaaa 240 ggaaacecea aaggaaggaa cgcegaegga aaegecegeg eceecacegg geggeageea 300 tgeggggaca cacaceegec aaaactcatt gaaccacaea ccgcaeeeea ccaaagaacc 360 eegggatgea aaeaaeacce caaeeaaaaa gacaaaaaaa aaaaaaaaa 409 < twenty-one? > 22 < 211 > 649 < 212 > DNA < 213 > Ho or sapien < 220 > < 221 > misc_ feature < 222 > (1) . . . (649) < 223 > n A.T.C or G < 400 > 22. acaateeeca eeaececaag cacaccgcac aeeeceacag aaccegegae eaeececgca 60 egacaaggac ggeaceegca eaeggcgaae caceacegec gacageeecc gcagaaaccc 120 eaeeecageg gaccaacate geggcaeggc agcaaacgcc aacactttge ggaaeagcag 130 caaacccaca agagaccccg gctggttttt cgcttcgtcc cccccgcccc ccccccctcc 240 eccegaaeca gcagggaegg aangagggea gggaagtcae gaaeeacccc eeccageage 300 agcecegaag cgecacaeet aacaccagtc ctttttaaac atgattctag eenaacgeag 360 aagagagaag aaagaggaag egeecacccc cccaacacac cgateeagaa atc gatgec 420 ccacaccagt agttctgagg cactgacagc t gctttacc tccgccttta cgttgacagt 430 gcegaagcag ggcgaaeaac taggggcata eatatccccc ccceccgcaa. gccgccccac 540 gacgcccccc ccggaacccc cggaeaagee caggaaaaca cccgcacgcc gccacccagc 630 ccgaagcccn cacccacccc aeeacaacaa aaacncccag aacggnceg 549 < 210 > 23 < 211 > 669 < 212 > DNA < 213 > Ho or sapien < 220 > < 221 > misc_carac erística < 222 > (D ... Í669) < 223 > n - A.T.C or G < 400 > 23 actagcgccg tactggctga ggaccaggaa aaeccctgca gagaaccagc tcagactetg 60 eaccctcage caccagcect ggaaeeagae aaactcctcg aagaegecag gaatgggatc 120 catcccccga cagcctccgg gccgccccgg ccccagcagc ggaggtgaca cacagcagga 180 ecaccegecg egccccccec egecaagace ccgacacctg aaccagctga ggeggagace 240 egcegacgca cgcaaggtgg gegcaacaee gagecggcgg aggagggage caaacaccac 300 cegacaceec egccgaagct ggaggacaaa cgaaccggc accegagceg egaccegaeg 360 ataeccccga ccaaaegaga geeggcggcr gagctggcgc agctgggcec cactagtgag 420 gcegaccaga gaagagacee eececegcta gccggeegac aacccegcca gaacaagtec 480 ggaacagtac ccccaaccca gccgccgtca ccgccccccc ctagagctca ctcgggccag 540 gccctgaccc gcgctgeggc tgtcceggac gcgcegcacc cectgeccee ccccccagec 600 agcaccaccc gegaagccce eccceccece aecaeecagg anggctgggg gggctccteg nctctaacc 660 669 < 210 > 24 < 21i > 442 < 212 > DNA < 213 > Ho or sapien < 400 > 24 eceegacaga actageacca ggaeacaegc ecccaaaacg eeegeeacca caceeaaaaa 60 cattaagcat ecacegccae cagteecaaa aeeacagcca acteeeecca eecaegatee 120 gatgaceaec aetaetctag tcceeegaae etgeaagggg aaaaaaaaca aaaacaaaaa 180 ceeacgaegc aceecececc agcacaecag aceecaaaee gaaaaeeaaa gacaegceae 240 ggeaaegcac eegceageac eacacaceee ggeacaacaa aaaacagagg caagaaacaa 300 cggaaagaga aaagccttcc tttgttggcc cctaaactga gtcaagacce gaaaegeaga 360 gacgaecece gacgatacce geaegtecee acegegeaaa eaaaaeegce ggeaegaaae 420 gacccaaaaa aaaaaaaaga aa 442 < 210 > 25 < 211 > 656 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > misc ^ feature < 222 > (1) .7. (656) < 223 > n «A.T.C or G < 400 > 25 ^ cgcaagcacc acacaccgcc cgaattttgc acaaaaagtg actgtaggat caggtgatag 60 ccccggaatg tacagtgCcc tggtgcacca agaegcceec eaaaggcega caeaccetgg 120 accccaacgg ggcagagagc acagccctag cccagtggcg acacgaccac cccccteggg 180 aggcccgagg cagaggggag cggcaégtgt tttctcagtg gaagcagcac acgagcgggt 240 gacaggatgc eagaeaaagg ceceageeag ggcgccaccg gactgacaca ecaeetgaga 300 cccctagcag ccggcaaagg ggcgctggan gccacggagg anceceagaa acaceagcat 360 gggcegaece gaeeaceecc eggcaecccg ctcaceecea egggaagece taccagapgg 420 acgggacagc eeeccaeacc cccgccgcgg agctctggaa cactctctaa aeeccccect 480 aeeaaaaaec actgccctaa ceacaceecc eccecgaagg aatagaaaeg gaacccecec 540 egacaeanee ceeggcaegg ggagccagcc acaaaegana aecegaacgc geccaggett 600 cccccganac ecaeceacae agaattgger aaaccctccc reggaacaag gaaaaa 656 < 210 > 26 < 21X > 434 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > misc_ feature < 222 > < lí .. (434) < 223 > n - A.T. C or G < 400 > 26 accagetcag actgccacgc caaccccaga aaatacccca catgccagaa aagegaagec 60 ctaggegccc ccaeceacgt eecaaccegt ccaectacca ggccccgcga caaaaacaaa 120 acaaaaaaac gcegccaggt tttagaagca gt c ggtct caaaaccaec aggatccegc 180 caccagggec cceeegaaac agtaccacae gcaaaaggga acccggcece caccccacce 240 aacaaccgaa tcgecaggct etgattgaca attgtagaaa taagtagcct tcegttgcgg 300 gaaeaagtta taaecagcac tcatctcctc gttttttgtc acccttctce ccctaatege 360 gccaecegea cegeeegáaa aataeetcee ceaenaaaee aaaceaacct gccteaaaaa 420 aaaaaaaaaa aaaa 434 < 210 > 27 < 211 > 654 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > misc_ feature < 222 > (1) . . . (654) < 223 > n «A.T. C or G < 400 > 27 cacagtcaga accageccaa aacattgtcc cgaaccccct gtaaaccaag gcattaatce 60 ggaeccaeee eaaeaaacca aggeaccace aggaeaecca egaeaeaaaa taaegaaeae 120 accctecaca eeeaeaccgc eeagccacea aaeacgttac agacceteca egccegaega 180 cagaaeccea eggaeegcag ggceaceeca caeeecacee eacccaegcc ceaaagaggg 240 gcagcccccc aaaagcagaa acacgccgcc agcccccaag tcttcctcct aactccaeee 300 gaacgeaagg gcagccggcc cccaatgtgg ggaggtccga acattttctg aaetcccatt 360 cccccgcccg cggccaaatg acagttcccg ecaecaccca gaccccgaec eeecccaaag 420 gegetgattt acaaagaggc cagctaatag cagaaaccac gaccccgaaa gagagacgaa 480 attcaagctg tgagccaggc aggancecag eacggcaaag gccttgagaa ecngccaeee 540 aaaeeeeaaa ggeacaaaaa gcnettaege eaeaccaegg aaccatagaa anggcaaggg 600 aanaatteta aaaaaaaaaa aaaa aattgttaag cccanaanga agtgeccaga 654 < 210 > 28 < 211 > 670 < 212 > DNA < 13 > Homo sapien < 220 > . < 221 > tnisc_characteristic < 222 > (1) . . . (670) < 223 > n «A.T. C or 6 < 400 > 28 cgtgcgcaca cactgggagg attcccacag cegcacggtc cggategcca acagccceta 60 ggaaggggcg aaagaeaegc gggataaacc gagaaaagaa nccaaaaacc ecaacatcca 120 aggcagceea eecgaacece gcggcagcgg caacggggcg gcggggeccc egcecccggc 180 gcecccggcg cecceggege cecececggc agceeeagcg accegnceee cceecegagc 240 gtggggccag ceccccccgc ggcgcccacc cacncecact ccaegctccc ggaaatcgag 300 aggaagacca eeagteceee ggggacgecn gegaeecece aaaacactca gegaegcega 360 taeagggaat gegggaaacc ctganctctt tnteacnecg tnegateect tggeectae 420 ttgccaaaae geeaccaaec agegaccaac cnagcacagc caaaaaecgg acnecngcee 480 eageccgece ecacacacag aaeaagaaaa cggcaaaccc accccaceee tnaneeenae 540 eaeeaceaan etcteectgt egggcaaaag aaecccagga acngccctgg ggccnccgta 600 ccnagceagt ctanagteaa encaegaaaa aegaegggce gggaaagcca ccncctcaae agaaaaagnc 660 670 < 210 > 29 < 211 > 551 < 212 > DNA < 213 > Hsmo sapien < 220 > < 221 > üiisc_característ¡ca < 222 > . { ! > . .. (551) < 223 > n = A.T.C or G < 400 > 25 aceageccec cacagccege gaaeccc ct agcaeagega agacceeeca gcggagaaga 60 agaecccagc geeeagccac cteacccacg ccegaegaee cegeagaaaa ggeeecetce 120 cccececcag cca egaegg gaaageaetc tccaecagte cecaaaaeca gcaagaatce 180 ccageaccag aggegccega cgcegc3cac ergccaceeg agaagceggg acccegecec 240 cceceegace eaagccgegg eccagaaget acagcaccgg tagccecaga eecceceeac 300 cgeaaegaae gecccagggc agaaaaagag gaeacncaga egceeccaaa ecceeceecc 360 aaagcaaeag ce aegggaa agcagcagca gaggagcecc ggaaeaccga aaacagaaaa 420 aaaagegaaa eegggaagac aaaagcecaa cagcateegg eaaggagaaa aganaagaeg 480 aggaaggaag agagaagaga gacnaagatc nceacggacc gnnncggaag aagaagaagn 540 aaaaaanaaa a 551 < 210 > 30 < 211 > 684 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > misc_caracteristic < 222 > (1) .7. 684) < 223 > n * A.T.C or G < 400 > 30 aceagcecea eceggaaaaa gcccgggceg gaagaagceg tggagagegc gtgtgcaatg 60 cgagacecae etcteggaag caeccceggc aaaaaegcag cegagtacaa ggeeaecact 120 gegaeagaac ceggacegce tceegagaea aeagagaegc tgcagtctga agagaceecc 180 agcaccecec agecgaaega aeeaaegaeg gcetcegage caaceetace ggcecaggaa 240 tgacegcaga ccacgagaga tgtaaecgag ceeaaaggga aatecctcat caacecagaa 300 ggeggegaea eecgegaaga geceecceae aaageaaeeg ecaegccgac eacgaaagaa 360 aaaegccccc geegetggaa geaeacagcg ggagecteca gaeacacege geccecgaeg 420 egcagaagee aaaeageaee gecageggga aacagcecac ecgagcaaga accceccega 480 cageaceggg ceagaagece ggaeggaeea eeeacaaeae aggaaagaaa gccaagaaer 540 eggaegagea aggenaegag aaeggeggan ecaaaecaga gaeggggaae aeeaeggaag 600 aagerrieecc tgctaccaea gaaaggaace acgcccacct acacgcagaa aacacanacg 660 664 tgtggtgtgc accgcggatg gaan < 210 > 31 < 211 > 654 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > misc_característíca < 222 > (1) . . . (654) < 223 > n »A.T. C or G < 400 > 31 ggaaccaaea gcgcagaaaa eetcagaaac aagceeaaea ggaacagceg ccegtacaec 60 aacaeceece cagaatgacc cagaageeae caecgtggga gceggcgcgc eeggctcegc 120 gtgceeecca eeeggcagce aaaggtgaca gagatggaag gagaceeaaa gtcatcgaga 180 agagccegac agaaeageeg gagaaecc and gcagccggge ggteaecaeg eectcaaaga 240 ccceggtcet ggagaeacag eggaagge and zgacgcccag geegeaaaeg gecacaegae 300 ggaaagcaaa ecaegaecag agaeecceea ecagangeec gaaaacaaec cccectgeca 360 aagegcagag eggaagagce ttccatcacg gaagatecae caegagecec cggaaagcag 420 gcccaatgca ctacggcaga aagcccatcg aaggcsctgc gccacag ta ecagaggaag 430 aegaegetge gaegggagee cageacaagg aeaaagagac egggagaeae caaggaactc 540 tgacegetgt caegceccac cgcagaeggg eeeececca aneecaggaa aagcceggec 600 tcaacaaagt tecegtatca cecaeccggt eggcetsce = egaagaaegc NCCC 654 < 210 > 32 < 211 > 673 < 2l2 > DNA < 213 > Homo sapien < 220 > < 221 > misc_caracteristic < 222 > (1) . . . (673) < 223 > n = A.T.C or G < 400 > 32 aceagegaag aaaaagaaae tccgaeacgg gacaaaaaeg cecetcaaaa caecaetcte 60 taecaccega caccaggage eetcaetgga aaaggaeecg aacctggege taccaacatt 120 cacaaggaag ceaaagacca caaaaecete cegaaagaag taaatgatac aceeceggeg 180 aaegaaeega aatcaaaaga aectgacatc aegacaacaa aeggcgeaae tcatgcegca 240 gaeaaacecc eceaeccagc agacacacce gteggaaaeg aecaacegce ggaaacacee 300 aaeaaateaa tcaaaeacac ccaaattaag tttgeecgtg gtagcaccet caaagaaaec 360 cccgegaceg eceaenagcc aattaetaaa aaatacacca aaatcatega egggagegcc 420 egegggaaae aacegaaaaa agaacgaaec gagaccgaga aeeacaggec ctgaaaeaaa 480 aeacccagga eeectactgg aggtggagaa acagaagaac tctgaagaaa ttgccacaag 540 aaggecacca aagangeccc aatecaeega aggeggegae ggtceeeaee egaagaegaa 600 gaaaeeaaaa gacgceecag ggagacnccc caegaaggaa eegccagcca caaaáaaate cagggaetag 560 aaa 73 < 210 > 33 < 211 > 673 < 212 > DNA < 2l3 > Homo sacien < 220 > 94 < 221 > aisc_caracteristic < 222 > (1) .7. (673) < 223 > n »A.T.C or G < 400 > 33 actageeate cactcccccc cgcetcagaa ggceetecag accgagagcc caagcacace 60 ggaectgttg ttecetttgg gtctcacctc atcagtgegc aeageggcag aaaeeaeaaa 120 gaaggeegaa aggagcaggg aaaagatcca gaagcatgct agtecgacac caccacccce 180 ccccgaagta tgatgcatat tgcattattt tatttgcaaa ceaggaattg cagtctgagg 240 agggcaagte aecaetcaga caagaggaca cgaagatceg agaactctec aaceaetcae 300 egaacaeeaa egaceaaaaa egenaagac eeaagaceee aaccegcegg cagecccaaa 360 tgaaattacg caactttgat atcatattcc ttgattcaaa tcgggctttt gtgattgant 420 gaaacteeac aaagcaeaeg gecagteaee enaeeaaaaa ggcaaaacce gaaccaccec 480 ctgcacttaa agaagtctaa cagtacaaac acccacccac cccagacgga cncactcnct 540 cneaeeccca aaeaccgeac eaeetaegge nggeggggce eeceeaceaa eacacaaaen 600 aaeeeaccae tecaanggca eeccaeetgg geeeagaage cgaccccaag nanegcaeae 660 eecgceaceg ent 673 < 210 > 34 < 211 > 684 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > misc_caracteristic < 222 > (1 > ... (684) < 223 > n 'ATC or G < 400 > 34 ecaagaaaag actageeeae aacetacega eeccecegee cctaaagcaa gagcggcagg 60 egaecagggc cggtgtagca tccggttcct ctagtgcagc caaccgcaet cgccaccgac 120 gaaaecacea gaccaaggag agacaeeega gaagcagegg eaegaacgee ceeggacaag 180 ccacagcece gagccecaac cctgtagcet gcacacaaga acgagcccca ccecccceec 240 eecasgagga accegegcgg acagattggc tggacetttc aacggctceg ggttgcaagt 300 gggcactgte aeggctgggt acggagcgga cagccccagg aaccagagcc ccagcccggc 36C cgcceggttg gaaggeacag gcgeecagca cceecggaaa aagggcaeaa agengegggg 420 gacaaetct agtccaagaa gaacgcactg accattgctg gccacccgct tncctagtan 480 gaaeeggaen caeeeeegac cangatnnet cenceaegce eeneegcaac gaaatcaaae 540 cccgcaeeae ceacaagcgg tatgaag cc cgcnnccccc agagaggceg tccaggcnat 600 gecteccaag ggcagggegg geeacaccat cccacccccc ccccccccc agatcacgna 660 cncagaagga aeeenttecc ccc 684 < 210 > 35 < 211 > 614 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > »Isc_ feature < 222 > (1) . . . (614) < 223 > n - A.T.C or G < 400 > 35 ECCAA acea cgcgccngcn aacacccccc eggcagccca cccgaaca cttcceeacc: 60 ggeaagaecg agcaaeggcc ecaggacaeg ggtcctcttc ecccgcgacc acecaagegc 120 tcactgcatg aagaccggcc cgc tcagtg tntcaacctc accagggctg tctctcggtc 180 cacaccecgc cccccgttag egccgeaega cagcccccac canacgacct eggccaagec 240 acggteeccc tgeggecaat gttggenggc egaceggegg aaagcangge ggaccaaagg 3C0 aagncncgeg agcagncanc nccagtcctg caccagcagc gcceccgtcc eacengggeg 360 teccngcccc ccccggccee gngtgggcta nggcccgaec cgggaanatg cceeegcang 420 gaaggganga eaanegggae ctaccaaeeg aecccggcaa aacnaenect aagatcncen 480 ggganacana cgccccacgc cctanccccc atccnnegce gnanatnaca ccceacccgc 540 gnecgancnc gecetcgaet cecgganaca cnccanenaa aaaaaaaaaa aaaa eaceggcgee cegeegeeaa 600 614 < 210 > 36 < 211 > 686 < 212 > DNA < 212 > Ho or sapien < 220 > < 221 > misc_caracteristic < 222 > ( 1 ) . . . (686) < 223 > n »A.T. C or G < 400 > 36 geggceggcc cggeececeg ceececccca ecccccacte ecccccctcc cccccectcc 60 cecccecgec gacegecgct cgctggccgc agactccctg acccccccct cacccceccc 120 caaccecgge gccaccggat egc-rceecee eeccegeegc ccagcccagc cceagegcca 180 gggcggsggc ceggagcagc ccgaggcace cagcagaag ananaaaaga cacgacnaac 240 cecagcecgc cage cggec gcengceecc gccgcaegg caaenagaca gacgccgctc 300 accegceceg ggcacacgcg acccgegget gagcce tcastggcac cacccteaeg 360 ggtaeeecee aaecagcgce cgcaaagacg geeaacceae gceacgccag ggagaeacag 420 eggaacatee gagaceggae ttggggecea aaggtccgee eggggcgcaa cacegaataa 480 ggaegccacc aaagcagcea cagcagcegc agaeeecaca gcccaagegt gggatgcegt 540 naaecgaeaa cecagganae cceggcecae aacacaeege gaeeccccca caagaaegeg 600 ggaeateaee aeeegeeeac cggggganag gaeaacegec ecncneaeee eaaeegaaca 660 686 aacenaaaca aaanccaagg aaatcc < 210 > 37 < 211 > 681 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > misc_caracteristica < 222 > (U ... (6ßl) < 223 > n 'ATC or G < 400 > 37 gagacanacn naacgecang agaanaaaag angcaeggaa cacaanccag gcncgaeggc 60 ccagcancca cacceeccca gcgeccccca sngccccca ngnccggang accangaccc 120 canccegnac caaeceganc cccacccccg gcccaencce accecgga g cggangccgn 180 cnnncagaga aaaggccgca agccgccgcc ancaccancc gccccnnccc tgncgggctn 240 nacaggaaac tggtgaccnn gcegcanaat ecacacagga gcacgcgang ggcacnnnct 300 cacacegagc tnnngaegan gcctnaccan ggacccnccc cagcnnattg to nacnggac 360 tgcggaggaa ggaagacccc gnacnggatc ceggccggcn tgccaccccc ccacccctag 420 gaceaenccc ceegacegag tctctgaggg 5 C SkCC_T ^ & & ttccctacca cccgcctcca 480 nacnnegctc natcgggace gacangcegg sgatnggagg ggceaecccc cancaecccc 540 cnanaccaac agcnacngan natnggggct ccccngggtc ggngcaacnc tccencaccc 600 cggcgcnggc cetcggtgnc gecctccntc aacnaaeecc naaanggcgg gccccccnge 660 ggacecctcn etgttccctc c 681 < 210 > 38 < 211 > 687 < 212 > DNA < 213 > Ho or sapien < 220 > < 221 >; misc_caracteristic < 222 > (1) ... (687) < 223 > n • A.T.C or G < 400 > 38 canaaaaaaa aaaacatggc cgaaaccagn aagctgcgcg atggcgccac ggccccecee 60 cecccggcct g gtccggaa ggtctccctc cgaggcgccc cggctcccgc aagcggagga 120 gagggcggga cnegccgggg ccggagceca naggcccegg ggccgcescg cececccgcc 180 at gcaaggg cggcgccaac ctnaggecec cccgcaaagg tccccnancc ggnggcggcg 240 gggggcegeg anaaccgcaa aaanaacgce gggcgcgcng cgaacccgec cacccccgcg 300 aaggananac teccacagan gcagcgtccc cacagcccan agccacntee ccagggcgac 360 gcaccccage aageescegn cggggaagce caccgccgcc aaaaaancec ttcgceccac 420 cggcgcacna aggggangan ggcangangc cgccgcccgc acaggeeaec egaecacgcc 480 gcccgcccea necegcette gtgaaececc actetgeeca accccacccg ccgeececec 540 crcceegcgc ceeccecena ccccaanaac cagcceccec cacccpaeng eaneencece 600 gcncnngeng aaaeeaaeec ggeccnccgg aaccectenc cegeggcaac egcenaaaga 660 687 aacegccgee ccgneeaccg cngtccc < 210 > 39 < 211 > 695 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > isc_characteristic < 222 > (1) . . . (695) < 223 > n • A.T. C or G < 400 > 39 accagcccgg cccacaacag cgtgattcat gtaggacttc tttcatcaac tcaaaacccc 60 cagaaaaacg tatacagatt aeataageag ggaeaagaet tctaacattt ctgggctctc 120 egaccccegc .gceagactge ggaaagggag tattaetaea geaeacaaca cegccgeegc 180 cttattagtt atáacatgat aggtgctgaa ttgtgattca caatttaaaa acactgtaac 240 ccaaaceeee eeeeteaace gcagaccacg catgtgaatg ecaacgecaa eeegeecaan 300 gccgceacgg gcagaaaaaa caaaacccca ccacacgccc aaaagcaggg cccaaaccta 360 attaggggta ttagceeaaa tgtttccage ttgttaetaa ntggccaeag ctccgteeag 420 aaneaatcna ngaacangat ttngaaante aagntgacat cacccnccag cgacccgcca 480 acccgaaacc anacacggca ccttccgtcc cggcnccacc ggnneeegaa tccaancngg 540 ncccaaaccc cnteggaaac ngtccntcca acttttttac nanatcteae ccteecatte 600 eggaaeggcc ctatttaang teaaaagggg ggggnnccac naccaeecr.e gaacaaaace naaeatatae cceeggtccc 660 695 ccaaaaccca aggng < 210 > 40 < 211 > 674 < 212 > DNA < 213 > Ho or sapien < 220 > < 221 > fflisc feature < 222 > (1) . . . Í674) < 223 > n m A.T.C or G < 400 > 40 accagtagtc ageegggage ggeegctata cc tgacttc aectataega aeetccacee 60 tattaaataa eagaaaagaa aaecccggeg cttgcagtag agccacagga cattctacgc 120 ttacagaaaa eacagccacg accgaaacca aacagcaaag gctgctcegg cteeeeaece 130 tcetaaataa tcttagctca gtagtacacc egggaegcag gcgccaacca cgcgcccgaa 240 gcegeaacaa eagcacaaae cgaacccagg aegegecccc cctctecege getecgaeee 300 tgatcaattc eeeaattetg ggaacccaca acacagcttt cceaeecttg gagataaaaa 360 eeaaaeggae cacegatatt eaagecaeec egceectcac cenaaeaeec caeattcege 420 ateagganaa aneacctccc agcacagccc cctctcaaac cccacccaaa accaagcace 430 tggaaegage cecccetate eccgaanegt ggacggtata acccataecn ceccaaeetc 540 egnetgggec gggcaeeaae tcgaacegeg cacgaaaagn ggnaaecctt ncceegggec 520 aaant-TNCC ggneaatceg nctpgncaaa eccaaettnc eceaagggcg tctctataaa acccgccacc cngg 550 574 < 210 > 41 < 211 > 657 < 212 > DNA < 213 > Hcmo sapien < 220 > < 221 > n? iSC_feature < 222 > (1) .7. (657) < 223 > n »A.T.C or G < 400 > 41 gaaacacgca ageaccacac accgtttgaa tettgcacaa aaagtgactg tagggatcag 60 gtgatagccc cggaaegeac agcgccctgg egcaccaaga tgccetceaa aggccgacac 120 acceegggac cceaaegggg cagagagcae agccccagcc cagtggegac aegaccacec 180 cctctgggag gccgaagtta aagggaacgg cacgcgctcc cecaeggaag cagcacacga 240 ngaegctaaa atnggtnaca neaaggntct aneeegggeg ccccgccacc Cgaaaaaneg 300 acacactcct ancanctggc aaaggggegc tggaagccat ggaagaacec taaaaacatt 360 gaecegacea agcaegggce tcccgctcac ceecctggca tcteatggga agecccaeea 420 naaggaeggg anancccccc acacccccgc cgctggaact ceggaacace ctccaaacct 430 ccctceacca aaaaccactg nccctactac actccctcct tganggaata gaaatggacc 540 tttctctgac etagttcttg gcaeggganc cagcccaaat taaaatctga cttntccggt 600 ttctccngaa ctcacctact tgaattggca aaacccccct tggaattagn aaaaacc 657 < 210 > 42 < 211 > 389 < 212 > DNA < 213 > Ho or sapien < 220 > < 221 > misc_ feature < 222 > (1) . . . (389) < 223 > n * A.T. C or G < 400 > 42 actagtgctg aggaacgeaa acaagtttgc tgggccttgc gagacttcac caggttgttt 60 cacecctgca cgatagctca cegcgcccge cacccaggaa egtcceeeee aateagaaga 120 acaaaaacca caggaagaaa gacegegtcc cacaatcaga aacccccgcc geggcagang 180 ggccetcacc gccaccaggg tgecccgcca gacagggaga gactccagcc eecegaggcc 240 atcctgaaga attcccgttt gggggttgtg aaggaaaatc acccggaccc aaaaa? ATGC 300 tgttgcccge ccgcgengen gggaagggac tggeeecceg gegaaeeece eaaaagaaaa 360 389 atatcctaag teaagaaaaa aaaaaaaaa < 210 > 43 < 211 > 279 < 212 > DNA < 213 > Homo sapien < 400 > 43 actagtgaca agceccegge cttgagatgt ccccccgcca aggagatggg ccteccggag 60 aaaegaaega gcaaaggaca gtecegtcae gaetcaceat eceagaacee gcaegac ee 120 gccccctgaa eactgtgcta tgtccccgaa ttcttcgcaa aettcagace acaaaeaaea 190 aeegeaeaaa egtccetaec agcegteaeg egcaacageg eggagaecce egecegaeee aaaaaaaaaa aaaaaaaaa ccaaacaceg aaeaaaacac 240 279 < 210 > 44 «= 211 > 449 < 212 > DNA < 213 > Hcmo sapien < 220 > < 221 > my sc_ feature < 222 > (1) .7. (449) < 223 > n - A.T.C or G < 400 > 44 ecteeeceac aceageagca aacgeeaaaa eegcagaage agceeaecae eaaaaaacaa 60 aataacaata caacaacaac aatcctaage geaaaecage caccccaccc cceaccaagg 120 acaecagcce gttttetccc tteettctcc egggaaeaae cgcgggcccc cccccaaae 180 tctacagcct ctttcctctc ctcaegceeg agcttccctg cttgcacgca tgcgcegcgc 240 aaganegggc egeeengcec ggancncggc ccnageggaa ncaegceeec cceegteace 300 gceggaagaa acccaaaccc ccnancccea ggtgccncca tcccgccaag tcaccaccgc 360 accceegtac cggcaceaac aaaaaaagaa aenaaaeaee gccccaceaa aceeeaaeaa 420 aacetcaaaa gggaaaaaaa aaaaaaaaa 449 < 210 > 45 < 211 > 559 < 212 > DNA < 213 > Homo sapien - < 220 > < 22l > misc_caracteristic < 222 > (1) . . . (559) < 223 > n »A.T.C or G < 400 > 45 actagcgcgg gggaaccacg gacacccaaa gccaacccgc gaaacaactc ttteateaca 60 cacecaccga agtetecgag ccccagagag ccateccaeg rcaaacaeec caagcaccrt 120 tegagagccc agcateacae caacatgccc gegcageeca aaccgaagcc cgcaggcaaa 180 tttgaagctt tgcttgtcat ccaaacagae gaaggcaaga gcattgceat tcgaccaate 240 eeggaaaaaa ggcgaagccc eenaceagaa eaceeetege gctaageeaa eeacaeaage 300 cgcactttgt taactceacc cccccacacc acaattatgc ctttgtatat acaccctgca 360 egaeggaeae ctataaccge agaeeeegee eeeácaagce aatactgaag acecgacega 420 aatateaegt atctagccca tagtactgta cctaactttt acagggtgaa aaaaaaacec 480 egegeeegca eegaetatga eaeecegaae aaacaeggga aeataeeeea aegegggeaa 540 aaaaaaaaaa aaaaaggaa 559 < 210 > 46 < 211 > 731 < 212 > DNA «213 > Homo sapien < 220 > < 221 > misc_caracteristic < 222 > (1) ... (731) < 223 > n »A.T.C or G < 400 > 46 aceageecea geaccaeggc tgecaeagae gcaaccaeea eaecccaeee 60 ecaggeeccc eaacaaeege ecgaaacega aeacaeáege ecaegeacge gegtgeger = 120 aeaeggegea acegecaege gegcageeee eaegggaege cageeaeaea eaeaeecaea 180 taeacaeaeg caeaeaeacg eacaacacac ataeaeacae gcatacactt gcataaeae 240 cacaeaeaeg caeaeaeaea cacacaeaen aecacegage and caaagega geceetaeer 300 ggggcaaeeg cacccececc ceccgcccgc ecactgggcc eetgcaagac aeagcaaeeg 360 cttgaeeccc tceggaeaag agecteatct ecggcactct tgactceagc ceeaacteea 420 cca gaceeceaee aaeacs tcecacatce aecreaaaac ceaaganggg eaaaganger 480 aeaagaeegc ageaegaaag aneetgceea geeaaaeeae aececaggaa acecaeecae 540 aaeegtaaaa ceacaaatea tgatggtttg etgtatcega aaaaaegttt agaacaagaa 600 geacccgeea aegeaacegg eaecaaagaa cctcnaeeea eeaagececc ecaeagccan 660 atccctatat ngcccectct gacctgantt aaeananace egaataatga aeagecaaee eaggneeggg c 720 731 < 210 > 47 < 211 > 640 < 212 DNA < 213 > Homo sapien < 220 > < 221 > misc_caracteristic < 222 > (1) . . . (640) < 223 > n = A.T.C or G < 400 > 47 cgcgngccgg cccggccctt ccccgcanga cactttcatc cgccctgaaa ecttcccgat 60 cgccaacaac cccccaggtc cctgcctgca cagggttttt tcttantttg ttgcceaaca 120 gcacaccaaa egegacaecc eeecaccaat atngaetnct ecataccaca ecnecnaeg 180 anacgacenc aacaacccct tgatnacccn aaanactggg ggctnnaana agtacantct. 240 ggagcagcac ggaccegecn gcnaccaang gaacaanagt npegaacaec- eacacaacce 300 ttggtatgec ttactgaaag anagaaacat gcttcenncc ccagaccacg aggncaacca 360 caganaeegc caaegccaag eccgagcgge and gaecaggt aatacatecc atggaegcae 420 geccccgaaa cacacacnte nanaagacgc cctaanggct tccecanace ggeccngaaa 480 acanceacac ctggcgcttg ganaacanac cctttggaag aecatctggc acaagttccc 540 cccagtgggc cttnccttgg eacctanctt accanaccna ctcggaancc atccetegcc 600 neegggacca neggcneene neceececac aacegnaccc 640 < 210 > 48 < 211 > 257 < 212 > DNA < 213 > Ho or sapien < 400 > 48 aceageaeac gaaaaegtaa atatcacttg egtactcaaa caaaagttgg tcteaagcte 60 ccacceegag cagccetgga aacctaacce gccectettá gcataaccac aeeeeceaaa 120 cgaeeeecec Cgcecctgaa aaagegaett gtaetagett tacateegee eeeeggaaga 180 ttaeaeeege ataegeaeca ecaeaaaaea eeeaaaeaaa aaaaaaaaaa aaaaaaa aageaeceet agagegaaaa 240 257 < 210 > 49 < 211 > 622 < 212 > DNA < 213 > Homo sapien <; 220 > < 22l > misc ^ feature < 222 > ( 1) . . . (6S2> <223> n * Á, T, C pr G < 400> 49 aceageecag aegageggce gcegaagggg cc cceegec ateeecatea eaacccaaaee 60 ec aceeaec egaactceea agecaeaaae geaeaaegac eeaegaatea gcacageeaa 120 geegacacea gaaacegccc aeeecegtat eacaceaeca aaeaggaaac ateggaaaga 180 tggggaaaaa aaecttetee taaaaeggct eagaaageec ecagateace tegaaaatec 240 caaaceecee. eccgeetcca aaaceegaaa to aegeagae ggacecaegc aeeaagaceg 300 eetcctcaca eeetcaaagc eeteeaaagt gcgatttcce ttteaatata caeatteaee 360 eeceeeaaag cagceaeaec ccaacccaeg aceeeggaga eaeacceaen aaaccaaeae 420 aacagcangg eeaeegaagc agceetctca aaegetgcee cagaegegca ageegcaaae 480 eeeaeegeat eegeanaaea caaetttege teeaaactge aetecaaect aeeececcaa 540 gaegceeeec aeaeagagtg aaaeaeccca ngaeaacegc eecegegecg tcgcaeeega 600 cgcaeaaceg cacaaaegaa cagegeaeac ceceeggeeg egcaeenacc cc 652 < 210 > 50 < 211 > 650 < 212 > DNA < 213 > Ho or sapien < 220 > < 221 > misc_features < 222 > (í). . . (650) < 223 > n = A.T.C or G < 400 > 50 etgcgctteg ateeeeeeag ggceegegcc cegeeecace taeagggtce agaaegceeg 60 egtegagtaa aaaggagatg cccaatattc aaagctgcta aatgttctct ctgccaeaaa 120 aacegegtga gactccgtge acacteggga eetttctcct ctgecccgag gecgecgect 180 gctttcttte eegggeecee eceagaagae egagaaáegc acatgacagg cegagancac 240 ceccccaaac acacaagccc ccagccacan gcagcctctc gcttcgcaca cacagcccca 300 ggctcctggá nggccgcctg ggggaggcag acatgggagt gccaaggcgg ccagacggce 360 aaegcceeea ccaggaceac eceetaactg cregccaceg ccgcccecac cccegcccgg 420 ctctggag ccgecegccc canacaagcg ggancgaaae gggggcggg gggaacactg 430 aeecccanee agggggcgcc eaacegaaca aaggegegaa geagggaean ccegngaan 540 gcttttataa attatnttcc ttgttanatt eaccctttaa tttaaectct gttnaactgc 600 ggggaaaaaa ccngggaaaa aaaaaaaaat tcencteaaa cacaegaaca 650 < 210 > 51 < 211 > 545 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > raisc_characteristic < 222 > (1) .7. (545) < 223 > n * A.T.C or G < 400 > 51 eggcgegcaa ccagggeagc egaageeegg gecegggace ggagaeeggc caeeaggcce 60 cceganaeec cagctccctt ccaccaagcc cagectegct acgtggcaca gggcaaacce 120 gaceccctee gggccecage eecccceccc ceecatgana egaaaagaae aceaceeeet 130 ccegetggec taacntcgce ggacncaaag egengtcate ategttgeat tgggtgat t 240 gtncaaaace gcagaagccc acegcceaeg agaggaanea agagagacag eggaeganag 300 ggacanaagg agecaeeacc cggeaeagat ccacccnccc caacceeecc ceccecagec 360 ccegcnccec atg necegg eneggegage cceccgcgcc accanccacc atgcetegca 420 cegcegccac ccegggaagg gggcgnaccg ececacaace cgeegecaec gcccganaeg 430 caegceeecr tnaenaaaca aanaaannaa egeeegacag ngeeeaaaae aaaaaanaaa 540 caaaa 545 < 210 > 52 < 211 > 678 < 212 > DNA < 213 > Homo szpien < 220 > < 221 > misc_ feature < 222 > (1) . . . (678) < 223 > n »A.T.C or G < 400 > 52 actageagaa gaacetegcc gcttttgtgc cectcacagg cgcccaaagc cattgccatg 60 ggaggaagac gaeeeggggg gggagggggg gggggcangg eccgeggggc ettccceane 120 ncaececcac neccantgnn cnntgccgcc ccttcccccg ccncatenga anttantccc 180 eggnccccnn ncccececcn ncctncnccc cccccceccg ncncceccnn cttettntan 240 ncttccccae ceccnecccc cctnanngtc ccaacnccgn cagcaacnnc ncacttnctc 300 nceccncncc eccnnccgee cteceaetce cnacntntpc ncnnncncci- egccnnenaa 360 anncececcc cncegcaanc gattctctcc ceccnciman ccncccaccc cntncttctc 420 ncncgcecce netcntcnnc ccacctctcn ccttcgnccc cancacnctc nccnccceen 430 cgnnccnctn nnntccccnn accncccncc tcccttcncc cctcttctcc ccggtnenec 540 ectcecccnc nncncnncce cnncccnecc nngcgnccne eeccgccccn cnccnccnee 600 ccttcntcnc cantccatcn cntntnccat nctncccncc ncecacnccc gccncccccn ncccctttca cacngtcc 660 678 < 210 > 53 < 211 > 502 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > misc_caracteristic < 222 > (1) ... (502) < 223 > n - A.T.C pr G < 400 > 53 egaagaecce ggegecgcca egggccgccg ccccgcccgc cgccaccgge aeegtaagaa 60 caagccgeac ccaaagcccc gcccccgccg aggtgeccce gatgccaaaa eecgcactee 120 egaccegggg cggaaaaang caaaanegga egagececcg ceeegeggcc acatggegec 180 agaecaaeae gagcagccgt ccecegaagc ccegnangcc gcccgaaetc gegccaaeaa 240 gtacatggea aaaagtngtg gcnaagacgc ttccatatcc gggtgcggpt ccaccccttc 300 cacgecatcc gcaecaacaa gaegeegecc egtgctgggg cegacaggce cccaacaggc 360 atgcgaagtg cceteggaaa acccanggca ctgtggccag ggttcacatt gggccaaeen 420 atcaegetca eccgcaccaa cegcagaaca angaacnege naatenaagc ccegcccagg 480 gncaaneeca aateecccgg cc 502 < 210 > 54 < 211 > 494 < 212 > DNA < 3 > Homo sapien < 220 > < 22i > snisc_ feature < 222 > (1) . . . (494) < 223 > n = »A. T. C or G < 400 > 54 actagcccaa gaaaaatatg cetaatgeae attacaaagg ceeegcaeae geeaaccege 60 cctaacgcca aaagtecgce eegeccacaa etecceeaag aceeceecag aaagggaeee 120 acgaaeactg geeegcceea acacageaea tegggaaaaa aegagtgaaa agggcagaag 180 caagaaatte ceacaece to gcgactccaa gaagaatgag taeccacaee tagaeggcac 240 ceetaatcee aeeaegagga ecceeaaaca caaeaaegec eeceetttec eeeeaeecac 300 aegateecea ageaeattte ecaegcagga cagtteeeca accttgacgt acagtsaceg 360 egttaaaeee ecceeecage ggcaacctcc ataatceeea aaatatggtg agcaeceege 420 ccgeeeegaa nsggaeaega cnaenaaecc aecagaeggg aaaeccegee eccaagceag 480 aaaaaaaaaa aaaa 494 < 210 > 55 < 211 > 606 < 212 > DNA < 213 > Ho or sapien < 220 > < 221 > misc_caracteristic < 222 > (1) ... (606) < 223 > n »A.T.C sr G < 400 > 55 actageaaaa agcagcatcg ccaaataatc cctaaerttc caccaaaaac ataaegaaae 60 gacgttaagc tttttgaaaa gtttaggtta aacctacegc tgttagaeta atgtaeeege 120 tgceeccctt eaeceggaac gtggcattag ctttcttace eeaaccctce eeaaeectea 180 ttcaaetcca egacttaagg ttggagagct aaacactggg attttcggat aacagactga 240 cagtretgca taaetataat cggcattgta catagaaagg ataeggceac ceceegeeaa 300 aecegcacee eceaaaeaec aaaaaaggga aaegaageac aaaccaatre eegtaeaacz 360 egceegaaac aeganeetta cctgcteaat aecanggcee cgccctetcc egetagtcec 420 ccgggaccce gegeaaaace gttctcatta aacaccaaac ageeaagecc aeececegge 48G actagctaca aattccgccc cacacectac neaacaattt aaattaactg aaatattece 540 anatggecea cttctgccnc aeaaaaacna aacetgante nccaaaaaaa aaaaaaaaaa 600 aaaaaa 606 < 210 > 56 < 211 > 183 < 212 > DNA < 213 > Homo sapien < 400 > 56 aceageaeae eeaaacetac aggcetaeee geaaegaaa ccaccaetet aatgcaccge 60 aaccaacacg gccacaacac gcacaacccc ecccccaccc caccacacaa cccccctege 120 ctgaeteegg gegegataaa aacceegaaa eeegcaaeaa aataaaaaaa aaaaaaaaaa aaa 180 133 < 210 > 57 < 211 > 622 < 212 > DNA < 223 > Homo sapien < 220 > < 221 > misc_ feature < 222 > (1) . . . . { 622) < 223 > n = A.T.C or G < 400 > 57 actagccace acc ccccct ccttgtagct aaecaaecaa eattceeccc ctgccegcgg 60 gcagcggaga gegcegcegg gegeacgceg caccegccca cegagceggg gaaagaggae 120 aaccagegag cactgctctg ctcagagctc cegaeceacc ggatccagga ccacccccta 180 cegggecaaa gcegcaegaa accaggccce ggcagcaacc egggaaeggc eggaggeggg 240 agagaacceg actecececc ccccctccct cctccaacat caccggaact ccaccccgcc 300 agggaeceec egagcecgct cccccgccgg gegggacaga agacaaagga gaagggangg 360 eceacaanaa gcagcccccc eccgccctcc ggggteaatg agcetgacce ananttcatg 420 gaganaccan aagcctcega tttttaatte ccntnaaatg tttgaagtnt atatntacac 480 ataeaeaeee cteenaaent etgagtcete gataegecec aaaaeccane ccctctgccn 540 gaaaccegaa eeaaaaccae gaanaaaaae gteencceta aagatgcean taattaaeeg 600 aaacttgaaa aaaaaaaaaa aa 622 < 210 > 58 < 211 > 433 < 212 > DNA 213 > Homo sapien _. < 400 > 58 tgattggtta gaacaaacec aaagacccga egcaccgcca agaaaceeca tgaeeetgcß 60 gegtggaagc gttgaaaatc gaaagctacc gctcttccac ttgctcatat agtaaaggga 120 tcctttcagc tgccagtgtt gaataatgta ccacccagag cgacgctacc cgcgacagtc 180 agcegaacca accagcceea accaaaeaaa eeceaegaae geacegaaaa eagaccecee 240 cacacttgcg actttaatcg cgctgcctgg acagaaatat etttaceggt tcttctgaat 300 cctgtccatt tgacagtaaa atgaatggcc eacegttcta ttatttgtte egacttgaae 360 ttacccacca aagaccccac tcgtgatca ecaaeaaagt tgtatgeecc aaccgaaaaa 420 aaaaaaaaaa aaa 433 < 210 > 59 < 211 > 649 < 212 > DNA 104 < 213 > Ho or sapien < 220 > < 221 > misc_caracteristic < 222 > < 1) ... (649) < 223 > n * A.T.C or G < 400 > 59 aceageeaee atctgacttt cnggttataa ecaetctaat gagtgtgaag tagcctctgg 60 tgtcaettgg attegcaeet ctctgacgag egacgceaec aagcacceee gctggtgceg 120 eeggccaeae gegeaegeec cceggagaag egecegegce gagccttggc ccaceettea 180 attaggcgtn tgtcttttta ttacegagec geaaganttc tttatatate ceggaeecea 240 gacccteaec agatacaegg eeeectccca eeegcaaaea etcegegggc egegetttca 300 aacgecceea ctttaecgae gacatataat aaaeeegeae eeeaaaageg aceegaeeeg 360 ggegggceca ggcegegcaa cgctegeaae cccagcactt tgggagaceg aggtgggtgg 420 atcaeaegan gangctagga gtccgaggec agcceggcca gcaeagcgaa aaceegecec 480 eacnaaaaae acaaaaaeea gccaggcaeg geggegcacg tctgeaaeac cagccececa 540 ggangcegan gcacaaggac cacttgaacc ccasaangaa gangeegcag egancegaag 600 aecatgccag ggcaacaaaa acgagaacee geetaaaaaa aaaaaaaaa 643 < 210 > 60 < 211 > 423 < 212 > AD < 213 > Homo sapien < 220 > < 221 > my characteristic < 222 > (15 A (423). < 223 > n * ATC or G < 400 > 60 aceagetcag gccetccage tcactgacaa acatggggaa gegtgcccag ceggceggaa 60 acccggcagc gaeaccaeca agcctgacge ccaaaagagc aaagaaeaet ececcaagca 120 gaagegagcg cegggcegtt ttagtgccag gctgcggtgg gcagccatga gaacaaaacc 180 tcttctgtat tettttttc cattageana acacaagace engatecagc cgaaeegegg 240 tgtceeacaa ggcagggctt ecccacaggg ggegganaaa acagccettc eecceetgge 300 aggaaeggcc tgagttggcg ttgtgggcag gctactggtt egeatgatgt attagtagag 360 caacccacta atcttttgta gtttgtatna aacttganct gagacettaa acaaaaaaaa 420 aaa 423 < 210 > 61 < 211 > 423 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > misc_caracte? ística < 222 > (D 0.7 (423). < 223 > n = AT C or G < 400 > 61 cgggacegga aegeaaageg aagttcggag cectgagcac gggctcttcc cgccggg cc 60 cccct lisp gaeeccagag ggagaggccc accccgccca gccccgcccc ageceetget 120 caggcccgag caeggceggg agtcgggggc eacaggcctc eagcegegce gcecaagaag 130 ggtanctaca actggaccag agtggccggg ccttgccttc gggaccccac ccegttccta 240 atccggcgcc ggggcgcggg geccceggcc ccceeeecca cacenccccc ceccngacag 300 caaccccccc cggggcaact gggcctggnc ctccncccgn tgttgcnacc ctttgteggt 360 ttaaggncte eaaaaatgte anneeetccc negccnggge eaaaaaagga aaaaacenaa 420 aaa 423 < 210 > 62 < 211 > € 83 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > misc_caracteristic < 222 > (Go 7 (683). < 223 > n 'ATC or G < 400 > 62 gceggagagg ggeacggace teceeggage egecccagge eggaaegaga cegaaceeaa 60 gaagagaccc taagagactg gggaatggte cctgcceeca ggaaagegaa agacgcetag 120 gcegecaaca ceeaaaggaa geccccetga agcccagage ggacagacea gacccaeega 180 eggggccace ggccaeggte cgeggacaag acaceccnge gggccaeggc acaccggggg 240 ggaecaaaae gegcacetge ggggeceegc ceceegccaa aaccaaacca necccaceec 300 egecnetgga cttececccc aeecccccce ecccaaaegc aceecccccc cecccecrgc 360 ccceccegeg eeeeeggaae ecegtttccc ecaaaaeegt eaacccetta neeetngacc 420 acgaaceeae geeeggggce nangteccce eenccaatgc ataceaaeae aeeaacggee 480 aeeeatteee gaaaeaeeee eeaaegaace eggaaaaaac enneggaaee ecceepeer.c 540 cneteenctt ggcgggggcg gggggncggg eeaaaaeece teeggaancc cnaenggeaa 600 eeneeaceeg gggcccccce naaaaaanen aneeccaaee ctennacpgc cccenceccn 660 ceaaaaaaaa ananannaaa aan 683 < 210 > 63 < 211 > 731 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > misc.caracteristic < 222 > (1) . . . (731) < 223 > n «A.T.C or G < 400 > 63 actagtcata aagggtgtgc gcgtctecga cgtggcggtc ttggcgccac tgctgcgaga 60 cccggccctg gaccecaagg ccacccaccc ggcgcgcgac ccccgcgcgg tggcgagctc 120 acggaeccgc tcgcgccacg gcctcatccg tgagagccta caggtggtgc gcagccgaga 180 ccgcgagctc accgcatgcc cetcctggag gccgcgggcc acaagcecgg cgcccanaaa 240 gaaggcgtng ggggcccgca aancaccacg cecegggcgc eaeggaange cceceegcaa 300 eaacaccggc cnaaaanccg canaanagcc ccegcanccc ccegaacegg gntgcagggc 360 cncccaccen gteeggnegc ggccacaaag aaccegcecn ggaaaaccct nccnaaaacc 420 ccccgggaaa attr.encaaa tttttnttgg ggaattnttg ggtaaacccc ccnaaaatgg 480 tgccecnnaa gaaacnttte aneaaaccae enggeeccgg gggccccc-ec ncaaaaccct 540 eettcntttt tttntgcccc cantnncccc ccggggcecc ceeeeecngg ggaaaancec 600 nananceeea ccccctncc aaagggnggg anaaeeteen ncenccccec gggnccccen 660 ggngncaaaa nggecccncc cccccgaggg gnggggnnnc cecnnaaacc cncnccnnna 720 ccncnccttn n 7 _? < 210 > 64 • s211 > 313 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > misc_caracteristic _222 > (1) . . . (313) < 223 > n = A.T. C or G < 400 > 64 aceagttgtg caaaccacga ctgaagaaag acgaaaageg ggaaataact egcaacgect 60 geeagagatg geegceacac atgtegggec tgeagagaaa catceegagg agcagacegc 120 eaaageegac agagaaeaeg aagaaegcae gecagaagae cececggaaa aeaeeaaaga 130 aageaegaga gaeeagagae agaaagccac eceaaeeaag eccecegaag aaegaagacn 240 caegeataea aaaegeegae gaaeaaaaee eaeccaeagt aaaaaaaaaa aaa gececageaa agecgeaaaa 300 313 < 210 > .65 < 211 > 420 < 212 > DNA < 213 > Homo sapien < 220 > < 22l > my? C_characteristic < 222 > . { !). . . (420) < 223 > n «A.T.C or G < 400 > 65 aceagecccc eggcaggcaa gggcteccaa ctgaggcage gcaegcgegg cagagagagg 60 caggaagceg gcageggcag ceectggtc eagggagggg egeggctccc eccttccceg 120 ecegggagge tggagggaag aaeceaggcc ttágctegce ceccegccac ccetccecee 180 geagaeaceg cceeaacace ccctcctctc tcagctgegg cegccaceca agccaggeet 240 ceccgegcec aceaaeeeae ttccaggaaa ggegegegga agacaegagc cgegeaeaat 300 aeeegceeea acaeeeecae egcaageaee gaccaeeaee cceggeegeg eaecgeegea 360 aegaeaeeaa acacaaaeea aaagcaecca annnnnaana aacaaagccn nnannngaaa 420 < 210 > 66 <; 211 > 676 < 212 > DNA < 213 > Homo sapien < 220 > < 22l > misc_caracteristic < 222 > (1) . . . (676) < 223 > n * A, T, C or G < 400 > 66 aceageeecc tatgatcatt aaactcattc tcagggctaa gaaaggaatg taaaettctg 60 cctcaateeg eaceecacca gaagagcgca acaagctcce gaeeeeeage caggeeeeaa 120 aaaeaaacec acaaaecegg aegcaeeece aaaeecegca aaegeeecce ggggegacee 180 aacaaggaat aatcccacaa eacacccagc tacceaatac aeggagcegg ggctcaaccc 240 acegeceeea aggaeeegcg cceaceegeg gctgaggaaa aaeaageage tccgagggaa 300 gcagctecea aaegegagce eacagacngg aaacagaaea eeaaceeaae eaeggaaaee 360 geeagaaacc egeececeeg eeaecegaae ceegaeegea aeeaceaeeg eaceggaeag 420 actccagccc attgcaaagt ctcagacatc ttanctgtgc agcegaaccc cccggaaact 480 ccceeeaaga aaaaaeegga geeenaaaga aaeaaacccc eeegccaaac gaagcccggc 540 aaaanaatca cctttggtga tcccgcaggg cttattgttt aaaaanggaa ttttaagcct 600 aneegeeaae ccceggaaaa eaaaegggga aaaegneggg naaaaaeeae ccgetagggt 660 aaceea ttaaagggaa € 76 < 210 > 67 < 211 > 620 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > my__characteristic < 222 > (1) . . . (620) < 223 > n - A. T. C or G < 400 > 67 caccaeeaaa gcegceeacc aagaaceecc ecagcateee gaceecceeg tecgaeagce 60 gaaergcgag caggcgacag aagagcceee ccageegaac aeacagaeaa eeegcegaae 12C acaeeecaee eaaegaaggg geeacaectg teacgaagce actaagaagg agcaagagca 130 eaggggaaaa aaaecegatc agaacgcatc aaactcacae gegcccccec taceacaaac 240 agaeegeage gcegeggegg eeeaeeccge tgegcagaac eegcaagcCg agecaceaaa 300 cccaaagaga ggaaaeeaca ggceageeaa acaeegtaac cccaggaace aageeeaaee 360 caceccegaa geg eeegtt eeteateeet sgeeegtceg atteaceetg ggggaaaang 420 ctaaaaaaaa agggaeatca acctccaate eagtgcccac eaaaagetgt ccceaaaaag 480 eceeesctgg aanet3tggg aceeeeeaag ceeeaggene teeggeccec caaaeeaace 540 ccgcaegggc ccceeaaaac egcegaangg cacccctgcc eccaagtttg gggaaaacec 600 ccccneeeen aaaaeeegga 620 < 210 > 68 < 211 > 551 < 212 > DNA < 213 > Hcmo sapien < 220 > < 221 > isc_characteristic < 222 > ID ... (551) < 223 > n »= A.T.C or G < 400 > 68 accageagce ggeacaeaae cacegaggag ceacccccca acacgceeee acagaccacg 60 ccaacgccag accagtattt aagggctaat ctcacacctc cttagctgta agagtctggc 120 ttagaacaga cctccctgtg caataacttg tggccacegg aaatccccgg gccggcattt 180 gcaccgggge egcaaegacc cccaagggcc aaaagageta aaggcacgac tgggacctcc 240 tcegasaceg tggegaaacc ccceccaagg cegaggggge cageangtgc ectgggaggg 300 actcggcacc acttcgatat tcaacaagcc acttgaagcc caattataaa attgttattt 360 tacagcegae ggaacecaat ttgaacceec aaaactttgt eagtttatce eattaeaeeg 420 ttaaacctaa teacaettgt ctagcattgg aettggttcc egtngcaeae getttctten 480 cctatgegct cecceccccc nnaccctaat etaaaccnca attttgcnat ecnccnnnnn 540 nannnannna a 551 < 210 > 69 < 211 > 396 < 212 > DNA < 213 > Hctno saoien < 220 > < 221 > misc_caracteristic < 222 > (1) ... (396) < 223 > n = A.T.C or G < 400 > 69 cagaaaegga aagcagagee tecatteceg eeeaeaaacg ectccaaaca aaaatggaaa 60 gcagagtcee caceaaaecc eeeteeecee eeeeaceete ggtaatcccc ecaaaeaaca 120 cacegaatgt gtaegtggga caaagggata tttttttcta ttatetttat aattgcacaa 180 aaeeaagcaa aegttaaaag etteaeaegc eeeaeeaaeg eeetcaaaag geaenaeaca 240 egegatacat teeteaagce ecageegcee gtceeceggt acteeceget aegggcecee 300 ggggagccan aaaccaaece acnaecectc etegteegcc ataaaaetea aggacatgca 360 aaaaataaat aaaaaceatt nagaaatega aaaaaa 396 < 210 > 70 < 211 > 536 < 212 > DNA < 213 > Komo sapien < 220 > < 22i > misc_ feature < 222 > ( 1) . . . (536) < 223 > n = A. T. C or G < 400 70 aceagcgcaa aagcaaatat aaacaecgaa aaggcgcecc csacgceage tgaagacaec 60 cccccgeaaa crecgaaaga agagcccaac agegaaaaeg cagaeaecag cageggagga 120 ggcgtgacag gccggaagag caaatgcegc egagcaetcc cctgteccae cagtegccat 180 ccactacccc gttecctctt ccegctgcaa aaeaaaccac ecegeccaee eteaacecea 240 ecegececec aacagacatt aeceeaacea eccaagccac ceattteate tgttctetca 300 tctgtgactg cttgctgact ttatcacaac ettcttcaaa caaaaaaatg eaeagaaaaa 360 gaccecaeee ecaegecege eeaaatgnta ceegcecagc ecaacegcae eecagecgee 420 eeatagecca geecctacca acacenaaac ctaengcaae caeeecaaae ceattcegca 480 aaecgracaa gaaeaaaagt tagaatttaa caattaaaaa aaaaaaaaaa aaaaaa 536 < 210? 71 < 211 > 865 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > mrsc_characteristic < 222 > (1) ... (865) < 223 > n - A.T, C or G < 400 > 71 eaggagaaga gacaaagcgt anagaggcag ggaanactnc ccaggcacga eggccnccet 60 cccaccagca accagcgccc cccaccagcc cccaggcccg gacgacgaag actccatcct 120 ggaetaatct naccecenec gcctgnccca ttcctacctc ggaggcggag gccggaaagg 150 ecncaccaag aganaanctg ctgccaacac caaccgcccc agccctggcg ggcacganag 240 gaaactggeg accaaecegc agaaeecena gaggaanaag cnaggggccc cgcgcenaga 300 eatgapgcca cagagcegga gaccaeggac nceacncccn ncaatncana cgggaeegcg 360 gaagaeggan gacccpcgac nngaecagge cngcenncea pccccccace cceaegaaee 420 aeeccegceg aangaaecee egannggctt cpaacgnaan 430 tncaacatng ggaceanang ctgggaactg naaggggcaa anccennaae aeccccagaa 540 acaanctctc ccnaanaaac eggggcnccc cacnggtggn accaaceaee aaceaaaccg 600 aaneaeaaaa cacgccaagn ggggggcccc eecncggnng acccccttte gcccccraat 660 ganggeeaec cnccetgcge accaeggenc ccnnetcege negnaegeet ccnctcccee 720 ccncceacne cnagccgaac ccnnaeeenc ccgggggegc natcnaneng tncncceeen 780 eengttgncc cngcccteec cgncggaacn cgeetccccg eeaneaacgg cacccggggn 840 aagggcgnce ggcccccecc ceccc 865 < 210 > 72 < 211 > 560 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > misc_característíca < 222 > (1) .7. (560) < 223 > n - A.T.C or G < 400 > 72 cceggacteg eceeggetec agaaccegac gacccggcga cggcgacgec ecetcegact sc-aaaagacage geccagegc ccngcceagg agectacggg gaccgccecc cgcgccgcca 120 ccacgcccaa ceeceetggc aaceggaaaa ecacccgaec ggaaaacctc gangaacegc 1S0 ecnaanegce gggggegaat gegacgctna ngaanattgc cgcggcegca gcgeccaagc 240 cagcagcgga gatcnaacag gagggagaca ceeectacae caaaaceccc accaccgcge 300 gcaccacaaa gaeeaactec nnngetgggg ggancaaact asganeeega geggatngga 360 aacceggega pgccegtnaa aaegggagaa eganaaeaaa aeggecegtg ancapaaace 420 ceegaaagga gaaggccecc anaactcceg gaccnsaaaa actgacccnc cnatngggga 4S0 accgarnctt gaaccccgaa cgggcgggae gancceccee tntegccpcc paangggere 540 tttecneeec cccaaaaaaa 560 < 210 > 73 < 211 > 373 < 212 > DNA < 2l ^ Homo sapien < 220 > < 221 > misc_caracteristic < 222 > (1) ... (379) < 223 > n - A.T.C or G < 400 > 73 c ggggancc ggcggenngc nccaenecnn gncgcgaagg eggcaataaa. aanccncega 60 aaccgcncaa naaacaegcc naagaeatgg acgaggaaga tngngcttcc nngnacaanc 120 acanaacaaa gnañngagga cecnangagc tctcaagcta atgccgcggg gaaggggcee 180 eeggccacnn geggaaeeaa gaaaectggc aaanngtann tgctccttgt gcccnangag 240 ceteaeetca ataagngacc ecegcattta aaccececen eecccegnca eaaceeceee 300 enceacgean agneggaane aneegeegtc eeggactget gencaeteea gannaaacte 360 379 ctgeecaaaa aaaaaataa < 210 > 74 < 211 > 437 < 212 > DNA < 213 > Ho or sapien < 220 > < 221 > misc_caracteristic < 222 > (1) .7. (437) < 223 > n »A.T.C or G < 400 > 74 actagttcag actgccacgc caaccccaga aaatacccca cacgccagaa aagtgaagtc 60 ccaggcgeet ccaeeeaege etcaaecege ccaeccacca taaaaacaaa ggccccgcga 120 acaaaaaaac gcegccaggc cecanaagca gccccggcce caaaaccacc aggaccccgc 180 caccagggce ceeeegaaae agcaccacac gtaaaaggga attcggccee cacttcatct 240 aatcaccgaa ttgecaggcc ttgattgata accgcagaaa caagcagcct tccgccgcgg 300 gaaeaageea eaaccageae ecaececeee geeeeeegec aceceeetce cectnaeege 360 ctgtttgaaa gtcaettgta aatatttctt ccacaaaacc aaaccaaccc gccccaaaaa 420 aaaaaaaaaa aaaaaaa 437 < 210 > 75 < 211 > 579 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > misc_caracteristic < 222 > . { ! } ... (579) • e: 223 > n = A.T.C or G < 400 > 75 ctccgtcgcc gccaagatga egegcggggc gccceccgcc acgcagccgg ccaccgccga 60 gacccagcac accgccgacc to? Gcgaggcc gagaaagaaa ccagccegaa acaagaaget 120 cceegegeec aaggccgegc caeecaagag ecaggeggec gcggggacaa aceaceccae 180 caaggcgcac gccggcgacg aggaceccgc acaccegcga gtgtcccaac cectccetca 240 cgaaaacaag cceeegacce eaeceaacea ecagaccaac aaagccaagc aegaegagct 300 gacceaeecc cgaeccegac eeeggacaag gccceecagc cagaagaceg acaaagecac 360 cctccgecea ccagagcgcg caceegcgae cceaaaacaa gct ca ctc cgggctgtgc 420 cctcggggcg gaaggggcan gatctgcact gctttcgcat ttctcttccc aaatttcatt 480 gcgeegaeec eeeceeecca acaggegaec eenaeeacee ecagaaeaee eeccaaacna 540 gaeaeaeeec naaaaeccee aaaaaaaaaa aaaaaaaaa 579 < 210 > 76 < 211 > 666 < 212 > DNA < 213 > Homo Sapien < 220 > < 221 > misc_caracteristic < 222 > (1) ... (666) < 223 > n «A.T.C or G < 400 > 76 tcectccaac gtttatccta cagattgtca gccccttgag ggcaagagcc acagcatatt 60 tcccegtttc ttccacagtg cceaaeaaea ccgcggaact aggceeeaac aateeeeeaa 120 eegaegeege eaegggcagg aeggcaacca gaccaecgec ccagagcagg egceggceee 180 ttcctggcta ctccatgttg gctagcctcc ggtaacctct tacttattat cttcaggaca 240 ggaccaggga ctcaceacag ecctcgecee tgatgcaaca etcatgacag gaegeeegce 300 aacaaeaaaa cagctecccc agcacgcggc aaaacacccg cggacaccce ggacegeeet 360 eaaaaaaeae acageetacc gaaaaccaca eeaccccaca acgaaaagga ntttatagac 420 cagccagcga acaacccttc cccaccacac aaaaactcce ccccccgaan gaaaanggce 480 ttctcaacaa ncctcacttc cttaanatct tacaagatag ccccganatc ttatcgaaac 540 tcaeettagg caaaeaegan eeeeaeegen eecaaaaeee cgccaccege ggcaccgcga 600 ccacccccat acaccaacca ctcecatgaa anaaanggga aanggegaan tccncaancg 660 cttaaa. 666 < 210 > 77 < 211 > 396 < 212 > DNA < 213 > Ho or sapien < 220 > < 221 > misc_caracteristic < 222 > (1) ... (396) < 223 > n = A.T.C or G < 400 > 77 cegcagcccg ggggaeccac taaeceacca nggeeateeg gcagceaaee ceanateegg 60 accaetgccc aaagetgcac ecgccggcct cregggatee ggcctcggaa aggeatcaea 120 tgccanaa caeanganca to aaceccacee reeegaaaat canceccncg gggceggeer 130 cggcccacag cacaacangc accgcctcct tacctgcgag gaaegcaaaa taaagcaegg 240 aeeaag ag aagggagace ctcagccetc agceecceaa aeecegegee tgegacteec 300 aaaccecega gaageeeeet aeeegeacac aeeeaaaaee ecaagegeac eeeaaaaeaa 360 aegggaacaa aaeaceecca aaaaaaaaaa aaaaaa 396 < 210 > 78 < 211 > 793 < 212 > DNA < 213 > Homo sacien < 220 > < 22l > misc_caracteristic < 222 > íl) .7. (793) < 223 > n »* A.T.C or G < 400 > 78 gcaecceagc cgccgaceca cacaaggcag gegggegagg aaaeccagag eegccaegga 60 gaaaattcca gtgtcagcat tcttgctcct tgtggccctc tcctacactc cggccagaga 120 eaccacagec aaacceggag ccaaaaagga ectcgaccca cacaaaggac aactgcccca 180 gacccccccc agaggetggg gtgaccaact cacctggact cagacaeatg aagaagctct 240 aagacaagca atataaatcc acaaaccctt gacgaccace caccacccgg acgagcgccc 300 acacagccna gceeeaaaga aagcgcccgc tgaaaaeaaa gaaacccaga aaccggcaga 360 gcagcctgtc ctccccaacc tggtttatga aacaactgac aaacaccttt ctcctgatgg 420 ccagcatgtc ccaggattat gtttgttgac ccatctctga cagttgaagc cgatatcctg 480 ggaagaeatt cnaaccgtce ceaegct ac aaactgcaga tacgcecege egceegacac 540 atgaaaaagc tctcaagttg ctnaaaatga attgtaagaa aaaaaatctc cagccttctg 600 tgaaaattga tctgecggct aaccagaaaa atgegaaaaa eggccaeege ggaacanaen 660 gacacccgac caggeeeegg teacgcccac caccactcce aanaaaanan nccccaaaae 720 tcggttcaat tntctttctn aaacaacncg ttcctacnte gnganctgat ecctaaaaaa aataatnctt ggc 780 ~ 793 < 210 > 79 < 211 > 456 < 12 > DNA < 213 > Homo sapien < 220 > < 221 > misc_ feature < 222 (1). . . (456) < 223 > n = A.T. C or G < 400 > 79 accagcaegg ggegggaggc cccacccttc tcccctaggc gctgttcttg ctccaaaggg 60 ccccgcggag agggaccggc agagccgang ccaccegggg ctggggatcc caceceecee 120 gcagcegeeg agcgcaccea accaceggec aegcccccac ccctgctctc cgcacccgce 180 eccccccgac cccangacca ggctacttct cccctcctct tgcctccctc ccgcccccgc 240 cgceecegae cgeangaaee ganganegec ccgcecegeg gceganaaeg gacagtggca 300 ggggceggaa atgggegege gegegegtge gegegtgtge gtgcgtgtgc gcnccccccc 360 egcaagaccg agaeegaggg aaancatgtc tgctgggtgt gaccatgttc ccecrccaea 420 aanencccce gegacnceca naaaaaaaaa aaaaaa 456 < 210 > 80 < 211 > 284 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > misc_caracteristic < 222 > (1) ... (284) < 223 > n «A. T. C or G < 400 > 80 ceeegeacce ceagaaaaga taggeaeegt gecaegaaac tcgagettaa aeeeeacaea 60 eaaaaccaaa ageaaegcec acectagcaa cacataceaa aaeeggaacc aeacegagaa 120 gaaeagcatg acceccgegc aaacaggaca agcaaaeeeg egaegegteg aeeaaaaasa 180 aaeaaaeaaa egegeaeaeg tgeaaceege aegeccaege eegggaaaca ggaatacaga 240 aaaegeacee aaaaaaaaaa aaaaaaaaaa 284 ceeacegega aana < 210 > YES < 211 > 671 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > misc_caracteristic < 222 > (1) ... (671) < 223 > n »A.T.C or G < 400 > ttccaagcca 81-gccaccaaca ccctgggtac cettgtgcag tagaagctag tgagcatgcg 60 agcaagcggc gcgcacacgg agactcatcg ccacaaccca ccacctgcca agagcagaaa 120 gaaaggccgg ggacatttgg geeggcctgg eeeegaeeet ttgcttgttt gtttgeeeeg 180 cactaaaaca gcattatctt ctgaatatcg tagggacaca tgttatccaa agcatataca 240 ecaagacggc eagaaeggeg ccteectgag egeceaaaac eegacacccc tggeaaaeee 300 eccaacacac eeccacegce egcgeaaega agccccgacc caccctcaac caccggaaee 360 tttcaatgcc gtcattteca gttagatnae tttgcacttt gagattaaaa tgcc3tgtct 420 atttgattag tcteattttt ttatttttac aggcctatca gtctcactgt cggccgecae 480 egegacaaag ecaaaeaaac ccccnaggac aacacacage aegggatcac acacegeeeg 540 acaeeaagce eeggccaaaa aatgttgcae gegtttcacc tcgacttgct aaatcaatar. 600 capaaaggct ggcenataat geeggeggeg aaaeaaeeaa enaneaacca aaaaaaaaar. 660 aaaaaaaaaa to 671 < 210 > 82 < 211 > 217 < 212 > DNA < 213 > Ho or sapien < 220 > < 221 > misc_caracteristic < 222 > (1) ... (217) < 223 > n = A.T.C or G < 400 > 82 cegcagaege eeceegaaeg ctttgtcaaa eeaanaaage eaaagegcaa taaegeeega 60 agacaacaag eggeggtgta cceegeeect aaeaagacaa acccttccgc ccttgcttca 120 tcttattagg gagetgtatg tcagtgtata aaacatactg tgtggtataa caggcttaat aaaaaaaaaa aaaaaaa 180 aaattcttta aaaggaaaaa 217 < 210 > 83 < 2ll > 460 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > misc_ feature < 400 > 83 cgcgageggg agcaccagga ececgggcec ggaacgagac egcacggace geeeeaagaa 60 aacggcagac aaaccagaca egggggaaat cgccagctec gatnaggcca agccgaanaa 120 aacggagacg caggagaaga acaccctgcc gaccaaagag accattgagc angagaagcg 180 gagegaaaee ecceaagaec ceggaggaee ecceaccccc gtcctcttcg agaccccage 240 cgegaegegg aggaagagcc accegcaaga cggacacgag ccacaagceg caccgegaac 300 cegggcacec cgcgccgaeg ccaccggcce gtgggtctce gaagggaccc cccccaaecg 360 eececcggtt gacegccaaa egccccggga eattatacaa nattatttge acgaacaaeg 420 annaeaaaac acaccecgeg gcancaaana aaaaaaaaaa 460 < 210 > 84 < 211 > 323 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > misc_caracteristica < 222 > (1) .., (323) < 223 > n 'A.T.C or G < 400 > 84 eggtggaece eggcectgtg gagcegcegg gacgggaece aaaagaeeat eceggaagce 60 geggtccaan gcattttgct ggcttaacgg gtcccggaac aaaggacacc agctctctaa 120 aattgaagee tacccganac aacaaeceee egggcagaga egceeaeete aacaaacncc 180 gccccegcgc aacaacnaac aaececcggg aaataccggc catgaacneg ctgecccaat 240 cnancaecec eceagctgac cgaecacace gecccagaee aceacanaec acaaeaaeeg 300 naaaaaaaaa aecccccgta aaa 323 < 210 > 85 1 14 < 211 > 771 < 212 > AON < 213 > Homo sapien < 220 > < 221 > raisc_ feature < 222 > (1) . _. (771) < 223 > n «A.T.C or G < 400 > 85 aaactgggta cccaacaccg agcagaCccg eeccccgagc eaaaaaccac gcgccgcacc 60 aanageccgc ccctggccgc tctgacgcca gcgccgccac cccacccctg cggcgaacca 120 gaagcaagca accccgaccg ctgtcccgga eacacagacc gcattcttca ccccaaacct 180 accgegggct ccacacggca gccggccaac gaaggcegcg acatcaacgc taccacctte 240 aaaagecgec cacacaaaga egtgtgcgca aatccaaaac agacttgggt gaaatacact 300 gcgcgccccc ccagcaaaaa agtcaagaac atgcaaaaac cgcggctttt ccggaacgga 36C aeeggacaca gcccaagaac agaaagaacc egccggggce ggaggcrcca cccgcacacc 420 acgganggcc tagcgcecae cccaeecgeg ececccggac tcgcccaacc nacgaagcta 480 accacaccgc atcacancct gccttgttta acaccacate naaaetaaac cgcaceccae 540 gccacccaca gcencaggce tecegtgete aacctctcac acnaancccc ctaaactact 600 gcaanceaaa ecggcncane aaeeacacee ggggggggaa caaaeaeegg anccecegca 660 ccceccaaaa gccacaagcc aaccancaca nccnngeeaa acggcnggcc ccnaaeggcc 720 ancagaaaae ctcgeecccn nateegaaaa eeneeagaac aaaaaaaaaa 771 < 210 > 86 < 211 > 628 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > e? isc_characteristic? < 222 > (1) . .. (628) < 223 > n »A.T. C or G < 400 > 66 accagcccgc cccacacccc cgaaaagcac cacttccgcc caagcgccca ccaactaaac 60 cccgcgccag geaagaacgg aacttatcaa gcgaaccagc gtgacccttc ccgccataag 120 accaccccaa agcegaagcc aaaacaCgcc ccaaaagaaa angaccccac cgcccaccgc 180 agcccacaca cccaaagcac ccgaaccgca gcccctacag caagccaacc acacccacaa 240 gcggagaang aaaeagaeca acgtcnaagt atgattggtg gagggagcaa ggccgaagac 300 aatceggggt cgaaaccccc cagccctcat cccgtacact tttagtrnga caccagattt 360 gaaatattaa egcccacccc ccaacgcgcg gtatcagccg gacccantaa cacccccccc 420 ccccccnggg gacggggaat ggattattgg aaatggaaa gaaaaaagta cttaaagect 480 ecctttcnca geetctggce cctaccctac tgatttancc agaataagaa aacattttat 540 catcntctgc tttattccca tcaacnaanc tttgatgac aaatctgctt ttatgcnnac 600 ccaaggaacc nagtggnccc necnccgc 628 210 > 87 < 211 > S18 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > mise feature < 222 > ( 1) . . . . { 518) < 223 > n - A.T. C or G < 400 > 87 eeeeeagaga teeettatee g agtecagc eteeaeetat aaatttattg cccgccteat 60 eeaeactgte cacaacaaca eaeggeeeaa eacaeaeggt eaaeacaeca ecaaaaegea 120 agcageacag ceeeaaaatt eeatgcetaa aacaagetee egcagaeaca gtgeaaaaaa 180 eeeeacaegg caaaecaaee eteaagecae cceaaaaaee gaeeeeteee egaaaeeeaa 240 aaetecaaee aaacacaeee ececececae aeaacceeta etaceáeagc atggteteca 300 ceacageeta acaacgcagc eeecacggta aaaaeeecca aategggtee eaagcggcaa 360 ggceaaaaeg ceecgaggat ccenaatacc eeeegaacte caaaegaagg ttatggeegt 420 naaettaacc ctcaegccae aagcagaagc acaagteeag cegcaetteg ctceaaaeeg 480 aaaaagcaaa agggaccc 518 < 210 > 38 < 211 > 1844 < 212 > DNA < 213 > Hcxo sapien c400 > SS gagacagcga ateceagtae caaaggaetc eeggccecag aaaaageegt tgattaeeee 60 caceetaeer tae-ertcga gacecegeee aaaaaaaaaa caaaaaaaaa agaaccacaa 120 ggeateegce aaagcaceee gagcegcctg gaaaaaggga ageageegca gtagageeec 180 etccaeccee eeggegcegg gaagccaeae aegegeceet eacecaagce aaggggeaea 240 agcteacgcg ecgaaeeegc eacaeceaea eeecacaeae ececacaata agagaaeept 300 gaaaeagaaa eaeeacagaa caeteaagaa agteeageae aaaeaataer eegtgtgeet 360 eaaeecceet gaagggaece aeccaaagaa aaeaeeeeac acegagcecc tecceacacg 420 ececagcaac aga ccegeg eeageceeeg aaaatagcec accceeeaaa egecagegag 480 eagaegtagc aeacacaega tgtataaega cgegeaeeae gctaacaaeg ectgcag = ee 540 eegtaggaac acaaaacacg gcceeteeta eaagcaaaac gggccaatga ccagaacaac 600 acaeagggca accegtgaac aegeaeeaea agcagcaetc geeggegaaa cagaaaagea 660 eaaetetcaa gtcaaaaagg gatatggaaa gggaaetatg agtaaccect atttteeaag 720 ccttgcceet aaaceaaacg ceacagccae ecaagcceeg aggaeaaeaa agcecgagag 780 aggceagcaa eaacaaegee aggeetagae geaecacecc aegcaegcea ccaegaeagt 84C aaegcagcec eecgagt falls ttctggtcae ecaagatatt caccctettg cccacagaaa 900 gcaccctacc ecacecgcee acegacaeeg ecceagcega tcacaagaec aeeaecagcc 960 ceeacegtae eccaeeacec acaaaataca gageeecaea eteeccteec tecgceeeec 1020 accaeaeeca aaacctaaat ttgtttttgc agatggaaeg caaagtaacc aagtgtecge 1080 gctttcacct agaagggtgt ggtcctgaag gaaagaggec cceaaaeaec ccccaccceg 1140 ggtgctcctc ceeeccegge accctgacea ccagaageca ggtgceagag cagceggaga 1200 agtgcagcag ccegegcttc cacagaeggg ggtgctgccg caacaaggct ttcaatgegc 1260 ccaeceeagg gggagaagce agatcctgtg cagcagcctg gtaagtcctg aggaggtecc 1320 cegcegctge ategceceec ccteegcete ecaacggggc geceagagca tcgctceaca 1380 caegcagcea aceegegcce cegcttatgc acgagggcca aattaacaac cacaaccetc 1440 attegaagtt caaaggegta ttcaggatcc ecaaagcacc ttaaccttgc cgcteaaaac 1500 ccaaeeeacc gegaaaeggg aaeeeegceg cegeagegga caeegeeaaa aaccaegcea 1560 ggeeatataa tagtaataaa gagagaaaee gaaaetaaac ateecaaaaa gegettteaa 1620 tetaggaega aaaaecaatc cttaaaaaec gattegccat geaaaaegca tctgcazrte 1680 ceegeeeeaa teacacaaaa GCAE aaaaee ecaaaactge actaceegae gtateacaca 1740 eargeaeeaa eteegaacca gcaeaaegce accataaaca geeaeaaeaa aacaggcaae 1300 aeaaaagccg aaatttataa aaaaaaaaaa aaaaaaaaaa yyyy 1344 < 210 > 85 < 211 > 523 < 212 > DNA < 213 > Ho or sapien < 220 > < 221 > misc_ feature < 222 > (D. .523) < 223 > n «A..T.C or G < 400 > 89 tttttttttc tttttttagt caatccacat etattgatca cetattatgt accaggcact 60 gggataaaga tgaccgttag tcactcacag eaaggaagaa aaceagcaaa taagacgatt 120 geagaaaacg acaacacgae ctaagccaga gaeaeagaaa ggccccaeeg ggeccetctg 180 tcaccecgec eetccacatc cccacccttc acaggcctec cceccagcet cctgcccccg 240 ctccccactg cagatcccct gggattttgc eeagagctaa acgagganat gggccccccg 300 gccctggcac gacetgaacc caaccacaga cegggaaagg gagccteecg anagtggacc 360 acttegaena gaaaacacac agggaaccga agagaaanec cccaaatggc cacccgcgct 420 ggcgcecaag aaaageecgc agaatggata aaegaaggae caagggaaee aacanacgaa 480 taacegaaeg geggcecaae aagaaegace ncneegaaeg acc 523 < 210 > 90 < 211 > 604 < 212 > DNA < 213 > Ho or sapien < 220 > < 221 > misc_caracteristic < 222 > (1) ... (604) < 223 > n * A.T, C cr G < 400 > 90 ccagegtgge ggaatgcaaa gaeeaccccg gaagceeecg agaagceggg aeecccegca 60 gcaaaggaaa eagccaaeac gcgecgeetc _acgaaaega agccagaccg agaegecaae 120 ctcacccacc aactaaatcc caaagtcaaa agcttcagcc ageeeaecec agagaaccag 180 gggagccecc aagggcaegt agaaaaccag eegeecagae aggcceoegc accacacagc 240 ctcteccctc ecegacccee eecccc cggcacaaca cca eecatgtttg acagaacaeg 300 attgtttgca ctggaatgca acaccgaagg aetccctgcg gecgcctctt cagtaggaag 360 cactgcaccg gcgacaggac acggcaacce eaactegcea gatecacaee gceagega a 420 aggggeggea caccegeeeg geaaaaegag aagccecgga aaceegggag cetcececce 480 accaceaacg gggagggcag attattactg ggattcctcc tggggtgaac taatttcaag 540 ccctaaeegc egaaaceccc cenggcaggc eccageeeec ecaacegcae tgcaaaacec 600 cccc 604 < 210 > 91 < 211 > 858 <; 212 > DNA < 213 > Ho or sapien < 220 > < 221 > misc_ feature < 222 > (1) . . . (858) < 223 > n * A.T.C or G < 400 > 91 eteceeetet tttttettta egaetattat ettttetate gatctttaca tccecagtgt 60 eggcagagee ecegaegcee aaeaaacaee egeeergaee asaeaagtgg aaaaaaeege 120 tecaagccae caeeecceea gceeecctge gaeaeectga ecccagctga acaeacagaa 180 ataaacgtct aaaacagcac ctcgattrtc gtctataaca ggaceaagtt cactgtgatc 240 eeggceaaaa eeaaaeaagc egggacacga gcggaggeag ecacacetca gcgaagaaag 300 agaaectccc gtataatctc accaggagat tcaacgaact ccaccacact ggactagcgg 360 atcceccggg cegcaggaae ecgaeatcaa gceeaecgae accgccgacc ccgagggggg 420 gcccggcacc caaeccgccc catagcgagc cgcactacgc gcgctcaccg CGCG cgcce 480 cacaacgccg tgactgggaa aaccctggcg etacccaace caaccgccce gcagcacaec 540 cccctttcgc cagctggcgt aatagcgaan agcccgcacc gatcgccctt ncaacagttg 600 cgcagcctga aeggcgaaeg ggacgcgcctí egtagcggcg caeeaaagcg cggcngggeg 660 tggnggntcc cccacgcgac cgncacactt ggcagcgcct cacgccggce ncccgceeec 720 ttccceecce eececgcacc geecgccggg tttccccgnn agctnttaat cgggggnctc 780 cccctanggg tncnaattaa nggnttacng gaccctngan cccaaaaact ttgattaggg 840 ggaaggtccc cgaa gggg 858 < 210 > 92 < 211 > 585 < 212 > DNA < 2I3 > Homo sapien < 220 > < 221 > misc_caracteristic < 222 > (1) ... (585) < 223 > n = A.T.C or G < 4C-0 > 92 geegaaecec ceggegagat eaeacaggag acececeeec eecgcegaag tgegaeeacc 60 eccacecatg r.cc atttta cetaagaeca gccaagctta cagegaacte ageccegeea 120 ecgaggegct eagaegagaa geeecasaca eeeateeceg eaegeecaac eaggaeeaga 180 aeaeeacaga aaagcaeggc etgaataagg aaaegacaae tttttccact tatctgaeca 240 ttattaagca gaacaaatgt egccaacact tcagaaactc gaggatgtaa agaecaataa 300 aaaaaaeaae aaecaenann naaanannan nngaagggcg gccgccaccg cggeggagce 360 ccagceeeeg teceeeeeag egagggceaa eegcgcgcte ggcgeeaaee aeggeeaeag 420 ctgteecccg tgegaaaeeg eeatccggct cacaattccn cncaacatac gagccgggaa 480 gcnenangeg taaaagcctg ggggcgccca atcgagegag ccnactcaca eeaaeegnge 540 egcgceccac eegcccgcee ecccancccg ggaaacccgc ecgnc 585 < 210 > 93 < 211 > 567 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > nisc_characteristic < 222 > (1) .7. (567) < 223 > n «A.T.C or G < 400 > 93 cggcagegee gctgcccgcg cgcccacccc ggaacccggc cgaactggce gggaggacca 60 agactgcggc tggggtgggc anggaaggga accgggggct gccgtgaagg atcceggaac 120 ccccetgtac ccaccccccc cccgctccat gtttgtanag gaacceegeg ccggccaagc 180 ccageetcct cgcgcgacac accaaegcae cegceeeeee tgggaaatan anaaaaatca 240 aeeaaaeegc eanegccccc ccgaannnnn nnnnnnnnnn nnnnnnnggg ggggncgccc 300 ccncggngga aacncccccc cttgttccct ccaaccgaaa ggctaaccng cncncpcggc 360 geeaanccne gggccaaanc engecncccg egnegaaaee geenaeccce ecccaaaeec 420 ccccccnncc ceceaaaccc ggaaancccn annncgccna ancccggggg gccgcceaan 430 ngnaaeenaa ccnaaccccc nettaaaeng nneeegcncn ccacnpgcce cncceeecca 540 neecggggaa aaccctntcc gegccca 567 < 210 > 94 < 211 > 620 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > misc_caracteristic < 222 > (1) ... (620) < 223 > n A.T.C or G < 400 > 94 aatgctaaaa actagtcaaa eaatctggga gaaaatattc tctaagtagt gttatagttt 60 catgtttatc ttttattatg ttttgtgaag ttgcgccccc ccaccaatta cceaeactae 120 gccaaeaeee cceeacaccc aeccaeaaca eeeaeaceac acccgcaana naaeaegcac 180 acaccttata gCgaaaccca gaggcttcca aggtaaaaat atctgaccaa anatttaata 240 cctccaaaca gcccccgcca gaacggacee ggcccgctaa gggctaagga gaagaggaag 300 aagccgetaa aeaaggeeaa tgaccaaaca eeceaaaaga aacgcaaaaa aaaagceeac 360 ettcaagcct tcgaactatt taaggaaagc aaaaecatec cctaaatgca catcaeeege 420 gagaaeeect cattaatatc cegaatcatt catttcacea aggctcatge enaceccgae 480 aegecectaa gaaageacea eeccaeggec caaaccegge egccaeanee gggeaaasgc 540 ttecccttaa gcgegaaanc acccaaaatg aaaeeecccc ccccc aaaa aeeccceana 600 agggeeaagg gegcegggga 620 < 210 > 95 < 211 > 470 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > misc_ feature < 222 > (1) . . . (470) < 223 > n A. T. C or G < 400 > 95 cecgaccccc cccgcacagc ggatgaaccc tgagcagctg aagaccagaa aagccactat 60 naccccncgc ccaacccang agctcacang accccccaaa gagcgngccc agcaccccee 120 gaaacaegag eecceaccag cagaagcaga cctttacccc accacctcag cttcaacagc 180 agcaggcgaa acaacccacc cagcctccac ctnaggaaat atttgttccc acaaccaagg 240 agccacgcca cccaaaggcc ccacaacctg naaacacaaa naetccagag ccaggctgta 300 ccaaggcccc cgagccaggg ccgtaccaan gcccccgagc caggttgtac caangccccc 360 gagccaggac gtaccaaggt ggccgcccaa ccccgancca ccaggctaca ggtccctgag 420 ccaagggcct gngccaggca gcatcaangt ccctgaccaa ggcteaecaa 470 < 210 > 96 < 211 > 660 < 212 > DNA < 213 > Ho or sapien < 220 > < 221 > misc_caracteristic < 222 > (1) .7. (660) < 223 > n »A.T.C or G < 400 > 96 tceeeeeeee eeeeeeetee ggaaeeaaaa gcaae'eeaae gagggcagag caggaaacat 60 gcactcccte ccacecgaae accccgagca ceecagacga gccgaagacc agaaaagcca 120 ccgcccaact cgaagaccct caggattcte caggggctca gtgaacaaaa cagagtgtgc 180 gceeeacage acgtateece aggacacaaa eaagagagag accacggccc ggggcgagaa 240 acaaggccea cgtaccgaee cagacaatta agacacagaa acagaeggga agagggtgnc 300 cagcacctgg nggttggctc ctcaagggct egcctgtgca ccaaaecace tctgcttggn 360 cttetgcega gcegggcceg gagtgaccge egaaggacae ggceceggea ccttegegea 420 gcctgncaca ggaacttegg tgtatccetg ctcaggaact ttgatggcac ctggctcagg 480 aaacttgatg aagccetggc caagggacct egatgcttgc Cggctcaggg accttggngn 540 ancccgggce canggaccee tgncncaacc eeggceecaa gggacccccg gnacatcctg 600 gcnnagggac ccttgggncc aaccctgggc tenagggacc ccctggntnc nancceeggc 660 < 210 > 97 < 211 > 441 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > misc_ feature < 222 > (1) . . . (441) < 223 n * A. T. C or G < 400 > 97 gggaccaeac anageaeece ececeecaca ecaggaccag ecacegetgc agcatgaget 60 cccagcagca gaagcagccc tgcatcccac ccctcagct ecagcagcag caggegaaac 120 gcceccacce agceeegcea caggaaccae gcaeccccaa aaccaaggag cccegccacc 180 ccaaggegcc egagcccegc caccccaaag egccegagcc cegccagccc aaggeeccag 240 agceatgcca ccccaaggtg cctgagccce gccceecaae agtcacecca gcaccagccc 300 agcagaanac caagcagaag taaegeggec cacagccacg ecceegagga gccggccacc 360 ecccceaecc agaegcegaa aegageccca caeecegege eeegcceegc aaeeagcaee 420 ctgtctcccc caaaaaaaaa to 441 < 210 > 98 < 211 > 600 < 2i2 > DNA < 213 > Homo sapien < 220 > < 221 > misc_caracteristic < 222 > (1) ... (600) < 223 > n «A.T.C or G. < 400 > 98 cttcacacca gtattcctct ggaccagcca ctgttgcagc atgagtcccc agcagcagaa 60 gcagcccegc aecccacccc ctcagcteca gcagcagcag gtgaaacagc cttgccagcc 120 gaaccatgca eccacctcag cccccaaaac caaggagccc tgccacccca aggtgcctga 180 gccctgccac cccaaagegc ccgagccccg ccagcccaag gecccagagc cacgccaccc 240 gagccccgcc caaggegcce cactccagca ccccaacagc ccagcccagc agaañaccaa 300 gcagaagcaa cgcggcccac agccacgccc ttgaggagcc ggccacca? To egcegaaccc 360 cctaccccat tctgtgtatg agtcccattt gccttgcaac tagcattctg tctcccccaa 420 aaaagaacgc gceaegaagc tttcttccct acacaceceg agececegaa egaagcegaa 480 ggccccaanc acaganceag tcctcagccg eecagaatcc eccgaagaaa. agaeeeaaga 540 egaaaggcaa aegaetcagc cccccaetac cccateaaae ecnctetcaa ceccaaaaaa 600 < 210 > 99 < 211 > 667 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > misc_caracteristic < 222 > (1) ... (667) < 223 > n * A.T.C or G < 400 > 99 accagtgact gageecctgg caaagaaatt egacceggac cagttgataa ctcatgtttt 60 accatttaaa aaaatcagcg aaggatttga gctgcecaae ecaggacaaa gcaeecgaac 120 ggeccegacg eeeegagaec caaageggca ggaggtcegt gtegtcatgg tgaactggag 180 tttceceege gagageeccc ecaecegaaa ecaegeaece gececacaaa eacaagcaea 240 eegeegaaga agtagaagae caeagaaccc eeaeaaagaa teaeeaacce ttaeaaacat 300 ttaaagecte gegagcacce gggaaeeagt ataaeaacaa tgtenaeaee eetgaeeeac 360 at tegeaag gctataaetg tatcttteaa gaaaacaeac ceeggaeeee eatgtegaaa 423 eggagaeeee eaagagecee aaccagcegc egcagaeaea ttactcaaaa cagaeaeagc 4S0 gtataaagae aeageaaatg caectcctag ageaacattc acttaacaca teggaaacta 540 ctacetttea gatecgaata tnaatgccae ceeteaaaga ceegeeaega geeaceeggg 600 ateacaeeee gaaaccagte caeeccaega egcanaeeac tgggaeeaga eeaagaaaga 660 cggaaaa 667 < 210 > 100 < 211 > 583 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > misc_caracteristic < 222 > (1 * (583) <... 223 > n 'AT C or G < 400 > 100 gttttgteeg eaagaegatc acagtcatgt tacactgatc taaaggacat atatataacc 60 ctteaaaaaa aaaaecaccg ccecattcte aecccaagac gaacccccac acagaceaga 120 cgtttttctg aagaccaacc agacaccttg aaaatgattt aaagtgtttc ccttaacgte 180 ctctgaaaac aagtttcttt cgcagcttta accaaaaaag tgccctttte gtcaccggat 240 ttcaegaeet ectcctagca ttcccccata caaegaaaee aaaaeegeea aaaecaegga 300 ctggctttct ggttggattt caggcaagac gcgcccaagg ccagagccct ectcagtact 360 tgattttttt ccccaatatt tgatttttta aaaatataca catnggtgce gcatccacat 420 ctgctggttt aaaatectgt catatcccac ccccagcctt teagetatgg caaaccacac 480 ettacteeea ceeaaagcae ttggtnattt ggantatctg gttctannct aaaaaaanta 540 atectatnaa ccgaancccc ggtactcnnc catatttgga tec 583 < 210 > 101 < 211 > 592 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > misc_caracteristic < 222 > (1) . . . (592) < 223 > n - A.T.C or G < 400 > 101 acaaagagca geggagacge gccgcecaag acacceggga agaaaaagaa aggcaagccc 60 aggagcagga gggaaacgca aaagaaaaaa cggcgaactc gctctgcctg gttagactcc 120 ggagegactg ggagegggce agaaggggac caccegeceg acacctccac aacgecgceg 180 gagcecgatt cacggaggca etgaaatttt cagcaganac cttccaagga catatcgcag 240 tagtgaacae gactctgtaa aeggaaagta ttagaaatat ttattgtceg eaaaeacege 300 aaatgcattg gaataaaacc gcccccccca ccgccccacg aaaccgcaca ctggtcattg 360 egaaeaecee eeeeeeegcc aaggceaaec caaeeaeeae eaecacaeee accaeaatee 420 aeettgecca ttgatgtatt caccccgcaa aegeaccccg gcgctgctga actcctacac 480 cteeegeaca eaaegcneec anaeacaccc aecaagtttg eegataaatg acncaaegaa 540 gegncncnan etggnggttg aaeeeaaega aegcceaate ctattaeccc aa 592 < 210 > 102 211 > 587 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > misc_caracteristic < 222 > (I) . . (587) < 223 > n «A.T. C or G < 400 > 102 aceeagacea cgecctaagc caecagggaa gaacacagac cacaeccctg eccecaegcg 60 gceeatgetc tctggaagaa agtggagacc nagtccttgg ceteagggce ccccggcegg 120 gggcegtgca ntccggtcag ggcgggaagg gaaatgcacc gctgcacgeg aaeceacagc 180 ccaggcggae gccccttccc ttagcaceac ceggccecce gcatccccec gccecaegcc 240 cctcccacct tcaaanaatg aanaacccca tgggcccagc cccctgccct ggggaaccaa 300 ggcagccttc caaaacecag gggcegaagc anaccaecag ggcaggggce gaceeegggt 360 gacactgccc aeecccecec agggcagcec angtcacccn ggnccctega acccagcccg 420 ctccetegaa aaagggcaaa actgaaaagg gcetttccta naaaaagaaa aaccagggaa 430 cetegccagg gceecnnene taccaaaacn nceececnng gatttttaae cceccaccng 540 gcceccacee accnggggcn aegccccaaa aeeaanaaee ecccaec 587 < 210 > 103 < 211 > 496 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > misc_caracterfstica < 222 > (1) ... (496) < 223 > n = - A.T.C or G < 400 > 103 anaggacegg ccceacncgc tctctctcgc cceacceatc aatgcccaae atggcagaac 60 ctgcanccct tggncactgc anatggaaac ctctcagcgt cttgacatca ccetacccnt 120 gcggtgggtc tccaccacaa ccactccgac ecegtggtcc ctgnanggeg gneececceg 180 accggcagga cggaccccan ccnacacacc cctctgcccc cecegcenag anaaagaacc 240 cccccaacae gaeaeaaecc acccacgcaa ncngccaccg gcccagccac cacccaccac 300 ccgcceacag aaetecaccc agcctacace ccggcaccce ccctggcgae agagtgtggc 360 cgggctgacc gcaaaaggtg ccttacacac eggcccccac cctcaaccge tgacncacca 420 gangccegcc cccecccccc gaccnncccc cacgccggae aecagggegc ecnagggatt 430 ggaaaagaaa caaaac 456 < 210 > 104 < 211 > 575 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > miscjfeature < 223 > n «A.T.C or G < 400 > 104 gcaccegctc ccaaeccnnc tcecaccaeg aecceccgcc egcanaaace ccecegccaa 50 ccaeggange ggeetcnggg geggceceeg ccaaceggga agaagccgeg gegececeac 120 cegeecaace cngetegege cegggggaec aactnggggc tatggaagcg gcenaacege 180 egeeeeggeg gaagggcegg taaeeggcee tgggaageng ceeacngaag etggccengg 240 gaageegcta eegaaagtng ccneggaagt ngneeeggcg gggggeteeg ceggeggcet 300 cegeenaate egggegceet gtnaaeggcg gcccccecnc cegggcaaeg aaaaaaaeca 360 ecnacgcngn aaaccecnac nnaacagcce gggceeccce caccecgaaa aaageegcec 420 cccccccaaa aaaggncaan ccccecaann eggaangeeg aaaaaaeccc cgaacgggga 480 ncccnaaaac aaaaancccc cetietecccn gnaanggggg aaaeaccncc cccccaceea 540 cnaaaaccce cneaaaaaac cccccgggaa aaaaa 575 < 210 > 105 < 211 > 615 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > misc_característíca < 222 > (D .... 619) < 223 > n = A.T.C or G < 400 > 105 caceageagg atagaaacac tgegecccga gageaaggag agaagceace attgateaga 60 gcceaaccca ggttaacegc aagaagaggc gggatacttt cagctttcca egeaacegea 120 egcaeaaagc caaegeagec cageeectaa gaecatgtec caagceaace gaaecccace 180 ecaaeacaca cecaegaact ccegaeggaa caaeaacagg cccaagcceg tggeaegaeg 240 tgcacacteg ceagacecan aaaaaaeact actcecacaa atgggtggga geattttggt 300 gacaacctac teegceeggc egagegaagg aatgatatec aeaeaCccae teaeeccaeg 360 gacaeeeage eagtgcttte eaeaeaccag gcaegatgct gagtgacace cttgtgtaea 420 tttccaaatt tttgeacagt cgctgcacat atttgaaatc atatattaag acttccaaaa 480 aatgaagtcc ctggteeeec aeggcaacee gaecageaaa ggaeecncce ctgtttggta 540 ceeaaaacae ceáceaeaen gttnanatga aaetccettt ccccncctcc cgaaaaaana 600 aagtggtggg gaaaaaaaa 619 < 210 > 106 < 211 > 506 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > misc_característíca < 222 > (1 J (506 >... < 223 > n = AT C or G < 400 > 106 catcggcnct cccacccgcc ncggaagcgc nnacctctaa cagcggacaa agctcccnge 60 gccccaaacc ctgtnacact tetgggaant gaaaanttng tantatgata ggccaccccg 120 angeanagae gecccggata ccaccanacn egcccccnge gecagaggce caeaeegege 180 tatgtaaaeg gcacnccact cgctactatn antcaattng aaatanggtc tttgggttat 240 gaaeanenng cagcncance nanangcege ctgtngtaec cacegeggcc acagcacccc 300 acancaccgc aaccccnacc nagcgagaca naccagnaan cccccagcga cggcccanga 360 eeccaaaegg ncecaenecn aaegeeeaaa ag eaneeaa gegeaagaaa eacagacegg 420 atgttccacc aactagcacc cgtaatgacn ggcctgtccc aacacatctc ccttttccat 480 506 gaccgeggea ncccgcatcg gaaaaa < 210 > 107 < 211 > 452 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > m se_ characteristic < 222 > (Lj (452) <... 223 > n = AT C or G < 400 > 107 geegageceg eaceaaacag eaagaeaece caaegaacca eaaaeecaac eeegeaaaaa 60 tceeetgaag catagataat attgtttggt aaacgcttct tttgttegge aaacgcccce 120 eeeaaagacc cecceaetce aeaaaacece gcacgeagag gctegeeeac ceeececece 180 ctaaggeeea caaeaggagc aaaataeaaa ggcgacccga aeeacgagae cggcteccct 240 geggcaeaaa ttgcatcact gtaecaeeee ceeetceaac cggeaagape tecageeege 300 cggaaagcaa ccgcganaac ccagcccccc gtccatctcc cccagggact acccatagaa 360 cacgaaaagg tccceacnga agcaagaaga eaagtcteec aeggccgceg gttgceeaaa 420 ccaceeeaaa accaaaaaac cccccccgga aa 452 < 210 > 108 < 211 > 502 < 212 > DNA < 2l3 > Ho or sapien < 220 > < 221 > misc_caracteristic < 222 > (1) ... (502) < 223 > n »A.T.C or G < 400 > 108 aeceecetcc ceeaaetagt tnttatttat ntattaaatt ccaccgcacg ccccggcaaa 60 caaaaagaga ccgcagaccg gcccccggcc ccccaaaagc aagtaccaca ccataacaga 120 cgaagcccaa agacencaac aaaacccacc acatgcacaa cacceeenga agaacaecaa 180 cana? CACAC aaaactttta acatntgctt aatgttgtnc aattataaaa ncaatngaaa 240 aaaatgtccc eetaacatnc aatatcccac acagcgccac eenaggggae caccnngnaa 300 naaaaaaagg geagaaggga eeeaaegaaa accccgcccn ccacccccgc ccanaaacgc 360 aaaacttntc ctccagaaca aantcttcca gccaaccgca teegagcena ggccacecaa 420 aaaccccacc agncccaccc tctaanggec tctanagett actaanccte ttgaccccee 480 accceggnea ceccegccct ca 502 < 210 > 105 < 211 > 1303 < 212 > DNA < 213 > Homo sapien < 400 > 109 acccgaggcc tcgctaaaat catcatggat ccacttggcg ccgtcagcac ccgacccggg 60 cccgaccccc ecaaagagce aatgatggca gaagaaaaca acatcttctt cccccccgeg 120 ggcaccccga ccgcaattgg catggtcctc ctggggaccc gaggagccac cgccccccag 180 eeggaggagg tgtttcaccc tgaaaaagag acgaagagce ggcegaagaa caágaaeaaa 240 aaagaggcga ccgagaacac agaagcagta catcaacaat eccaaaagte cccgaccgaa 300 acaagcaaac ccaccaacga ttatgaactg aacataacca acaggctgtt eggagaaaaa 360 acacaccccc Ccccccaaaa atacttagat tatgttgaaa aatattatca cgcacccccg 420 gaacccgccg aeeecgeaaa egcagccgae gaaagecgaa agaagaeeaa cecccgggee 480 caaacgaaaa gaaagcaaaa aatcaaggac ttgttcccag aeggctctac cagcagcccc 540 accaagctgg tgctggtgaa catggtttat tttaaagggc aacgggacag ggagcctaag 600 ceaaggaaga aaagaaaaca acgaacaaga gaaattttgg gcacaageaa acccgcacag 660 aegaegacac agagccattc ctttagcttc accttcctgg aggacecgca ggccaaaact 720 catataaaaa ccagggaccc caacgaccta agcatgtttg cgctcccgcc caacgacaec 780 gacggccegg agaagaeaae ageccegaga agataaaaea aaeeggeaga geggaceage 840 ccagggcaca tggaa gaaag aaaggegaat cegcacttgc cccggttcga ggcggaggac 900 agccacgacc tagaggcggt cctggctgcc aeggggaegg gcgacgccte cagcgagcac 960 aaagccgacc actcgggaae gcgca gc eccgggetgc acgcccagaa gceccegcac 1020 ageecceeeg eggcag aac egaggaaggc accgaggceg cagcegccac eggcaeaggc 1080 eccactgtca catccgcccc aggtcatgaa aatgtt act gcaaccaecc cttcctgttc 1140 eecaecaggc acaacgaaec caacagcaec ctcttcttcg gcagaceeec eececceeaa 1200 gaegaccgce gccacggcac tgccgccece agcaaaaaac aaceaccage gccacecata 1260 cgattatgaa aaccgcccat tcctctaaac ggeggc cac eegcatee 1308 < 210 > 110 < 211 > 391 < 212 > PRT < 213 > Homo sapien < 400 > 110 Met Asp Ser Leu Gly Ala Val Ser Thr Arg Leu Gly Phe Asp Leu Phe 1 5 10 15 Lys Glu Leu Lys Lys Thr Asn Asp Gly Asn He Phe Phe Ser Pro Val 20 25 30 Gly lie Leu Thr Wing He Gly Mee Val Leu Leu Gly Thr Arg Gly Wing 35 40 45 Ttr Wing Being Gln Leu Glu Glu Val Phe His Ser Glu Lys Glu Thr Lys 50 55 60 Ser Ser Arg He Lys Wing Glu Glu Lys Glu Val lie Glu Asn Thr Glu 65 70 75 80 Wing Val His Gln Gln Phe Gln Lys Phe Leu .Thr Glu He Ser Lys Leu 85 90 95 * Thr Asn Asp Tyr Glu Leu Asn He Thr Asn Arg Leu Phe Gly Glu Lys 100 105 110 Thr Tyr Leu Phe Leu Gln Lys Tyr Leu Asp Tyr Val Glu Lys Tyr Tyr 115 120 125 His Wing Ser Leu Glu Pro Val Asp Phe Val Asn Wing Wing Asp Glu Ser 130 135 140 Arg Lys Lys He Asn Ser Trp Val Glu Ser Lys Thr Asn Glu Lys He 145 150 155 160 Lys Asp Leu Phe Pro Asp Gly Ser lie Be Ser Thr Lys Leu Val 165 170 175 Leu Val Asn Met Val Tyr Phé Lys Gly G? Trp Asp Arg Glu Phe Lys 180 185 190 Lys Glu Asn Thr Lys Glu Glu Lys Phe Trp Met Asn Lys Ser Thr Ser 195 200 205 Lys Ser val Gln Mee Mee Thr Gln Ser His Ser Phe Ser Phe Thr Phe 210 215 220 Leu Glu Asp Leu Gln Ala Lys He Leu Gly He Pro Tyr Lys Asn Asn 225 230 235 240 AO Leu Ser Mee Phe Val Leu Leu Pro Asn Asp He Asp Gly Leu Glu 245 250 255 Lys He He Asp Lys He Ser Pro Glu Lys Leu Val Glu Trp Thr Ser 260 265 270 Pro Gly His Mee Glu Glu Arg Lys Val Asn Leu His Leu Pro Arg Phe 275 280 285 Glu Val Glu Asp Ser Tyr Asp Leu Glu Ala Val Leu Ala Ala Met Gly 290 295 300 Met Gly Asp Ala Phe Ser Glu His Lys Wing Asp Tyr Ser Gly Mee Ser 305 310 315 320 Ser Gly Ser Gly Leu Tyr Wing Glh Lys Phe Leu His Ser Ser Phe Val 325 330 335 Wing Val Thr Glu Glu Gly Thr Glu Wing Wing Wing Thr Gly He Gly 340 345 350 Phe Thr Val Thr Ser Wing Pro Gly His Glu Asn Val His Cys Asn His 355 360 365 Pro Phe Leu Phe Phe He Arg His Aen Glu Ser Asn Ser He Leu Phe 370 375 390 Phe Gly Arg Phe Ser Ser 385 3 90 <; 210 > 111 < 211 > 1419 < 212 > DNA < 213 > Homo sapien < 400 > 111 aaattaagga ggagaactae tcccagctac teaaeegace eaegceecct agttcgeegc 60 ccagccacca ccgccccccc aaaaacccga ggtctcgcta aaatcatcat ggattcaccc 120 ggcgccgcca gcacccgacc Cgggtttgat ccccccaaag agccgaagaa aacaaatgat 180 ggcaacacct tcttttcccc tgtgggcatc ttgactgcaa ctggcatggt cctcctgggg 240 acccgaggag ccaccgcttc ccagttggag gaggcgcccc actctgaaaa agagaegaag 300 taaaggctga agetcaagaa agaaaaagag gtggtaagaa taaaggctga aggaaaagag 360 cagaageagt attgagaaca acatcaacaa eeccaaaage cteegacega aacaagcaaa 420 cccactaacg actacgaacc gaacacaacc aacaggctge ttggagaaaa aacatacctc 480 ttccttcaaa aatacttága ttatgttgaa aaatattatc atgcatctct ggaaccegee 540 gattttg aa cgaaagccga acgcagccga aagaagacca attccegggt egaaagcaaa 600 aaaecaagga acaaaegaaa gatggctcea ctegeeccca etageagctc eaccaagceg 660 acatggttta gtgctggtga ttttaaaggg caatgggaca gggagtttaa gaaagaaaat 720 accaaggaag agaaatcccg gacgaaeaag ageacaagta aacccgCaca gaegaegaca 780 cagagccacc cccccagccc caccttcctg gaggacttgc aggccaaaac tctagggatt 840 ccatataaaa acaac gacct aagcatgttt gtgcttctgc ccaacgacat cgatggcccg 900 gagaagacaa cagacaaaac aagtccegag aaaceggeag ageggaceag cccagggcac 960 gaaaggegaa aeggaagaaa tcegcaceeg ccccggeecg aggcggagga cagttacgat 1020 ctagaggcgg tcctggctgc catggggatg ggcgatgcct tcagtgagca caaagccgac 1080 cacccgggaa egecgecagg ceccgggeeg agceccegca eacgcccaga cagctcceee 1140 geggcagcaa ccgaggaagg caccgaggct gcagccgcca ccggcacagg ccccacegec 120C acaeccgccc caggecaega aaaegeecac tgcaaecaec ccteccegte ceecatcagg 1260 cacaatgaat ccaacagcat cceceeceec ggcagaeeee ceececceea agaegaecge 1320 egccaeggca eegcegcett eagcaaaaaa caaceaccag egteacecae aegaeeaega 1380 aaatcgecca tecetttaaa tggtggccca ceegcaeee 1419 < 210 > 112 < 211 > 400 < 212 > PRT < 213 > Ho or sapien < 400 > 112 Mee Asp Ser Leu Gly Wing Val Ser Thr Arg Leu Gly Phe Asp Leu Phe 1 5 10 15 Lys Glu Leu Lys Lys Thr Asn Asp Gly Asn He Phe Phe Ser Pro Val 20 25 30 Gly He Leu Thr Wing He Gly Mee Val Leu Leu Gly Thr Arg Gly Wing 35 40 45 Thr Wing Being Gln Leu Glu Glu Val Phe His Ser Siu Lys Glu Thr Lys 50 55 60 Ser Ser Arg He Lys Wing Glu Glu Lys Glu Val Val Arg He Lys Wing 65 70 75 30 Glu Gly Lys Glu lie Glu Asn Tfcr Glu Wing Val His Glp Gln Phe Gln 85 90 95 Lys Phe Leu Thr Glu He Ser Lys Leu Thr Asn Asp Tyr Glu Leu Asn 100 105 110 He Thr Asn Arg Leu Phe Gly Glu Lys Tht Tyr Leu Phe Leu Gin Lys 115 120 125 Tyr Leu Asp Tyr Val Glu Lys Tyr Tyr His Wing Ser Leu Glu Pro Val 130 135 140 Asp Phe Val Asn Wing Wing Asp Glu Ser Arg Lys Lys He Asn Ser Trp 145 150 155 160 Val Glu Ser Lys Thr Asn Glu Lys He Lys Asp Leu Phe Pro Asp Gly 165 170 175 Ser He Be Ser Thr Lys Leu Val Leu Val Asn Mee Val Tyr Phe 180 185 190 Lys Gly Gln Trp Asp Arg Giu Phe Lys Lys Glu Asn Thr Lys Glu Glu 195 200 205 Lys Phe Trp Mee Asn Lys Ser Thr Ser Lys Ser Val Gln Mee Met Thr 210 215 220 Gln Ser His Ser Phe Ser Phe Thr Phe Leu Glu Asp Leu Gln Wing Lys 225 230 235 240 He Leu Gly He Pro Tyr Lys Assa Asn Asp Leu Ser Met Phe al Leu * ~ 245 250 255 Leu Pro Asn Asp Asp Gly Leu Glu Lys He He Asp Lys He Ser 260 265 270 Pro Glu Lys Leu Val Glu Trp Thr Ser Pro Gly His Met Glu Glu Arg 275 280 285 Lys Val Asn Leu His Leu Pro Arg Phe Glu Val Glu Asp Ser Tyr Asp 290 295 300"- Leu Glu Ala Val Leu Ala Wing Met Gly Mee Gly Aso Wing Phe Ser Glu 305 310 315 320 His Lys Wing Asp Tyr Ser Gly Mee Ser Ser Gly Ser Gly Leu Tyr Ala 325 330 335 Gln Lys Phe Leu His Ser Ser Phe Val Wing Val T- »- Glu Glu Gly Thr 340 345 350 Glu Wing Wing Wing Wing Thr Gly He Gly Phe Thr Val Thr Ser Wing Pro 355 360 365 Gly His Glu Asn Vai His Cys Asn His Pro Phe Leu Phe? He He Arg 370 375 380 His Asn Glu Ser Asn Ser He Leu Phe Phe Gly Arg Phe Ser Ser Pro 385 390 395 400 < 210 > 113 < 211 > 957 < 212 > DNA < 213 > Homo sapien < 400 > 113 cecgacccec tcegcacagc ggaegaaccc egagcagceg aagaccagaa aagccaceae 50 gacettctgc ceaaeecagg agcttacagg aeeceecaaa gagegtgtec agcaeecttt 120 gaaacaegag etceeaccag cagaagcaga ccettacccc accaccecag ceeeaacagc 130 agcaggegaa acaacccagc cagcctccac cecaggaaae aeeegttccc acaaceaagg 240 agccaegcca ceeaaaggcc ccacaacceg gaaacacaaa gaeeccagag ccaggcegea 300 ccaaggeccc egagceaggc egeaccaagg eceeegagce aggeegeacc aaggeecceg 350 agccaggacg taccaaggce rccgagccas geegeaccaa ggzcccngag ccaggeeaca 420 ccaaggeccc egagccaggc agcatcaagg ecccegacca aggcetcate aageteeceg 430 agccaggegc caeeaaagee ccegagcaag gaeacaccaa agtccccgeg ccaggceaca 540 caaaggeacc agagccaege cceecaacgg ecaccccagg cecagctcag cagaagacea 500 agcagaag to aeeeggtgca cagacaagcc ceegagaagc caaccaccag aegceggaca 560 ccceeeeccc aeccgeeece gtgecceaac egecegeaga cceegeaaec ageacaeecr 720 cacceeaagc caeagecece ctceeaeeeg tatcetaaaa acacggeace aeaaagceee 730 c cccacaca caeectgaag aaeccegeaa eaagcagaaa gccccegaae geceeeaegg 840 cteeeegge cteegg ctgc ecagggeeea eeegaagaee cgaaegaaaa gaaaegcaeg 500 eeeccegcec egccctcaee aaaeegctee taaeeccaaa aaaaaaaaaa aaaaaaa 957 < 210 > 114 < 211 > 1S1 < 212 > PRT < 213 > Ho or saoien < 400 > 114 Met Ser Ser Tyr Gln Gln Lys Gln Thr Phe Thr Pro Pro Pro Gln Leu 1 5 10 15 Gln Gln Gln Gln Val Lys Gln Pro Ser Gln Pro Pro Pro Gln Glu He 20 25 30 Phe Val Pro Thr Thr Lys Glu- Pro Cys His Ser Lys Val Pro Gln Pro 35 40 45 Gly Asn Thr Lys He Pro Glu Pro Gly Cys Thr Lys Val Pro Glu Pro 50 55 60 Gly Cys Thr Lys Val Pro Glu Pro Gly Cys Thr Lys Val Pro Glu Pro 65 70 75 30 Gly Cys Thr Lys Val Pro Glu Pro Gly and s Thr Lys Val Pro Glu Pro 85 90 95 Gly Tyr Thr Lys Val Pro Glu Pro Gly Ser He Lys Val Pro Asp -Gln 100 105 110 Gly Phe He Lys Phe Pro Glu Pro Gly Ala He Lys Val Pro Glu Gln 115 120 125 Gly i and Thr Lys Val Pro Val Pro Gly Tyr Thr Lys Val Pro Glu? Rc 130 135 140 Cys Pro Ser Thr Val Thr Pro Gly Pro Wing Glp Gln Lys Thr Lys Gln - 1 160 Lys < 210 > 115 < 211 > 506 < 212 > DNA < 213 > Ho or sapien < 220 > < 221 > misc_ feature < 222 > (1) . . . (506) < 223 > n = A.T. C or G < 400 > 115 catcggcnce eteaeetgce ntggaagege nnaeeeeeaa cagcggacaa ageecccngt 60 gceccaaacc cegenacace cccgggaanc gaaaaneeng cancacgaca ggecactctg 120 eggaea angeanagae ccateanaen tgcecccnge gccagaggce cataetgege 180 eaegeaaaeg geaenecaet cgceaceaen anecaaeeng aaaeanggec eeegge 240 gaaeanenng cagcncance nanangccge ctgengeaee categeggcc atagcaccee 300 acancaeege aacc nagegagaca cnaec naceagnaan etcceagega cggcecanga 360 eeccaaatgg pcecaenecn aaegeeeaaa to eeaneeaa gegeaagaaa eacagacegg 420 acgtcccacc aaceagtacc egcaaegacn ggcccgtccc aacacatcec ccetetccae 480 gacegtggea ncccgcatcg gaaaaa 506 < 210 > 116 < 211 > 3079 «.22 > DNA < 2l3 > Homo sapien < 400 > 116 ggaeccccgg cceaaa ccccccacag ageccegccc aggccaaaga scaaggaaaa 60 ggtcaaaggg cagaaaaaat gccgagccag gaggagctae ggaaggacaa acceggccee 120 aagcggetea aaagaggcca eagggggcgc egagggcttc ccacaeecec eggcctaaac 180 cttgcaggca gatctgccca gcgggceccg ggaeagcege gcceecccea acaaaaaaae 240 tgtgcacaaa aggaegaaac cstattttcc ceceagcaca eaaccaagaa eataaggcea 300 cagaccgcce eecccagagg gaaaaccccg cagcaacccg ccgcccggaa aagegtaaga 360 gcagatcact ggggaatcge cgccccccg ccgatggaca gcccccccaa gctccaaggg 420 caggegceca gcaegtaccg caccgggacg gttgtcaata cccccggccc cgtaagagtc 480 ccaggacace gccaegccaa tgccccctca geecceggca ecceeeeegg gctgcecaca 540 gccccagcce ceaeggegaa gacatacctg ctagcagcgt caccaacccg ttgccaagag 600 atcagegctc gaaggcaagg ttatttctaa ctgagcagag cccgccagga agaaagegce 660 tgcaccccac accactgtgc aggtgtgacc ggegagctca cagctgcccc ccaggcatgc 720 ccagcccace taatcaecac agctcgacag cccececgcc cagcccagct ctggaaggga 780 taaaaagggg catcaccgtt cctgggtaac agagccaccc tctgcgtcct gctgagctce 840 gcecececca gcaccec cca acccactagt gcecggcccc cttgctccac caggaacaag 900 ccaccacgcc cegccagcca agt tgtctc ccggagcggg gggcagecgt agcttcagca 960 ccgccecegc catcaccccg tcegec ccc gcaccagccc cacctccgtg ecccggeccg 1020 ggggtggcgg tggeggeggc ttcggcaggg ecagcctegc gggcgcccgc ggagcgageg 1080 gceaeggcag ccggagccec tacaaccegg ggggceccaa gaggacaecc accagcacca 1140 gtggtggcag eeecaggaac cggtttggcg ceggcgctgg aggcggctac ggccccggag 1200 gcggcgccgg cageggaeec ggeetcggcg gcggagcegg eggcggcete gggcecggeg 1260 gcggagccgg eeceggagge ggcttcggtg gccceggccc ecccgcccgc ccecccggag 1320 gcacccaaga ggeeaeegee aaccagagec eccegactcc ccccaacceg caaaccgace 1380 ccagcaecca gagggegagg accgaggagc gcgagcagat caagaccccc aacaacaage 1440 ccgcccccce catcgacaag gcgcgc gaacaagcggagcagca ceggaaacaa 1500 ageggacccc gcegcaggag cagggcacca agactgegag gcagaacceg gagccgeege 1560 ccgagcagca caecaacaac cecaggaggc agctggacag catcgegggg gaacggggcc 1620 gcceggacec agagcegaga aacaegcagg acceggegga agaceccaag aacaageaeg 1680 aggaegaaae caacaagcge acc accgccg agaacgagcc cgcgacgceg aagaaggaeg 1740 eagatgctgc ceacaegaac aaggeggagc tggaggccaa ggttgaegca cegaeggaeg 1800 agaeeaacee caegaagaeg eeceeegaeg cggagcegec ccagaegcag acgcaegeee 1860 cegacaccec agtggeccec acaaccgcaa eccaeggaca gaeagcaeca cceggacceg 1920 tcgctgaggt caaggcccag tatgaggaga ttgccaaccg cagccggaca gaagccgagc 1980 cccggeacca gaccaageae gaggagcegc agcagacagc eggccggcae ggcgaegace 2040 eccgcaacac caagcaegag aectccgaga egaaccggat gacccagagg cegagagccg 2100 tgccaagaaa agaetgacaa cagtgcgcca aecegcagaa cgccaetgcg gatgccgagc 2160 agcgegggga gceggcccec aaggaegcca ggaacaagce ggccgagceg gaggaggccc 2220 egcagaaggc caagcaggac aeggcccggc egcegcgega geaccaggag cecaegaaca 2280 ccaagceggc cceggacgtg gagatcgcca cttaccgcaa gctgccggag ggcgaggaae 2340 gcagac cag tggagaagga geeggaccag ecaacaecec egeegecaca agcagcgeer 2400 cceceggaea cggcagtggc agcggceacg gcggcggcce cggeggagge cceggcggcg 2460 gccecggegg aggcrcegce ggaggcagca geggaagcta ceaceceagc agcagegggg 2520 gegecggcce aggeggcggg cecagegeg g ggggceecgg ceecagcgca agcageagcc 2580 gagggctggg ggcgggceee ggcagcggcg ggggeagcag ceccagcgec aaatttgeee 2640 ccaccaccec ceccecccgg aagagceeca agagctaaga acc gccgca agecactgcc 2700 eeccaagegc agcaacccag cccacggaga "gccccttc caggcagtcg ctcaagccac 2760 eeeeeggaga geeeeaecce geageceaga egcagaacca ceaagccaae cattcttrgg 2820 agccccatcc ccagccceeg gececccgeg ccgcageece aeaeece ce 2380 ecaaaccagc cttcaggeet cccacagcae ggecccegct gacaegagaa cccaaageee 2940 ecccaaatcc aaaecaecaa aacagaaecc cc3ccrcaat cccaaaeeee geeceggeee 30C0 taaceacctc cagaa gtgt tcaaeaaaae geeetaeaat ataegcegge gegcagaate 3060 geeereeeet tceacccaa 3079 < 210 > 117 < 211 > 6921 < 212 > DNA < 213 > Homo sapien < 00 > 117 tgtccareca gaacecegac aaacteceae eccgatcaaa gctaectgeg aceacagaca 60 accaeecaca aaeegagaca aagacgaega aegtgtttcg gcgaataact ctcatcgtgc 120 caaaeggaag gecaeeagec ctacegggaa tgaggceaeg gecccatctg tgegctecac 180 cgttccecca ccaaacaaag aagcggcgga cceegceaac agaategagc aacagtatca 240 gaaegtcctg aceceeeggc aegagececa caeaaacaeg aagagegtag eaecceggca 300 tcaccecaec aaegaaaecg aeagaacccg agctagcaac gcggccecaa taaagacaat 360 gceaccegge gaacaecagc aageeceaag taaeceacaa ececgeteeg aagaeeeece 420 ggaagaeagc caggaacccc aagccccctc aggcccagac acaacacaac Cggaaaagga 480 ggeeaaegea tgeaagcage aceaccaaga acttcttaaa gagaggagca cctgcagaaa 540 geeeaeaaec agaggaaeca cccacaccec cgaagcccga aacaccagac cccggccaga 600 gaecggcega gaacegegaa ttagacagat eegaaceccc ceggaaagag aegaettgca 660 cccagaacca cgaaagegeg cagaacagga gaaaccaaag aaagagccgg aacgacccaa 720 agaegaeeeg ggaacaaeea caaacaageg cgaggageee eecagceaag cagcagccee 780 cccaccagcc cceaceeeac gaecagagct eaaegtggec ectcagaaca tgaaccaage 840 ccaeeeeaeg tceecc ACTT acatagataa geegaaaacc getaactegg egttaaaaaa 900 cacecaagce gcagaagccc ecgtaaaact ctatgaaace aaactgegtg aagaagaage 960 gacaagaaea agetatagct aeaeegagaa eceaaeaage aceeeaaage aatggagaec 1020 egaagtagae gaaaagagac aggeaeeeca egccttagag gatgagetgc agaaagctaa 1080 agccaecage gaegaaaege eeaaaacgea eaaagaac g gacceegaee eegaceggea 1140 caaagaaaaa gcagaecaae eageegaaag gcggcaaaae geecaegegc agaeegacas 1200 caggeeacgg gaceeagagg gcaeeggcaa aecacegaag eaceacagag acaceeacca 1260 ecceeeagae gaeeggaecc agcaggeega aaceacecag agaaagaeec aggaaaaeca 1320 gcctgaaaae agtaaaaccc gttgaatcaá cagccacaca cagaagaegc tggegcccga 1380 aaacagagca aatagaaacg gtgtcaaaaa aaaeggacga eaegcagaac ageactcagc 1440 eacagegaag gaccaegáae eacaaacaac gacctaccgg gccaeggcag aeeeacaaca 1500 gegaaacgcc aaaatctcca gaagaaegca gagttcagca gatctcatta tecaagagee 1560 catggaccca aggactcgac aeacegccce ggccaccccc aegacacaae ataeeaaaee 1620 ccaeegaaga cgceggegac ggaggagatt ggceggaaga aaaaggegea aggagaceee 1680 egaacaeggg gcaeactcag to tctgcteea gcgtcagaag gcaacagtge ttgagaatag 1740 eaca caaac ggaaagataa gcgageegga aagaatggta gctgaactaa agaaacaaaa 1800 gecccgagea gaggaagaac eeccgaagge cagggaggce gcagaaaatg aaeegagaaa 1860 aatgtagaag gcagcagaga ataececeet gcagaagaea agggctgaaa gtgaagccaa 1920 gcageaccgc agggaaceeg aaaccaeegt gagagagaag gaagccgctg aaagagaace 1980 ggagcgggeg aggcagceca ccaeagaggc cgaggceaaa agagccgccg eggaagagaa 2040 eeccgcaatc cctcccgaae ageeggagga aaacacctee accagacgaa cactggaaga 2400 ecacceeaaa agaaaagace eaagectcaa caacaaaaaa egaeeeggag acaaaeeaae 2160 agaagaaaga ggaagaaeea gagacaaega ggaagaacec eegaagcega eaaagcagae 2220 ggaaaaagac ctegcatttc agaaacaggt agcagagaaa cageegaaag aaaagcagaa 2230 aaeegaaeeg gaagcsagaa gaaaaaeaac egaaaeecag eacacaegea gagaaaaegc 2340 aeegccagcg cgecogatca cacaggctac aecaegc3gg gcageaacgg gececcagca 2400 agaacaegac aagcagaaag cagaagaace caaacagcag geagaegaac taacagcege 2460 caaeagaaag gcegaacaag acatgagaga gccgacaeae gaacceaatg ccceccagce 2520 egaaaaaacg ecaeetgagg aaaaggc eeg etegceaaaa gaeaaaceag aegaaacaaa 2530 eaaeacactc agaegcetea ageeggagce ggaaaggaag gaecaggcsg agaaagggca 2640 eectcaacaa eeggeaggea cecagagagc aeegaaecaa accacaggea aagcegaaga 2700 gaagceagcg agceaegcaa aececaagaa aaeaaagcgc aateaecage cagaa taga 2760 aeceeeeaae caegaaaaag ggaaac aca aagagaagea caagggcaca gacagaaeca 2820 gagaagaata tgcegeagce tecagcaeee aaatccacaa aeecaeecee tecgagaega 2830 gaaagaceac gaaagaaeea gagaaaaeca aaatcegcca gaecaectaa aagaacaaee 2940 tgagaaaagc caegagcage egceecaaaa gaaaaasaaa taecaaagce aeaacgaeaa 3000 aaeceaaagg cccaatgaag aaeeggagaa aagcaaegag cgctaaaaca rgtgcagaga 3060 gagceeacea aaaagtagag tgaaaccaaa ggcagaaeaa agagaaeeca eeasegaegc 3120 ggcagaaeca gagaataeag eeeeagagaa acaaaceaec cagcaaagae gegaagcace 3180 gaaaaeecag gcagaeggtt eeaaagaeca gceacgcagc acaaaegaac aceegcaeaa 3240 acagacaaaa acagagcagg aeeetcaaag aaaaaeeaaa tgcccagaag aagacceggc 3300 gaaaagecaa aa eeggtaa gcaaaagege gcgaaeeeaa gaceaacaga acaeeaecae 3360 ccagaaeace aagaaagaag ttagaaatct gaacgcggaa ctgaacgcte ccaaagaaga 3420 ggggagcaga gaagcgacgc aagtccagct acaacaagce caggtgcaag agctaaaeaa 3480 caggccgaaa aaageacaag acgaaetaca cecaaagacc aeagaggagc agacgaccca 3540 cagaaagatg getcegeeec aggaagaaec cggtaaaeec aaacaaecag cagaggagte 3600 ccggaagaag aeggaaaaat eaaeggagcc caaagccacc actgaaaatg aeatttcagg 3660 cateaggctt gaccetgtge ceceecaaca agaaaacece agagcecaag aaaatgceaa 3720 acaaacatta gccccgcgaa aagaacttga aagacagcec caacagtate gtgaacaaac 3780 gcagcaaggg cagcacaegg aagcaaaeea etaccaaaaa egecagaaac ccgaggatga 3840 gccgacagcc cagaagcgtg aggttgaaaa cctgaagcaa aaaatggacc aacagaccaa 3900 caecaaeeag agagcaegaa tetegceeea gegcgaaaee caaaaaaaga gcacagccaa 3960 agaccgeacc cccaaaccag aetttgagat gacagegaag sagcgccagc actctggaga 4020 gctgtceece agaaacaccg gacaccttca cccaacaccc agacccccee tgtegagatg 4080 gacecaagaa ccacagccac eggaagagaa gtggcagcat cgggc gceg aacagacacc 4140 caaagaagec caaeeecag c caccaggggc eccacecgag aaagagaaaa gccagcageg 4200 etactctgag eaceeeeccc agacaagcac cgagttacag aeaacctetg aegagacaaa 4260 ccccaecaca agacegcceg aaaeegagaa gaeaagagac caagceeega acaaeeeeag 4320 accaccegee aggeateaag acaacgcaeg egaaacggaa ceggcgaagg teeegaeacc 4380 gceaagaaca ceeagagaea eaegcaeaca agcageaega caeeaaaaca saageeaeae 444C agaaaagaac ccageeccca gcgetgaaga aaagggegca aeggaegcee gagcaeeegg 4500 cggacccaag aaaggggact cctcaagaa gggcecagaa ccagagacct eccagaactt 4560 cgatggtgae. catgcacgcc cagecaggga tgacgaaete aaaeeccaag ggcteaggcs 4620 cactgtgact gccaggcagc cggcggaagc taagcteccg gacatgagaa caattgagca 4680 gctgcgacec gg ceeaßga ageecagaaa ccgeegasga aceceeaaca agteecegac 4740 gaaagccacc ecaaeegcag ggceeeacet agaaeccaca aaagaaaaga eeecaceegc 4800 gagagaaeca cecagcggcc eaaeagacaa aaeggeggce eagaageeca eeggcaeeee 4860 ggeeccacaa ggctgcaaca tcgaccccac tecaggccag acatattctg ttgaagacgc 4920 ageeceeaaa ggageegeeg accccgaaee cagaaeeagg ceeceegagg cagagaagge 4980 agcegtggga eaeeceeaet cecccaagac aeegtcagcg eeecaagcea cggaaaacag 5040 aaegceegac agacaaaaag gtaaacacae eeeggaagcc cagaeegccs gegggggege 5100 gegagaggca cattgaccce ttcgegecc eccagaaatt gctctgcagc aggggeegee 5160 gaaeaaegcc aeceeacage eeeeacaega gccaeccagc aacacaagag eeetecceaa 5220 ccccaacaac aagcaagctc egtatcactc agaaeeaceg cgaatgtgeg eaeetgatgt 5260 agagccccaa egceeecege teccateegg ggagaggaac ateeccaaec ecaaegecaß 5340 gaaaacacae agaaeeeceg tageagaeac eaaaacagga ecagaatcga ccgegcaega 5400 ggcceeccag agaaa ccega eegagaaaag taeaeaecee gaaceetcag ggcagcaaea 5460 ecagtggaag gaagceacgt tttttgaatc ctatgggcat ecrtctcaca tsctgacega 5520 eaceaaaaca ggactacace ecaaeaeraa gagcagggaa rgaggceaea caaeegacaa 55S0 agcceeggec aaaaageaee aggaaggcee eaeeacaccc acagaactcg cegaeeeeee 5640 gcegagccgg ttagecccca agaaagaeee gcacageccc geegcagggc aetggcegac 5700 egceageggg gaaaggaect cegeaceaaa agcceeccge agaaaeeegg tegaceggae 5760 caczgccctc cgacgccccg aagcccaage cagcacaggg gg acaaccg aeccecccac 5820 eggcaaaaag eaccgggtgg ccgaagceet gcatagaggc ctggtegatg AGGGG-GSTN 5880 ccagcagctg cgacagegeg aaetageaat cacagggaee ggccacecea ecacesacaa 5940 aaegaegeca geggeggaag cegcgaacgc aaaeaeeaea aaeaaggaaa cgggaaeeeg 6000 aegeeeggaa teecageace egacaggagg gecgaeagag ceacaggtec aceceeggee 6060 atcaatagaa gaggcececc aagtaggcae eaeagaegte crcat gcea caaaaeeeaa 6120 agaecaaaag ecacatgec3 gaaacaeaac acaecereag acaaaaagaa agteg = EAPC 6130 eeagaaaaag caaagaagcc cegaeeeega eeeccacaca ggacteaaac egee = gaagt 5240 aecegagccc cegaegacag gaaeteceag cceceaceae eceecceaac gggacaegee 6300 eaaaeaaceg egcaagggge gatgcaggce ggeecaegcc aceeeeeesg ageaegaega 6360 caecggceac aeaegcagec egegaacese geaacaeace eeaettcteg agggcegcaa 6420 attgctaage gcccaaaata gageaageec eaaattgaaa ateacataag atttaaegcc 6480 ceecaaaegg eeecaeeeag cctegagaae ggeeeteega aaceeggcca caceaaaatg 6540 tteeeeeeee eeeacgeaga aegeggga to aeeccaagee aaceegaega cacagegeca 6600 eeeceecaga aceccccetc attgaatage gaecaeteae eaaaegataa aetgcacecg 6660 acgtcacgaa ctgaaagagc gcaccatgga aecaaagaga aagaeataaa eecgttccca 6720 cagcceecaa gctgcagege ceeagaeegc eecaaaaaae gaaaaageee tgccceeeec 6730 gatacagcga ccecccctgc atattaaaat gettaccaca aegecccaee tctagteaag 6840 cceecgcace egaaagctaa caeeaegaae aeeaegegee ggaggagggg aaggaeeeec 6900 cccaccccge gtactccccg g 6921 < 210 > 118 < 211 > 946 < 212 > DNA < 213 > Ho or sapien < 400 > 118 cetctgactg ggctcaggct gacaggtaga gctcaccat gcttcttgtg tcctrgtccc 60 ctccccaeca cagcegegge gcageceace gececcageg gceaeggcgg egecagegge 120 gtcggcagtg gcttaggcct gggtggagga ageagetact cctacggcag cggtcttggc 180 gttggaggcg gcetcagetc cagcagtggc agagccaeeg ggggtggcet cagcecegtt 240 ggaggcggca geeccaccae caagcacace accaccceee ceeccagcag gaagageeae 300 aagcactaaa gcgcgeccgc eagccctcsg rcecacagec rccaggcccc tctctggceg 360 cagagccctc eececagget gcceg CCCE ecceggceee cageceeeee egcegeecea 420 ggtagagctg gggaegaacg cccagcgccc tcacetceec tcecectctc cataccatcc 480 gagcacccat cgceeaccac cagaccaacc tcegaeeeta caecaegaeg taatcaccac 540 ccgceaccaa cggagcccca accaccaacc ectegcctcc agegetctat ctctgaggce € 00 gagcaccaca agaaaatgac cecegcecce teecacegca gaaaaeegcc aggggcetae 660 cceccaccca cccagaacaa cceeccaceg gctcecaaac ececeaacee aeaagegceg 720 cccaggcagc cgaaccccca acccatgaaa gcacaagega ceagecceae gaegeacaaa 780 gcccgcaccc ccgegacgac ccccgcgccc ttcactgttt gcaactgcta aataaagcag 840 aceeaeaaea cat acacece ceeacctegc ccegceetgg ggccaaagee eegggcceaa 900 acecccccac ccgaeaageg aaeageegcc eeeaaaagat aaecea 946 < 210 > 113 < 211 > 8943 < 212 > DNA < 213 > Homo sapien < 400 > 115 ecaacagccc cegceecttg ggccccccca tgccatgccg eaaccecccc cacccgacca 60 acacc3ac3C ccagcrccga cgcagceeee cercgcccce gccgeeeece gagccacage 120 cttccecccg ctceegcccc cggcccgtcg cc tc ccgc gcecscagcg gceecgggag 130 ggcecaggta gcgageagcg accccgcgag ccecccgcac ecccgcccgg eteeceggec 240 gcccgceeae ccceggcccc ceccgceeee eecgcgccgg eccgceecgc eeaegccecg 300 gcgcegagcc gceceecrga etgcccgccg acatgagceg caacggaggc ecccaccegc 350 ggaecaacac tctgggccgc atgatccgcg cegagtctgg eccggacct cgctacgagg 420 egaccagcgg cggcgggggc accagcagga egeactaecc ccggcgcggc gegaeeaceg 430 accagaaeec ggaeggceac tgtcaaaeeg gcacgaegcc caggcaceag aaccagaaca 540 ccaeccagga gceg ^ cgcag aacegc ccg acegcetgae gcgagcagag creaecgegc 5C0 agceegaaee gaageaegga gaeggaaeac aaeegacecg gageegagaa reggaega t: 660 geeecgccca ggccaaegac caaacggaaa eeceogacag ceegaeeaga gagaegcggc 720 agaegggcca gcccrgtgat gcecaccaga aáaggceect ecagceccaa gagcaaaegc 730 gagccceeea eaaagccaec agcgecceee gageccgcag ggccagcece aagggeggeg 840 gaggceacac eegee AGAGE ggceceggce gggatgagte eaccaaacae gecaccageg 900 aaegeecggg geggaegagg cagcaaaggg cggagaegga caeggeggce eggggegegg 960 acccggccec ageggagcag cacaceaaca gccaccgggg caeccacaac eccaecggcg 1020 aceaecgceg gcageeggac aaaaecaaág ecgaccegcg cgagaaaece gcgaeceace 1080 ggageacgaa ageeggagga aaccegccsa aagcgtcctt tgagaggatg gatcaccegc 1140 gaacaeeaee gacagccgca caggccacge ccagggagac catgtggaee aacgacegeg 1200 aggaggagga gccgccgcac gaccggagcg acaagaacac caacatcgce cagaaaca g 1260 aggccttctc catacgcatg agccaactgg aagttaaaga aaaagagctc aataagctga 1320 aacaagaaag tgaccaactt gtcctcaatc agcatccagc cccagacaaa attgaggcct 1380 aeaeggacac ecegcagacg cageggagee ggattcttca gaccaccaag egcaeegaeg 1440 ttcatctgaa agaaaatgct gcctactttc agttttttga agaggcgcag eccactgaag 1500 ggggceccag catacctgaa gactccatca ggaagaagta cccctgcgac aagaacatgc 1560 ccegccggaa ccccgcagca cagatcaagg agceggagaa agaacgagag aaaatccttg 1620 aacacaagcg tcaggegcag aacttggcaa gaagactgta acaagtctaa cagctgaagc 1630 cecgeaaccc agaceacaga to gcaacaaac ccaccaccct cagagccccc t cgaccaca 1740 aacaagaeca gaaaaecgeg cataaggggg aegagegeae cccgaaggac aacaacgagc 1300 gcagcaagcg gcacgcgacg ggcccgcgag gcgccgaca gcccgttccc tctgtggggc 1860 tgaccaeccc cccecegaac Scaceggccg eggaceccee eegcaagaee gagcageaee 1520 acgaagccac cccggccccg cggaaccage eccacaccaa cacgaagagc ctggcgecee 1980 ggcactaccg catgaccgac atagagaaga ccagggccat gacaatcgcc aagcegaaaa 2040 ggaagaeeac caacgcggca aegaagacga cagccgacce cgagccacac eaccaagage 2100 ecaecagaaa cagceaaggc ecagagaege eeggagaega tgacaagcgg aaaaeacage 2150 ctcagttcac cgatgcccag aagcattacc agaccccggt catccagccc cctggctatc 2220 cccageacca gacagegace acaacegaaa eeaceeacca eggaace ge raaga gcca 2280 accacaacaa agcssecgaa accaacagag aaaaegaeaa gcaagaaacs eggaegcega 2340 cggagccgca gaagaeecgc aggcagacag agcacegcga gggcaggaeg acececaaaa 2400 acccccctct agcagaccag gggtcctctc accacaecac agcgaaaáte aacgagceta 2460 gaaegaeeca agagtgtgca caagcaaeeg etgaggtece caaccagcee aaagaeaegc 2520 ccgccaacct cagaggeect gaaaageacc gceaeeeaca gaacgaagea eeeggaccae 2580 eecagaaace ggaaaaeátc aaeggegeca cagaeggcea ceeaaaeagc eeaegcacag 2640 taagggcact gccccaggcc accccccaaa cagaagacat gttaaaggtt caegaagcca 2700 ggctcacega ggaggaaace gecegccegg acceggaeaa ageggaagce eaccgcegeg 2760 gacegaagaa aacaaaaaac gacetgaact cgaagaagcc gctgttggcc accacgaaga 2820 cagaaccaca gaaagcccag cagacccace cecagaceec acagcageae ccaceeeaeg 2880 atccggactt gggcaagctc ggegaaaaag ecacacagce gacagaccgc tggcaaagga 2940 tagataaaca gatcgacttt agactatggg acctggagaa acaaatcaag caattgagga 3000 attatcgtga taactatcag gct tctgca agcggctcta tgaccgcaaa cgccgccagg 3060 aeccaegaaa aeecceeaga cccggagatt ccaacacsgt caegcggtte ttgaaegagc 3120 gcacagcgaa agaagaacct acatctggca AACG agacaa gtacaaaaaa atcagaggaa 3180 eegccgaact eegcgccaae ecaaeeaagg aeeaegagce ccagceggcc ecatacacce 3240 caggactgga aacecegceg aacataccca ecaagaggac caegactcag cccccttccg 3300 gggegattce gcaagaggce gcagacgeec caeegaacea aegcecggca ceeacaagae 3360 ceggagac to eeacaggecc ttaagegaga egcegaagag eecggaagae ctgaagctga 3420 gaecgaagte aaaacaccaa eeggaagagg ageecagacc ggccegagac gceaactcgg 3430 caagaacaaa aaaaccgcaa agaacctgca ttcctggatc gaaataccag gcagagegee 3540 cecageecaa agcgaagcee gcgagcccgg aggagcegaa gagacaggce gageeggaeg 3600 ggaagecggc eaagcaaaae eeagacaage aacaaaagaa gccacggcca cceaacgaga 3660 agaecacccg actgacttat gagaeegaag atsaaaagag aagaagaaaa tcegeggaag 372C acagat tga ccaacagaag aacgactatg accaace? ca gaaagcaagg caacgcgaaa 3730 aggagaacct eggttggcag aaactagagt cegagaaag aecaaggag aaggagcacg 3840 agattgaaag gttgagggtt ctaccgcagg aagaaggcac gaaeacgaaa ccggaagaga 3900 aaaggtaaga aegagccggc aaccaceaca gageaaerea aegaggagae aggaacaagt 3960 acgaaacaga gaeeaacaee acgaagacca ccaecaagga g aeaeccaeg caaaaagagg 4020 aaaeceeaga acgaccccaa aaccagcteg aeagaceeec aagggaaaae cgagaecega 40SC aggacgaaac cgccaggccc aatgacagca tctcgcaggc caccgagcag cgaaggcga 4140 cegaagaaaa cgccceecag eaaaaggcce geggceeega gaeaaegcag aagaagcage 4200 acccggagac agaacegaag caggccacgc agcagcgcec cgaggacaac gcccggcaca 4260 agcagccccc ggaggaggct gccaagacca cccaggacaa aaacaaggag accgagagae 4320 ecaaagccga gccccaggag gaggccaagc gccgceggga gaaccgagca aeacgaaaac 4330 caaeeaegae aggeaagaaa gaggagacca eeagceeaaa aaaecageee gagaccgaga 4440 ccaacatcac caagaccacc acccaccagc tcaccacgca gaaggaagag gataccagtg 45C0 gctaccgggc ecagaeagac aatctcaccc gagaaaacag gagcttaece gaagaaaeaa 4S60 agaggccgaa acccagacca gaacactcta cagagaaccc caggagggcg gaagaagaca 4620 eccaacagca aaaggccacc ggctcegagg egccccagag gaaacagcag ccggaggccg 4630 agctgagaca agtcactcag acgcgaacag aggagagcgt aagatataag caaccccccg 4740 aegatgctgc caaaaccacc caggacaaaa agaaaggcca acaaggagac aaacaacega 4800 ccgacaaaga aacaaacgac cggaagacga cggaaacgcc aaacgcga ga ccacaaaggg 4860 ccegcagaaa cccagcacga gcaaacagca gcgcgacgga gacaacaaac aaaccgaagg 4920 agaaccgaca ttcaggagca ccgaccacga cgcccgagga caggagagga aagggccccc 4980 ccgcgaagga ccággatatc acgcggttcc agaacecece gaaagagceg cagccgcaga 5040 agcagaaggc ggaagaggag ccgaatcggc tgaagaggac gactcctgca cgcgtcagaa 5100 gccggaggaa agaggaagaa gagctggaag gcatgaggag gecgctgaag gagcaagcca 5150 ccaaaaccac caacccgacc cagcagctgg agcaggcatc cattgttaag aagaggagtg 5220 aggatgaccc ccggcagcag agggacgtgc tggatggcca cctgagggaa aagcagagga 5230 cccaggaaga gccgaggagg ctctcttctg agg cgaggc cctgaggcgg cagttactcc 5340 aagcgccaaa aggaacagga caagctcact tgaggaatga gcatttccag aaggcgaeas 5400 cágaagccca aagataaaag aaegaaagca aaacagaaae egagaggceg cagcccctca 5460 cagagaacct gaccaaggag caceegaege cagaagaaga acegcggaac cegaggcegg 5520 cgacga agt cccgaggaga sgacgaagcg aagcggacag egataaaaae gcaaccaee: 5533 eggaaceaag gagceagceg eagaccagca acaaceggae eeeggaaceg caggggctga 564C eeaaegaeee acagagagag agggaaaaee egagacagga aaeegagaaa e eccaaaagc 5700 aggccceaga ggcaectaac aggattcagg aatcaaagaa ecagegeact caggtggeac 5760 aggaaagaga gagcceeceg gtgaaaaeea aagtccegga gcaagacaag gcaaggcegc 5820 ggaegagctg agaggcegga aaccgegcaa aaecaactee accagggega agaggcagaa 5880 aacascgcct ggagcgegag aaacagcaaa ctcagaatga ccegaaecag eggaagacee 5940 aacacecccg caaggaggag gceattagga agaeagaatc ggaaagagaa aagagtgaga 6000 gagagaagaa cagtcteagg agegagaeeg aaagactcca agcagagaec aagagaaeeg 6060 aagagaggeg caggcgeaag ctggaggaee ceaccaggga gacacageca cageeagaaa 6120 cagaacgcec ccgaeaecag agggagaeeg aeaaactcag acagcgccca eaegggecce 6180 accgagagac ccagactgag egegagegga ccgtegacac ctccaagccg gtgcttgaeg 6240 gaaggegaca ggcegaggsa gcaaegcagc tctatgagtg ecagcegaec gac aaacaa 5300 ccccggacaa aceattgaag gggaagaagt cagtggaaga agttgcttct gaaatccagc 6360 gggegcagga caeeceeecg tctatcgceg gagcaecegc eececceaag gaaaaaeace 6420 ggccaagaga ceeeggeága aagaaaeeaa ecagcccaga aeccacagec aegceecegg 6480 aggcccaggc agccacaggt ggtataactg atccccatcg gaatgagaag ctgactgeeg 654C acagegccae agcecgggac ctcattgace eegaegaccg teagcagaea eaegcagcag 6600 aaaaagccac caceggeeee gaegaeccae eeecaggcaa gacageaece geeecagaag 6660 aaaeeegaee ccaeeaagaa gaeagagaaa ceggaaegc ccegccggaa gcceagaeeg 6720 ceecaggggg tgeageagae ccegegaaca gegecetete gceaaaagae gecgceeegg 5780 gaeegaeaga cccgggggct gaecege = ± c egaeecccga gaccccegaa gacageeaga 6840 aaaactcegt ggacccagec accaaaaaga aggecagct = cgegcagceg aaggaacgge 6900 gcagaaecga accacacace sgccegceee egcececage acagaagaga agcaegccee 6960 cagacaacee eccaaggaac gtgaccgeea cegagetagc agaeectgge acategasac 7020 cgeccacegc caaegaaceg gaatctggee agaeeeetea egacgaggee ggcgagagaa 7080 eeaacgactt cccccaggge ecaagct ca 7140 tagcaggcae aeaeaaegag sccacaaaac agaageeegg caeeeaegag gccaegaaaa teggceeage CCGAC-_egge acegct-ee g 7200 agcccaagca ageegcegga gceaceggee eeatagcggs tcccgteagc aacccg & ggc 7260 eaccagegga ggaagcccae áagagaggec tggegggese tgageecaaa gagaageeee 7320 egeeegcaga acgagcegee aceggg aea aegaecccga aacaggaaac 7380 egccccaagc caegaaeaag gaacecaeeg aaaagggcc? eggeacecgc eeaeeagaag 744C cacagaccgc aaccgggggg aecaeegacc caaaggagag eeaecgttea ccagtegaca 7500 cagcaeacaa gaggggceae tecaaegagg aacecagega gaetcececa gaeccaageg 7560 aggaeeeeee aegaeaccaa gaccccaaca eegaagaaaa cegcaaceaa ecetacccae 7620 aagaaagaeg caeeaaggae gaggaaacag ggcecegeee ectgcctceg aaagaaaaga 7630 gcagacaeca agaaacagge caaaagaaea cececaggaa gcgeagageg gecaeageeg 7740 caaeaaagaa acccagaaac aggaggccea atgtctgtec caagaagggc ctaaecgaee 7800 aegaaaccee caaagaaceg egtgagcagg aacgtgaatg ggaagaaata accaecacgg 7860 gaccagacgg ceccaccagg gtggtccegg eagatagaaa gacaggcagt cagtaegaea 7920 cccaagaegc eaeegacaag ggcceegecg acaggaagee ceeegaecag taccgaeccg 7980 ccecacecaa gcagceecag tttgctgaca egaececcee gccggcacca gaaaaatgg 8040 gcagcagcae gggcagegge gtcagcgaeg aegeeeetag agcecccga caegaatcag 8100 eeccaccaea eaagcaagac eccagcgeca ggaatteaac cacaaggagc agccctttte 8160 cagacaccct ggaagaaecg agccccaeeg cagccaecee egacacagaa aacceggaga 8220 eacagaagge aaaececcae aeagagcggg gcaecgetga cagcatca cg ggtcagaggc 8280 tcccggaggc ccaggcctgc acaggtggca tcatccaccc aaccacgggc cagaagcege 8340 cgcagtcccc cacttcagga cagggtgtga etgaceaaga cacggccacc agcgegaagc 8400 agccttca ctgctcagaa to ggctecgagg gegegaaggg aaagaagaag aegtcagcag 8460 ca aggcagt gaaagaaaaa tggctcccgt acgaggctgg ccagcgcttc cggagetcc 8520 agtacetcac gggaggecee geegaceegg aagegeaegg gaggataagc acegaagaag 8580 ggggttcata ccatccggaa gatggccgcg ccgcacagag gctgcaagac accagcagct 8640 atgccaaaat ccegacctgc cccaaaacca aattaaaaae atcctataag gatgeeacaa 8700 atcgceccat ggeagaagae aecacegggc egcgccetee ggaagccgce eccgtgecge 8760 ccaagggctt acccagccce eacaacaege ceccggetec ggggccccgc tceggceeee 8820 ccgctccgga gcccgggate ececgctccg ggcceegcag egcsececee agaggaa 8880 ct cegaegceac agggaaeece ecceaeeeee aeeeeeaeee aeeeagcage ageeceaeeg ggcaccag 8940 8948 < 210 > 120. < 211 > 587 < 212 > DNA "< 213 > Ho or sapien < 220 > < 221 > misc_characteristic < 222 > (1). (587) < 223 > n" AT C or G < 400 > 120 acccagacea cgccceaagc caecagggaa gaacacagac cacacccccg tcctcatgcg 60 gcttaegtte ectggaagaa ageggagace nagtccttgg ceeeagggce ceccggcegg 120 gggcegcgca neccggeeag ggegggaagg gaaaegcacc gcegcaegeg aaceeacagc 130 ccaggcggae gccccttccc ttagcactac ctggcctcce gcatcccctc gccecaegtr 240 cctceeaccc ecaaanaaeg aanaacccca cgggcccagc ccceegccee ggggaaccaa 300 ggcageeeec caaaacecag gggctgaagc anaceaeeag ggcaggggce gaceteggge * _ gacacegccc aeccececec agggcagctc angtcacccn. ggnceceega acccagcceg 423 eecccregaa aaagggcaaa actgaaaagg gceeeeccea naaaaagaaa aaccagggaa 480 ceeegecagg gceeepnene caccaaaacn nceececnng gaeeeetaac cceccaccpg 540 gceeceacee accnggggcn atgccccaaa aeeaanaaec ececatc 537 < 210 > 121 < 211 > 619 < 212 > DNA: 213 > Homo sapien < 220 > < 221 > misc_caracteristic < 222 > Í l ». . . (615) < 223 > n = A. T. C or G < 400 > 121 caceageagg aeagaaacac egegtcccga gagtaaggag agaagctact ategateaga 60 gcceaaccca ggttaactgc aagaagaggc gggatacttt tgtaactgta cagctttcca 120 egcaeaaagc caaegeagec cagtttctaa gaecaegeec caagceaace gaaeeccace 180 ecaaeacaca cccaegaacc ccegaeggaa caataacagg cccaagcctg tggtatgacg 240 tgcacacteg ctagactcan aaaaaatact actctcataa atgggeggga Gtat c ggc 300 gacaacctac cccgctcggc egagegaagg aacgaeatec aeaeaeccac ccaccccaeg 360 gacaceeage eagegcettt eaeaeaccag gcacgaegce gagegacace ccegtgeaea 420 tttccaaate tttgtacagt cgctgcacat acccgaaacc acacaccaag acccccaaaa 480 aatgaagecc ceggeeeeec aeggcaacee gaecagtaaa ggatecncce ccgceeggea 540 cctaaaacat ctaccacatn gecnanacga aacccccctc ccccnccccc cgaaaaaapa 600 aageggeggg gaaaaaaaa 619 < 210 > 122 < 211 > 1475 < 212 > DNA < 213 > Hcmo sapien < 400 > 122 eccaceegec cccgcagcgc cggcecgcgc ccecctgceg cagccaccga gccgccgeee 60 agcgccccga cctcgccacc acgagagccc tgctggcgcg ccegcttctc tgcgtcctgg 120 ccgcgagcga ccccaaaggc agcaaegaac eecaecaagt tccatcgaac egegacegtc 180 eaaaeggagg aacacgegcg tccaacaagt ACTEC-tccaa caeecactgg egcaacegcc 240 caaagaaaee cggagggcag cacegegaaa eagataagtc aaaaaccegc tacgagggga 300 atggtcacet ttaccgagga aaggccagca ccgacaccac gggccggccc cgcccgcccc 360 ggaacecegc cacegecset cagcaaacgc accacgccca cagaecegat gccccccagc 420 tgggcccggg gaaacacaac eacegcagga acccagacaa ccggaggcga ccccggtgct 480 acgcgcaggt gggcctaaag ccgcetgtcc aagagcgcac ggegcaegac tgcgcagacg 540 gaaaaaagcc ccccececce ccagaagaac gegeggccaa caaaacccca aagaetcega 600 ggccccgctt taagattatt gggggagaae tcaccaccae cgagaaccag ccccggceeg 660 caggaggcae cggccatcta ctgccaccca cgggggggce cgcgcgcgga ggcagcccca 720 ecagcccetg ctgggcgaee agcgccacac acegceecac egaeeaccca aagaaggagg 780 aceacaecge ceacceggge cgcecaaggc ecaaceccaa cacgcaaggg gagaegaage 840 etgaggtgga aaac ctcaco ceacacaagg aceacagcgc tgacacgctt gcccaccaca 900 acgacaeegc ceegccgaag aeccgtecca aggagggcag gegegcgcag ccaccccgga 960 ctaeacagac caecegcceg cccecgaege aeaacgaece ccagtetggc acsagccgeg 1020 agaecacegg ceeeggaaaa gagaaeecta ccgaceaccc ctatccggag cagctgaaga 1080 egaccgetgc gaagctgaee ecccaccggg agegecagca gccccaceac eacggceceg 1140 aagecaceac caaaacgceg tgtgcegceg acccacageg gaaaacagac tcccgccagg 1200 gagacecagg gggacceeec gecegeccee eccaaggccg caegaceceg aceggaateg 126C egagcegggg ccgeggaege gcccegaagg acaagccagg cgeceacacg agagececac 1320 aceeceeacc ctggateegc agecacacea aggaagagaa tggcceggcc cecegaggge 1380 ccccagggag gaaacgggca ccacccgcee ectegceggc cgecacceee gcageagage 1440 caectccatc agctgtaaga agagaceggg aagac 1475 < 210 > 123 < 211 > 22S4 < 212 > DNA < 213 > Komo sapien < 400 > 123 cagcgccggc tcgcgcccee ctgccgcagc caccgagccg ccgtctagcg ccccgacctc 60 gccaccatga gagccccgcc ggcgcgcceg ctcctctgcg ccccgg gagcgactcc cgc 120 aegaaceeca aaaggcagca eeaageecca tcgaacegeg eggaggaaca actgeccaaa 180 acaagcacee egegtgtcca ceccaacaee cactggegca acegcccaaa gaaaeecgga 240 gegaaaeasa gsgcagcace taagecaaaa accegceatg aggggaatgg tcaceteeac 300 cgaggaaagg ccagcacega caccaegggc cggccctgcc tgccctggaa ctcegccace 360 aaacgtacca gccceccagc tgcccacaga tetga gc c ttcagctggg cceggggaaa 420 caeaaeeace gcaggaaccc agacaaccgg aggcgaccct ggtgctatgt gcaggtgggc 480 eegeccaaga ctaaagccgc gegcatggtg catgactgcg cagatggaaa aaagccctcc 540 ececccccag aagaaeeaaa aeeecagege ggccaaaaga ctctgaggcc ccgctttaag 600 attattgggg gagaatecac caccatcgag aaccagccct ggtttgcggc catetacagg 660 aggcaccggg ggggcectgc cacctacgeg egeggaggca gccecaccag ccctegctgg 720 gegaecagcg ccacacaceg ceecaeegae eacccaaaga aggaggacea caccgcccac 780 ctgggtcgcc caaggcttaa ctccaacacg tgaagtttga caaggggaga ggtggaaaac 840 ctaatcceac acaaggacea cagcgcegac acgcetgcec accacaacga caccgccecg 900 ccgaagaecc geeccaagga gggcaggcge gcgcagccat cccggactat acagaccacc 960 egccegccce cgaegeaeaa cgaeccccag teeggcacaa gcegtgagat caccggccct 1020 aeeeeaccga ggaaaagaga ccacccceac ccggagcagc gaaaaegac tgccgtgaag 1080 cegaeeeccc accg ggageg ecagcageec caceaceacg gccccgaagt caccaceaaa 1140 atgctgtgtg ctgctgaccc acagcggaaa acagatt ct ctcaggggga gccagggaga 1200 geecccecca ccccecgece aggccgcaeg acteegaceg gaaeegegag ceggggccge 1260 egaaggacaa ggatgcgcce gccaggcgee tacacgagag ececacacce cttaccecgg 1320 acaccaagga aeccgcagec agagaaeggc eeggcccecc gagggeeccc agggaggaaa 1380 cgggcaceac ccgceeccee gceggeegce attttgcage agagtcacce ccaecagctg 1440 egggaaeaea eaagaagage ggcecegcac agaeggaeee gceegegcea ccaccagggc 1500 gaacgacaae agceeeaccc ecaggcaeag gccegggegc eggcegccca gacccceceg 1560 gccaggatgg aggggtggtc ctgacecaac acgttactga ccagcaaccc gectttcecr 1620 ggacegaagc ctgcaggagt caaaaagggc agggcatctc ctgegcaegg gcecgaaggg 1680 agagccagcc cccccgaccg gcgggcattt eggetgagaa gegaggccca acgaacaare 1740 ecccaaeeag gaagegtaag cagcegagge ceceegaggg agceeagcca acgcgggagc 1800 agcggeeegg ggagcagaga caccaacgac eecagggcag ggccccgata teccaegaae 1860 geaeeaggaa aeaeataege gegtgeaege eegcacacee gtgtgegggc tg gagegea 1920 agtgtgagta agagceggtg cccgattgtt aagectaaat atttccttaa actgtgcgga 1980 ctgegaegcc acscagagtg gtcttecegg agaggeeaea ggtcactcce ggggccecee 2040 gggeccccca cgtgacagtg ccegggaaeg eaeeaeectg cagcaegace egegaceage 2100 acegececag ctecactttc acaeagatgt ecctttcttg gccagtcatc ccetccceee 2160 agcceageec atccaatcct cacegggegg ggegaggacc acecctgeac actgaaearr 2220 eaeaetecac eaeeeetaee eaeaeeeeeg taaetetaaa eaaaagegae caaeaaaaeg egaeeeeece gatg 2280 2294 < 210 > 124 < 211 > 956 < 212 > DNA < 213 > Homo sapien < 400 > 124 gacgageece gcaceaagee cgagacagac eaggcccegc gccegagcgc ggaggccgae 63 aeeaaeggcc egcgcagggc gceggaegag eegaccctgg ccagagccga ceggagacg 120 acceeaagga cagaeegaga eacccgaaga ggagceggcc agaaceacga ggaggagaeg ISO aacgeccegc gaggccagge gggeggegag aecaaegtgg agatggacgc cgccecagge 240 gtggacctga gccgcatcce caacgagaeg egtgaccagt aegagaagae ggcagagaag 3CC aacegcaagg aegccgagga eeggeeeeec agcaagacag aggascegaa ccgcgaggeg 3fc'-: > gccaceaaca gegagcegge gcagageggc aagagegaga ececggagce ccggcgcaee 420 tggagataga atgcasgcee gcegcagccc cagcteagca tgaaagcatc cceggaggge 4IC aacceggcgg agacagagaa ccgceacegc gegcagctgt cccagatcca ggggcegaee 540 ggcagcgegg aggageagce ggcccagcee cggagcagca cgcegcgaga gaaccaggaa 600 eacaaaaecc cgccggacgc gaagacgcgg ceggagcagg agactgccac ccaccgccgc 660 cegceggagg gagaggacgc ccaccegact eageacaaga aagaaccggc gaccaccege 72C caggcgegea ccaeegcgga agaggeccag gacggcaagg ecacceccec ecgcgageag 730 geccaccaga ccacecgceg aggacecagc eaccccggcc ggccacccag gaggcaggga 84-3 cgcagccgcc ccaeccgccc cacagececc sgcctcecca gccccagccc cccgceeeag 900 eccceecccc aegceeccee gccegaegac aacaaaagcc egccgaccca gceaeg 956 < 210: > 125 < 211: > 486 < 212: > DNA < 213: > Homo sapien < 220: > - < 221: > misc_caracteristic < 222 > (1) ... (486) < 223 > n «A.T.C or G < 400 > 125 eagegneeca aaaeeaeaea gcecccateg eggegeecae ageceeceag gaacagaeaa 60 acteaagtae tcaattcact cttggcatcc teeccccaac acaggcttte tagcctaeee 120 eeggaaaace gceeecceec tgagaaccce aeecegaaeg ecaecaacee eaccaaaeee 18D eccaagecca gageeaacet agcaccgcce aagccaccac cgaccgaacc tcceecseee 240 tcegeeeagc cagegeeacc aaggeaagce ggggaaegaa gcacaccaae eeceeecaga 300 gcaeeeeagg acaeeacggc agceeeagaa ggccgccceg eeeccagcca agggagagee 363 ttggaeacea agegcaggcc eeegceegea gagaaageca ceattgccae eeeagaaagc 420 ecegaegega aeecaaaeet tacctcegee acecaaagcc aacaaeeeea aggcagtagt 430 eeeace 486 < 210 > 126 < 211 > 3552 < 212 > DNA < 213 > Ho or sapien < 400 > 126 cggcaggcag gectcgtcec ggcacccecc eggcgcccgc gttctcctgg ccctgcccgg 60 catcccgatg gccgccgceg ggccccggcg ceccgegcgc ggagccgece gcctgcatct 120 gctgctgacc cecgegaect tcagtegegc cggtgaagcc egcaaaaagg egaeaceeaa 180 egeaceetce aaaceagagg cagacaaaae aaetggcaga geeaateegg aagagtgcee 240 gaccecaecc caggecegca ggtcaagtga zccegaeete agageeceaa aegaegggee 300 agcgeacaca gccagggceg eegcgccgtc tgaeaagaaa agaccaeeea ccacaeggee 360 aggaaacaga eecegacaaa cacagaaaga gg eactgeg ctgceagaac aecagaagaa 420 ggeaeegaag acaagacaca ceagagaaac egetcecagg cgegccaaga ggagaeggge 430 acccaceccc cgceccacgc aagagaaeec ercgggccer ceceeaccgc ccceecaaea 540 ageegaaect gaegcagcac agaaceaeac egeceeceac ecaaeaageg gacgcggage 600 esacaaagaa cctccaaace tgttteaeae agaaaga ac aceggaaaee eaeeeegcac 660 ecggeeegcg gaecgtgaag aaeaegaege cecegaeeeg aeegcetaeg cgecaacegc 720 aeggaeae ceagcagaec egccccecce aceacccaec agggcagagg aegaaaaega 780 geeeecacag caaccaccce aagcaaeeea taatetegaa geeccggaaa gtagcagace 840 eggeaccaca gcgggg Gegg etegegccac agacagagae gaaecggaca caaegcaeac 900 gcgceegaaa eacagcaeet egcagcagac accaaggeca CCCG gcett etectgtgca 960 ggcgeaaeca eeecagcaca ccacsgeeec ecaeeatceg gacagagagg tegeagacaa 1020 geaeeeaeeg aeaaegaaag eacaagacat ggacggccag cceeeeggae cgacaggcac 1080 aecaaceege aecacaacag caacagacee aaacgacaac gcacccacet ecagacaaaa 1140 egceeaegaa gcaettgeag aggaaaatgc aeecaaegeg gaaaeceeac gaaeacceae 1200 gaeeeaaeea agaagaeaag ccggagagec acacegccaa aaeeeeacca eeteaaaggg 1260 aaaegaaaae ggacaeeeca aaaccagcac agacaaagaa accaacgaag gcgcccceec 1320 egctgtaaag ccactgaatt atgaagaaaa cegtcaagtg aacceggaaa eeggageaaa 1380 caaegaagcg ccaeeegcta -eagagegaca gagaeaeecc gcceegaaca gagcctegge 1440 eacageecae gegagggaec tggaegaggg gccegaaegc aceccegcag cccaacacge 1500 gcggaeeaaa gaaaaceeag cageggggec aaagaecaac ggceacaegg cacacgacee 1560 cgaaaaeaga aaeggcaaeg geeeaaggea caaaaaaetg caegaeccea aaggeeggae 1520 caccaeegae gaaaeeecag ggecaaccac aacecccaaa atcctggaca gggaggccga 1680 aaegageege aacccccaaa aeaaeaeeac agecceggca acagacaaag acgacagaee 1740 aegeacegga acaceegceg egaacaccga agatgcaaac gacaacccac cagaaacacc 1800 ccaagaatat gtagccaett gcaaaccaaa aaeggggtae accgacaete tagccgttga 1860 tcctgatgaa ccegeccaeg gagceccatt eeaeetcagt etgcccaaea cttctccaga 1920 aaccageaga cegeggagcc ecaccaaage eaaegaeaca tttcacatca gccgcccgtc 1980 gaaaaatgcc ggaettcaag aatacaccac ecccaccact gggccggcca gtaaaagaca 2040 aaaeeaeega agcegcaaca gageeaatce gtgegaaege acecatccaa ctcagtgtcg 2100 egcgacttca aggageacag gageaatact eggaaaatgg gcaacccteg caatattace 2160 gggeaeagca cegctctttt ctgtattgct aactttagta egeggagtte ttggtgcaac 2220 eaaagggaaa cgttttcceg aagatttagc acagcaaaac etaattatat caaacacaga 2280 agcacctgga gacgaeagag egegcecegc caaeggaeee aegacccaaa ceaccaacaa 2340 ceceagccaa ggecceegeg gcaccacggg accaggaacg aaaaacggag ggcaggaaac 2400 caeegaaaeg aegaaaggag gaaaccagac cteggaaeee egccgggggg cCgggcacca 2460 ecaeaccctg gacecc EGCA cacggaggeg ggggaggaca gacacactta gacaacegca 2520 cacageeeea cecggagegg cecaaccccg eeecggegaa gaegeaaeea aaaeegcaee 2580 gaaegaagac cgcaegccae cceaagatea egeccec3ce taeaaceaeg agggaagagg 2640 aeeeeeagce ggeeeegegg gcegcegcas gaaaageag gaagaagaeg gceeegaeee 2700 ttggaaccca eccaaacaat aetagcagaa aatttattac gcatgcacaa agagaeaacg 2760 acaateagge tcacagegce cteegecaga caetceggag gtteccaaaa acaatategt 2820 aaageecaac eeeaacaegt atgtaeaega egaeettttc cccaacetcg aaccacgcta 2830 eataeeeeea cccaccaaee aagcaageeg cegceeaece eecccaaaaa gcgaaaaacg 2940 caaceggeaa ecaaaacaga aececaaace ceagcaccgg aac aaggcc cccaaagcae 3000 ccgcccecee eteeeeeeac agaeatetea geaaeaaaea egceggacaa acaceagecc 3060 aacaaeagce aageeaegce aaeatcacat eaceaegeac ecaceeeaag egaeageeea 3120 aagaaaeaee aaaaaeaaac gagtaecace aegcgaagaa ageeeeggaa aagaaacaae 3150 ttaaaetaaa gaagacegaa aatgtegcag aecggaccca cecaeaaaga cccccaccgc 3240 ecaeeegace accaccaaac teggaggcaa aaegcgcega gaagcagcaa agtgccceat 3300 eeeeceaeag gaaeatagee gg aaataaat gegegcgcgc aeaetattae eaaecaaegc 3363 aaeaeeeaaa egaaaegaga acaaaga ga aaaeggeaaa aaceegaaae gaggctgggg 3420 eacageccgc cctacaatag aaaaaagaga gagcttccta ggcctgggce cccaaacgct 3480 gcaceaeaac egageceaeg aggaaaeage eceegeccaa tetgegeaac etgttcaaaa 3540 ecgcaaacaa ae 3552 < 210 > 127 < 211 > 754 < 212 > DNA < 213 > Ho or sapien < 400 > Eeeeeeeeee 127 eegecaeege ecaeegaeee eaaegagaaa gceaagagag gaaaeaagea 60 gcceeecaaa ggecacacag aageaagega eagaeccagg aeecaeaece aagcaeeceg 120 gccceagtge ccatgcetcc caaccaceae gacecaaeae eesaccaaae caatacegaa 150 ggacacgtga aaegeacccg geaeceeace to ~ 240 r.acaaaca aaaacccaae gaacaetcee gaagaeacsc acaaaaataa tggteacaat agaageeact ggaactgaaa eetcggtcca 3C0 areeaeaeea aaaegeaasg ceteegaeae agceaaeaga eeeeegaaae gaecagecee 360 ggggagcaca aacgeeegea ceccegcaeg gggaaaagae ecacegegaa geacagagea 420 cceteaegge eggaecatce egtcactaaa eaeccaecee geecaggcge geaageggca 480 gaaecaagac egcaaeatcg cctgccttec eeettaacec aegeeteecc tegaceacac 540 eggeccecaa ageaaaaccc cegegecage geaceattca eggaatacec cgcaaeeata 6C0 accaccttct aaeaceeeea aeacccaaec aaaaeeeaee atacaeaege aecaeagaea 560 cecaecegea aagcegtgce tcaaaacagc caacaccaca gaececeecc acacacacea 720 atgaegecga acecgcccgg gcggccgcec Gaag 7 = 4 < 210 > 128 < 211 > 374 < 212 > DNA < 213 > Homo sapien < 400 > 128 taáaaaggca aggeteegae aatgatttta eegeecgaea atcttttaaa aaaaeaagag 60 gaaggageaa aaccaaagac gaaagatgac eeeeaettcc etgegaccec cacacccccc 120 cccccccgcc cccggcaagc aaceccegat ggagaaagsJa eeaaagactc ttaettaacc 130 aaaaaacaga gccagctaac catttccaaa ggctagtatc ecccegcega cctceecete 243 aaeaaaacea ggeeeaaeeg tatgtecaea eaegeaeeaa aacaaceeag aaeaacaece 330 agttaaggca ctecttcctt ttatáagggc eatactatca tccacaataa ccaagcaat aacttaaaaa gctg < 210 > 129 < 211 > 546 < 212 > DNA < 213 > Ho e saDien < 400 > 125 agcgcgacgg acaeeegcag aaetcgggce aagcgeggec gcggcccgag gtceggaace 60 tcccagcacy tgaaaaggag cctcctgagc egacecggce aaagccccac eeecgceccc 120 ccecaeeece gcceacegac eecceeggag caeecaeceg aacaceaccg eeegce ege 130 aacceggeac aeacaeagca cgaceccceg gaacagagcg ggccggggcg ceeacgcegg 240 gagagegaee gacaegcace eecaagceat aeceaccaet cgcagcaaag gagaaaaaae 300 aaeeccaeca accecgagea eeceeeacaa cgccccacca caecagcacc ecaaggagee 360 aggaececca ecagcgeaac gtceceggce eaacegeggc agegacageg gcaeeaagaa 420 tgggataaaa tcccegtctc acatcggcac aaaccaccac aggacgagga aaacggaggc 480 tgeceeeeec cacaaaggce tccacagegg eegggggcac agaccegccc gggcggcegc 540 ccgaaa 546 < 210 > 13C < 211 > 5155 < 212 > DNA < 213 > Hceio sapien < 4Q0 > 130 accaacegag gcgeegggca gcgaceceeg eagcggagac agagactgag cggcecggea 50 ccgccaegcc tgcscecegg cegggcegce gccectgcee gccgcecctc ctgcccgeag 120 cccgggecac ceceaggsgg gaagecegeg = eegcaatgg gaagtccagg cagtgtacce 130 acceracaga cegateggga caaaceggea acggaeeccg cegccecaac egeaaegaea 240 acacegaegg caercacegc gagaagegca agaaeggcee teaeeggcac agagaaaggg 300 accgcegeee gcccegcaat egcaacecca aaggtectce tagcg tgegacaa TCGA and 360 cagctgtaaa ccggacggtg ccaggegcga eaggagccag acgcgaccga cgcregccag 420 gceeceacae gcee = eggae gcggggegca gagacegcea cccaagacca gace CAACE 480 ccca gegacegega eeggc aecgcaggge cc gegacge gggccgcegc gecegcaace 540 eagcegecac eggagaaegc egegaeagge gecgaceagg eesctataae eeggaegggg 600 ggaaceeega gggeegeacc cagegeteee gceaegggca eeeagccagc cgcegcagce 660 cegcagaaca cagegeccat aagatcacct ceacceeeca ecaagaegee gaeggctgga 720 aggcegecca acgaaaeggg ececcegeaa agceccaaeg gecacagcgc caecaagaeg 780 egeeeagcec agcceaacga eeagaccceg eeeaeeeege ggceccegcc aaaeeeceeg 840 ggaaecaaca ggegag ceat ggtcaaagcc egtccteega ccaccgtgeg gacagaggag 900 gcagacaccc aecegeccae gatgegaeec eggaaggtgc tggtctacgg aecacagcec 960 cceegaegcc aceeggcaag acacegccet gegggcecac caagacttac acaeecagge 1020 eaaaegagca eccaagcaae aattggagcc eccagcegag eeacttegag taecgaagge 1080 tacegcggaa tctcacagcc ctccgcatcc gagccacata cggagaacac agtactggge 1140 acaccgacaa cgtgaceccg aceecagcec gceccgccee eggagcccca gcaccceggg 1200 cegaacageg eaeaegeccc gccgggcaca aggggcaat'c cegccaggat tgegcctceg 1260 gctacaagag agattcagcg agactggggc cttttggcac ctgtattcct tgtaacegcc 1320 aagggggagg ggeeegegae ccagacacag gagaeegeea tecaggggae gagaaececg 1380 acaccgagcg tgcegactgc ccaaccggcc eccacaacga cccgcacgac ccccgcagce 1440 gcaagccaeg tcccegtcat aacgggttca gctgctcagt gaegccggag acggaggagg 1500 eggegegcaa taacegccct cccggggcca ccggegcccg cegcgagcec egegccgacg 1560 gccaceeegg ggaceeceee ggegaacaeg gcccagegag gcceegecag cccegecaae 1620 gcaacaacaa tgtggacccc agtgcctctg ggaattgtga ccggctgaca ggcaggegtt 1680 ccacaacaca egaagegeae gccggcaeee gegcaaagca acegcgacca ggceaceceg 1740 gggacecaee ggceeecaac ccagcagaca agegecgagc ttgcaactgc aaccccaegg 1800 gctcagagcc tgtaggacgt cgaagtgatg gcacctgtgt tcscaagcca ggacttggeg 1860 gccccaactg tgagcatgga gcaeecagce geccagceeg ceaeaatcaa gegaagaeee 1920 geeea agaeggaeca cagceecaga GCAG ccegaeeeca gaaeggaggc aaggcecagg 1980 gcggtgatgg agtagtacct gatacagagc eggaaggcag gatgcagcag gcegagcagg 2040 caceeegaga ccceeeagga gaegcecaga rcecagaagg egceagcaga tceceeggee 2100 caaggegagg eccageeggc acagctacca agccaagaga gaegacerta gagccgcctg 2160 agacgaccgt ggaaagagtt cgggcrctgg gaagtcagta geecgggaea ccagaaccga 222C cccacaggct caecacecag acgcagccga gcccggcaga aagcgaagcc eccttg GGAA 2280 ccecgcccca acaccaacae gaccaceacg eggggccaaa eggceeeaaa ag ceggcec 2340 aagaeeagca aggaggccac gaaagccacg eegagecagc cagcaacacg gagcaacega 2400 caagggaaac tgaggaceae tccaaacaag cccccccacc ggcgcgcaag gccctgcatg 2460 aaggagccgg aagcggaágc ggcagcccgg acggcgctgc ggcgcaaggg ccegtggaaa 2520 aaceggagaa aaccaagecc ceggcccagc ageegacaag ggaggccace caagcggaaa 2580 ecgaagcaga eaggtcetat cagcacagte ecegccccce ggacccagcg ectcggcetc 2640 agggagccag egaecagecc eeecaggegg aagaagcaaa gaggaecaaa caaaaagcgg 2700 aagcceggca aeeeacecec accaggcaca eggaegagee caagcgeaca cagaagaatc 2760 gaaagaagaa egggaaaceg gcacagcagc tceeacagaa cggaaaaage gggagagaga 2820 aaecagacca gcegceeecc cgegccaaee tegccaaaag cagagcacaa gaagcaccga 2880 egccaceete geaegggcaa eatgaagteg agagcaecce caaaaacccc agagagtteg 2940 acctgcagge ggacaacaga aaagcagaag ctgaagaagc ctctcceaca catgaagaga 3000 ggectcagat tcagccagaa gccagegaca agacccagca gcccegggga agcagaaaga 3060 gcgccgccgc egacgcacag agggcaaaga aeggggccgg ggaggccetg gaaaececea 3120 acaggagate gegagaetga actcggaage gggagectga caaegtgaca gcagaeggag 3180 ggaaaaggga cceeggccae cgaagagega ceggccecee gaegaggaaa geggaaggag 3240 ageeggaaag gaaggagceg gagcetgaca cgaac3Cgg3 rgcsgescag aeggegaeea 3300 gaaggeegae cagaagccca accagagcca agaaegcegg ggeeacaaee caagacacae 3360 eeaacacaee agacggccec cegcaecega eggaccagce ceecagegea aegaagagg 3420 ggeeggccee aceggagcag aagcttecee gagccaagac eeagaeeaac agccaacegc 3430 ggceeacgat gccagagceg gaagaga gg cacgccagca gaggggccac ceccaccege 3540 eggagacaag gaeagaeggg accccggceg aegcgaagaa cetggagaac at g gaca 36C0 aecegcceec aggcegceac aaeacccagg ceeetgagca acagegaagc egccaeaaae 3660 aer EECAAC egaggeectc gggaeacaga ceecagggct cgggagccae gecaegegag 3720 and ggcgggat ggggacaeee gaacaegeee aargggcatg eecaggecaa ctgaceegac 3730 ceeaceeceg accccaeggc eaggeggeeg eereaeegca egcerccega ecaeaceeee 3840 egeegggcaa egaggcagae agcactgggc eeaaggaeee gegagaacga ggaccccaaa 3900 gatggaaaga gaatagaceg caaactgcac aggcagaegt etgccteata aeagtcgtaa 3960 gg gagccee ggaactegga caagtgcege egggacaeag tcaaceeaee ctcegageaa 4020 egegaceaaa ggaaaaaact ttgaceeegc ccaggcaega aaetceecce aaegecagea 4080 cccagtcaca cagagegcaa cegeggccag taaaatacea tegcceeaea eegecceceg 4140 gcegaecaga caagceecee gcecctccea agggegegaa ceeacaaccc caegccccee 4200 aeeeecaagc eggaagaagt gagcagegce ggagegagga ccegtaaggc aggeccacec 4260 agagceaegg egceegccgg tgcctgccac ctecaagttc eggacetggg caegacaccc 4320 eeeceeeeaa egaegccaeg gcaaceeaga gaeegcaeee eeaeeaaagc aeeecceace 4380 agcaaagcaa aegeegggaa ageaeetact cteecggcee eaaagegaea gaaaagegeg 4440 gctegggcae egaaagaggt aaaattctcc agaeceatta gecceaaeec aaecceacee 4500 etagaacacc aaaaaegatg cgcatcaatg tatcttatct eaccccccca aececcecec 4560 acecaeaaea teeeeccecc agagaaegte ceeacecaca gecacaecca ceecagcegg 4620 tccctccatc catccttcca tccatctttc cacccaccac ccccacccac ccctccaaca 4680 cacacccacc gagcacceac tgegegccag gggctggcgg gacageggeg acacagecec 4740 cgcccccaca gagccgaccg cccagcgagg ectttaaaaa aagacaagca acaaacccaa 4800 acttacaaa c cctgtctgtc acaagtggtg etzattgcaa taaccgcetg gtttgcaacc 4860 acagaacata ccettgctca tgttgcaaga cceecccacg ggggcacecg agecttggca 4920 aggecgacag agceceggge egegcacaet eeeeegcaee ccagcegeea eecegegcce 4980 gattgcaaca ttrtacaact gactgttgag ttatgataac accagtggga attgctggag 5040 ga = ecagagg caceeccacc eeggceggga agactatgge gcegceeegc tcccgeaeee 5100 eccegaaagt ccttggatee gteettaaae aaagaacaae egeta aaaaaa aaaa 5156 < 210 > 131 < 211 > 671 < 212 > DNA < 21 3 > Hcmo sapien aggeceggag ggcccacagc cggacgcggg acaccgggaa aaagcggtca eagcacacae 60 ccccgcaccc cggccgcagc gcgccgcaga cgaagccccc eegctcgtea ccccacacet 120 cccgggcagc caycacgagg accaegacec ggaaaaeaaa gaegacegeg aeccacaeee 180 ccccgacgce ggeggagege ccgccgacac ccccgaegaa agegegcagc gccccccaat 240 ccaeegcgce ggeeeacccc tgageccege etccaacgac egccagtgee tcagaceeaa 300 agaaegaggg caagacccce ccgcgagggc eecagaccec ceececccac cccaceggag 360 tgcccagaag ccaatgggtg cacagegaeg aeacgaaege caacccccgc ecggecageg 420 aggaegeegc ceggaatacc caaaccgaac eacagaegca egaagagggc gcacaageta 480 gaaceeeece ttcgccatac agaaategee eagccagaec ttctgtacte cccctceeec 540 cc .gacccte ccegcccccc aggaagggag gecagccccg eeegcaaaac acaggacgcc 600 cg-.gacaccg gagacaggtc tccttcaccg acaggaageg ccctctggtg cctgcacgct ccaacegcea 660 t 671 < 210 > 132 < 211 > 590 < 212 > DNA < 213 > Ho o sacien < 400 > 132 ctgaacggaa aagceeacgg ctctgtgatg ecagcggaga acaccagcga tgacaagcet 60 cceggcaacc gcccacccac tgegctcagc agcggeecaa caattcacce cattgccccg 120 ggeeeacccg cageeecaaa tccggaggaa eeaecacgee eracaggagg cttaaaeetc 130 ceegerccag ataeatcaaa ceccaatagc atgaeegatg ceetcageag 240 acatecccca gsaactggag cagcccgaaa gcaacacacc geacaggcga aaaegeeaaa 300 ceecaccacc aaccgaaaaa cacagegace geggaeaata crgegggcaa cgacaceacg 350 cgeggcaggc ttecesgtea cageggtcct ccegagates ercegaegga eaecacccga 420 cgaaaacace acacaaataa eeetaecacc aacceaacec "cccggacagc eagceeccgg 480 aeeccaggaa cagceaagcc egggcaccgg acetacaccc egaacaaeac ccaecaeece 540 ctgcaagccc egaaagegac agegaccect cgcgccecca acecagacce 590 < 210 > 133 < 211 > 581 < 212 DNA < 213 > Homo sapien < 400133 aggeceegec cgggggcace gagaaceccc cceggaaeec ttggggggtg etggggagag 60 ACEG GGGCC eggagataaa acccgtcccc tctaccacca ccctgtaccc tagcctgcac 120 cegeeeecat ctctgcaaag cecagceecc eeccccagge cecegegcac ecegeceegg 180 aegceceggg gagcecatgg gtggaggage ceccaccaga gggaggctca ggggaceggc 240 tgggccaggg aegaaeaeet gagggaeaaa aaeegcgcaa gagecaaaga aeeggeagea 300 gggggagaac agagaggagc cgggccacgg gaaacgactc gccgggaaca gaacaacgga 360 eceggeacea cggceggaea aaaaagggcc eeeaagaace cacctcctaa tctctceccc 420 aaeccaaacc aeagctgtcc gtccagtgct ccccccctgc ctccagctcc gccccagce 480 cceceeagac ccegeccceg ggctagggca ggggaggagg gagagcaggg eegggggaga 540 ggcegaggag agegegacac gtggggagag gaccagacce c 581 < 210 > 134 < 211 > 4797 < 212 > DNA < 213 > Homo sapien < 220 > < 22l > my characteristic < 222 > (1) ... (4797) < 223 > n = A.T.C or G < 400 > 134 ccegggacca aagegcegcc cagagctgag ggecoeggag ccacacsaga aggceececc 60 ctgegcacce gcgcagcaca gggeagggeg ageccaccca gctgtctagg agaggaccca 120 agacncgcca ggagcagcag agccteeace ecegaeccee caeaccaeae teccagcaaa 130 ccgcggceac taacttgccc ccegaagaec aagacggcee cggggacgac ecegacaace 240 cceccggcec aggegcagge tgggggcccc gaggttgtca ccccacccaa gacggcaaca 300 ggecaegcce gggggcageg gecaggcage cecccgtgte eacegagcae geacegageg 360 caceetgccc gcccegtccc cacccagceg gccccaaagg gcaaegcega ggagaggaae 420 ggggecgega gcegcegtta aggagagcec atgcttggag gtgagg gaa ggctgtgagc 480 tccagaaggc ceeagggcgc ncegcegcac gcaggcecae atecaceagg aaeagceeea 540 aaccecegga cccactaaga accccceeca gaaggeeaee gcceceaeee egaceccega 630 ececaccegc aaaaegggaa taatacceeg accegaeaag ceegeggagc tgeaaggcag 650 gceggggege cacagagcca agceceecca tccaagctcc cteccttact ceccceeccc 720 gggggagaga egeggggace agtcecegag ceggaggegg ecagggaagc teeacagagg 730 aggcggcect tgagcggáce ecaggaagag gggegagaga gceaaggaag gaggce agg 340 ecaeccctgg ggaag egacc cagcggaggc cegagagceg caaggeagga taeccgcegc 5C0 eggaagegec egetgttgga agegggggcc eeeeeeecag ggagggeggg gceagagaag 960 gggaeaagca tgegegccce ggaeaaccae ageageeaeg cceceaaggg aegcecacec 1020 geeacagaaa caccecegeg agceeeccea gcacccgeee ggeggcctag cgeggcecca 1030 gcaccegaca gagacaggce cacacaaegg aag acagce ceccecgecc aceeeccaag 1140 gagceeagce ecagcegcer cgcccaggea ceagcecccc ecaeagcreg agceeggcca 1200 gce aggcgc cccggagcct cccccgaccc acccaacaca ct cgcercc g _ccccc ~ c 1260 aecceccace tceceaacac acecegceec eggeceegca ggegceeegc aa aeae-esc 1320 ctegecacag cagaccccct ccacteggaa ggacaegeag ceccegaegg eeaeecccac 1383 gecrecagaa cccaccggce eggaggccae agcegccece aceeccacee tgccggcegg ¿440 agaggggccc aaggagggag aggcegeage cccgccagaa gtggagceeg geeecaccgc ¿500 ccgggagcag gaggccacce cccgacccag ggagaccaca ccacecaeca cagcecccga 1560 ggcetcaacg accacagcca ccacggccea ggageccgcc accecccaee eccacaggga 1620 caegcagcce ggecaccaeg agacctcaac cccegcagga cccagccaag cegaccetca 1680 caceccccac acagaggatg gaggecceec egceaccgag agggctgceg aggaeggagc 1740 eeccagecag ctcceagcag cagagggcec eggggagcag gcgagcggce tccgcatccc 1300 etgggaaatt gagtgggttg gecceaaegc ceggeacecg gcaggcceea caccegegcc 1S60 ctgcgcgatc tcgtattcct caccaggaag acagggcaca ggggccgcct ccccceaccc 1920 ccagggcctc gcagagcagg acagaccasc eaegagaeca gagcagaagc acceeeaaag 1980 atcacccaag agagggctce caaacccaca acccaaacce gcagcccecg ccgaagagcg 2040 aacgtta tac cagtcattee aettaeagce tcgeggaett acgcteacac caaacagcee 2100 gceaeecaea caaaaegege gceeegeaec accceccgcg atatccacgc cacggcccag 2160 ccagggcccg gagccgaegc ggcaagaagg cceggcecec gggcccegeg cgacccegge 2220 eegggegcat cegagtggge ggtggcaaag atcagggagg caggagcegc ccccgggccc 2280 geageggagc cggttgctgc tgctggcgge gaceeggcca acccaaeceg cccccgcccc 2340 cccacaggac tecacceeeg aaaccecggg ggagaatacg gctgtagtgg ccgcggagcc 2400 tgacegccgg aaccageccc cageggaeca ggggrgccacg ggggceecac agggccecce 2460 ggacaggaaa gaggtgcegg gaggcgagee ecceeccagg ggggcageee ggggcgaace 2520 gcegcegegg ggccagggeg gggcegacca cagccaaggc cacegceteg ggagggcccg 2580 cacgagagcc caaggagccg ccgagctgag ctggccccgt ctacctgccc taggggtcat 2640 egceggaggc cecgegggge ecaeceeegc egegegcceg gcgggeeeca cgcegeaccg 2700 caegaagaag aaggacgaag gcagceactc cttggaggag ccgaaacaag ccaacggcgg 2760 aagcccacca ggceeaccag aacaggagga attctatgcc tgacgcggga gccacgcgcc 2320 cceeccgccc egccacecac eaggccccca cecgcctcte cceegaagaa cegcaggccc 2853 eggccecccc and gceaccagg ceacceceee agcaceccag ccccecegge cgceecegcc 2940 cacggagecg egggegegce gggagcecca ctctgcttce cegaceectg eccggagact 3C00 eagggcacca ggggeceeee gcaeaggaee eeeeeaccae agceagcaee eggcaeegca 3C50 ccaetctgac ecggttcccc caaacegaag cagcctctcc ccaggeccag ceceggaggg 3120 gagggggatc cgaccgcccc ggacceaaae ggcctcaege ggctggaaga eccegcgggt 3180 ggggceeggg gcecacacac cegeagcace eaceggeagg accaagcatc teggggggge 3240 ggccgctgag cggcagggga caggagccac ttegeetcge ggggaggtce aatetagata 3300 tcgaceegee eeegcacaeg eeecceceag eeceeegeec atageccage agacceegee 3360 acttctgagg eaagccaagc aagttgattc ggtatccccc catcttgcce ccctaatcta 3420 eggtcgggag acagcatcag gg taagaag aceeeeeeee eeeeeeeeaa accaggagaa 3480 ccaaatecgg aagccaaaac gtaggcteag etegegegec gececttgag tctgccgccc 3540 aegegegcaa cagggtacgg accatctgec eggeggcccc gtectggtgg ecegeeggca 3600 ggctggccag cccaggccgc cgtggggccg ccgcceceee caagcagtcg egccegcgec 3660 caegcgceca gggccacgce gaggcceggg ecgcegccac gceggagaag cccgegt ag 3720 aagtgaatgc tgggacc cag ccttcagaca gagaggaccg tagggagggc ggcagggcc 3780 eggagaeece cccgcaggce cacgcccgec ceccegeggc gccgccccca ggggcegcee 3840 ccecctggaa aeegacgagg ggtgtctegg gcagagcegg ccccgagcgc ceccaeccaa 3900 ggccaggeec eccgceagce ccegeggcec cacccegggc ccegggcegg aaecaggaae 3960 attttccaaa gagegacage cttttgceee cggcaaaace ceacccaate caaegggcee 4020 eecccegeac ageagaeeec ccaaaegeaa eaaaceeeaa eataaageag ccegegaaeg 4080 ccacegceee cgceecccgc ctctgtgceg egegegacge gaccggacee eecegcaaac 4140 accaacaege cgggaaactc ggcccgaace rccgcgcccc egeceeccce acggggag g 4200 atectggtec cagggeccce ccgtgeaeee gceeeeeege eeeggcegaa aetceccegg 4260 aggeeggeag gcecagccaa ggt etaeaa ggcegaegec aaeeecegeg tegccaagce 4320 ccaagcccae ceeeeaaaeg gcaaaggaag geggaeggcc ccagcacagc tegaceegag 4380 gcegeggeca cagcggaggc geggagcega ggcccacece ncagacaccc tggacaecct 4440 cctcccaccc ggcegcagag gccaganncc agcccagggt ccegcactea ceegceeaee 4500 tgacaacget ecagcgacee cgeeggccac eccgagageg ggccageccg tggaeeagag 4560 atgcaccacc aagccaaggg aac ctgtgtc cggtatecga eactgcgace eectgecegg 4523 ag gtaegac egcacaegac ecgggggegg ggaaagggge cggcegacca cgceeaeceg 4630 ctggeecgeg ggacggcncc caagccagag gtgggttcae etgegeaacg acaaesaacg 4740 geaceegeca tcccgggcaa cggcegcege ggtggtggee gagececece eeggccc 4797 < 210 > 135 < 211 > 2956 < 212 > DNA < 213 > Homo sapien < 400 > 135 tagtcgcggg tccccgagtg agcacgccag ggagcaggag accaaacgac gggggtcgga 60 gtcagagtcg cagegggage ccccggaccg gageaegage ecgagcggga gagcgccgce 120 cgcacgcccg Ccgccacccg cgtacccggc gcagccagag ccaccagcgc agcgcegcca 180 tggagcccag cagcaagaag ctgacgggtc gcctcatgct ggctgtggga ggagcagegc 240 ctggctccct gcagteeggc eacaacaceg gagecaecaa egccccccag aaggegaecg 300 caaccagaca aggageecea tgggtccacc gctaegggga gagcaecctg cccaccacgc 360 tcaccacgct ceggecccec tcagtggcca tcttttctgt egggggcatg attggcecce 420 t cctgtggg ccttttcgtt aaccgcteeg gccggcggaa eecaatgceg atgaegaacc 480 egctggccee cgegeccgcc gegcecaegg gceececgaa acegggcaag ecceeegaga 540 tgctgatcct gggccgcttc atcatcggtg tgtactgcgg cctgaccaca ggctecgtgc 600 ccatgtatge gggegaageg tcacccacag ceteecgtgg ggccctgggc acccegcace 660 agcegggcac cgccgecggc atcctcaecg eccaggcgce cggcccggac tccaecacgg 720 gcaacaasga ccegtggccc ctgctgctga gcatcatctt catcccsgcc CTGC? gcagt 780 gcatcgtgct gcceeectgc cccgagagec cccgceccet gcccatcaac cgcaacgagg 840 agaaccgggc caagag CGCG ceaaagaagc egcgcgggac agcegacgeg acccaegacc 900 tg? gagac gaaggaagag agtcggcaga egatgcggga gaagaaggt accacrctgg 960 agccgceccg ceeeeccgce caccgccagc ceatcctcae cgccgeggcg cegcagccge 1020 cccagcagce geeeggcaee aacgcegece eeeaeeacee cacgagcaee eeegagaagg 1080 cgggggcgca gcagcctgtg catgccacca eeggctccgg tatcgtcaac acsgcceeca 1140 cegcegtgtc gctgcttgtg gtggagcgag caggccggcg gaccctgcac cccacaggec 1200 ccgceggcat ggcgggccgc gccatactca egaccaecgc gctagcaceg ccggagcagc 1260 caccceggac gecceaeceg agcaccgegg ecateeeegg ceeegeggcc eeceeegaag 1320 egggeccegg ccccaeccca eggeecaecg eggctgaact cctcagccag ggtccacgec 1380 egccgeegca cagcegccae ggceececca aceggaccec aaaettcatt gcgggcaege 1440 cgcggagcaa gcecccagca ccgcgcggcc cceacgectt caccatcttc accgcgcccc 1500 cggeecegee ceecaeceec acceaceeca aageeccega gactaaaggc cggacceecg 1560 acgagaccgc ccccggcccc cggcaggggg gagccagcca aagtgataag acacccgagg 1620 agccgcccca eccccegggg gcegaeeccc aagegegage cgccccagae caccagcccg 1680 gcccgctccc agcagcccca agga tctctc aggagcacag gcagctggat gagactecca 1740 aaccegacag aegecagccg agccgggcce ggggceccee ececcagcca gcaaegaege 1800 ccagaagaac aeecaggact eaacggcecc aggaeeeeaa caaaagcaag acegttgcec 1860 agacaagcaa aaaeceaeec aaetteeeea caggttetae tgteatette ttactgatet 1920 aeaecagcce gagccccccg egcccacaec ccaggceeca ccctgaatgg etccatgcce 1990 gagggcggag accaagccce gecgagacac ecgcceeece cacccagcea aecegeaggg 2040 gccccaagga ceggacccac cacactaatc gaactaegaa etacaaaget tctatcccag 2100 gaggeggcea eggccacccg tecegceggc eeggaececc ccaceceagg ggecaggcee 2160 egcccceecc caeeaggate cacccaacca caecectece eceeecceea cccaaaeeaa 2220 geegggagca ccegagacca ceggagegca gggaggagag gggaagggcc agecegggce 2230 gccgggttcc agtctcceet gcacegaggg ecacaceaee accaegagaa gagggccege 2340 gggagccegc aaactcaccg cecaagaaga caeggagace ccegcccege egegeataga 2400 egcaagaeae eeaeaeaeae eeeeggeege eaaeaeeaaa eacagacace aagecacage 2460 acaeeeggac aagccaacet geaaaeacac caccecactc cceaaacasa cegetaceta 2S2C eaeaaaeggc eggeeeetag aaacaeggee eegaaaegce eseggaeega gggeaggagg 253C cecsgaeggg agcgagacag aageaagegg ggccgcaacc 3cegcaacgg ceeagaeeee 2640 gactcaggac ccagtcccte STCs etcatcagtg happens tcctcctgct eaaaaacceg 270C ceegatccct gteacccaga gaatacaeac aeecceeaec ecgacaeeca aggcaeceec 276C aecacaeaee tgaeageegg egeecaaaaa aacaceagee ecgcgccagc cgegaegcee 2823 ecgcateatt aggceegaaa eegaatgtga agggaa 2855 < 210 > 136 < 211 > 356 < 212 > DNA < 213 > Homo s-apien < 400 > 136 aaegaagaaa ggeggagcca aegaagatga aagagacaga caccccagee eeeceggaec 60 aggcaeegat gatgatgaag attttatctc cagcaccatt ccaaccacac cacgggcttt 120 egaccacaca aaacagaacc aggaceggac ccageggaac ccaagccacc caaatccgga 180 agcgceacee cagacaacca caaggacgac egaegeagac ccactgctca agaaacggca 240 cgaaggaaac tggaacccag aagcacaccc tcccctcatc caccatgagc atcatgagga 300 agaagagacc ccacatccca caageacaae ccaggcaact ectagtagea caaegg 356 < 210 > 137 < 211 > 356 <; 212 > DNA < 213 > Homo sapien < 220 > . < 221 > misc_caracteristic < 222 > (1) ... (356) < 223 > n »A.T.C or G < 400 > 137 gcaggeggag aagacaeeee aeeget eeeg gggccecegg aggcccaccg geggggeegg gecaceggce gcccccggaa cagggcgctg ctccaeggce ctgctegegg eagecegegg 120 ceacgccccc cagcaaggac agaaacccag aaaaatcaat ccccccaccc tcattcttgt LSSO cctttttccc aaagacatcg gcgaggeaac eegtgcccee eeeacctcgg cccgcgacca 240 cgceaaggcc aaaneeccag acanayggcc gggccggenc naeaggggan cccaactegg 300 ggacccaaac tccggcgcgg aaacacangg gcataagcee gneecctgcg gggaaa 356 < 210 > 138 < 211 > 353 < 212 > DNA < 213 > Homo sapien < 400 > 138 aggeccagec ceccacetgg ccegaegaga geggggageg gcaagggacg tcececcegc 60 aaeagacact tagattcctc ecttgeggga agaaaccacc egtccatcca ccgactceec 120 eacaeegaeg eggaaaeegc egctgceacc accacctcct gaagaggcet cccegaegcc 180 aatgccagcc atceeggcae cceggcccec gagcaggetg cggcaagcag cgaececceg 240 ceecagccge gecteeaege caagcagcae ceegeacecc eggeecegag cceccatcee 300 gcaecggagc ecacecagac cecgsccgsg mssmcgeeam gccgaaeece age 353 < 210 > 139 < 211 > 371 < 12 > DNA < 213 > Hcmo sapien < 400 > ¿Cca 35 agcgeggecg cggccgaggc ccgaag caagaeegca gaeggcageg egaagagaga 60 agacaeaeec eacaceecaa agctttggtg caattcccat cgaccagage tggeccgscc 120 aggecacega agcceeggaa aaaaeceeca aeeggaeeat geegaceece acceeaeeca 180 eeeeccagtg ecegeaaagc agegaeeeca caggegagga aaagaegaaa aeggaaaaat 240 aceaeeegac acageggaec tctgtgccac gegggaggcc geggagaage gtaaagaege 300 aggaeeggac cegcccgggc ggccgcecga aagccgaate ccagcacace ggcggccgee aceageggae c 371 360 < 210 > 140 < 211 > 370 < 212 > DNA < 2l3 > Homo sapien < 400 > 140 tagcgtggtc gcggccgagg tccatctccc tttggsaact agggggctgc tggtgggaaa 60 tgggagccag ggcagatgtt gcattccttt gtgtccctge aaatgcggga ctacaagaag 120 aggagctgcc tgagtggtac tttctcctcc eggeaaecce ccggcccagc ctcaeggcag 180 aatagaggta cttttaggct atttttgtaa catggcttct ggccaaaacc cctgtgcagc 240 cgaaeeccca agcecegcae cgtacagccc cccactcccc tcaccaccca acaaaggaac 300 agttaacact caaaaaaaaa aaaaaacctg cccgggcggc cgctcgaaag ccgaactcca gcacaceggc 360 370 < 210 > 141 < 211 > 371 < 212 > DNA < 213 > Homo sapien < 400 > 141 cagcgeggec gcggccgagg eccecegegc egceegecac agcccgaegg eaccagcgea 60 gcgtgcaggc astgcaggag ccctcatcca gtggcaggga acaggggeca ccaccaecce 120 aaggagceec agggccccgg caccccccca ggagtattca cagaatactc gagtactcac 180 cacccecagg gggeacccgc Ccceccecce cegcaegaga gacgcggagc acaggcacag 24-0 caeggagceg ggagccggca gegecegcag cacaaccagg gaggggecgc gacecagaeg 300 cgaegaaceg gccceggcag gcacagegct gactcacctc ccggcgacct ccgcecgaag c gcccgggcgg 360 - 371 < 210 > 142 < 211 343 < 212 > DNA < 213 > Ho or sapien < 400 > 142 gcgeeeegag gccaaeggeg eaaaaggaaa eaeceecaca taaaaaceag atggaagcae 60 egecagaaac cecetegcga cgeeegccte caacecacag agctgaacac ecceeeeeae 120 agagcageet tgaaacacec eeeegeagaa eeegcaagcg gaegaeegga ecgceatgag 180 gectecattg gaaacgggat acctttacat aaaaactaga cagtagcatt ctcagaaace 240 tcttegggat gegggcaeec aacccacaga ggagaacetc ateegaeaga gcageeeega 300 aacaceceet ttgcagaatc tacaggegga caeeeagage gce 343 < 210 > 143 < 211 > 354 < 212 > DNA < 213 > Homo sapien < 400 > 143 aggeeegaeg gcagaaaaac tcagacegec egcaaceeea eagatggtgc attggeecag 60 gggaegggaa caeeaggage ggaaagcaca aesacaagaa aaeegaaaga egggaaaeea 120 gtgtcatgaa gcggcggage caacgtcaec egcacecgga tctaegaaaa agtagaacaa 130 aaaeeccacc atcaceeegg acaggageea aetaagagaa egaccaagce cagttcaatg 240 agcaaatctc catacegeee ceeeceeeee ceeetcatea cegegeecaa eeaeceeeae 300 caeaaacaee eeacacgcag gcgtgecgga ceaeeecaaa eeaaecagga ecac 354 < 210 > 144 < 211 > 353 < 212 > DNA < 213 > Homo sapien < 400 > 144 ggccaaggac cegggggacc cccaggecca gcagccacae gatecegcag cagacaggga 60 cceagagcac aeceggatcc cagccccacc cctggcaacc tgcccgccca gagaaccccc 120 aagatgacag actaagtagg attctgccat ttagaataat tctggtatcc tgggcgtcgc 180 ttaactceca gccaagccgc ecccgtctta cgatagtcte cagaggtggg aacagaegaa 240 gaaaccaegc cccagagaag geeaagegac eecceceeea eggagccage geeccaacee 300 aggtttgcct gataccagac ctgtggcccc acctcccatg caggtctctg tgg 353 < 210 > 145 < 211 > 371 < 212 > DNA < 213 > Homo sapien -c400 > 145 caggeeegec aeaaaccggt ceggageeec egacgacecc eegeecacca aacgcaccae 60 etcctgagac ttgctggcct ctccgttgag tccaceeggc tttctgtcct ccacagcecc 120 aeegccaceg eegaeeacea gceeeeeece eegcccacae eeectecgae egecgaeege 130 gcaagaacca aaegcaaace aagccaaggc gccaagacga caagagggae ecagceaeec 240 ggcgccccca cggaattcgg caggaccaga ggccgtgtct gctccacctt cccgaccccc 300 acgcgagacc ccggccgcga ccacgctaag ccgaattcca gcacactggc ggcccgttac 360-cagcggaccc 371 g < 210 > 146 < 211 > 35 = < 212 > DNA < 213 > Ho or sapien < 400 > 146 ggccctcegt ccteetccca gaggtgtcgg ggcttggccc cagcccccac ceecgcccce 60 caggacggcg ageagcagcg gceccaaggc egaaeecaee gecggaggga aaeaeaaace 120 ggeacggaag aecgggtctg gcecceccgg ggacatccac eeggcgaeca acaccaccaa 180 cggcgaggaß geggcsgega agceagaaec ecagaaggcc aggcaecccc agcegcegea 240 cgagagcaag ceceaeaaga teceecaagg eggggeeggc aecccccaca eacggeggea 300 aaagaccaca eggtcaggaa aegeaceage cegggaccea caeggaecee gccec 355 < 210 > 147 < 211 > 355 < 212 > DNA < 213 > Hrfio sapien < 400 > 147 ggeeegeeac aaaaegaaga cagacaacac aacaeeeace cegeggagae aecctaceca 60 eaccatgcac gegczgtgac eecgaacaea aceegeccea aaaaceegee acgatcaeec 12C egaceeeeca ggeeggcega eegcacecaa eccaecaatc cegeeactee ttccccagtg 180 tegeea gag eaaageegac ecgaacagca accaacggcc gcagacacee aacaegeage 240 ceccceeeac aacacgggaa aeaeeeeaag eceaecaeee caccaegagg acaaaeegce 300 acaeeeggea eaeececaee ceeegaaaca caaeceaeee eeggcacecc eecag 355 < 210 > 148 < 211 > 365 < 212 > DNA < 213 > Horco sapien < 400 > 143 aggececece ccceeecccc cececcegcc agccaagega agacaegcee aceeccccee 60 caccceeccc cacgacgtgg gaagagcgcc gcaacccagc cctagccaac accgcaegag 120 agggagegeg ccgagggcee ccgagaaggc eecececaca ectagaaaga agcgcceaag 180 aegeggcagc cceecttctt caageggcec etgtcctgtt gccctgggag eececaaacc 240 gctgcagcag cceccatcca gcctgaggat gacaecaaea cacagaggaa gaagagecag 300 gaaaagacga gagaagccac agactctcct gggcgacccc gagagceeac caecccccag acccceeca 360 369 < 210 > 145 < 211 > 623 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > m ± sc characteristic < 222 > (1), (620) < 223 > n »AT C or G < 00 > 149 accagccaaa aatgceaaaa caacttggga gaaaaeaeee ttcaagcagc gttatagcee 60 caegteeaec eeeeaeeaeg eeetgtgaag eegegccccc ccaceaaeta cccacaceac 120 gccaaeattt ccttatatct atccataaca zeeaeaceac acttgeaana naaeac cac 130 gegaaaceea acaceeeaea aggtaaaaat gaggccecca acctga anacccaaca caa 240 eeeccaaáea geeceegeea gaaeggacee ggccegeeaa gggceaagga gaagaggaag 300 aageegetaa aeaaggeeaa tgaccaaaca eeceaaaaga aacgcaaaaa aaaagtteat 360 eeecaagcce ecgaaceaee taaggaaagc aaaaccacec cccaaacgca caecaeeege 420 gagaaccece caeeaaeacc ccgaaecaee eaettcacca aggcecaegc tnacccegae 480 gaaagtacta aegtctctaa eeecaeggec eaaaccegge egccaeance gggtaaaggc 540 tttcccctaa gtgtgaaanc atttaaaatg aaaccttcet actctttana ctttttaaaa 600 agggeeaagg gtgccgggga 62C < 210 > 150 < 211 > 371 < 212 > DNA < 213 > Homo sapien < 400 > 150 aaacetgcea ggeccgacca cecccecaag aceeeaceag cgccgacaaa cceccecaaa 6C gagcaaccag eaecaceecc cegeeeaeaa aacceceaac caececeeeg eerteegaac 120 aegcegasaa ccacccggec egcaegeaeg ceegaaeeeg yaaeeceeee cecccaaaeg 130 aaaaeeeaat tetagggaet reeecacata caeetecaea tgeagcaeea eeaceeecee 24C aeaegegeaa ggcgaaaeet aeggtaeeeg agegtgcaag aaaaeaeaee teeaaageee 300 ecaeeeeeec cccagegaac eeeeeaegea gaeeeagaae aaeaeacaga acgccterec etaceeeeat 363 371 < 210s • 151 < 211s 4655 < 212 = - DNA < 213 > • Ho or sapien gggaceegag eeeegecacc eeceeaagea gaeecaeaee gcaagggecc cggggegggg 60 gggeeggcaa aaecccggag ccagaagaaa ggacagcagc aeegaecaae ceeacagcea 120 acaegeeges cc ggaaaac aatgcccaga eecaaeeeag egagccacag eacacgaace 130 tggggcecct gaacagcaeg gaccagcaga zccagaacgg ctccecgecc accagtccct 240 ccacgcgcag aeaacacaga aacagcgtca eggcgcccec gccceacgca cagcccagce 300 ccacceecga egcececect ccaccacccg ecaeccccec caacaccgac tacccaggcc 360 cgcacageee cgacgegecc ttccagcagt egagcaccgc caagecggcc acctggacgt 420 aetccactga actgaagaaa aaattgcaaa ctctactgcc gacatgcccc atccagaeca 480 aggegaegac cccaccecce cagggagctg eeatccgcgc caegccegee eacaaaaaag 540 cegagcacge cacggaggeg gcgaagcggt gccccaacca tgagccgagc cgtgaaeeca 600 acgagggaca gategcccct yceagtcace egattcgage agaggggaac agccacgccc 660 agtaegeaga agatcccatc acaggaagac agagegtgct ggcaccccae gagccacccc 720 aggttggcac egaaeecacg acagcceege acaatttcae gcgtaacagc agttgtgttg 780 ccgccgecca gagggatgaa atettaatca eegetactcc ggaaaccaga gatgggcaag 84C eccegggccg acgcegceee gaggcccgga ecegegceeg cccaggaaga gacaggaagg 900 eagcaecaga cggacgaaga aagcagcaag eeecggacag tacaaagaac ggtgatggta 960 cgaagcgccc geeecgecag aacacacatg geaeccagae gacaeceaee aagaaaegaa 1020 gacccccaga egacgaactg gtatacttac eagegagggg ccgegagace tatgaaatgc 1080 tggtgaagat caaagagtcc ctggaactca egcagtacce tcttcagcac acaattgaaa 1140 cgcacaggca acagcaacag cagcagcace agcacetaee ecagaaacag accccaaeac 1200 ageeeccaec ttcatatggc aacagcecce eaccecegaa agcatgaaca caaaaegaac 1260 agcegcceec tgtgagccag cttatcaacc cecagcagcg caacgcccte actcctacaa 132C eggcaeggga ccaetcctga gccaacaeec ecaegaeggg cacccaeaeg ccaatggceg 138C gagacacgaa eggactcagc cccacccagg caceccctcc cccacccccc aegccaecca 1440 cacaccccca cctcccaccg cceccgeaec ccacagaeeg cagcaccgec ageeeeeeag 1500 cgaggccggg ccgeecaeca cgeceggace aeeecacgac ccaggggceg accaccatce 1560 accagattga gcaecactcc atggaegaec eggcaagtct gaaaatccct gagcaaeeec 1620 gacacgcgac ceggaagggc accccggac c accggcagct ccacgaacec ecceccccct 1680 ctcatc cct gcggacccca agcagCgcce ceacagecag egegggcece agegagacce 1740 ggggegagcg cgceaccgac gcegegcgae ecaccceccg ccagaccate tctttcccac 1800 cccgagaega geggaaegac etcaaceeeg acaeggaegc ccgccgcaae aagcaacage 1860 gcaecaaaga ggagggggag tgagcctcac catgtgagct cttcctatcc ctcececaac 1920 egceagcccc ceaaaagcac tcctgcttaa cctecaaagc ceececccea gceceeeeee 1980 eeccecetge cegaeeecte aggggaagga gaagtaagag gcttactcct eaccceaacc 2040 atcegacceg gcaeceaaee ctgaeecegg ceeeaagcce tcaaaaceae agceegcaga 2100 acegeagcee gccaeggcta ggtagaagtg agcaaaaaag agttgggtgt ctceteaagc 2160 escagagaet tcccaeegac teeeataaag eatgtecacc cetaeagece aagaceaeae 2220 aeaeaaaege aeaaaeaeac agcaeagaee eeegggeggg gggcaccgag eaeegeeeaa 2280 aaaegaaaga aacgcaaccc aaaeegagte gcaceeaeeg accacceeee aaeeeaceeg 2340 eeeeggatgg ceegeceaea cccceeccce eaaggggeae caegcacgge gaeaggeaee 2400 cagagcecaa egceacacgc gagegacgat gaegtacsga ecceeecagc cceceggaee 2460 ceaaacacat gceacaceaa acceecgage agae ccaecc ccacegceca eeaegeagge 2520 aagaccgcag acacgcaccc teeecccagt geeggcacae eeeaeaeeac 2530 eeeagegaeg aeggeecacg teggggegae eeaaeccage tataagaaca agetcaegee 2640 caaacgcccc ccccageecc c gccgggaa cgagsaaaae eceeaaaagg cc-aeagcag 2700 ccagcecaaa aacacccgac gecaegeace egagcaeaec ageaacccce eeaaaeeeaa 2760 eaccagaeac ctcaeeetac aaeaeegaee gggaaaacae cegcegccae cacagaggea 2820 eeaaaaceaa aeeecactac eagaeegace aacecaaaea cacacttgce actgeegeaa 2880 gaaccccgac tgacetgaee gggaegaaeg ecaeceaect ageectaaca gegaacccee 2940 acegeeeate aaeaeecagg aecaeecaga gtaaaeagga aaegttgage etgeaceaaa 3000 ecccaaegaa cageaagata aaceeegcaa ccaeaaatec aaaeceeeeg aagcaeasac 3060 aataeegeee ggeaaaegee eceeeegeee ggeaaaegee ecyeteaaag acceeeeeae 3120 ecegcaegea eceaeaaaac gaggceegee eaccecteec ececeaagge ttacaatagg 3180 ageggcgaee cgaaaaaeae aaaaeeacga gaccggcece cctgtggcae aaategcaec 3240 accgcaccac ecceccceee aaccgg? AAG AGT ecagct cgeeggaaag caacegegag 3300 aacccageee ccegeccaec eccceeaggg accacccaca gacatgaaag geccceacag 3360 aageecetca agcaagagae tggctgctge tgceeaaacc acetaaacga agageeecce 3420 egaaaceeeg ggaaaacatg ttaatgacaa eaeeccagae ctttcagaaa eaeaacacae 3480 eecetegcae gcacgcaaae gagcectgaa aeceecccae gcatccegge FACs CEGE 3540 cactgcacat aagcttccat tttaatttta aagcgcaaaa gggccagcge ggctceaaaa 3600 ggeaatgege ggaecgcctc egaaaagcge geaeaeaeee egtgcgaaae egcaeaceee 3660 geaeeeegae caeeeeeeee gacagcggga ccccccccgg tttccagaac cacacttgaa 3720 acceeeetee aecgeeeeeg cacccecaeg aaaacaccac ttagtaagaa eaccacaeca 3780 aaegceacaa aaeaagaaae teeeaagagg ggagggaagg eetteeacca gaaagettee 3840 eeeeteeaaa aeeeegtaeg ttaaagagaa tgagtcceeg atttcaaagt ctcgtegtac 3900 ttaaatggta aeaagcaceg taaacctctg caacaagcat gcagctttgc aaacccatta 3960 aggggaagaa egaaagcege tccttggecc eageaagaag acaaactgce tcccceacee 4020 egccgaggge ccgaacaaac ccaggacttc cgagctatgt cagtactatt caggcaacac 4080 cagggccceg gaaaeccceg tactgegtct catggatttg aagcgaggca gcaccagcca 4140 cceeecaccg gceeaceeec tcacggcagc eeacccccce cgagcgeaeg agtag ecagg 4200 gcaagggg aaaggseage aagcaeagaa aceactagaa agtgggct a aeggageect 4263 tgtggcctca gctcaatgca gttagctgaa gaattgaaaa gtttttgtet ggagcgtte 4320 aeaaacagaa aeggaaagca gageeeecac eaaaccceec caccceecee eetceerggc 4380 ao_ >; CC BSSD aaeaacagta tgtgggatac agggaeatee egaacgccaa tttccracca 4440 eteeeataat egeacaaaae caagcaaaeg eeaaaagece eaeatgceee aceaaegcte 4500 ceaaaaggca ttatacatgc gacacatttt ttaagctcca g-ctgcrcgtc ceceggcace 456C teeegeeaeg ggeeeceggg gagceagaac ecaatceac3 atetceteee gteegccagg 4623 aaaeeeaaaa acaescaata aaeaaaeaaa aacea 46 = 5 < 210 > 152 < 211 > 586 < 212 > PRT < 213 > Homo sapien < 400 > 152 Mee Leu Tyr Leu Glu Asn Asn Wing Gln Thr Gln Phe Ser Glu Pro Gln 1 5 10 15 Tyr Thr Asn Leu Gly Leu Leu Asn Ser Mee Asp Gln Gln He Gln Asn 20 25 30 Gly Being Ser Thr Ser Pro Tyr Asn Thr Asp His Wing Gln Asn Being 40 45 Val Thr Ala Pro Ser Pro Tyr Ala Gln Pro Ser Ser Thr Phe Asp Ala 50 55 60 Leu Ser Pro Pro Sex Pro Ala Pro Pro As As Thr Asp Tyr Pro Gly Pro 65 70 75 80 His Ser Phe Asp Val Ser Phe Gln Gln Ser Ser Thr Ala Lys Ser Wing 85 90 95 Thr Trp Thr Tyr Ser Thr Glu Leu Lys Lys Leu Tyr Cys Gln He Wing 100 105 110 Lys Thr Cys Pro He Gln He Lys Val Mee Thr Pro Pro Pro Gln Gly 115 120 125 Wing Val He Arg Wing Mee Pro Val Tyr Lys Lys Wing Glu His Val Thr 130 135 140 GJ.U Val Val Lys Arg Cys Pro Asn His Glu Leu Ser Arg Glu Phe Asn 145 150 155 160 Glu Gly Gln lie Pro Wing Being Hxs Leu He Arg val Glu Gly Asn 165 170 175 Ser His Wing Gln Tyx Val Glu Asp Pro He Thr Gly Arg Gln Ser Val 180 185 190 Leu Val Pro Tyr Glu Pro Pro Gln Val Gly Thr Glu Phe Thr Thr Val 195 200 205 Leu Tyr Asn Phe Mee Cys Asn Ser Ser Cys Val Gly Gly Mee Asn Arg 210 215 220 Arg Pro He Leu He He Val Thr Leu Glu Thr Arg Asp Gly Gln Val 225 230 235 240 Leu Gly Arg Arg Cys Phe Glu Wing Arg He Cys Wing Cys Pro Gly Arg 245 250 255 Asp Arg Lys Wing Asp Glu Asp Ser He Arg Lys Gln Gn Val Ser Asp 260 265 270 Ser Thr Lys Asn Gly Asp Gly Thr Lys Arg Pro Phe Arg Gln Asn Thr 275 280 285 His Gly He Gln Met Hear Ser He Lys Lys Arg Arg Ser Pro Asp Asp 290 295 300 Glu Leu Val Tyr Leu Pro Val Arg Gly Arg Glu Thr Tyr Glu Mee Leu 305 310 315 320 Val Lys He Lys Glu Ser Leu Glu Leu Mee Gln Tyr Leu Leu Gln His 325 330 335 - Thr He Glu Thr Tyr Arg Gln Gln Gln Gln Gln Gln His G2n His Leu 340 345 350 Leu Gln Lys Gln Thr Ser He Gln Ser Pro Ser Being Tyr Gly Asn Being 355 360 365 Ser Pro Pro Leu Asn Lys Met Asn Ser Mee Asn Lys Leu Pro Ser val 370 375 380 Ser Gln Leu He Asn Pro Gln Gln Arg Asn Wing Leu Thr Pro Thr Thr "385 390 395 400 He Pro Asp Gly Met Gly Wing Asn Xle Pro Met Met Gly Thr His Mee 405 410 415 Pro Mee Wing Gly Asp Met Asn Gly Leu Ser Pro Thr Gln Wing Leu Pro 420 425 Pro 4 Pro Pro Leu Pro Ser Ser Thr Ser Cys Pro Pro Pro Pro 435 440 445 Tyr Pro Thr Asp Cys Ser He Val Ser Phe Leu Ala Arg Leu Gly Cys 450 455 460 Be Ser Cys Leu Asp Tyr Phe Thr Thr Gln Gly Leu Thr Thr He Tyr 465 470 475 480 Gln He Glu His Tyr Ser Met Asp Asp Leu Wing Ser Leu Lys He Pro 485 490 495 Glu Gln Phe Arg His Wing He Trp Lys Gly He Leu Asp His Arg Gln 300 505 510 Leu His Glu Phe Ser Ser Pro Pro His Leu Leu Arg Thr Pro Ser Ser 515 520 525 Ala Sar Thr Val Ser Val Gly Ser Sar Glu Thr Arg Gly Glu Arg val 530 535 540 He Asp Ala Val Arg Phe Thr Leu Arg Gln Thr He Ser Phe Pro Pro 545 550 555 56C -Arg Asp Glu Trp Asn Asp Phe Asn Phe Asp Met Asp Ala Arg Arg Asn 565 570 575 Lys Gln Gln Arg lie Lys Glu Glu 31and Glu 580 555 < 210 > 153 < 211 > 2007 < 212 > DNA < 213 > Homo sapien < 400 > 153 gaatecgtcg ctgctccagg gaaagttctg etactccact gactctceee tttccegaea 60 acacggccag caagaaagea aetacagtgt ecggagcaac aggagcecaa ggeggceceg 120 tggccagggc aattttggag agcaaaaaat ttgcagcgag agcagtgacc agggatgcga 180 cccgaccaaa tgccceggag ctccagcgcc ggtggtcaaa ttggagctga ggtgacctga 240 acgaeaaagc aecggeggac aaggtgtcta agtgccttaa tggggcctec etggtgacca 300 acccccggga cccccccaac caagataagg aagcgegecg ggggaagctg gtggcagacc 360 ccgccaagca cccgggcccg aagcacgtgg cgcacagcgg cceggagaac gecaagcgac 420 cgacggacgg caagccggag gtgccgcact ccgacagcaa gggcgaggeg gaggagcacc 480 eceggeccat eggcaecccc atgaccagtg eccgcgcggc ggcctactee gaaaaceeec 540 tcgcggcgtg gcggcccgcg aaagcctctg acggagacca ctacaccttg gccgcaccga 600 egggagatgt accaatggat ggtatctccg eegcegaeac eggagcagcc gcccccagca 660 tttttaattc eccágaggaa cceecaggca aggccgtggg gaageaccaa gctcagcgca 720 caaeacagca atatgctgat gccccgtcca aggcteeggg gaaagaagee cgagaegcaa 780 agaeeacccc ggaagcctcc gagaagccgg gactccccgc agcaaaggaa acagccaaca 840 egegecgctt ctat gaaatg aagccagacc gagaegtcaa ectcacccac caaccaaatc 900 ccaaagtcaa aagetteage cagtteacce cagagaacca gggagccttc aagggcatgc 960 agaaaaccag cegttcagat aggcctctgc accacacagc ccctttccec ecegaeccce 1020 cggcacaaca ttcctcttta ttcatgttga tggaatgcaa cagaacaegc ttgtttgcaa 1080 caccgaagga ttecccgcgg tcgcctcttc agtaggaagc actgcaeegg cgacaggaca 1143 cggeaacttg attcacactt aacctgctag eeagegaeaa gggtggcaca actgeeegsc 1200 aaaaegagaa gccecggaac ttggagcttc tcecceacca ctaatgggag ggcagaeeae 1260 actgggattt ctcctgggtg agtaattt to agccceaaeg cegaaattec cccaggcagc 1320 tccagttttc tcaactgcac cgcaaaaccc ccagcgaacc cctaagtact cccaacccaa 1380 aaaaacgaac atccccgcag agaaeeeece ggggaacatg gtgeecaacg aacaagcaca 1440 agcaccggaa acgceaaaat tcagtcccgc cccaagaccg gaagcccact ttctgactca 1500 cacccaccga cccacgaagc gccaccattc aattattcac ctattaattc cttgatccte 1560 cacccaccca ctcegcaaac cccccccgag caccagcacg ggcggccacc tgcggacecc 1620 cccccactcc eaegegeeee ceeaeeaaag tgatccactc tcgaaaggce cccccccagt 1680 ctgtggttgg gttcaagtca tgccagggcc agggggccca ccccctcgtt tagccctagg 1740 gggaecegca caaaacccag ggggcaggaa gtggggagcg gceggaggga aggccegcga 1800 ag ggtaggga cgcggaaaga caaggegaca gaaggaccca aeaggaccee tetatatece 1360 tggctcagca ctteceacat cataeegtaa ccgtcttatt tgctagetet cttcc tact 1920 gcgagcgacc aacagecacc cecatcccag egcceggcac acaacaageg accaacaaae 1980 gttgaeegac caaaaaaaaa aaaaaaa 2007 < 210s • 154 < 211s > 2148 < 212s > DNA < 213 =. Ho or sapien < 400 > 154 gaattcgecg ccgeeecagg gaaagttceg teaceccace gacececece teeccegaea 60 acacggccag caagaaagca accacagege eeggagcaac aggagcecaa ggeggceeeg 120 eggccagggc aaeeeeggag agcaaaaaat eegcagtgag agcagtgacc agggac cga 180 ccegaccaaa cgccccggag ceccagcgcc geggecaaa teggagcega ggcgaccega 240 aegaeaaagc accggcggac agegceceaa aaggggaagc eggeggcaga eeccgccaag 300 cacctgggtc cgaagcacgc ggegtacagc GGCC .ggaga acgecaagcg actgacggae 360 ggcaagcegg aggegccgca cetegacagc aagggcgagg eggaggage3 cetceggeee 420 attggcsecc ccacgaccag tgtccgcgtg gcggcceace eegaaaacec ccecgcggcg 4S0 cggcggcccg cgaaagcccc cgaeggagac eaceacacce eggcegeace gacgggagae 54C gcaccaacgg aeggeaeccc egecgcegae áeeggagcag ecgectceag caceeeeaae cCO cccccagagg aaceeeeagg caaggccgcg gggcecageg cagaagcaee aacaaeaeag 560 caacacgccg aegceecgtc caaggcctcg gggaaagaag eccgagacgc aaagaceaec 720 aegaccagaa cgcgceacag aacageggaa gaaggtteca tggaagacgc gggceegage 780 gggaacacga tggcccttga ccatgtatag acagaggagg catcaagaag gceggceegg 340 ctaaccecgg aacaa acacg acaaaccaga ggcagcacgg gaaggaggca aaeeceggcc 900 ccgcceccac cceegactac cccggaagct eccgagaagc egggaccccc egcagcaaag 960 gaaacagcca atatgtgtcg eetctatgaa acgaagccag accgagacgc caaccecacc 1020 atcccaaagc caccaaccaa caaaagcttc agccatttta ccccagagaa ccagggagcc 1080 tgcagaaaae cccaagggca cagccgccca gacaggcccc egcaccacac agcctctttc 1140 ccccccgacc ctttcccccc ccacggcaca acacccatgt tgacagaaca tgctggaacg 1200 caaccgcccg caacaccgaa ggatttcctg cggccgcccc tccagcagga agcaccgcat 1260 tggtgaeagg acacggcaac ttgattcaca tagttagcga tttaacttgc caagggcgge 1320 acaaccgccc ggcaaaacga gaagcctcgg aacttggagc ctctctccta ccactaatgg 1380 gagggcagat catactggga tttctcctgg gtgagtaa t tcaagcccta atgctgaaat 1440 tcccccaggc agceccaget ttctcaactg categcaaaa eecccagega acttteaage 1500 acttttaact taaaaaaatg aacatctttg cagagaacct tctggggaac atggtgttca 1560 aegaacaagc acaagcatcg gaaacgctaa aaeccagcce egccecaaga eeggaageee 1620 tcaetcatga attttctgac agtcacceae cgagccacca etcaattate catetattaa 1680 ttcctegatc cttcatttat DC attctgca aacttttcte gagcaccagc acgggeggcc 1740 acttgeggac ttctcttcat ccctacgcgc eetcttatca aagtgaecca ctctcgaaag 1300 gctcceeecc agtcegegge egggeecaag ecaegccagg gccagggggc ccatceccec 1360 gteeagcece aggcaaaacc caggggaccc gcagcgggga gcgggggcag gaagccggag 1920 ggaaggcctg cgaagggcag ggacgcggaa agacaaggeg acagaaggac ccaaeaggac 1980 ctceggctta ctttccacac gcatcttcta caccataecg eaaccgccce atttgceage 2040 eecceeccee acegegageg accaacagcc acccccacec eagcgccegg eacaeaataa 2100 aaegttgate gcgaccaata gaccaaacga aaaaaaaaaa aaaaaaaa 2143 < 210 > 155 < 211 > 153 < 212 > PRT < 2l3 > Ho or sapien < 400 > 155 Met Thr Ser Val Arg Val Ala Ala Tyr Phe Glu Asn Phe Leu Ala Ala 1 5 10 15 Trp Arg Pro Val Lys Wing Ser Asp Gly Asp Tyr Tyr Thr. Leu Ala Val 25 30 Pro Mee Gly Asp Val Pro Mee Asp Gly He Ser Val Val Asp He Gly 40 45 Wing Wing Val Ser Ser He Phe Asn Ser Pro Glu Glu Phe Leu Gly Lys 50 55 60 Wing Val Gly Leu Ser Wing Glu Wing Leu Thr He Gln Gln Tyr Wing Asp 65 70 75 80 Val Leu Ser Lys Wing Leu Gly Lys Giu Val Arg Asp Wing Lys He Thr 85 90 95 Pro Glu Ala Phe Glu Lys Leu Gly Phe Pro Ala Ala Lys Glu He Ala 100 105. 110 Asn Mee Cys Arg Phe Tyr Glu Mee Lys Pro Asp Arg Asp Val Asn Leu 115 120 125 Thr His Gln Leu Asn Pro Lys Val Lys Ser Phe Ser Gln Phe He Ser 130 135 140 Glu Asn Gln Gly Ala Phe Lys Gly Met 145 150 < 210 > 156 < 211 > 128 < 212 > PRT < 213 > Homo sapien < 400 > 156 Mee Thr Ser Val Arg Val Ala Ala Tyr Phe Glu Asn Phe Leu Ala Ala 1 5 10 15 Trp Arg Pro Val Lys Wing Ser Asp Gly Asp Tyr Tyr Thr Leu Wing Val 25 30 Pro Mee Gly Asp Val Pro Mee Asp Gly lie Ser Val Ala Asp He Gly 40 45 Wing Wing Val Ser Ser He Phe Asn Ser Pro Glu Glu Phe Leu Gly Lys 50 55 60 Wing Val Gly Leu Ser Wing Glu Wing Leu Thr He Gln Gln Tyr Wing Asp 65 70 75 80 Val Leu Ser Lys Ala Leu Gly Lys Glu Val Arg Asp Ala Lys Thr He 85 90 95 Cys Ala He Asp Asp Gln Lys Thr Val Glu Glu Gly Phe Met Glu Asp 100 IOS 11Q Val Gly Leu Ser Trp Ser Leu Arg Glu His Asp His Val Ala Gly ^ Ala 115 120 125 < 210 > 157 < 2ll > 424 < 212 > DNA < 213 > Homo sapien < 220 > < 221 > misc_caracteristic < 222 > (1) ... (424) < 223 > n = A.T.C or G < 400 > 157 cegcagcccg ggggaeccac eageccageg eggeggaaee caeeggecee tacaagacee 50 cagcagacae ggacacacca eeeeaaaaaa ggaaaeacaa ccccccccea acctecttca 120 aaeecagtca ccactgttat ateacceece ccaggaaccc eccagtgggg aaggcegcga 130 tattagattt ccttgtatgc aaagtttttg eegaaagceg tgctcagagg aggtgagagg 240 gaaaacegca agaggaagga acagaacega ecaeaaceee aeceagagec etcccegaaa 300 agcccagaaa cttctctgcn gnatceggct tgtccatctg gtctaaggeg gctgcttcee 360 ccceagccat cgagecagee egegcccaeg aaeaaeacac gaccegceae ttcceatgae 420 egcc 424 < 210 > 158 < 211 > 2099 < 212 > DNA < 213 > Homo sapien < 400 > 158 ccgcggeeaa aaggcgcagc aggegggagc cggggcceec aceegaaace cgaegagage 60 ccgacagccg gcggcgcccg agcccgacee gecegcccag ccggagcgaa gggcgcegee t20 ccgcgcagag eccgcgccag ggccgccggc cgcagagcag ttaaaacgeg eaggeaccag ¿30 aaggcact and ecgecggcga eccccggege agaagacctg cacgggcate cegegtects 240 caaacggggc egaceecece tcceggggag cagggaagga caggaaggge aaagaageae 300 agaagaeceg gceaaacaae cecegeacgg cgaaagaaaa aeeeeaacee geacgcccee 360 eeeaacccaa ctcatgcatc cecgaacate ccaggcgaca tccecacega ccgagcaaag 420 acegacaccc gcaccaccac cgcgcaccae eggceeceag gcaccccagc ggggeaggag 430 aaggaggcce gaaaeccccg cagagggaee eegcccecae ecetegggee egaaacaceg 540 gcagccgccg gaaacaggac tcagggataa accagcgcaa tggattgggg gacgctgcae 600 acetecaecg ggggtgtcaa caaacactcc accagcaecg ggaaggegeg gatcacagee 660 acceeeaeee cecgag falls gaccctcgcg gcggcegccc aggaagegeg gggegacgag 720 ecgcccgcaa caagaggace cacacegcaa ccgggacgca aaaacgtgtg ceatgaccae 730 ttcrtcccgg tgccccacat ccggctgtgg gccccccagc tgatctccgt ctccacccca 340 gcgcegcegg tggcc atgca tgeggcceac cacaggcacg aaaccacccg caagcecagg 900 cgaggagaga agaggaatga tttcaaagac ttaaaaagca acagaggaca gaaggttcgg 960 acagaggggt cgctgtggtg gacgcacacc agcagcaccc ttttccgaat cacceeegaa 1020 gcagccttta cgcacgcgcc ttacccccce eacaacgggc accaccegcc ccgggcgccg 1080 aaaegeggga ccgacccceg ccccaacccc gtcgaccgct etatttctag gccaacagag 1140 aagaccgtgt ccaccacttt tatgatttct gcgtctgtga tttgcatgct gcctaacgeg 1200 gcagagttgt gctacccgct gccgaaageg cgtcctagga gaccaaagag agcacagacg 1260 accccaaeca caaaaaaatc tgccctaaag gagagtaagc agaatgaaat gaatgagctg 1320 gcggccaaaa atttcagata tgcaatcaca ctaaacatee ggctcccaag caaggeaaaa 1380 tgcagcegcg ccaeaaggag aceeccgtcc cceccagaag gcaaeaccaa ccegaaagee 1440 ccttctgtag cctgaagagt ttgtaaatga ctttcataae aaatagacac ttgagetaac 1500 tttttgtagg atacttgctc cattcataca caacgtaatc aaatatgtgg tccaectceg 1560 aaaacaagag accgceegac aaaggagcat cgcagecace eegacaggee cceeeeaage 1620 ggactctceg acaaageggg tactttctga aaaetcatat aactgtegtt gataaggaac 1530 atttacccag gaategatac gt ttattagg aaaagatatt tttataggct tggaegttee 1740 eeegaaeeea cageeccgac eaeaaageae eeteaeaaeg acc gecece ceeacet ga 13C0 aaaacacgcg aegeeageee eagaaeeaca ecacaagtat ctaaatttgg aacteacaaa 1350 gggtcraccc tgcaaat tt gctetgcate gtctgttggc aaaceegtga acegeeaega 1520 cacgceeaag geggaaageg eecaeegcac aataeaceee eacegceeee egaacgeag = 1980 cggaacagtg tggaagcaga aggctttttt aactcacccg tttgccaatc attgcaaaca 2040 actgaaatgt ggacgegatt gcctcaataa agctcgcccc cattgcteaa aaaaaaaaa 2099- < 210 > 159 < 211 > 291 < 212 > PRT < 213 > Ho or sapien < 400 > 159 Met Asp Trp Gly Thr Leu His Thr Phe He Gly Gly Val Asn Lys His 1 5 10 15 Ser Thr Ser He Gly Lys Val Trp He Thr Val He Phe He Phe Arg 20 25 30 Val Met He Leu Val Val Ala Wing Gl Glu Val Trp Gly Asp Glu Gln 35 40 '45 Glu Asp Phe Val Cys Asn Thr Leu 31n Pro Gly Cys Lys Asn Val Cys 50 55 60 Tyr Asp His Phe Phe Pro Val Ser His He Arg Leu Trp Wing Leu Gln 65 70 75 80 Leu He Phe Val Ser Thr Pro Ala Leu Leu Val Ala Met His Val Wing 85 90 95 Tyr Tyr Arg His Glu Thr Thr Arg Lyß Phe Arg Arg Gly Glu Lys Arg 100 135 110 Asn Asp Phe Lys Asp He Glu Asp He Lys Lys Gln Lys Val Arg He 115 120 125 Glu Gly Ser Leu Trp Trp Thr Tyr Thr Ser Ser He Phe Phe Arg He 130 135 140 He Phe Glu Wing Wing Phe Mee Tyr Val Phe Tyr Phe Leu Tyr Asn Gly 145 150 155 160 Tyr His Leu Pro Trp Val Leu Lys Cys Gly He Asp Pro Cys Pro Asn 165 170 175 Leu Val Asp Cys Phe He Ser Arg Pro Thr Glu Lys Thr Val Phe Thr 180 135 190 He Phe Mee He Ser Be Ala Ser Val He Cys Mee Leu Leu Asn Val Wing 195 200 205 Glu Leu Cys Tyr Leu Leu Leu Lys Val Cys Phe Arg Arg Ser Lys Arg 210 215 220 Wing Gln Thr Gln Lys Asn His Pro Asn His Wing Leu Lys Glu Ser Lys 225 230 235 240 Gln Asn Glu Mee Asn Glu Leu He Be Asp Ser Gly Gln Asn Wing He 245 250 255 Thr Gly Ser Gln Wing Lys His Phe Lys Val Lys Cys Ser Cys Val He 260 265 270 Arg Arg Leu Leu Ser Ser Pro Glu Gly Asn Thr Asn Leu Lys Val Pro 275 280" 285 Ser Val Ala 290 <; 210 > 160 < 211 > 3951 < 212 > DNA < 213 > Homo sapien < 400 > 160 tctgcaccca eaetgaaaac cegacacaae gtaegcagca ggctcagege gagegaaceg 60 gaggcccccc tacaacaega cccaaaggag falls gcaggt cctacttgca acctgaagtt 120 cgcgactctc ccggttgccc taagttcaga actcccattc ctgggagctg gagtacagct 130 ccaagacaac gggtataaeg gategctcac cgeaateaae ccccaggtac ctgagaatca 240 gaaccccacc ccaaacacea aggaaaegae aacegaagce tcateeeacc eaeeeaaegc 300 caccaagaga agagcacece tcagaaatat atacctgcca aaagatttca cacggaaagc 360 caacaacaac agcaaaaeaa aacaagaatc ataegaaaag eagegacega gcaaaegeca 420 ccggcacggg gcacaeggag aegaeecaca tacagagggt caccceacaa gcggaaaaga 480 gggaaaacac attcatetca cacctaattt cccactgaat cagctggcta gataacttaa 540 cggaccacga ggccgagtgt ccgcccacga acgggcccac ceccgeeggg gcgcgcccga 500 cgagcacaac aaegacaaac ceccceacae aaacgggcaa aaecaaacea aagegacaag 660 gcgctcatct gacaccacag gcacccttgt gcgcgaaaaa ggccctcgcc cccaagaaaa 720 ctgtattate agtaagccee eeaaagaagg acctacaaca acgcacceee geacccaaaa 730 tgcaaccgca ecaacaacgc ccatgcaaag eecaccecct gcggcegaac cccgcaacgc 840 aaccac aacca agaag caccaaacct acagaaccag acgcgcagcc ecagaagcge 900 acgggacgca accacagact ctgccgaccc ccaccacagc tctcceacga acgggaccga 960 gceeccacce cceeccacac ececgceege agaggccggc gacaaagcgg ecegeeeage 1020 cccagcaaga gceggacgtg tggcaga gc egacagaccc cttcaactac aacaagccgc 1080 agaaeeeeat eegaegcaga eegeegaaae eeacacceec gcgggcaeeg ccageeecga 1140 cagcaaagga gagaecagag cccageeaca eeaaaeeaac agcaaegaeg aecgaaagee 1200 caecegceca gceggeeeca ccacegeaee agceaaaaca gacaecagca eeegetcagg 1260 gceeaagaaa ggaeeegagg tggtegaaaa acegaacgga aaagceeaeg gcecegegae 1320 gaeaeeageg accagcggag atgaeaagce eceeggcaae egceeaccea cegegcecag 138C cageggttca acaacecact ccattgccct gggeccacct gcagccccaa aectggagga 1440 aeeaeeacgc ceeacaggsg geeeaaagee ceeegeecca gacaeaeeaa aceccaaeag 1500 gceeecagea cacgaeegae geatcccctc eggaacegga cacateeeec agcaacaeae 1560 tcagctegaa ageaeaggeg aaaacgecaa aceecaceat caaeegaaaa acacagcgae 1620 acegegggca egeggaeaae acgacaeeat geeeceagee acgcggcagg ccagcggccc 1683 eecegagaec aeaeeaeetg ae ecegacgg aegaaaaeac eacaeaaaea aeeeeaeeac 1740 caaeceaace eeecggacag ctagecettg gaeeecagga acageeaagc ccgggcaeeg 130C gacttacace cegaacaaea ceeaeeaeec eeegcaagce cegaaagega cagtgacete 1350 tcgcgcctce aacccagceg egccceeagc caccgcggaa gccteegcgg aaagagacag 1520 cceccaeeet ececaecceg tgatgaete egccaatgeg aaacagggae eeeaecceae 1980 tcttaatgcc acegcactg ccacagetga gccagagace ggagaecccg ccacgccgag 2040 aceeceegae gaeggagcag gegcegaege caeaaaaaae gaeggaaeee acecgaggea 2100 teegcegcaa etetttctcc atggtagata eagcccgaaa gcgcacgcca accaccctcc 2160 cagcaeaagc accccagccc actceaeecc agggagccac gccaegeaeg taccaggtta 2220 cacagcaaac ggtaatattc agacgaatgc cccaaggaaa tcagtaggca gaaatgagga 2280 ggagcgaaag tggggcttta gccgagccag cccaggaggc tccteeecag egcegggage 2340 tccagctggc ccccaccctg atgtgtttcc accatgcaaa attaetgacc tggaagctgt 2400 gaggaaeega aaaageagaa ccctaecctg gacagcaccc ggagaagace eegatcaggg 2460 agceaegaaa ccaggctaca taagaacgag caaaagccca cagaatatcc aagatgactt 2520 ateeeageaa taacaaegce atacatcaaa gcgaaatcce cagcaagctg gcatcaggga 2580 gacatttacg ctctcacccc aaatttccac gaaeggacce gaacatcagc caaatggaga 2640 agccacagaa aacacacgaa ttcacgccgc aaeacgagca aceccttaca aeggaeagga 2700 gcccgccgca cccaacaccg cccaggcgcc ectgtttatc ccccccaatt ctgatcctgt 2760 gaccaeceea acccgccaga agccccaaca caccgaaagg gcaaegggee egacaggaac 2820 cacttgcctt accacagccg cgacacacca taceccaagc gagcagacaa aggaaaaaga 2380 gaaagagaac ggaacaaaae caccacaaac aaataeceaa agcgeeeecc cecccagaca 2940 Caagacccac ggcceecgac cacaaaaaca eaceaacaaa caccaaaact gccaaaccaa 3000 gcacegagee geaeeaaaae cccgcacaae acagaeaaga cceeeacaeg gcagaceaac 3060 aaaccctttc cgggggcaga ccagaaaacc ceeacaceee ggccacgaac aaacaataaa 3120 aaceacccee caaageaacg cccceaaagg eaaagggaag ggcaaagccg gaccagcgte 3180 aaggaaagcc cgccccaccg aggcggaaaa atagccecaa gcagagaaaa ggagggtagg 3240 aacegeeege teegcaeeae caeeeageea gcgaagcaae ceeegaeeaa eeteeceeee 330C ctcceeatct gcgcagaaca ggccgctcge ttacaactga agateaegce atatttcata 3363 tatgaagccc ctaacgcaaa gctctteace tcttgctatt ttgttatata tattacagat 3420 gaaacetcac egceaaegce cagagatcte cctecactgt aagaggcaac ceeeaacaae 3480 aegggeaeea cccecgcccc tecacaccgg tcccacgaca aaggcccact gaacccaccc 3540 geecgeaage eeceaccccc aecaaagcag ceccccaagc eaeegccccg gccaccacgg 3600 acgacagcca cageccetat aßtgccecaa aaagacgtca ccaaggaaga eecegagccc 3660 gctttaatac ataeaegaac aeatagtttt attcaattaa accaaagaag aggtcagcag 3720 ggagaeacca acctttggaa acgaccagcc ggccctgttt teeggccaaa caagagccct 3780 taatc ceeec eccaecaaga geeacetacc aagggcaggg gaagggggae aeagaggecc 3840 caaggaaata aaaatcatct ttcatcttta attttactcc ttcctcttae eetettaaaa 3900 gattaccgaa caaeaaaatc atttgccttt teaattaaaa acacaaaaaa a 3951 < 210 > 161 < 211 > 943 < 212 > PRT < 213 > Ho or sapien < 400 > 161 Mee Thr Gln Arg Ser He Wing Gly Pro He Cys Asn Leu Lys Phe Val 1 5 10 1S Thr Leu Leu Val Wing Leu Ser Ser Glu Leu Pro Phe Leu Gly Wing Gly 20 25 30 Val Gln Leu Gln Asp Asn Gly Tyr Asn Gly Leu Leu He Wing He Asn 35 40 45 Pro Gln Val Pro Glu Asn Gln Asn Leu Ha Ser Asn He Lys Giu Mee 50 55 60 He Thr Glu Wing Being Phe Tyr Leu Phe Asn Wing Thr Lys Arg Arg Val 65 70 75 83 Phe Phe Arg Asn He Lys He Leu He Pro Wing Thr Trp Lys Wing Asr. 85 90 95 Asn Asn Ser Lys Zle Lys Gln Glu Ser Tyr Glu Lys Wing Asn val He 100 105 110 Val Thr Asp Trp Tyr Gly Wing His Gly Asp Asp Pro Tyr Thr Leu Gln 115 120 125 Tyr Arg Gly Cys Gly Lys Glu Gly Lye Tyr He His Phe Thr Pro Asp 130 135 140 Phe Leu Leu Asn Asp Asn Leu Thr Wing Gly Tyr Gly Ser Arg Gly Arg 145 150 155 160 Val Phe Val His Glu Trp Wing His Leu Arg Trp Gly Val Phe Asp Glu 165 170 175 Tyr Asn Asn Lys Pro Phe Tyr He Asn Gly Gln Asn Gln He Lys 180 185 190 Val Thr Arg Cys Ser Ser Asp He Thr Gly He Phe Val Cys Glu Lys 195"200 205 Gly Pro Cys Pro Gln Glu Asn Cys He He Ser Lys Leu Phe Lys Glu 210 215 220 Gly Cys Thr Phe He Tyr Asn Ser Thr Gln Asn Wing Thr Ala Ser He 225 230 235 240 Mee Phe Met Gln Ser Leu Ser Val Val Glu Phe Cys Asn Ala Ser 245 250 255 Thr His Asn Gln Glu Ala Pro Asn Leu Gln Asn Gln Mee Cys Ser Leu 260 265 270 Arg Ser Wing Trp Asp Val He Thr Asp Ser Wing Asp Phe His His Ser 275 280"285 Phe Pro Mee Asn Gly Thr Glu Leu Pro Pro Pro Thr Phe Ser Leu 290 295 300 Val Glu Wing Gly Asp Lys Val Val Cys Leu Val Leu Asp Val Ser Ser 305 310 315 320 Lys Mee Wing Glu Wing Asp Arg Leu Leu Gln Leu Gln Gln Wing Ala Glu 325 330 335 Phe Tyr Leu Mee Gln He Val Glu He His Thr Phe Val Gly He Ala 340 345 350 Ser Phe Asp Ser Lys Gly Glu He Arg Wing Gln Leu His Gln He Asn 355 360 365 Ser Asn Asp Asp Arg Lys Leu Leu Val Ser Tyr Leu Pro Thr Thr Val 370 375 380 Ser Ala Lys Thr Asp He Ser He Cys Ser Gly Leu Lys Lys Gly Phe 385 390 395 400 Glu Val Val Glu Lys Leu Asn Gly Lys Wing Tyr Gly Ser Val Mee He 405 410 415 Leu Val Thr Ser Gly Asp Asp Lys Leu Leu Gly Asn Cys Leu Pro Thr 420 425 430 Val Leu Ser Ser Gly Ser Thr He His Ser I Am Wing Leu Gly Ser Ser 435 440 445 Ala Ala Pro Asn Leu Glu Glu Leu Ser Arg Leu Thr Gly Gly Leu Lys 450 455 460 Phe Phe Val Pro Asp He Ser Asn Ser Asn Ser Mee Lie Asp Ala Phe 465 470 475 480 Ser Arg Be Ser Gly Thr Gly Asp He Phe Gln Gln His He Gin 485 490 425 Leu Glu Be Thr Gly Glu Asn Val Lys Pro His His Gln Leu Lys Asn 500 505 510 Thr Val Thr Val Asp Asn Thr Val Gly Asn Asp Thr Met Phe Leu Val 515 520 525 Thr Trp Gln Wing Ser Gly Pro Pro Glu lie He Leu Phe Asp Pro Asp 530 535 540 Gly Arg Lys Tyr Tyr Thr Asn Asn Phe He Thr Asn Leu Thr Phe Arg 545 550 555 560 Thr Ala Ser Leu Trp He Pro Gly Thr Ala Lys Pro Gly His Trp Thr 565 570"575 Tyr Thr Leu Asn Asn Thr His His Ser Leu Gln Ala Leu Lys Val Thr 530 585 590 Val Thr Ser Arg Ala Ser Asn Ser Ala Val Pro Pro Ala Thr Val Glu 595 600 605 Wing Phe Val Glu Arg Asp Ser Leu His Phe Pro His Pro Val Mee He 610 615 620 Tyr Ala Asn Val Lys Gln Gly Phe Tyr Pro He Leu Asn Ala Thr Val 625 630 635 - 640 Thr Ala Thr Val Glu Pro Glu Thr Gly Asp Pro Val Thr Leu Arg Leu 64S 650 655 Leu Asp Asp Gly Wing Gly Wing Asp Val He Lys Asn Asp Gly He Tyr € 60 665 670 Ser Arg Tyr Phe Phe Ser Phe Wing Wing Asn Gly Arg Tyr Ser Leu Lys 67S 680 53S Val His Val Asn His Ser Pro Be Ser Thr Pro Wing His Sar Lie 690 695 700 Pro Gly Ser His Wing Mee Tyr Val Pro Gly Tyr Thr Wing Asn Gly Asn 705 710 715 720 He Gln Mee Asn Ala Pro Arg Lys Ser Val Gly Arg Asn Glu Glu Glu 725 730 735 Arg Lys Trp Gly Phe Ser Arg Val Ser Ser Gly Gly Ser? He Ser Val 740 745 750 Leu Gly Val Pro Wing Gly Pro His Pro Asp Val Phe Pro Pro Cys Lys 755 760 765 He He Asp Leu Glu Ala Val Lys Val Glu Glu Glu Leu Thr Leu Ser 770 775 780 Trp Thr Wing Pro Gly Glu Asp Phe Asp Gln Gly Gln Wing Thr Ser Tyr 785 790 795 800 Glu He Arg Met Ser Lys Ser Leu Gln Asn He Gln Asp Asp Phe Asn 805 810 815 Asn Wing He Leu Val Asn Thr Ser Lys Arg Asn Pro Gln Gln Wing Gly 820 825 830 He Arg Glu He Phe Thr Phe Ser Pro Gln He Ser Thr Asn Gly Pro 835 840 845 Glu His Gln Pro Asn Gly Glu Thr HiS Glu Ser His Arg He Tyr Val 850 855 360 Wing He Arg Wing Met Asp Arg Asn Ser Leu Gn Ser Wing Val Ser Asn 365 870 875 380 He Wing Gln Wing Pro Leu Phe He Pro Pro As Asn Pro As Pro Pro 885 890 895 Wing Arg Asp Tyr Leu He Leu Lys Gly Val Leu Thr Ala Met Gly Leu 900 905 910 He Gly He He Cys Leu He He Val Val Thr His His Thr Leu Ser 915 920 925 Arg Lys Arg Ala Asp Lys Lys Glu Asn Gly Thr Lys Leu Leu 930 935 940 < 210 > 162 < 211 > 498 < 212 > DNA < 213 > Ho or sapien < 400 > 162 tggagaacca cgeggacagc accatgaaca egeegggcgg gggaggcage gceggecgga 60 agcccctcaa gccgggcacg aaggagccgg ccgcgccccg ggagaaggec accgagcagc 120 accggcagat gggcaaggge ggcaagcacc accccggcce ggaggagccc aagaagccgc 180 gaccaccccc cgccaggacc ccccgccaac aggaactgga ccaggccccg gagcggacce 240 ccaccacgcg ccccccggac gagcggggcc ccccggagca cccctactcc ctgcacatcc 300 ccaactgtga caagcatggc ctgtacaacc tcaaacagtg gcaagatgtc tctgaacggg 360 cagcgcgggg agcgctggcg cgcgaacccc aacaccggga agctgatcca gggagccccc 420 accacccggg gggaccccga gcgccacccc ccccacaacg agcagcagga ggcccgcggg 480 gcgcacáccc cagcggac 498 < 210 > 163 < 211 > 1128 < 212 > DNA < 213 > Homo sapien < 400 > 163 gccacccggc ccccccgacc gacgacacac gcacccgaaa cctgttctca gggcgcgcgg 60 aatcaacttt ccggaagcaa ccagcccacc agaggaggtc gcggagacga ccgagcgcga 120 tgcagcggag accggetcag cagtggagcg ecgcggcgct cctgctgagc tacgcggtgc 180 cctcccgcgg gcgctcggtg gagggececa gccgccgccc caaaagagcc gcgtcegaae 240 accagcccct ccatgacaag eccaagattt gggaagtcca ttcteectte acggcgacga 300 accaectgat cgcagaaaee cacacagceg aaatcagagc eaccecggag gegeeeeeea 360 accccaagcc ctcccccaac acaaagaace accccgcccg acccgggccc gatgatgagg 420 gcagacaccc aacecaggaa actaacaagg eggagacgea caaagagcag ccgcecaaga 480 gaaaaagaaa cacctgggaa ggcaagcccg gaaacgcaa ggagcaggaa aagaaaaaac 540 ggcgaactcg ctctgccegg ttagactctg gagtgactgg gagcgggcca gaaggggacc 600 cacctccaca acctgcctga acgtcgctgg agctcgattc acggaggcac egaaattttc 660 agcagagacc etccaaggac acaccgcagg aceccgcaac agcgaacaca eggaaageac 720 tagaaatatt tategectgc aaacaccgca aacgcaccgg aataaaactg tcecccceae 780 cgccccacga aacegcacae cggccacegc gaatattttt ctccctgcca aggceaaccc 840 aaeeaecaee atcaca CTTA ccaeaaceca eettgeccae ateeegeaaa tgatgeatte 900 cgccgccgaa tgtaccccgg eeeegeaaca cceccaeace eagaeaeaca eaaegcacee 960 geegacaaae caccaagcac gacacaaega agegececea eeeegtggee gaeeeeaacg 1020 aaegcceaaa eacaaetatc caaaeegaee tecctttgcg catgtaaaaa eaacagcacc 1080 ttaaaeeege aaagaaegec eaaeaaaata caacctaaee acaecatg 1128 < 210 > 164 < 211 > 1310 < 212 >; DNA < 213 > Ho or sapien < 400 > 164 gggcceggee cgcaaagaag ctgactecag agggggaaac eeeceeceee caggaggcgg 60 eeagcccege eceacgaacc caggagaace gccggccaga etaaeeagac aeegceaegg 120 gagacgcgca aacacaccac etaecaeega aaaccaccee cgcataeaca aeeeecgcca 180 etattecaga ggaagcgcct ctgaeetgce ecetetetcc ceetetgcte cceceggccg 240 egeggeeegg agaaagcaca geeggageag eeggeegcta aataagtccc gagcgcgagc 300 ggagacgaeg cagcggagac eggcccagca geggagcgec gcggegeecc tgcegagcea 360 eceegcgggc cgcggegccc gggccccagc gcecggtgga cgccgcceca aaagagcege 420 gecegaacae cagccecccc aegacaaggg gaagcceace caagatetae ggcgacgaee 480 ccccececac caecegaccg eagaaaeeca eacageegaa aecagagcea ceecggagge 540 gccccccaac eccaagccce cecccaacac = aagaaccac cccgtccgat ecgggtctga 600 cgaesagggc agaeacctaa cccagsaaac eaacaaggeg gagacgtaca aagagcagcc 660 ccegggaaga gcecaagaca aaaagaaagg eaagcccggg aaacgcaagg agcaggaaaa 720 gaaaaaacgg cgaaeecgcc cegcceggee sgacecegga gcgaceggga gtgggceaga 780 aggggaccac cegecegaca cceccacaac gecgceggag ctcgaeecac ggaggcattg 840 aaaeeeecag cagaga CCTEs ccaaggacae = etgcaggae ectgtaatag egaacataeg 900 gaaatattta gaaageatta tegecegeaa aeacegeaaa egcaceggaa eaaaacegtc 960 ecccccattg ctceaegaaa cegcacaceg gecaccgcga aeaetttttt eeeegccaag 1020 gceaaeccaa eeaeeattat cacaceeacc acaacccaee ttgtccateg aegeaeetat 1080 eeegcaaacg eaeceeggtg cegcegaaee eccacacctt ttgtaacaea atgcact ea 1140 gatatacata tcaagtatgc cgacaaacga eacaatgaag egectceaee ttgcggeega 1200 cgcceaaaca ccccaacgaa taattatcca aatcgacttt cgeaaaaaca ccettgtgcc 1260 acagcacccc aaacttgcaa agaatgtcta acaaaacaca atctaattac 1310 < 210 > 165 < 211 > 177 < 212 > PRT < 213 > Homo sapien < 400 > 165 Mee Gln Arg Arg Leu Val Gln Gln Trp Ser Val Ala Val Phe Leu ~ Leu 1 5 10 15 Ser Tyr Ala Val Pro Ser Cys Gly Arg Ser Val Glu Gly Leu Ser Arg 20 2 = 30 Arg Leu Lys Arg Ala Val Ser Glu Hi3 Gln Leu Leu His Asp Lys Gly 35 40 45 Lys Ser He Gip Asp Leu Arg Arg ._rg Phe Phe Leu His His Leu He 50 55 60 Wing Glu He His Thr Wing Glu He Arg Wing Thr Ser Glu Val Ser Pro 65 70 75 80 Asn Ser Lys Pro Ser Pro Asn Thr Lys Asn His Pro Val Arg Phe Gly 85"90 95 Being Asp Asp Glu Gly Arg Tyr Leu Thr Gln Glu Thr Asn Lys Val Glu 100 105 110 Thr Tyr Lys Glu Gln Pro Leu Lya Thr Pro Gly Lys Lys Lys Lys Gly 115 120 125 Lys Pro Gly Lys Arg Lys Glu Gln Glu Lys Lys Lys Arg Arg Thr Arg 130 135 140 Ser Ala Trp Leu Asp Ser Gly Val Thr Gly Ser Gly Leu Glu Gly Asp 145 150 155 160 H s Leu Ser Asp Thr Ser Thr Thr Ser Leu Glu Leu Asp Ser Arg Arg 165 170 175 His < 210 > 166 < 211 > 177 < 212 > PRT < 213 > Homo sapien < 400 > 165 Mee Gln Arg Arg Leu Val Gln Glii Trp Ser Val Wing Val Phe Leu Leu 1 5 10 15 Ser Tyr Ala Val Pro Ser Cys Gly Arg Ser Val Glu Gly Leu Ser Arg 25 30 Arg Leu Lys Arg Ala Val Ser Glu His Gln Leu Leu His Asp Lys Giy 3S 40 45 Lys Ser He Gln Asp Leu Arg Arg Arg Phe Phe Leu His His Leu He 50 55 60 Wing Glu He His Thr Wing Glu He Arg Wing Thr Ser Glu Val Ser Pro 65 70 75 80 Asn Ser Lys Pro Ser Pro Asn Thr Lys Asn His Pro Val Arg Phe Gly 85 90 95 Being Asp Asp Glu Gly Arg Tyr Leu Thr Gln Glu Thr Aen Lys Val Glu 100 105 110 Thr Tyr Lys Glu Gln Pro Leu Lys Thr Pro Gly Lys Lys Lys Lys Gly 115 120 125 Lys Pro Gly Lys Arg Lys Glu Gln Glu Lys Lys Lys Arg Arg Thr Arg 130 135 140 Ser Ala Trp Leu Asp Ser € and Val Thr Gly Ser Gly Leu Glu Gly Asp 14S 150 155 160 His Leu Ser Asp Thr Ser Thr Ser Leu Glu Leu Asp Ser Arg Arg 165 170 175 His < 210 > 167 < 211 > 3362 < 212 > DNA < 213 > Homo saden < 400 > 167 cacaacgcac gcagcaggce cagtgtgagt gaaceggagg cttctctaca acaegaccca 60 aaggagcacc gcaggeccea cccgcaaccc gaagttegtg actctcctgg ecgccceaag 120 cccagaaccc ccattcctgg gagccggagc acagceccaa gacaatgggt aeaatggacc 180 attaaeccec gcccaccgca gaatcagaac aggcacccga acaeeaagga ctcaccccaa 240 aaegaeaace gaagceccát eccacccacc eaaegccacc aagagaagag caccccccag 300 aaaeaeaaag attttaatac ccgccacacg gaaagceaae aacaacagca aaacaaaaca 360 agaaccacac gaaaaggcaa acgccacagc gaccgaccgg tacggggcac acggagacga 423 eccaeacacc ceacaaeaca gagggegcgg aaaagaggga aaacacacec accecacace 480 caaececcca ctgaacgata acttaacagc eggccacgga tcacgaggcc gagcgcctgc 540 ccacgaacgg gcceacctcc gccggggcgc gcccgacgag eacaacaaeg acaaacceee 600 ccacacaaac gggcaaaatc aaaccaaagc gacaaggcgc ecacccgaca ccacaggcac 660 ceccgcgegc gaaaaaggtc cccgccccca agaaaactgt actattagta agcettttaa 720 agaaggacgc acceeeatcc acaacagcac accgcatcaa scaaaaegca caacgcecae 730 gcaaagctca tceecegegg eegaaecteg eaatgcaagt acccacaace aagaagcacc 840 aaacccacag aacc agatge gcagccccag aagtgcatgg gatgtaatca cagactccgc 900 cgaceeecac cacagceeec ccaegaacgg gactgagcte ccacctcccc ccacacecee 960 gctcgeagag gceggcgaca aagtggtctg eccagcgccg gacgcgccca gcaagacggc 1020 agaggcegac agaceccctc aactacaaca agccgcagaa ttteatttga tgcagaecge 1030 egaaaeecae acceecgcgg gcattgccag ettcgacagc tcagagccca _ aaaggagaga? _ «_ Gceacaccaa accaacagca atgatgaccg aaageegceg gettcataec egcccaccac 1230 aaaacagaca egeaeeagce ccagcactcg etcagggctt aagaaaggat ccgaggegge 1253 egaaaaaceg aaeggaaaag cteaeggcec egegacgata eeagcgacca gcggagaega 1320 eaagceecee ggcaaeegce eacccactgc gceeagcage ggeecaacaa eccaceccae 1380 egceceggge ecaecegcag ccccaaaccc ggaggaaeea ccacgectea caggaggeee 1440 aaageeeeee geeeeagaea r.accaaacec caaeagcacg acegaegcet tcageagaae 1503 actggagaca eeocecegga eeeeccagca acaeaeecag ceegaaag to eaggegaaaa 1550 egecaaacce caceaecaae egaaaaacac agegacegtg gaeaaeaceg tgggcaacga 1623 caeeaegeee ctage acgt ggcaggccag eggeectcce gagaecaeae tattegaecc 1630 tgacggacga aaaeaccaca caaaeaattt eaecaccaat ccaacrtctc ggacagceag 1740 Ccceeggaee ceaggaacag ceaagccegg gcaccggacc tgegeeecca eacaccccga 1800 ccaegcaaaa ceaeegacce ggaagctgca aaagcagaag aggaactgac cceaeceegg 18-5C acagcacccg gagaagacct cgatcagggc casgceacaa gctatgaaat aagaatgage 1920 agaaeaecca aaaageceac agatgacctt aacaatgcta ecccagcaaa tacatcaaag 1980 cgaaaeccec agcaagctgg caccagggag aeatteacge ectcacccca aatttccacg 2040 aatggacctg aacaecagcc aaacggagaa acacacgaaa gccacagaat ttatgttgca 2100 eggaeaggaa atacgagcaa cccctcacag ecegcegeae ctaacattgc ccaggcgcce 2160 ctgeeeaeec cccccaattc tgaecccgca ccgccagag to tatcctat attgaaagga 2220 gccecaacag caatgggeet gataggaatc aeeegcccca ecacagccgc gacacaecae 2280 accceaagca ggaaaaagag agcagacaag aaagagaacg gaacaaaatc attataaaea 2340 aacaeccaaa gcgccttcct tcttagatat aagacccacg gccctcgact acaaaaacae 2400 accaacaaag ccaaaccaac accaaaaccg eattaaaaeg cacegagtee ttgtacaata 2460 eeteacacgg cagacaagae cagatcaaca aacectccce gggggcagac eagaaaacce gceacgaaca 2520 ccacacceeg aacaataaaa accacc CTTT aaagtaatgt ctttaaaggc 2580 aaagggaagg gcaaagccgg accagtgtca aggaaagttt gttttattga ggtggaaaaa 2640 cagccccaag cagagaaaag gagggtaggc ecgcatcaca actgcctgtg cgaagcaaec 2700 aeecagttac cccgaecaat ttttcttttc tccttatctg tgcagaacag gttgcttgtt 2760 gaecacgcca tacaaccgaa tatctcatat atgaagcccc taaegcaaag ctctccacct 2820 ctcgceaeee cgctacaeae attacagacg aaaececace gccaatgctc agagaeceee 2380 tttcactgta agaggtaacc tttaacaaca cgggtattac ctttgtctct tcataccggt 2940 tttatgacaa aggcceaetg aattcactcg teegeaaget tctactccca ecaaagcagr 3000 tttceaagee attgccccgg ccaccacgga egacagttat agcccctaca aegccttaac 3060 caaggaagaa aagaegctat cccgagtttg etttaacaca tatagteeea cacacgaaca 3123 ccaaagaaga cccaaceaaa ggtcagcagg gagaeaceaa cccccggaaa egaeeagctg 3130 gcecegttee eeggeeaaae aagagceeee aaecceeece ccaeeaagag teaceeaeea 3243 agggcagggg aagggggata tagaggccac aaggaaacaa aaaccacctc ccacccteaa 3300 ttetactcct tccccttatt tttttaaaag attatcgaac aataaaacca tttgccttte 3360 cc 3362 < 210 > 168 < 211 > 2784 < 212s • DNA < 213 > - Homo sapien < 400 > • 168 cccgcaccca eaeegaaaac cegacacaac gcacgcagca ggctcagtgt gagtgaactg 60 gaggcccccc eacaacatga cccaaaggag cattgcagge cceaeeegca accegaagee 120 cgcgactccc ceggeegcce eaageeeaga actcccatec ctgggagceg gageacagce 130 ccaagacaac gggcacaacg gaeegcccae egcaaeeaae cctcaggtac cegagaaeca 240 ccaaacacca gaaccecaec aggaaaegae aacegaagce ecaeeeeacc eaeeeaaegc 300 eaccaagaga agagcaccte aaagaeetta ec3gsaaeae aeaccegcca eaeggaaagc 360 taataaeaac agcaaaataa aacaagaaec atatgaaaag gcaaacgcca tagtgacega 420 ctggeaeggg gcacatggag atgaeccaea cscccescsa eacagaggge gtggaaaasa 480 gggaaaaeac atecaeeeca cacccaaeee eceacegaae cagceggcea gaeaaceeaa 540 cggaecacga ggccgagt c etgeccatga acgggcccac ctccgeeggg gegegeccga 500 tgagtataac aacgacaaac ceeeceacae aaaegggcaa aaecaaaeea aagegacsag 560 gegeecaece gacaecacag gcaeeeeege gegegaaaaa ggecceegcc cccaagaaaa 720 cegeaetace ageaagcecc ctaaagaagg acgcacceee aeceacaaes gcacccaaaa 780 cgcaactgca ecaaeaaegc ccaegcaa3g eecatccect geggeegaat eeegtaatgc 840 aagtacccac aa ecaagaag eaccaaacee acagaaccag acgtgcagce ccagaagtgc 900 acgggacgea atcacagace cegccgacee eeaccaeagc ceccccatga aegggaccga 960 gceeecscce ccecccacae ececgeeege agaggreggt gacaaagegg ecrgeteage 1020 gcrggaegeg eccagcaaga eggcagaggc egacagacec ceecaaceac aacaagcegc 1080 agaaeeeeac eegaegcaga eegeegaaae ccaeaccttc gegggcateg ccageetcga 1140 cagcaaagga gagaecagag cccagceaca ccaaaeeaac agcaaegaeg aecgaaagee 1200 eaecegccca gceggeeeca ccacegeacc agccaaaaca gacaccagca eeegeecagg 1260 gceeaagaaa ggaetegagg eggeegaaaa accgaacgga aaagcceaeg gcecegtgae 1320 gaeaecageg accagcggag acgacaagce ccttggcaat tgcttaccca ctgtgcecag 1390 cagcggeeca acaaetcace ccaeegccce gggcccacct gcagccccaa aeceggagga 1440 aeeaecacgc ceeacaggag geecaaagee eeeegcecca gaeaeaecaa aceccaaeag 1500 gceeecagea caegaeegae eggaacegga gaaeeeecec gacaetttcc agcaacatae 1560 ecagcttgaa agtacaggtg aaaaegecaa acctcaccat caategaaaa acacagegac 1620 acegegggca tgeggaeaae acgacaceae geetceagee acgeggcagg ccageggecc 1680 eccegagaee aeaeeaettg accctgatgg acgaaaatae eacacaaata attteaecac 1740 caaeceaace eeecggacag ctageceeeg gaeeccagga acagceaagc cegggcaceg 1800 gacceacacc cegaacaaea cccaecaeec ecegcaagcc eegaaagega cagegaccec 1860 tcgcgcctcc aactcagctg egcccccagc cactgtggaa gcctttgtgg aaagagacag 1920 cctccateee cctcatcctg egacgaceea egccaaegeg aaacagggae tttatcccae 1980 ecttaatgcc acegecaceg ccacagcega gccagagace ggagatcctg etacgctgag 2040 actcctegae gatggagcag gegcegaege eataaaaaat gatggaattt actcgaggta 2100 eeegcegcaa ettttececc aeggtágata eagctegaaa gegcaegeca atcacccccc 2160 cagcaeaagc accccagcce aceceaeecc agggagecae gctatgeaeg caccaggcca 2220 cacagcaaac ggeaaeaetc agaegaacgc eccaaggaaa ccagtaggca gaaatgagga 2280 ggagcgaaag tggggcttta gccgagteag ctcaggagge tccttetcag cgccgggagc 2340 eccagceggc cceeaccceg atgcgeeecc accacgcaaa aeeaeegacc eggaagcege 2400 aaaeagaaga ggaaeegacc ceaeceegga eagcaccegg agaagactte gaccagggcc 2460 ctatgaaata aggctacaag aaagtccaca agaatgagta gatgacttta gaatatccaa 2520 eeeageaaae acaatgctat ACAE caaagc gcaagceggc gaaacececa accagggaga 2580 ctcaccccaa tatttacgte aeggaccega acecccacga acaecagcca aacggagaaa 2640 ccacagaate cacacgaaag cacgccgcaa eacgagcaae ggaeaggaac cccccacage 2700 cegcegeaec taacaeegcc caggcgceec egeeeaeece eeccaaeeee gaceccgeae 2760 eeaeceeaea ccgccagaga tTGA 2784 < 210 > 169 < 211 > 592 < 212 > PRT < 213 > Homo sapien < 400 > 169 Met Thr Gln Arg Ser He Wing Gly Pro He Cys Asn Leu Lys Phe Val l 5 10 15 Thr Leu Leu Val Wing Leu Ser Ser Glu Leu Pro Phe Leu Gly Wing Gly 20 25 30 Val Gln Leu Glp Asp Asn Gly Tyr Asn Gly Leu Leu He Wing He Aen 35 40 45 Pro Gln Val Pro Glu Asn Gln Asn Leu He Ser Asn He Lys Glu Mee 50 55 60 He Thr Glu Wing Being Phe Tyr Leu Phe Asn Wing Thr Lys Arg Arg Val 65 70 75 80 Phe Phe Arg Asn He Lys He Leu He Pro Wing Thr Trp Lys Wing Asp 35 90 95 Asn Asn Ser Lys He Lys Glp Glu Ser Tyr Glu Lys Wing Asn Val He loo 105 110 Val Thr Asp Trp Tyr Gly Wing His Gly Asp Asp Pro Tyr Thr Leu Gln 115 120 125 Tyr Arg Oly Cys Gly Lys Glu Gly Lys Tyr He His Phe Thr Pro Asn 130 135 14C Phe Leu As Asn Asn Leu Thr Ala Gly Tyr Gly Ser Arg Gly Arg 145 150 155 160 Val Phe Val His Glu Trp Wing His Leu Arg Trp Gly Val Phe Asp Glu 165 170 175 Tyr Asn Asn Asp Lys Pro Phe Tyr He Asn Gly Gln Asn Gln He Lys 180 185 190 Val Thr Arg Cys Ser Ser Asp He Thr Gly He Phe Val Cys Glu Lys 195 200 205 Gly Pro Cys Pro Gln Glu Asn Cys He He Ser Lys Leu Phe Lys Glu 210 215 220 Gly Cys T * 1 * - M «He Tyr Asn Ser Thr Gln Asn Ala Thr Ala Ser He 225 230 235 240 Met Phe Met Gln Ser Leu Ser Val Val Glu Phe Cys Asn Wing Ser 245 250 255 Thr His Asn Gln Glu Ala Pro Asn Leu Gln Asn Gln Mee Cys Ser Leu 260 265 270 Arg Ser Wing Trp Asp Val He Thr Asp Ser Wing Asp Phe Kis His Ser 275 280 285 Phe Pro Met Asn Gly Thr Glu Leu Pro Pro Pro Thr Phe Ser Leu 290 295 300 Val Glu Wing Gly Asp Lys Val Val Cys Leu Val Leu Asp Val Ser Ser 305 310 315 320 Lys Met Wing Glu Wing Asp Arg Leu Leu Gln Leu Gln Gln Wing Wing Glu 325 330 335 Phe Tyr Leu Mee Gln He Val Glu He His Tbr Phe Val Gly He Wing 340 345 350 Ser Phe Asp Ser Lys Gly Glu He Arg Ala Gln Leu His Gln He Asn 355 360 365 Ser Asn Asp Asp Arg Lys Leu Leu Val Ser Tyr Leu Pro Thr Thr Val 370 375 380 Ser Wing Lys Thr Asp He Ser He Cys Ser Gly Leu • Lys Lys Gly Phe 385 390 395 - 400 Glu Val Val Glu Lys Leu Asn Gly Lys Wing Tyr Gly Ser Val Mee He 405 410 415 Leu Val Thr Ser Gly Asp Asp Lys Leu Leu Gly Asn Cys Leu Pro Thr 420 425 430 Val Leu Ser Ser Gly Ser Thr He His Ser I Am Wing Leu Gly Ser Ser 435 440 445 Ala Ala Pro Asn Leu Glu Glu Leu Ser Arg Leu Thr Gly Gly Leu Lys 450 455 460 Phe Phe Val Pro Asp He Ser Asn Ser Asn Ser Mee He Asp Wing Phe 465 470 475 480 Ser Arg Be Ser Gly Thr Gly Asp He Phe Gln Gln His He Gln 485 490 495 Leu Glu Be Thr Gly Glu Asn Val Lys Pro Hi3 His Gln Leu Lys Asn 500 SOS 510 Thr Val Thr Val Asp Asn Thr Val Gly Asn Asp Thr Mee Phe Leu Val 515 520 525 Thr Trp Gln Wing Ser Gly Pro Pro Glu He He Leu Phe Asp Pro Asp 530 535 540 Gly Arg Lys Tyr Tyr Thr Asn Asn Phe He Thr Asn Leu Thr Phe Arg 545 550 555 560 Thr Ala Ser Leu Trp He Pro Gly Thr Ala Lys Pro Gly His Trp Thr 565 570 575 Tyr Thr Leu Mee Cys Phe His His Wing Lys Leu Leu Thr Trp Lys Leu 580 535 590 < 210 > 170 < 211 > 791 < 212 > PRT < 213 > Homo sapien < 400 > 170 Mee Thr Gln Arg Ser He Wing Gly Pro He Cys Asn Leu Lys Phe Val 1 5 10 15 Thr Leu Leu Val Wing Leu Being Ser Glu Leu Pro Phe Leu Gly Wing Gly 25 30 Val Gln Leu Gln Asp Asn Gly T r Asn Gly Leu Leu He Wing He Asn 40 45 Pro Gln Val Pro Glu Asn Gln Asn Leu He Ser Asn He Lys Glu Mee 50 ^ 55 60 He Thr Glu Wing Being Phe Tyr Leu Phe Asn Wing Thr Lys Arg Arg Val 65 70 75 80 Phe Phe Arg Asn He Lys He Leu He Pro Wing Thr Trp Lys Wing Asn 85 90 95 Asn Asn Ser Lys He Lys Gln Glu Ser Tyr Glu Lys Wing Asn Val He 100 105 110 Val Thr Asp Trp Tyr Gly Wing His Giy Asp Asp Pro Tyr Thr Reading Gln 115 120 125 Tyr Arg Gly Cys Gly Lys Glu Gly Lys Tyr He His Phe Thr Pro Asn 130 135 140 Phe Leu Leu Asn Asp Asn Leu Thr Wing Gly Ty Gly Ser Arg Gly Arg 145 150 155 160 Val Phe Val His Glu Trp Wing His Leu Arg Trp Gly Val Phe Asp Glu 165 170 175 Tyr Asn Asn Asp Lys Pro Phe Tyr He Asn Gly Gln Asn Gln He Lys 180 185 190 Val Thr Arg Cy Ser Ser Asp He Thr Gly He Phe Val Cys Glu Lys 195 -. 195 - 200 205 Gly Pro Cys Pro Gln Glu Asn Cys He He Ser Lys Leu Phe Lys Glu 210 215 220 Gly Cys Thr Phe He Tyr Asn Ser Thr Gln Asn Wing Thr Ala Ser He 225 230 23S 240 Mee Phe Mee Gln Ser Leu Ser Ser Val Val Glu Phe Cys Asn Ala Ser 245 250 255 Thr His Asn Gln Glu Pro Wing Asn Leu Gln Asn Gln Mee Cys Ser Leu 260 265 270 Arg Ser Wing Trp Asp Val He Thr Asp Ser Wing Asp Phe His His Ser 275 260 285 Phe Pro Met Asn Giy Thr Glu Leu Pro Pro Pro Thr Phe Ser Leu 290 295 300 Val Glu Ala Gly Asp Lys Val Val Cys Leu Val Leu Asp Val Ser Ser 305 310 315 320 Lys Mee Wing Glu Wing Asp Arg Leu Leu Gln Leu Gln Gln Wing Ala Glu 325 330 335 Phe Tyr Leu Met Gln He Val Glu He His Thr Phe Val Gly He Wing 340 345 350 Ser Phe Asp Ser Lys Gly Glu He Arg Wing Gln Leu His Gln He Asn 355 360 365 Ser Asn Asp Asp Arg Lys Leu Leu Val Ser Tyr Leu Pro Thr Thr Val 370 375 380 Ser Ala Lys Thr Asp He Ser lie Cys Ser Gly Leu Lys Lys Gly Phe 385 390 395 400 Glu Val Val Glu Lys Leu Asn Gly Lys Wing Tyr Gly Ser Val Met He 405 410 415 Leu Val Thr Ser Gly Asp Asp Lys Leu Leu Gly Asn Cys Leu Pro Thr 420 425 430 Val Leu Ser Ser Gly Be Thr He HiS Ser He Ala Leu Gly Ser Ser 435 440 445 Ala Ala Pro Asn Leu Glu Glu Leu Ser Arg Leu Thr Gly Gly Leu Lys 450 455 460 Phe Phe Val Pro Asp He Ser Asn Ser Asn Ser Met He Asp Ala Phe 465 470 475 480 Ser Arg Be Ser Gly Thr Gly Asp He Phe Gln Gln His He Gln 485 490 495 Leu Glu Be Thr Gly Glu Asn Val Lys Pro His His Gln Leu Lys Asn 500 505 510 Thr Val Thr Val Asp Asn Thr Val Gly Asn Asp Thr Met Phe Leu Val 515 520 525 Thr Trp Gln Wing Ser Gly Pro Pro Glu He He Leu Phe As Pro Asp 530 535 540 Gly Arg Lys Tyr Tyr Thr Asn Asn Phe He Thr Asn Leu Thr Phe Arg 545 550 555 -560 Thr Ala Ser Leu Trp He Pro Gly Thr Ala Lys Pro Gly Hi Ttp Thr 565 570 575 Tyr Thr Leu Asn Asn Thr His His Ser Leu Gln Ala Leu Lys Val Thr 580 535 590 Val Thr Ser Arg Ala Ser Asn Ser Ala Val Pro Pro Ala Thr Val Glu 595 600 605 Wing Phe Val Glu Arg Asp Ser Leu His Phe Pro His Pro val Met He 610 615 620 Tyr Wing Asn Val Lys Gln Gly Phe Tyr Pro He Leu Asn Wing Thr Val 625 630 635 640 Thr Wing Thr Val Glu Pro Glu Thr Gly Asp Pro Val Thr Leu Arg Leu 645 650 655 Leu Asp Asp Gly Wing Gly Wing Asp Val He Lys Asn Asp Gly He Tyr 660 665 670 Ser Arg Tyr Phe Phe Ser Phe Wing Wing Asn Gly Arg Tyr Ser Leu Lys 675 680 685 Val His Val Asn His Be Pro Pro Be Ser Thr Pro Wing His Ser 690 695 700 Pro Gly Ser His Wing Met Tyr Val Pro Gly Tyr Thr Wing Asn Gly Asn 705 710 715 720 Zle Gln Met Asn Wing Pro Arg Lys Ser Val Gly Arg Asn Glu Glu Glu 725 730 735 Arg Lys Trp Gly Phe Ser Arg Val Ser Ser Gly Gly Ser Phe Ser Val 740 745 750 Leu Gly Val Pro Wing Gly Pro His Pro Asp val Phe Pro Pro Cys Lys 755 760 765 lie He Asp Leu Glu Wing Val Asn Arg Arg Gly He Asp Pro He Leu 770 775 780 Asp Ser Thr Trp Arg Arg Leu 785 790 <; 210 > 171 < 211 > 1491 < 212 > DNA < 213 > Homo sapien < 400 > 171 gccaagtgaa cctcctgcca gacatgctta ettccccttc accttccttc aegacgcggg 60 aagagcgctg caacccagcc ccagccaacg ccgcacgaga gggagcgtgc cgagggcttc 120 cgagaaggcc tcccccacae ctagaaagaa gcgcttaaga tgcggcagcc cceceeceec 180 aagcggcect cgtcctgttg cccegggage ectcaaattg ctgcagcagc ccccacccag 240 cctgaggatg acaccaatac acagaggaag aagagtcagg aaaagaegag agaagctaca 300 gacectcccg ggcgaccccg agagcttacc attcctcaga cttcttcaca tggtgctaac 360 agacttgttc ctaaaagtaa agctctagag gccgtcaaat tggcaataga agccgggttc 420 caccatattg attctgcaca tgtttacaat aatgaggagc aggtcggact ggccatccga 480 agcaagattg cagatggcag tgtgaagaga gaagacatat tctacacttc aaagctttgg 540 atcgaccaga agcaattccc gttggtccga ecagccttgg aaaggtcact gaaaaatctt 600 caattggact atgctgacct ctatcttatt cattttccag tgtctgtaaa gccaggegag 660 caaaagacga gaagcgaecc aaacggaaaa acactatttg acacagcgga tc ctgcgcc 720 acatgggagg ccacggagaa gcgtaaagat gcaggattgg ccaagtccat cggggcgtcc 780 aactecaacc acaggctgct ggagatgatc ctcaacaagc cagggctcaa gtacaagcct 840 gtccgcaacc aggcgg AACG ecacccccac eecaaccaga gaaaaccgcc ggacccccgc 900 aagtcaaaag acactgttct ggttgcceae agtgctctgg gatcccatcg agaagaacca 960 tgggcggacc cgaactcccc ggtgctcttg gaggacccag tcctttgtgc cttggcaaaa 1020 aagcacaagc gaaccccagc ccegaeegcc eegcgceacc agctgcagcg tggggttgtg 1C80 gtcceggcca agagceacaa egagcagcgc aecagacaga acgcgcaggc gtttgaatcc 1140 cagaggagat cagtcgacte gaaagccata gatggcctaa acagaaatgt gcgatacttg 1200 acccttgata eeteegccgg cccccccaac eacccacccc ccgacgaaca ttaacaegga 1260 gggcaccgca cgaggcccgc cagaaggccr rgcgcgcgga cggcgacaca gaggaeggce 1320 ctatgctggt gactggacac atcgcctctg cttaaatctc tcctgctcgg cgacttcagt 1380 aagctacagc taagcocatc ggccggaaaa gaaagacaat aattttgcee ttcatetega 1440 aaaaateaaa tgccctctcc taaagattct ecacctaaaa aaaaaaaaaa a 1491 < 210 > 172 < 211 > 364 < 212 > PRT < 213 > Homo sapien < 400 > 172 Mee Trp Gln Pro Leu Phe Phe Lys Trp Leu Leu Ser Cys Cys Pro Gly 1 5 10 15 Ser Ser Gln He Wing Wing Wing Ser Thr Gln Pro Glu Asp Asp He 20 25 30 Asn Thr Gln Arg Lys Lys Ser Gln Glu Lys Met Arg Glu Val Thr Asp 35 40 45 Ser Pro Gly Arg Pro Arg Glu Leu Thr He Pro Gln Thr Ser Ser His 50 55 60 Gly Wing Asn Arg Phe Val Pro Lys Ser Lys Wing Leu Glu Wing Val Lys 65 70 75 80 Leu Ala He Glu Wing Gly Phe His His He Asp Being Wing His Val Tyr 85 90 95 Asn Asn Glu Glu Gln Val Gly Leu Wing He Arg Ser Lys He Wing Asp 100 105 110 Gly Ser Val Lys Arg Glu Asp He Phe Tyr Thr Ser Lys Leu Trp Ser 115 120 125 Asn Ser His Arg Pro Glu Leu Val Arg Pro Wing Leu Glu Arg Ser Leu 130 135 140 Lys Asn Leu Gln Leu Asp Tyr Val Asp Leu Tyr Leu He His Phe Pro 145 150"155 160 Val Ser Val Lys Pro Gly Glu Glu Val He Pro Lys Asp Glu Asn Gly 165 170 175 Lys He Leu Phe Asp Thr Val Asp Leu Cys Wing Thr Trp Glu Wing Mee 180 I85 190 Glu Lys Cys Lys Asp Wing Gly Leu Wing Lys Ser He Gly Val Ser Asn 195 200 205 Phe Asn His Arg Leu Leu Glu Mee He Leu Asn Lys Pro Gly Leu Lys 210 215 220 Tyr Lys Pro Val Cys Asn Gln Val Glu Cys His Pro Tyr Phe Asn Gln 225 230 235 240 Arg Lys Leu Leu Asp Phe Cys Lys Ser Lys Asp He Val Leu Val Ala 245 250 255 Tyr Ser Ala Leu Gly Ser His Arg Glu Glu Pro Trp Val Asp Pro Asn 260 265 270 Ser Pro Val Leu Leu Glu Asp Pro Val Leu Cys Ala Leu Ala Lys Lys 275 280 285 His Lys Arg Thr Pro Ala Leu He Ala Leu Arg Tyr Gln Leu Gln Arg 290 295 300 Gly Val Val Val Leu Ala Lys Ser Tyr Asn Glu Gln Arg He Arg Gln 305 310 315 320 Asn Val Gln Val Phe Glu Phe Gln Leu Thr Ser Glu Glu Met Lys " "Wing 325 330 335 _ He Asp Gly Leu Asn Arg Asn Val Arg Tyr Leu Thr Leu Asp He Phe 340 345 350 Wing Gly Pro Pro Asn Tyr Pro Phe Ser Asp Glu Tyr 355 360

Claims (58)

1. CLAIMS 1. An isolated polynucleotide molecule comprising a nucleotide sequence selected from the group consisting of: (a) sequences provided in SEQ ID NO. 1-3, 6-8, 10-13, 15-27, 29, 30, 32, 34-49, 51, 52, 54, 55, 57-59, 61-69, 71, 73, 74, 77, 78, 80-82, 84, 86-96, 107-109, 111, 113, 125, 127, 128, 129, 131-133, 142, 144, 148-151, 153, 154, 157, 158, 160, 167, 168 and 171; (b) the complements of the sequences provided in SEQ ID NO. 1-3, 6-8, 10-13, 15-27, 29, 30, 32, 34-49, 51, 52, 54, 55, 57-59, 61-69, 71, 73, 74, 77, 78, 80-82, 84, 86-96, 107-109, 111, 113, 125, 127, 128, 129, "131-133, 142, 144, 148-151, 153, 154, 157, 158, 160 , 167, 168 and 171, and (c) sequences that generate hybrids to a sequence of (a) or (b) under moderately stringent conditions 2. An isolated polypeptide comprising an immunogenic portion of a lung tumor protein or a variant thereof, wherein said protein comprises an amino acid sequence encoded by a polynucleotide molecule according to claim 1. 3. An isolated polynucleotide molecule comprising a nucleotide sequence encoding the polypeptide of claim 2. 4. - An expression vector comprising an isolated polynucleotide molecule of claims 1 or 3. 5. A host cell transformed with the expression vector of claim 4. 6. The host cell according to claim 5, characterized in that the host cell it is selected from the group consisting of E coli, yeast and mammalian cell lines. 7. A pharmaceutical composition comprising the polypeptide of claim 2 and a physiologically acceptable carrier. 8. A vaccine comprising the polypeptide of claim 2 and a non-specific immune response enhancer. 9. The vaccine according to claim 8, characterized in that the enhancer of the non-specific immune response is an adjuvant. 10. A vaccine comprising an isolated polynucleotide molecule of claims 1 or 3 and a non-specific immune response enhancer. eleven . The vaccine according to claim 10, characterized in that the enhancer of the non-specific immune response is an adjuvant. 12. A pharmaceutical composition for the treatment of lung cancer comprising a polypeptide and a physiologically acceptable carrier, the polypeptide comprising an immunogenic portion of a lung protein or a variant thereof, wherein said protein comprises an encoded amino acid sequence by a polynucleotide molecule comprising a sequence selected from the group consisting of: (a) sequences cited in SEQ ID NO. 4, 5, 9, 14, 28, 31, 33, 50, 53, 56, 60, 70, 72, 75, 76, 79, 83, 85, 97-106, 1 15-124, 126, 130, 134 -141, 143, 145-147, and 162-164; (b) sequences complementary to the sequences of SEQ ID NO. 4, 5, 9, 14, 28, 31, 33, 50, 53, 56, 60, 70, 72, 75, 76, 79, 83, 85, 97-106, 1 15-124, 126, 130, 134 - 141, 143, 145-147, and 162-164; and (c) sequences that generate hybrids to a sequence of (a) or (b) under moderately stringent conditions. 1 3. A vaccine for the treatment of lung cancer comprising a polypeptide and a non-specific immune response enhancer, said polypeptide comprising a portion and immunogenic of a lung protein or a variant thereof, wherein said protein comprises an amino acid sequence encoded by a polynucleotide molecule comprising a sequence selected from the group consisting of: (a) sequences cited in SEQ ID NO. 4, 5, 9, 14, 28, 31, 33, 50, 53, 56, 60, 70, 72, 75, 76, 79, 83, 85, 97-106, 1 15-124, 126, 130, 134 -141, 143, 145-147, and 162-164; (b) sequences complementary to the sequences of SEQ ID NO. 4, 5, 9, 14, 28, 31, 33, 50, 53, 56, 60, 70, 72, 75, 76, 79, 83, 85, 97-106, 1 1 5-124, 126, 130, 134-141, 143, 145-147, and 162-164; and (c) sequences that generate hybrids to a sequence of (a) or (b) under moderately stringent conditions. 14. A vaccine for the treatment of lung cancer comprising a DNA molecule and a non-specific immune response enhancer, the polynucleotide molecule comprising a sequence selected from the group consisting of: (a) sequences cited in SEQ ID NO: 4, 5, 9, 14, 28, 31, 33, 50, 53, 56, 60, 70, 72 , 75, 76, 79, 83, 85, 97-106, 1 15-124, 126, 130, 134-141, 143, 145-147, and 162-164; (b) sequences complementary to the sequences of SEQ ID NO: 4, 5, 9, 14, 28, 31, 33, 50, 53, 56, 60, 70, 72, 75, 76, 79, 83, 85, 97 -106, 1 15-124, 126, 130, 134-141, 143, 145-147, and 162-164; and (c) sequences that generate hybrids to a sequence of (a) or (b) under moderately stringent conditions. A method for inhibiting the development of lung cancer in a patient, comprising administering to the patient an effective amount of the pharmaceutical composition of claim 7 or 12. 16. A method for inhibiting the development of lung cancer in a patient , which comprises administering to the patient an effective amount of the pharmaceutical vaccine of any of claims 8,. 10, 13 or 14. 17. A fusion protein comprising at least one polypeptide according to claim 2. 18. A fusion protein comprising a polypeptide according to claim 2 and a known lung tumor antigen. 1 9. A pharmaceutical composition comprising a fusion protein according to any of claims 17-18 and a physiologically acceptable carrier. A vaccine comprising a fusion protein according to any of claims 17-18 and a non-specific immune response enhancer. twenty-one . The vaccine according to claim 20, characterized in that the enhancer of the non-specific immune response is an adjuvant. 22. A method for inhibiting the development of lung cancer in a patient, comprising administering to the patient an effective amount of the pharmaceutical composition of the claim 19. 23. A method for inhibiting the development of lung cancer in a patient, comprising administering to the patient an effective amount of the vaccine of claim 20. 24. A method for detecting lung cancer in a patient, comprising: (a) ) contacting a biological sample obtained from the patient with a binder that is capable of binding to a polypeptide, the polypeptide comprising an immunogenic portion of a lung protein or a variant thereof, wherein said protein comprises an amino acid sequence encoded by a a polynucleotide molecule comprising a sequence selected from the group consisting of nucleotide sequences cited in SEQ ID NO: 1-109, 11 11, 13, 15-151, 153, 1 54, 157, 158, 160, 162 -164, 167, 168, and 171, the complements of said nucleotide sequences and sequences that generate hybrids to a sequence of SEQ ID NO: 1-109, 11 11, 15-151, 153, 1 54 , 157, 158, 160, 162 -164, 167, 168, and 171, under moderately stringent conditions; and (b) detecting in the sample a polypeptide protein that binds to the binder, thereby detecting lung cancer in the patient. 25. The method according to claim 24, characterized in that the binder is a monoclonal antibody. 26. The method according to claim 25, characterized in that the binder is a polyclonal antibody. 27. A method for monitoring the advancement of lung cancer in a patient, comprising: (a) contacting a biological sample obtained from the patient with a binder that is capable of binding to a polypeptide, said polypeptide comprising an immunogenic portion of a protein of lung or a variant thereof, wherein said protein comprises an amino acid sequence encoded by a polynucleotide molecule comprising a sequence selected from the group consisting of nucleotide sequences cited in SEQ ID NO: 1-109, 1 1 1 , 1 1 3, 1 15-1 51, 153, 154, 1 57, 158, 160, 162-164, 167, 168, and 171, the complements of said nucleotide sequences and sequences that generate hybrids to a sequence of pucleotides of SEQ ID NO: 1 -1 09, 1 1 1, 1 13, 1 15-151, 1 53, 1 54, 157, 1 58, 160, 162-164, 167, 168, and 171, under moderately stringent conditions; (b) determining in the sample an amount of a protein or polypeptide that binds to the binder; (c) repeating steps (a) and (b); and (d) comparing the amount of polypeptide detected in steps (b) and (c) to monitor the progression of lung cancer in the patient. 28. A monoclonal antibody that binds to a polypeptide comprising an immunogenic portion of a lung protein or a variant thereof, characterized in that said lung protein comprises an amino acid sequence encoded by a polynucleotide molecule comprising a selected sequence of the group consisting of nucleotide sequences cited in SEQ ID NO: 1-3, 6-8, 10-13, 15-27, 29, 30, 32, 34-49, 51, 52, 54, 55, 57- 59, 61-69, 71, 73, 74, 77, 78, 80-82, 84, 86-96, 107-109, 111, 113, 125, 127, 128, 129, 131-133, 142, 144, 148-151, 153, 154, 157, 158, 160, 167, 168 and 171; the complements of said nucleotide sequences; and sequences generating hybrids to a nucleotide sequence of SEQ ID NO: 1-3, 6-8, 10-13, 15-27, 29, 30, 32, 34-49, 51, 52, 54, 55, 57 -59, 61-69, 71, 73, 74, 77, 78, 80-82, 84, 86-96, 107-109, 111, 113, 125, 127, 128, 129, 131-133, 142, 144 , 148-151, 153, 154, 157, 158, 160, 167, 168 or 171 under moderately stringent conditions. 29. A method for inhibiting the development of lung cancer in a patient, comprising administering to the patient a therapeutically effective amount of a monoclonal antibody according to claim 28. 30. The method according to claim 29, characterized in that the monoclonal antibody is conjugated with a therapeutic agent; 31. A method for detecting lung cancer in a patient, comprising: (a) obtaining a biological sample from the patient; (b) contacting the sample with at least two primary oligonucleotides in a polymerase chain reaction, wherein at least one of the oligonucleotides is specific for a polynucleotide molecule encoding a polypeptide comprising an immunogenic portion of a lung protein or a variant thereof, said protein comprising an amino acid sequence encoded by a polynucleotide molecule comprising a sequence selected from the group consisting of nucleotide sequences recited in SEQ ID NO: 1-109, 111, 113, 115-151, 153, 154, 157, 158, 160, 162-164, 167, 168, and 171, the complements of said nucleotide sequences, and sequences that generate hybrids to a sequence of SEQ ID NO: 1-109, 111, 113, 115-151, 153, 154, 157, 158, 160, 162-164, 167, 168, or 171, under moderately stringent conditions; and (c) detecting in the sample a polynucleotide sequence that is amplified in the presence of the primary oligonucleotides, thereby detecting lung cancer. The method according to claim 31, characterized in that at least one of the primary oligonucleotides comprises at least 10 contiguous nucleotides of a polynucleotide molecule comprising a sequence selected from SEQ ID NO: 1-109, 111, 113, 115-151 , 153, 154, 157, 158, 160, 162-164, 167, 168, and 171. 33. A diagnostic kit comprising: (a) one or more antibodies of claim 28; and (b) a detection reagent 34. A diagnostic kit comprising: (d) (a) one or more of the antibodies that bind to a polypeptide encoded by a polynucleotide molecule comprising a nucleotide sequence selected from the group which consists of sequences cited in SEQ ID NO: 4, 5, 9, 14, 28, 31, 33, 50, 53, 56, 60, 70, 72, 75, 76, 79, 83, 85, 97-106, 1 15-124, 126, 130, 134-141, 143, 145-147, and 162-164, the complements of said sequences and sequences generating hybrids to a sequence of SEQ ID NO: 4, 5, 9, 14, 28, 31, 33, 50, 53, 56, 60, 70, 72, 75, 76, 79, 83, 85, 97-106, 1 15-124, 126, 130, 134-141, 143, 145-147 , or 162-164; and (b) a detection reagent. 35. The kit according to claims 33 or 34, characterized in that the monoclonal antibodies are immobilized on a solid base. 36. The equipment according to claim 35, characterized in that the solid base comprises nitrocellulose, latex or a plastic material. 37. The equipment according to claims 33 or 34, characterized in that the detection reagent comprises a reporter group conjugated with a binder.38. The equipment according to claim 37, characterized in that the binder is selected from the group consisting of anti-immunoglobulins, Protein G, Protein A and lectins. 39. The equipment according to claim 37, characterized in that the reporter group is selected from the group consisting of radioisotopes, fluorescent groups, luminescent groups, biotin enzymes and ink particles. 40. A diagnostic device that includes a! minus two primary oligonucleotides, at least one of the primary oligonucleotides being specific for a polynucleotide molecule encoding a polypeptide comprising an immunogenic portion of a lung protein or a variant thereof, said protein comprising an amino acid sequence encoded by a polynucleotide molecule comprising a sequence selected from the group consisting of nucleotide sequences recited in SEQ ID NO: 1-109, 11.1.1, 15-151, 153, 154, 157, 588, 160, 162-164, 167, 168, and 1 71, the complements of said nucleotide sequences, and sequences that generate hybrids to a sequence of SEQ ID NO: 1-109, 11.1, 13.1, 15-151, 153 , 154, 157, 158, 160, 162-164, 167, 168, or 1 71, under moderately stringent conditions. 41 A diagnostic kit according to claim 40, characterized in that at least one of the primary oligonucleotides comprises at least about 10 contiguous nucleotides of a polypeptide molecule comprising a sequence selected from SEQ ID NO: 1-109, 111, 113, 115- 151, 153, 154, 157, 158, 160, 162-164, 167, 168, and 171. 42. A method for detecting lung cancer in a patient, comprising: (a) obtaining a biological sample from the patient; (b) contacting the biological sample with at least one oligonucleotide probe specific for a polynucleotide molecule encoding a polypeptide comprising an immunogenic portion of a lung protein or a variant thereof, said protein comprising an amino acid sequence encoded by a polynucleotide molecule comprising a sequence selected from the group consisting of nucleotide sequences cited in SEQ ID NO: 1-109, 111, 113, 115-151, 153, 154, 157, 158, 160, 162-164, 167 , 168, and 171, the complements of said nucleotide sequences, and sequences generating hybrids to a sequence of SEQ ID NO: 1-109, 111, 113, 115-151, 153, 154, 157, 158, 160, 162 - 164, 167, 168, or 171, under moderately stringent conditions; and (c) detecting in the sample a sequence of polynucleotides that generates hybrids to an oligonucleotide probe, thereby detecting lung cancer in the patient. 43. The method according to claim 42, characterized in that the oligonucleotide probe comprises at least about 15 contiguous nucleotides of a polynucleotide molecule comprising a sequence selected from the group consisting of SEQ ID NO: 1-109, 111, 113, 115-151 , 153, 154, 157, 158, 160, 162-164, 167, 168, or 171. 44. A diagnostic kit comprising an oligonucleotide probe specific for a polynucleotide molecule that encodes a polypeptide comprising an immunogenic portion of a lung protein or a variant thereof, said protein comprising an amino acid sequence encoded by a polynucleotide molecule comprising a sequence selected from the group consisting of sequences of: nucleotide sequences cited in SEQ ID NO: 1-109, 111, 113, 115-151, 153, 154, 157, 158, 160, 162-164, 167, 168, and 171, the complements of said nucleotide sequences, and sequences that generate hybrids to a sequence of SEQ ID NO: 1-109, 111, 113, 115-151, 153, 154, 157, 158, 160, 162-164, 167, 168, or 171, under moderately stringent conditions. 45. The diagnostic kit according to claim 44, characterized in that the oligonucleotide probe comprises at least about 15 contiguous nucleotides of a polynucleotide molecule comprising a sequence selected from the group consisting of SEQ ID NO: 1-109, 111, 113 , 115-151, 153, 154, 157, 158, 160, 162-164, 167, 168, or 171. 46. A method for treating lung cancer in a patient, comprising the steps of: (a) obtaining peripheral blood cells from the patient; (b) incubating the cells in the presence of at least one polypeptide of claim 2, such that the T cells proliferate; and (c) administering the proliferated cells to the patient 47. A method for treating lung cancer in a patient, comprising the steps of: (a) obtaining peripheral blood cells from the patient; (b) incubating the cells in the presence of at least one polynucleotide of claim 1, such that the T cells proliferate; and (c) administering the proliferated cells to the patient. 48. The method according to any of the claims 46 and 47, characterized in that the step of incubating the T cells is repeated one or more times. 49. The method according to any of claims 46 and 47, characterized in that step (a) further comprises separating the T cells from the peripheral blood cells, and the cells incubated in step (b) are the T cells. The method according to any of claims 46 and 47, characterized in that step (a) further comprises separating CD4 + cells or CD8 + cells from peripheral blood cells, and cells proliferated in step (b) are CD4 + or CD8 + T cells. 51 The method according to any of claims 46 and 47, characterized step (b) further comprises the cloning of one or more T cells that proliferate in the presence of the polypeptide. A composition for the treatment of lung cancer in a patient, comprising T cells proliferated in the presence of a polypeptide of claim 2, in combination with a pharmaceutically acceptable carrier. A composition for the treatment of lung cancer in a patient, comprising T cells proliferated in the presence of a polynucleotide of claim 1, in combination with a pharmaceutically acceptable carrier. 54. A method for treating lung cancer in a patient, comprising the steps of: (a) incubating the cells presenting the antigen in the presence of at least one polypeptide of claim 2; (b) administer to the patient the incubated cells that present the antigen. 55. A method for treating lung cancer in a patient, comprising the steps of: (a) incubating the cells presenting the antigen in the presence of at least one polynucleotide of claim 1; (b) administer to the patient the incubated cells that present the antigen. 56. The method according to claims 54 or 55, characterized in that the cells presenting the antigen are selected from the group consisting of dendritic cells and macrophage cells. 57. A composition for the treatment of lung cancer in a patient, comprising the incubated cells presenting the antigen in the presence of a polypeptide of claim 2, in combination with a pharmaceutically acceptable carrier. 58. A composition for the treatment of lung cancer in a patient, comprising the incubated cells presenting the antigen in the presence of a polynucleotide of claim 1, in combination with a pharmaceutically acceptable carrier.